[{"PMID": 10626836, "id": 1, "text": "Analysis of splice variants and site-directed mutants of the AMPA receptor GluR3 expressed in Xenopus oocytes has shown that lithium produces a large potentiation of the GluR3 flop splice variant and suggested that lithium might inhibit rapid desensitization, which is characteristic of this receptor (Karkanias, N. and Papke, R., Subtype-specific effects of lithium on glutamate receptor function.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [125, 132], "name": "lithium", "tok_span": [24, 25], "new_tok_span": [24, 25]}, {"ent_type": "CHEMICAL", "char_span": [215, 222], "name": "lithium", "tok_span": [41, 42], "new_tok_span": [41, 42]}, {"ent_type": "CHEMICAL", "char_span": [359, 366], "name": "lithium", "tok_span": [74, 75], "new_tok_span": [74, 75]}, {"ent_type": "CHEMICAL", "char_span": [370, 379], "name": "glutamate", "tok_span": [76, 77], "new_tok_span": [76, 77]}, {"ent_type": "CHEMICAL", "char_span": [61, 65], "name": "AMPA", "tok_span": [11, 13], "new_tok_span": [11, 13]}, {"ent_type": "GENE", "char_span": [170, 180], "name": "GluR3 flop", "tok_span": [31, 36], "new_tok_span": [31, 36]}, {"ent_type": "GENE", "char_span": [370, 388], "name": "glutamate receptor", "tok_span": [76, 78], "new_tok_span": [76, 78]}, {"ent_type": "GENE", "char_span": [61, 74], "name": "AMPA receptor", "tok_span": [11, 14], "new_tok_span": [11, 14]}, {"ent_type": "GENE", "char_span": [75, 80], "name": "GluR3", "tok_span": [14, 17], "new_tok_span": [14, 17]}], "relation_list": [{"subject": "lithium", "sbj_char_span": [125, 132], "object": "GluR3 flop", "obj_char_span": [170, 180], "rel_type": "activator", "sbj_tok_span": [24, 25], "obj_tok_span": [31, 36], "new_sbj_tok_span": [24, 25], "new_obj_tok_span": [31, 36]}], "umls_entity_list": [], "new_text": "Analysis of splice variants and site - directed mutants of the AMPA receptor GluR3 expressed in Xenopus oocytes has shown that lithium produces a large potentiation of the GluR3 flop splice variant and suggested that lithium might inhibit rapid desensitization, which is characteristic of this receptor ( Karkanias, N. and Papke, R., Subtype - specific effects of lithium on glutamate receptor function."}, {"PMID": 15276688, "id": 4, "text": "The first model was induced by tranylcypromine, a nonselective monoamine oxidase (MAO) inhibitor (3.5 mg/kg) and fluoxetine, a selective serotonin reuptake inhibitor (SSRI) (10 mg/kg).", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [31, 46], "name": "tranylcypromine", "tok_span": [6, 11], "new_tok_span": [7, 12]}, {"ent_type": "CHEMICAL", "char_span": [63, 72], "name": "monoamine", "tok_span": [16, 18], "new_tok_span": [19, 21]}, {"ent_type": "CHEMICAL", "char_span": [113, 123], "name": "fluoxetine", "tok_span": [33, 36], "new_tok_span": [38, 41]}, {"ent_type": "CHEMICAL", "char_span": [137, 146], "name": "serotonin", "tok_span": [39, 40], "new_tok_span": [46, 47]}, {"ent_type": "GENE", "char_span": [63, 80], "name": "monoamine oxidase", "tok_span": [16, 19], "new_tok_span": [19, 22]}, {"ent_type": "GENE", "char_span": [82, 85], "name": "MAO", "tok_span": [20, 22], "new_tok_span": [24, 26]}], "relation_list": [{"subject": "tranylcypromine", "sbj_char_span": [31, 46], "object": "monoamine oxidase", "obj_char_span": [63, 80], "rel_type": "inhibitor", "sbj_tok_span": [6, 11], "obj_tok_span": [16, 19], "new_sbj_tok_span": [7, 12], "new_obj_tok_span": [19, 22]}, {"subject": "tranylcypromine", "sbj_char_span": [31, 46], "object": "MAO", "obj_char_span": [82, 85], "rel_type": "inhibitor", "sbj_tok_span": [6, 11], "obj_tok_span": [20, 22], "new_sbj_tok_span": [7, 12], "new_obj_tok_span": [24, 26]}], "umls_entity_list": [{"mention": "tranylcypromine", "char_span": [31, 46], "sem_type": "Pharmacologic Substance", "tok_span": [6, 11], "new_tok_span": [7, 12]}, {"mention": "monoamine", "char_span": [63, 72], "sem_type": "Pharmacologic Substance", "tok_span": [16, 18], "new_tok_span": [19, 21]}, {"mention": "fluoxetine", "char_span": [113, 123], "sem_type": "Pharmacologic Substance", "tok_span": [33, 36], "new_tok_span": [38, 41]}, {"mention": "selective serotonin reuptake inhibitor", "char_span": [127, 165], "sem_type": "Pharmacologic Substance", "tok_span": [38, 44], "new_tok_span": [45, 51]}], "new_text": "The first model was induced by <START=Pharmacologic Substance> tranylcypromine <END=Pharmacologic Substance>, a nonselective <START=Pharmacologic Substance> monoamine <END=Pharmacologic Substance> oxidase ( MAO ) inhibitor ( 3. 5 mg / kg ) and <START=Pharmacologic Substance> fluoxetine <END=Pharmacologic Substance>, a <START=Pharmacologic Substance> selective serotonin reuptake inhibitor <END=Pharmacologic Substance> ( SSRI ) ( 10 mg / kg )."}, {"PMID": 3917545, "id": 2, "text": "Phenylbutazone (PB), a nonsteroidal anti-inflammatory drug, is an efficient reducing cofactor for the peroxidase activity of prostaglandin H synthase (PHS). Most reducing cofactors for the peroxidase protect PHS and prostacyclin synthase from inactivation by hydroperoxides.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 14], "name": "Phenylbutazone", "tok_span": [0, 4], "new_tok_span": [1, 5]}, {"ent_type": "CHEMICAL", "char_span": [125, 140], "name": "prostaglandin H", "tok_span": [28, 30], "new_tok_span": [37, 39]}, {"ent_type": "CHEMICAL", "char_span": [16, 18], "name": "PB", "tok_span": [5, 6], "new_tok_span": [7, 8]}, {"ent_type": "CHEMICAL", "char_span": [216, 228], "name": "prostacyclin", "tok_span": [47, 50], "new_tok_span": [61, 64]}, {"ent_type": "CHEMICAL", "char_span": [259, 273], "name": "hydroperoxides", "tok_span": [54, 58], "new_tok_span": [69, 73]}, {"ent_type": "GENE", "char_span": [125, 149], "name": "prostaglandin H synthase", "tok_span": [28, 31], "new_tok_span": [37, 40]}, {"ent_type": "GENE", "char_span": [151, 154], "name": "PHS", "tok_span": [32, 34], "new_tok_span": [42, 44]}, {"ent_type": "GENE", "char_span": [208, 211], "name": "PHS", "tok_span": [44, 46], "new_tok_span": [56, 58]}, {"ent_type": "GENE", "char_span": [216, 237], "name": "prostacyclin synthase", "tok_span": [47, 51], "new_tok_span": [61, 65]}], "relation_list": [{"subject": "hydroperoxides", "sbj_char_span": [259, 273], "object": "PHS", "obj_char_span": [208, 211], "rel_type": "inhibitor", "sbj_tok_span": [54, 58], "obj_tok_span": [44, 46], "new_sbj_tok_span": [69, 73], "new_obj_tok_span": [56, 58]}, {"subject": "hydroperoxides", "sbj_char_span": [259, 273], "object": "prostacyclin synthase", "obj_char_span": [216, 237], "rel_type": "inhibitor", "sbj_tok_span": [54, 58], "obj_tok_span": [47, 51], "new_sbj_tok_span": [69, 73], "new_obj_tok_span": [61, 65]}], "umls_entity_list": [{"mention": "Phenylbutazon", "char_span": [0, 13], "sem_type": "Pharmacologic Substance", "tok_span": [0, 4], "new_tok_span": [1, 5]}, {"mention": "peroxidase", "char_span": [102, 112], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [25, 26], "new_tok_span": [32, 33]}, {"mention": "peroxidase", "char_span": [189, 199], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [42, 43], "new_tok_span": [53, 54]}, {"mention": "an", "char_span": [36, 38], "sem_type": "Gene or Genome", "tok_span": [12, 13], "new_tok_span": [15, 16]}, {"mention": "an", "char_span": [63, 65], "sem_type": "Gene or Genome", "tok_span": [18, 19], "new_tok_span": [23, 24]}, {"mention": "an", "char_span": [133, 135], "sem_type": "Gene or Genome", "tok_span": [28, 29], "new_tok_span": [37, 38]}, {"mention": "an", "char_span": [212, 214], "sem_type": "Gene or Genome", "tok_span": [46, 47], "new_tok_span": [59, 60]}, {"mention": "hydroperoxide", "char_span": [259, 272], "sem_type": "Pharmacologic Substance", "tok_span": [54, 57], "new_tok_span": [69, 72]}], "new_text": "<START=Pharmacologic Substance> Phenylbutazone <END=Pharmacologic Substance> ( PB ), a nonsteroidal <START=Gene or Genome> anti <END=Gene or Genome> - inflammatory drug, is <START=Gene or Genome> an <END=Gene or Genome> efficient reducing cofactor for the <START=Amino Acid, Peptide, or Protein> peroxidase <END=Amino Acid, Peptide, or Protein> activity of <START=Gene or Genome> prostaglandin <END=Gene or Genome> H synthase ( PHS ). Most reducing cofactors for the <START=Amino Acid, Peptide, or Protein> peroxidase <END=Amino Acid, Peptide, or Protein> protect PHS <START=Gene or Genome> and <END=Gene or Genome> prostacyclin synthase from inactivation by <START=Pharmacologic Substance> hydroperoxide <END=Pharmacologic Substance>s."}, {"PMID": 23266270, "id": 7, "text": "Taken together, the results of this study demonstrate that DPEP inhibits LPS-stimulated inflammation by blocking the NF-κB and MAPK pathways in macrophages.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [59, 63], "name": "DPEP", "tok_span": [10, 12], "new_tok_span": [10, 12]}, {"ent_type": "GENE", "char_span": [117, 122], "name": "NF-κB", "tok_span": [20, 24], "new_tok_span": [20, 24]}, {"ent_type": "GENE", "char_span": [127, 131], "name": "MAPK", "tok_span": [25, 26], "new_tok_span": [25, 26]}], "relation_list": [{"subject": "DPEP", "sbj_char_span": [59, 63], "object": "NF-κB", "obj_char_span": [117, 122], "rel_type": "inhibitor", "sbj_tok_span": [10, 12], "obj_tok_span": [20, 24], "new_sbj_tok_span": [10, 12], "new_obj_tok_span": [20, 24]}, {"subject": "DPEP", "sbj_char_span": [59, 63], "object": "MAPK", "obj_char_span": [127, 131], "rel_type": "inhibitor", "sbj_tok_span": [10, 12], "obj_tok_span": [25, 26], "new_sbj_tok_span": [10, 12], "new_obj_tok_span": [25, 26]}], "umls_entity_list": [], "new_text": "Taken together, the results of this study demonstrate that DPEP inhibits LPS - stimulated inflammation by blocking the NF - κB and MAPK pathways in macrophages."}, {"PMID": 11246672, "id": 0, "text": "Minocycline inhibits the production of inducible nitric oxide synthase in articular chondrocytes.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 11], "name": "Minocycline", "tok_span": [0, 4], "new_tok_span": [1, 5]}, {"ent_type": "CHEMICAL", "char_span": [49, 61], "name": "nitric oxide", "tok_span": [9, 11], "new_tok_span": [12, 14]}, {"ent_type": "GENE", "char_span": [39, 70], "name": "inducible nitric oxide synthase", "tok_span": [8, 12], "new_tok_span": [11, 15]}], "relation_list": [{"subject": "Minocycline", "sbj_char_span": [0, 11], "object": "inducible nitric oxide synthase", "obj_char_span": [39, 70], "rel_type": "regulator", "sbj_tok_span": [0, 4], "obj_tok_span": [8, 12], "new_sbj_tok_span": [1, 5], "new_obj_tok_span": [11, 15]}], "umls_entity_list": [{"mention": "Minocyclin", "char_span": [0, 10], "sem_type": "Organic Chemical", "tok_span": [0, 3], "new_tok_span": [1, 4]}, {"mention": "inducible nitric oxide synthase", "char_span": [39, 70], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [8, 12], "new_tok_span": [11, 15]}], "new_text": "<START=Organic Chemical> Minocyclin <END=Organic Chemical>e inhibits the production of <START=Amino Acid, Peptide, or Protein> inducible nitric oxide synthase <END=Amino Acid, Peptide, or Protein> in articular chondrocytes."}, {"PMID": 23382458, "id": 3, "text": "The P-gp- and BCRP-facilitated transport of apixaban was concentration- and time-dependent and did not show saturation over a wide range of concentrations (1-100 μM). The efflux transport of apixaban was also demonstrated by the lower mucosal-to-serosal permeability than that of the serosal-to-mucosal direction in isolated rat jejunum segments.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [44, 52], "name": "apixaban", "tok_span": [12, 15], "new_tok_span": [13, 16]}, {"ent_type": "CHEMICAL", "char_span": [191, 199], "name": "apixaban", "tok_span": [45, 48], "new_tok_span": [48, 51]}, {"ent_type": "GENE", "char_span": [4, 8], "name": "P-gp", "tok_span": [1, 4], "new_tok_span": [1, 4]}, {"ent_type": "GENE", "char_span": [14, 18], "name": "BCRP", "tok_span": [6, 8], "new_tok_span": [6, 8]}], "relation_list": [{"subject": "apixaban", "sbj_char_span": [44, 52], "object": "P-gp", "obj_char_span": [4, 8], "rel_type": "product or substrate", "sbj_tok_span": [12, 15], "obj_tok_span": [1, 4], "new_sbj_tok_span": [13, 16], "new_obj_tok_span": [1, 4]}, {"subject": "apixaban", "sbj_char_span": [44, 52], "object": "BCRP", "obj_char_span": [14, 18], "rel_type": "product or substrate", "sbj_tok_span": [12, 15], "obj_tok_span": [6, 8], "new_sbj_tok_span": [13, 16], "new_obj_tok_span": [6, 8]}], "umls_entity_list": [{"mention": "apixaban", "char_span": [44, 52], "sem_type": "Pharmacologic Substance", "tok_span": [12, 15], "new_tok_span": [13, 16]}, {"mention": "apixaban", "char_span": [191, 199], "sem_type": "Pharmacologic Substance", "tok_span": [45, 48], "new_tok_span": [48, 51]}], "new_text": "The P - gp - and BCRP - facilitated transport of <START=Pharmacologic Substance> apixaban <END=Pharmacologic Substance> was concentration - and time - dependent and did not show saturation over a wide range of concentrations ( 1 - 100 μM ). The efflux transport of <START=Pharmacologic Substance> apixaban <END=Pharmacologic Substance> was also demonstrated by the lower mucosal - to - serosal permeability than that of the serosal - to - mucosal direction in isolated rat jejunum segments."}, {"PMID": 17645691, "id": 5, "text": "Moreover, melatonin (but not silymarin) upregulated several proteins involved in the cellular protection against the oxidative stress in rats with OCP. These included, biliverdin-IX alpha reductase and the sodium-dependent vitamin C transport proteins SVCT1 and SVCT2, whose expression levels were enhanced in maternal and fetal liver by melatonin treatment.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [168, 178], "name": "biliverdin", "tok_span": [31, 34], "new_tok_span": [37, 40]}, {"ent_type": "CHEMICAL", "char_span": [206, 212], "name": "sodium", "tok_span": [40, 41], "new_tok_span": [46, 47]}, {"ent_type": "CHEMICAL", "char_span": [223, 232], "name": "vitamin C", "tok_span": [43, 45], "new_tok_span": [49, 51]}, {"ent_type": "CHEMICAL", "char_span": [338, 347], "name": "melatonin", "tok_span": [66, 67], "new_tok_span": [79, 80]}, {"ent_type": "CHEMICAL", "char_span": [10, 19], "name": "melatonin", "tok_span": [2, 3], "new_tok_span": [3, 4]}, {"ent_type": "CHEMICAL", "char_span": [29, 38], "name": "silymarin", "tok_span": [6, 9], "new_tok_span": [9, 12]}, {"ent_type": "GENE", "char_span": [168, 197], "name": "biliverdin-IX alpha reductase", "tok_span": [31, 38], "new_tok_span": [37, 44]}, {"ent_type": "GENE", "char_span": [252, 257], "name": "SVCT1", "tok_span": [47, 50], "new_tok_span": [56, 59]}, {"ent_type": "GENE", "char_span": [262, 267], "name": "SVCT2", "tok_span": [51, 54], "new_tok_span": [62, 65]}], "relation_list": [{"subject": "vitamin C", "sbj_char_span": [223, 232], "object": "SVCT1", "obj_char_span": [252, 257], "rel_type": "product or substrate", "sbj_tok_span": [43, 45], "obj_tok_span": [47, 50], "new_sbj_tok_span": [49, 51], "new_obj_tok_span": [56, 59]}, {"subject": "vitamin C", "sbj_char_span": [223, 232], "object": "SVCT2", "obj_char_span": [262, 267], "rel_type": "product or substrate", "sbj_tok_span": [43, 45], "obj_tok_span": [51, 54], "new_sbj_tok_span": [49, 51], "new_obj_tok_span": [62, 65]}, {"subject": "melatonin", "sbj_char_span": [338, 347], "object": "SVCT1", "obj_char_span": [252, 257], "rel_type": "regulator", "sbj_tok_span": [66, 67], "obj_tok_span": [47, 50], "new_sbj_tok_span": [79, 80], "new_obj_tok_span": [56, 59]}, {"subject": "melatonin", "sbj_char_span": [338, 347], "object": "SVCT2", "obj_char_span": [262, 267], "rel_type": "regulator", "sbj_tok_span": [66, 67], "obj_tok_span": [51, 54], "new_sbj_tok_span": [79, 80], "new_obj_tok_span": [62, 65]}], "umls_entity_list": [{"mention": "silymarin", "char_span": [29, 38], "sem_type": "Pharmacologic Substance", "tok_span": [6, 9], "new_tok_span": [9, 12]}, {"mention": "proteins", "char_span": [60, 68], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [12, 13], "new_tok_span": [17, 18]}, {"mention": "proteins", "char_span": [243, 251], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [46, 47], "new_tok_span": [53, 54]}, {"mention": "SVCT1", "char_span": [252, 257], "sem_type": "Gene or Genome", "tok_span": [47, 50], "new_tok_span": [56, 59]}, {"mention": "SVCT2", "char_span": [262, 267], "sem_type": "Gene or Genome", "tok_span": [51, 54], "new_tok_span": [62, 65]}, {"mention": "melatonin", "char_span": [10, 19], "sem_type": "Pharmacologic Substance", "tok_span": [2, 3], "new_tok_span": [3, 4]}, {"mention": "melatonin", "char_span": [338, 347], "sem_type": "Pharmacologic Substance", "tok_span": [66, 67], "new_tok_span": [79, 80]}], "new_text": "Moreover, <START=Pharmacologic Substance> melatonin <END=Pharmacologic Substance> ( but not <START=Pharmacologic Substance> silymarin <END=Pharmacologic Substance> ) upregulated several <START=Amino Acid, Peptide, or Protein> proteins <END=Amino Acid, Peptide, or Protein> involved in the cellular protection against the oxidative stress in rats with OCP. These included, biliverdin - IX alpha reductase and the sodium - dependent vitamin C transport <START=Amino Acid, Peptide, or Protein> proteins <END=Amino Acid, Peptide, or Protein> <START=Gene or Genome> SVCT1 <END=Gene or Genome> and <START=Gene or Genome> SVCT2 <END=Gene or Genome>, whose expression levels were enhanced in maternal and fetal liver by <START=Pharmacologic Substance> melatonin <END=Pharmacologic Substance> treatment."}, {"PMID": 1665782, "id": 5, "text": "When delta-receptor binding was determined by using [3H]DPDPE, a 40-50% decrease in binding in the midbrain and cortex, and 25-35% decrease in binding in the striatum were observed after 3 or 4 days of DPDPE treatment.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [202, 207], "name": "DPDPE", "tok_span": [51, 54], "new_tok_span": [58, 61]}, {"ent_type": "CHEMICAL", "char_span": [52, 61], "name": "[3H]DPDPE", "tok_span": [9, 16], "new_tok_span": [13, 20]}, {"ent_type": "GENE", "char_span": [5, 19], "name": "delta-receptor", "tok_span": [1, 4], "new_tok_span": [3, 6]}], "relation_list": [{"subject": "[3H]DPDPE", "sbj_char_span": [52, 61], "object": "delta-receptor", "obj_char_span": [5, 19], "rel_type": "regulator", "sbj_tok_span": [9, 16], "obj_tok_span": [1, 4], "new_sbj_tok_span": [13, 20], "new_obj_tok_span": [3, 6]}, {"subject": "DPDPE", "sbj_char_span": [202, 207], "object": "delta-receptor", "obj_char_span": [5, 19], "rel_type": "regulator", "sbj_tok_span": [51, 54], "obj_tok_span": [1, 4], "new_sbj_tok_span": [58, 61], "new_obj_tok_span": [3, 6]}], "umls_entity_list": [{"mention": "delta", "char_span": [5, 10], "sem_type": "Gene or Genome", "tok_span": [1, 2], "new_tok_span": [3, 4]}, {"mention": "delta", "char_span": [5, 10], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [1, 2], "new_tok_span": [3, 4]}, {"mention": "DPDPE", "char_span": [56, 61], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [13, 16], "new_tok_span": [18, 21]}, {"mention": "DPDPE", "char_span": [202, 207], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [51, 54], "new_tok_span": [58, 61]}], "new_text": "When <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> delta <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> - receptor binding was determined by using [ 3H ] <START=Amino Acid, Peptide, or Protein> DPDPE <END=Amino Acid, Peptide, or Protein>, a 40 - 50 % decrease in binding in the midbrain and cortex, and 25 - 35 % decrease in binding in the striatum were observed after 3 or 4 days of <START=Amino Acid, Peptide, or Protein> DPDPE <END=Amino Acid, Peptide, or Protein> treatment."}, {"PMID": 20497523, "id": 13, "text": "In the TT-specific DTH model, EE and the selective ERalpha agonist ERA-63 suppressed the TT-specific swelling response in WT and ERbetaKO mice but not in ERalphaKO mice.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [30, 32], "name": "EE", "tok_span": [9, 10], "new_tok_span": [9, 10]}, {"ent_type": "CHEMICAL", "char_span": [67, 73], "name": "ERA-63", "tok_span": [16, 20], "new_tok_span": [18, 22]}, {"ent_type": "GENE", "char_span": [51, 58], "name": "ERalpha", "tok_span": [13, 15], "new_tok_span": [14, 16]}, {"ent_type": "GENE", "char_span": [129, 135], "name": "ERbeta", "tok_span": [30, 32], "new_tok_span": [32, 34]}, {"ent_type": "GENE", "char_span": [154, 161], "name": "ERalpha", "tok_span": [37, 39], "new_tok_span": [40, 42]}], "relation_list": [{"subject": "ERA-63", "sbj_char_span": [67, 73], "object": "ERalpha", "obj_char_span": [51, 58], "rel_type": "agonist or antagonist", "sbj_tok_span": [16, 20], "obj_tok_span": [13, 15], "new_sbj_tok_span": [18, 22], "new_obj_tok_span": [14, 16]}], "umls_entity_list": [{"mention": "ERalpha", "char_span": [51, 58], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [13, 15], "new_tok_span": [14, 16]}, {"mention": "ERalpha", "char_span": [154, 161], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [37, 39], "new_tok_span": [40, 42]}], "new_text": "In the TT - specific DTH model, EE and the selective <START=Amino Acid, Peptide, or Protein> ERalpha <END=Amino Acid, Peptide, or Protein> agonist ERA - 63 suppressed the TT - specific swelling response in WT and ERbetaKO mice but not in <START=Amino Acid, Peptide, or Protein> ERalpha <END=Amino Acid, Peptide, or Protein>KO mice."}, {"PMID": 16829128, "id": 2, "text": "Menthol, popularly known for its cooling effect, activates TRPM8--a cold-activated thermoTRP ion channel.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 7], "name": "Menthol", "tok_span": [0, 3], "new_tok_span": [1, 4]}, {"ent_type": "GENE", "char_span": [59, 64], "name": "TRPM8", "tok_span": [13, 16], "new_tok_span": [16, 19]}, {"ent_type": "GENE", "char_span": [83, 104], "name": "thermoTRP ion channel", "tok_span": [22, 27], "new_tok_span": [26, 31]}], "relation_list": [{"subject": "Menthol", "sbj_char_span": [0, 7], "object": "TRPM8", "obj_char_span": [59, 64], "rel_type": "activator", "sbj_tok_span": [0, 3], "obj_tok_span": [13, 16], "new_sbj_tok_span": [1, 4], "new_obj_tok_span": [16, 19]}, {"subject": "Menthol", "sbj_char_span": [0, 7], "object": "thermoTRP ion channel", "obj_char_span": [83, 104], "rel_type": "activator", "sbj_tok_span": [0, 3], "obj_tok_span": [22, 27], "new_sbj_tok_span": [1, 4], "new_obj_tok_span": [26, 31]}], "umls_entity_list": [{"mention": "Menthol", "char_span": [0, 7], "sem_type": "Pharmacologic Substance", "tok_span": [0, 3], "new_tok_span": [1, 4]}, {"mention": "TRPM8", "char_span": [59, 64], "sem_type": "Gene or Genome", "tok_span": [13, 16], "new_tok_span": [16, 19]}, {"mention": "ion", "char_span": [93, 96], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [25, 26], "new_tok_span": [30, 31]}], "new_text": "<START=Pharmacologic Substance> Menthol <END=Pharmacologic Substance>, popularly known for its cooling effect, activates <START=Gene or Genome> TRPM8 <END=Gene or Genome> - - a cold - activated thermoTRP <START=Amino Acid, Peptide, or Protein> ion <END=Amino Acid, Peptide, or Protein> channel."}, {"PMID": 16829128, "id": 4, "text": "Similar to menthol, both camphor and cinnamaldehyde (initially reported to be specific activators of TRPV3 and TRPA1, respectively) also modulate other thermoTRPs. Therefore, we find that many \"sensory compounds\" presumed to be specific have a promiscuous relationship with thermoTRPs.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [11, 18], "name": "menthol", "tok_span": [2, 4], "new_tok_span": [3, 5]}, {"ent_type": "CHEMICAL", "char_span": [25, 32], "name": "camphor", "tok_span": [6, 8], "new_tok_span": [9, 11]}, {"ent_type": "CHEMICAL", "char_span": [37, 51], "name": "cinnamaldehyde", "tok_span": [9, 12], "new_tok_span": [14, 17]}, {"ent_type": "GENE", "char_span": [101, 106], "name": "TRPV3", "tok_span": [21, 24], "new_tok_span": [28, 31]}, {"ent_type": "GENE", "char_span": [111, 116], "name": "TRPA1", "tok_span": [25, 28], "new_tok_span": [33, 36]}, {"ent_type": "GENE", "char_span": [152, 162], "name": "thermoTRPs", "tok_span": [34, 38], "new_tok_span": [42, 46]}, {"ent_type": "GENE", "char_span": [274, 284], "name": "thermoTRPs", "tok_span": [60, 64], "new_tok_span": [68, 72]}], "relation_list": [{"subject": "menthol", "sbj_char_span": [11, 18], "object": "TRPV3", "obj_char_span": [101, 106], "rel_type": "activator", "sbj_tok_span": [2, 4], "obj_tok_span": [21, 24], "new_sbj_tok_span": [3, 5], "new_obj_tok_span": [28, 31]}, {"subject": "camphor", "sbj_char_span": [25, 32], "object": "TRPV3", "obj_char_span": [101, 106], "rel_type": "activator", "sbj_tok_span": [6, 8], "obj_tok_span": [21, 24], "new_sbj_tok_span": [9, 11], "new_obj_tok_span": [28, 31]}, {"subject": "cinnamaldehyde", "sbj_char_span": [37, 51], "object": "TRPV3", "obj_char_span": [101, 106], "rel_type": "activator", "sbj_tok_span": [9, 12], "obj_tok_span": [21, 24], "new_sbj_tok_span": [14, 17], "new_obj_tok_span": [28, 31]}, {"subject": "menthol", "sbj_char_span": [11, 18], "object": "TRPA1", "obj_char_span": [111, 116], "rel_type": "activator", "sbj_tok_span": [2, 4], "obj_tok_span": [25, 28], "new_sbj_tok_span": [3, 5], "new_obj_tok_span": [33, 36]}, {"subject": "camphor", "sbj_char_span": [25, 32], "object": "TRPA1", "obj_char_span": [111, 116], "rel_type": "activator", "sbj_tok_span": [6, 8], "obj_tok_span": [25, 28], "new_sbj_tok_span": [9, 11], "new_obj_tok_span": [33, 36]}, {"subject": "cinnamaldehyde", "sbj_char_span": [37, 51], "object": "TRPA1", "obj_char_span": [111, 116], "rel_type": "activator", "sbj_tok_span": [9, 12], "obj_tok_span": [25, 28], "new_sbj_tok_span": [14, 17], "new_obj_tok_span": [33, 36]}], "umls_entity_list": [{"mention": "menthol", "char_span": [11, 18], "sem_type": "Pharmacologic Substance", "tok_span": [2, 4], "new_tok_span": [3, 5]}, {"mention": "camphor", "char_span": [25, 32], "sem_type": "Pharmacologic Substance", "tok_span": [6, 8], "new_tok_span": [9, 11]}, {"mention": "cinnamaldehyde", "char_span": [37, 51], "sem_type": "Pharmacologic Substance", "tok_span": [9, 12], "new_tok_span": [14, 17]}, {"mention": "TRPV3", "char_span": [101, 106], "sem_type": "Gene or Genome", "tok_span": [21, 24], "new_tok_span": [28, 31]}], "new_text": "Similar to <START=Pharmacologic Substance> menthol <END=Pharmacologic Substance>, both <START=Pharmacologic Substance> camphor <END=Pharmacologic Substance> and <START=Pharmacologic Substance> cinnamaldehyde <END=Pharmacologic Substance> ( initially reported to be specific activators of <START=Gene or Genome> TRPV3 <END=Gene or Genome> and TRPA1, respectively ) also modulate other thermoTRPs. Therefore, we find that many \" sensory compounds \" presumed to be specific have a promiscuous relationship with thermoTRPs."}, {"PMID": 16395286, "id": 7, "text": "At the enzymatic activity level, doxycycline started to suppress MMP-9 activity at 5 mg/kg/day (P<0.001), while minocycline had an effect at a lower dose, 1 mg/kg/day (P<0.02).", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [112, 123], "name": "minocycline", "tok_span": [33, 37], "new_tok_span": [33, 37]}, {"ent_type": "CHEMICAL", "char_span": [33, 44], "name": "doxycycline", "tok_span": [6, 9], "new_tok_span": [6, 9]}, {"ent_type": "GENE", "char_span": [65, 70], "name": "MMP-9", "tok_span": [12, 15], "new_tok_span": [12, 15]}], "relation_list": [{"subject": "doxycycline", "sbj_char_span": [33, 44], "object": "MMP-9", "obj_char_span": [65, 70], "rel_type": "inhibitor", "sbj_tok_span": [6, 9], "obj_tok_span": [12, 15], "new_sbj_tok_span": [6, 9], "new_obj_tok_span": [12, 15]}], "umls_entity_list": [{"mention": "an", "char_span": [128, 130], "sem_type": "Pharmacologic Substance", "tok_span": [38, 39], "new_tok_span": [39, 40]}], "new_text": "At the enzymatic activity level, doxycycline started to suppress MMP - 9 activity at 5 mg / kg / day ( P < 0. 001 ), while minocycline had <START=Pharmacologic Substance> an <END=Pharmacologic Substance> effect at a lower dose, 1 mg / kg / day ( P < 0. 02 )."}, {"PMID": 16395286, "id": 11, "text": "This study provided the evidence that the tetracyclines inhibit stimulated cerebral MMP-9 at multiple levels and are effective at very low doses, offering great potential for therapeutic use.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [42, 55], "name": "tetracyclines", "tok_span": [7, 10], "new_tok_span": [8, 11]}, {"ent_type": "GENE", "char_span": [84, 89], "name": "MMP-9", "tok_span": [13, 16], "new_tok_span": [16, 19]}], "relation_list": [{"subject": "tetracyclines", "sbj_char_span": [42, 55], "object": "MMP-9", "obj_char_span": [84, 89], "rel_type": "inhibitor", "sbj_tok_span": [7, 10], "obj_tok_span": [13, 16], "new_sbj_tok_span": [8, 11], "new_obj_tok_span": [16, 19]}], "umls_entity_list": [{"mention": "tetracyclines", "char_span": [42, 55], "sem_type": "Organic Chemical", "tok_span": [7, 10], "new_tok_span": [8, 11]}, {"mention": "MMP-9", "char_span": [84, 89], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [13, 16], "new_tok_span": [16, 19]}], "new_text": "This study provided the evidence that the <START=Organic Chemical> tetracyclines <END=Organic Chemical> inhibit stimulated cerebral <START=Amino Acid, Peptide, or Protein> MMP - 9 <END=Amino Acid, Peptide, or Protein> at multiple levels and are effective at very low doses, offering great potential for therapeutic use."}, {"PMID": 10864881, "id": 0, "text": "Betaxolol, a beta(1)-adrenoceptor antagonist, reduces Na(+) influx into cortical synaptosomes by direct interaction with Na(+) channels: comparison with other beta-adrenoceptor antagonists.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 9], "name": "Betaxolol", "tok_span": [0, 4], "new_tok_span": [1, 5]}, {"ent_type": "CHEMICAL", "char_span": [121, 126], "name": "Na(+)", "tok_span": [31, 35], "new_tok_span": [40, 44]}, {"ent_type": "CHEMICAL", "char_span": [54, 59], "name": "Na(+)", "tok_span": [17, 21], "new_tok_span": [22, 26]}, {"ent_type": "GENE", "char_span": [121, 135], "name": "Na(+) channels", "tok_span": [31, 36], "new_tok_span": [40, 45]}, {"ent_type": "GENE", "char_span": [13, 33], "name": "beta(1)-adrenoceptor", "tok_span": [6, 14], "new_tok_span": [8, 16]}, {"ent_type": "GENE", "char_span": [159, 176], "name": "beta-adrenoceptor", "tok_span": [40, 45], "new_tok_span": [51, 56]}], "relation_list": [{"subject": "Betaxolol", "sbj_char_span": [0, 9], "object": "beta(1)-adrenoceptor", "obj_char_span": [13, 33], "rel_type": "agonist or antagonist", "sbj_tok_span": [0, 4], "obj_tok_span": [6, 14], "new_sbj_tok_span": [1, 5], "new_obj_tok_span": [8, 16]}, {"subject": "Betaxolol", "sbj_char_span": [0, 9], "object": "Na(+) channels", "obj_char_span": [121, 135], "rel_type": "regulator", "sbj_tok_span": [0, 4], "obj_tok_span": [31, 36], "new_sbj_tok_span": [1, 5], "new_obj_tok_span": [40, 45]}], "umls_entity_list": [{"mention": "Betaxolol", "char_span": [0, 9], "sem_type": "Pharmacologic Substance", "tok_span": [0, 4], "new_tok_span": [1, 5]}, {"mention": "adrenoceptor antagonist", "char_span": [21, 44], "sem_type": "Pharmacologic Substance", "tok_span": [11, 15], "new_tok_span": [14, 18]}, {"mention": "adrenoceptor antagonist", "char_span": [164, 187], "sem_type": "Pharmacologic Substance", "tok_span": [42, 46], "new_tok_span": [54, 58]}, {"mention": "Na", "char_span": [54, 56], "sem_type": "Gene or Genome", "tok_span": [17, 18], "new_tok_span": [22, 23]}, {"mention": "na", "char_span": [83, 85], "sem_type": "Gene or Genome", "tok_span": [24, 26], "new_tok_span": [31, 33]}, {"mention": "Na", "char_span": [121, 123], "sem_type": "Gene or Genome", "tok_span": [31, 32], "new_tok_span": [40, 41]}, {"mention": "beta-adrenoceptor antagonists", "char_span": [159, 188], "sem_type": "Pharmacologic Substance", "tok_span": [40, 46], "new_tok_span": [51, 57]}], "new_text": "<START=Pharmacologic Substance> Betaxolol <END=Pharmacologic Substance>, a beta ( 1 ) - <START=Pharmacologic Substance> adrenoceptor antagonist <END=Pharmacologic Substance>, reduces <START=Gene or Genome> Na <END=Gene or Genome> ( + ) influx into cortical <START=Gene or Genome> synapt <END=Gene or Genome>osomes by direct interaction with <START=Gene or Genome> Na <END=Gene or Genome> ( + ) channels : comparison with other <START=Pharmacologic Substance> beta - <START=Pharmacologic Substance> adrenoceptor antagonists <END=Pharmacologic Substance> <END=Pharmacologic Substance>."}, {"PMID": 10864881, "id": 5, "text": "None of the drugs caused a significant inhibition of [(3)H]-saxitoxin binding to neurotoxin receptor site 1, even at concentrations as high as 250 microM.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [53, 69], "name": "[(3)H]-saxitoxin", "tok_span": [9, 20], "new_tok_span": [11, 22]}, {"ent_type": "GENE", "char_span": [81, 107], "name": "neurotoxin receptor site 1", "tok_span": [22, 27], "new_tok_span": [26, 31]}], "relation_list": [{"subject": "[(3)H]-saxitoxin", "sbj_char_span": [53, 69], "object": "neurotoxin receptor site 1", "obj_char_span": [81, 107], "rel_type": "regulator", "sbj_tok_span": [9, 20], "obj_tok_span": [22, 27], "new_sbj_tok_span": [11, 22], "new_obj_tok_span": [26, 31]}], "umls_entity_list": [{"mention": "drugs", "char_span": [12, 17], "sem_type": "Pharmacologic Substance", "tok_span": [3, 4], "new_tok_span": [4, 5]}, {"mention": "saxitoxin", "char_span": [60, 69], "sem_type": "Organic Chemical", "tok_span": [16, 20], "new_tok_span": [19, 23]}, {"mention": "receptor", "char_span": [92, 100], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [24, 25], "new_tok_span": [29, 30]}], "new_text": "None of the <START=Pharmacologic Substance> drugs <END=Pharmacologic Substance> caused a significant inhibition of [ ( 3 ) H ] - <START=Organic Chemical> saxitoxin <END=Organic Chemical> binding to neurotoxin <START=Amino Acid, Peptide, or Protein> receptor <END=Amino Acid, Peptide, or Protein> site 1, even at concentrations as high as 250 microM."}, {"PMID": 15126366, "id": 5, "text": "In all of the three cell types, I3A inhibited cell proliferation with somewhat lower potency than did PMA. In intact CHO-K1 cells, I3A was able to translocate different green fluorescent protein-tagged PKC isoforms, visualized by confocal microscopy, with equal or higher potency than PMA. PKC-delta in particular showed a different pattern of translocation in response to I3A and PMA. I3A induced a higher level of secretion of the inflammatory cytokine interleukin 6 compared with PMA in the WEHI-231 cells and displayed a marked biphasic dose-response curve for the induction.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [483, 486], "name": "PMA", "tok_span": [97, 98], "new_tok_span": [122, 123]}, {"ent_type": "CHEMICAL", "char_span": [32, 35], "name": "I3A", "tok_span": [8, 11], "new_tok_span": [9, 12]}, {"ent_type": "CHEMICAL", "char_span": [102, 105], "name": "PMA", "tok_span": [20, 21], "new_tok_span": [23, 24]}, {"ent_type": "CHEMICAL", "char_span": [131, 134], "name": "I3A", "tok_span": [30, 33], "new_tok_span": [39, 42]}, {"ent_type": "CHEMICAL", "char_span": [285, 288], "name": "PMA", "tok_span": [58, 59], "new_tok_span": [73, 74]}, {"ent_type": "CHEMICAL", "char_span": [373, 376], "name": "I3A", "tok_span": [74, 77], "new_tok_span": [91, 94]}, {"ent_type": "CHEMICAL", "char_span": [381, 384], "name": "PMA", "tok_span": [78, 79], "new_tok_span": [97, 98]}, {"ent_type": "CHEMICAL", "char_span": [386, 389], "name": "I3A", "tok_span": [80, 83], "new_tok_span": [101, 104]}, {"ent_type": "GENE", "char_span": [455, 468], "name": "interleukin 6", "tok_span": [93, 95], "new_tok_span": [117, 119]}, {"ent_type": "GENE", "char_span": [169, 194], "name": "green fluorescent protein", "tok_span": [39, 42], "new_tok_span": [49, 52]}, {"ent_type": "GENE", "char_span": [202, 205], "name": "PKC", "tok_span": [44, 45], "new_tok_span": [56, 57]}, {"ent_type": "GENE", "char_span": [290, 299], "name": "PKC-delta", "tok_span": [60, 63], "new_tok_span": [76, 79]}, {"ent_type": "GENE", "char_span": [446, 454], "name": "cytokine", "tok_span": [92, 93], "new_tok_span": [115, 116]}], "relation_list": [{"subject": "I3A", "sbj_char_span": [131, 134], "object": "PKC", "obj_char_span": [202, 205], "rel_type": "regulator", "sbj_tok_span": [30, 33], "obj_tok_span": [44, 45], "new_sbj_tok_span": [39, 42], "new_obj_tok_span": [56, 57]}, {"subject": "PMA", "sbj_char_span": [285, 288], "object": "PKC", "obj_char_span": [202, 205], "rel_type": "regulator", "sbj_tok_span": [58, 59], "obj_tok_span": [44, 45], "new_sbj_tok_span": [73, 74], "new_obj_tok_span": [56, 57]}, {"subject": "I3A", "sbj_char_span": [373, 376], "object": "PKC-delta", "obj_char_span": [290, 299], "rel_type": "regulator", "sbj_tok_span": [74, 77], "obj_tok_span": [60, 63], "new_sbj_tok_span": [91, 94], "new_obj_tok_span": [76, 79]}, {"subject": "PMA", "sbj_char_span": [381, 384], "object": "PKC-delta", "obj_char_span": [290, 299], "rel_type": "regulator", "sbj_tok_span": [78, 79], "obj_tok_span": [60, 63], "new_sbj_tok_span": [97, 98], "new_obj_tok_span": [76, 79]}, {"subject": "I3A", "sbj_char_span": [386, 389], "object": "cytokine", "obj_char_span": [446, 454], "rel_type": "regulator", "sbj_tok_span": [80, 83], "obj_tok_span": [92, 93], "new_sbj_tok_span": [101, 104], "new_obj_tok_span": [115, 116]}, {"subject": "I3A", "sbj_char_span": [386, 389], "object": "interleukin 6", "obj_char_span": [455, 468], "rel_type": "regulator", "sbj_tok_span": [80, 83], "obj_tok_span": [93, 95], "new_sbj_tok_span": [101, 104], "new_obj_tok_span": [117, 119]}, {"subject": "PMA", "sbj_char_span": [483, 486], "object": "cytokine", "obj_char_span": [446, 454], "rel_type": "regulator", "sbj_tok_span": [97, 98], "obj_tok_span": [92, 93], "new_sbj_tok_span": [122, 123], "new_obj_tok_span": [115, 116]}, {"subject": "PMA", "sbj_char_span": [483, 486], "object": "interleukin 6", "obj_char_span": [455, 468], "rel_type": "regulator", "sbj_tok_span": [97, 98], "obj_tok_span": [93, 95], "new_sbj_tok_span": [122, 123], "new_obj_tok_span": [117, 119]}], "umls_entity_list": [{"mention": "PMA", "char_span": [102, 105], "sem_type": "Pharmacologic Substance", "tok_span": [20, 21], "new_tok_span": [23, 24]}, {"mention": "PMA", "char_span": [285, 288], "sem_type": "Pharmacologic Substance", "tok_span": [58, 59], "new_tok_span": [73, 74]}, {"mention": "PMA", "char_span": [381, 384], "sem_type": "Pharmacologic Substance", "tok_span": [78, 79], "new_tok_span": [97, 98]}, {"mention": "PMA", "char_span": [483, 486], "sem_type": "Pharmacologic Substance", "tok_span": [97, 98], "new_tok_span": [122, 123]}, {"mention": "K1", "char_span": [121, 123], "sem_type": "Gene or Genome", "tok_span": [26, 28], "new_tok_span": [32, 34]}, {"mention": "K1", "char_span": [121, 123], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [26, 28], "new_tok_span": [32, 34]}, {"mention": "isoforms", "char_span": [206, 214], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [45, 46], "new_tok_span": [58, 59]}, {"mention": "protein", "char_span": [187, 194], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [41, 42], "new_tok_span": [52, 53]}, {"mention": "I3A", "char_span": [32, 35], "sem_type": "Pharmacologic Substance", "tok_span": [8, 11], "new_tok_span": [9, 12]}, {"mention": "I3A", "char_span": [131, 134], "sem_type": "Pharmacologic Substance", "tok_span": [30, 33], "new_tok_span": [39, 42]}, {"mention": "I3A", "char_span": [373, 376], "sem_type": "Pharmacologic Substance", "tok_span": [74, 77], "new_tok_span": [91, 94]}, {"mention": "I3A", "char_span": [386, 389], "sem_type": "Pharmacologic Substance", "tok_span": [80, 83], "new_tok_span": [101, 104]}, {"mention": "cytokine", "char_span": [446, 454], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [92, 93], "new_tok_span": [115, 116]}], "new_text": "In all of the three cell types, <START=Pharmacologic Substance> I3A <END=Pharmacologic Substance> inhibited cell proliferation with somewhat lower potency than did <START=Pharmacologic Substance> PMA <END=Pharmacologic Substance>. In intact CHO - <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> K1 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> cells, <START=Pharmacologic Substance> I3A <END=Pharmacologic Substance> was able to translocate different green fluorescent <START=Amino Acid, Peptide, or Protein> protein <END=Amino Acid, Peptide, or Protein> - tagged PKC <START=Amino Acid, Peptide, or Protein> isoforms <END=Amino Acid, Peptide, or Protein>, visualized by confocal microscopy, with equal or higher potency than <START=Pharmacologic Substance> PMA <END=Pharmacologic Substance>. PKC - delta in particular showed a different pattern of translocation in response to <START=Pharmacologic Substance> I3A <END=Pharmacologic Substance> and <START=Pharmacologic Substance> PMA <END=Pharmacologic Substance>. <START=Pharmacologic Substance> I3A <END=Pharmacologic Substance> induced a higher level of secretion of the inflammatory <START=Amino Acid, Peptide, or Protein> cytokine <END=Amino Acid, Peptide, or Protein> interleukin 6 compared with <START=Pharmacologic Substance> PMA <END=Pharmacologic Substance> in the WEHI - 231 cells and displayed a marked biphasic dose - response curve for the induction."}, {"PMID": 12826271, "id": 6, "text": "Treatment with diclofenac resulted in nuclear condensation (a morphological change due to apoptosis of NSCs) 24hr after the treatment and activated caspase-3 after 6 hr, indicating that diclofenac may cause apoptosis of neuronal cells via activation of the caspase cascade.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [15, 25], "name": "diclofenac", "tok_span": [2, 6], "new_tok_span": [3, 7]}, {"ent_type": "CHEMICAL", "char_span": [186, 196], "name": "diclofenac", "tok_span": [37, 41], "new_tok_span": [42, 46]}, {"ent_type": "GENE", "char_span": [148, 157], "name": "caspase-3", "tok_span": [28, 31], "new_tok_span": [31, 34]}, {"ent_type": "GENE", "char_span": [257, 264], "name": "caspase", "tok_span": [51, 52], "new_tok_span": [59, 60]}], "relation_list": [{"subject": "diclofenac", "sbj_char_span": [15, 25], "object": "caspase-3", "obj_char_span": [148, 157], "rel_type": "activator", "sbj_tok_span": [2, 6], "obj_tok_span": [28, 31], "new_sbj_tok_span": [3, 7], "new_obj_tok_span": [31, 34]}, {"subject": "diclofenac", "sbj_char_span": [186, 196], "object": "caspase", "obj_char_span": [257, 264], "rel_type": "activator", "sbj_tok_span": [37, 41], "obj_tok_span": [51, 52], "new_sbj_tok_span": [42, 46], "new_obj_tok_span": [59, 60]}], "umls_entity_list": [{"mention": "diclofenac", "char_span": [15, 25], "sem_type": "Pharmacologic Substance", "tok_span": [2, 6], "new_tok_span": [3, 7]}, {"mention": "diclofenac", "char_span": [186, 196], "sem_type": "Pharmacologic Substance", "tok_span": [37, 41], "new_tok_span": [42, 46]}, {"mention": "activated caspase-3", "char_span": [138, 157], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [27, 31], "new_tok_span": [30, 34]}, {"mention": "cascade", "char_span": [265, 272], "sem_type": "Pharmacologic Substance", "tok_span": [52, 53], "new_tok_span": [61, 62]}, {"mention": "via", "char_span": [235, 238], "sem_type": "Gene or Genome", "tok_span": [47, 48], "new_tok_span": [54, 55]}], "new_text": "Treatment with <START=Pharmacologic Substance> diclofenac <END=Pharmacologic Substance> resulted in nuclear condensation ( a morphological change due to apoptosis of NSCs ) 24hr after the treatment and <START=Amino Acid, Peptide, or Protein> activated caspase - 3 <END=Amino Acid, Peptide, or Protein> after 6 hr, indicating that <START=Pharmacologic Substance> diclofenac <END=Pharmacologic Substance> may cause apoptosis of neuronal cells <START=Gene or Genome> via <END=Gene or Genome> activation of the caspase <START=Pharmacologic Substance> cascade <END=Pharmacologic Substance>."}, {"PMID": 23123425, "id": 6, "text": "The results showed that oral administration of quercetin at doses of 30-60 mg/kg to hyperlipidemia rats for 14 days were highly effective in decreasing the levels of serum total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), alanine aminotransferase (ALT) and aspartate aminotransferase (AST). It could decrease lipid accumulation in the hepatocytes, and reduce serum levels of pro-inflammatory cytokines TNF-α and IL-6 via regulating the expressions of Sirt1, NF-κB p65 and iNOS. Thus, dietary quercetin had significant therapeutic benefits and could be explored as a potential promising candidate for the prevention of NASH.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [531, 540], "name": "quercetin", "tok_span": [118, 121], "new_tok_span": [131, 134]}, {"ent_type": "CHEMICAL", "char_span": [47, 56], "name": "quercetin", "tok_span": [7, 10], "new_tok_span": [8, 11]}, {"ent_type": "CHEMICAL", "char_span": [178, 189], "name": "cholesterol", "tok_span": [36, 37], "new_tok_span": [38, 39]}, {"ent_type": "CHEMICAL", "char_span": [196, 209], "name": "triglycerides", "tok_span": [41, 42], "new_tok_span": [44, 45]}, {"ent_type": "CHEMICAL", "char_span": [240, 251], "name": "cholesterol", "tok_span": [50, 51], "new_tok_span": [54, 55]}, {"ent_type": "CHEMICAL", "char_span": [261, 268], "name": "alanine", "tok_span": [57, 58], "new_tok_span": [61, 62]}, {"ent_type": "CHEMICAL", "char_span": [296, 305], "name": "aspartate", "tok_span": [64, 66], "new_tok_span": [68, 70]}, {"ent_type": "GENE", "char_span": [324, 327], "name": "AST", "tok_span": [69, 70], "new_tok_span": [74, 75]}, {"ent_type": "GENE", "char_span": [431, 440], "name": "cytokines", "tok_span": [89, 90], "new_tok_span": [96, 97]}, {"ent_type": "GENE", "char_span": [441, 446], "name": "TNF-α", "tok_span": [90, 93], "new_tok_span": [98, 101]}, {"ent_type": "GENE", "char_span": [451, 455], "name": "IL-6", "tok_span": [94, 97], "new_tok_span": [102, 105]}, {"ent_type": "GENE", "char_span": [490, 495], "name": "Sirt1", "tok_span": [102, 105], "new_tok_span": [112, 115]}, {"ent_type": "GENE", "char_span": [497, 502], "name": "NF-κB", "tok_span": [106, 110], "new_tok_span": [118, 122]}, {"ent_type": "GENE", "char_span": [503, 506], "name": "p65", "tok_span": [110, 112], "new_tok_span": [122, 124]}, {"ent_type": "GENE", "char_span": [511, 515], "name": "iNOS", "tok_span": [113, 114], "new_tok_span": [125, 126]}, {"ent_type": "GENE", "char_span": [216, 239], "name": "low-density lipoprotein", "tok_span": [46, 50], "new_tok_span": [50, 54]}, {"ent_type": "GENE", "char_span": [253, 256], "name": "LDL", "tok_span": [52, 53], "new_tok_span": [56, 57]}, {"ent_type": "GENE", "char_span": [261, 285], "name": "alanine aminotransferase", "tok_span": [57, 60], "new_tok_span": [61, 64]}, {"ent_type": "GENE", "char_span": [287, 290], "name": "ALT", "tok_span": [61, 62], "new_tok_span": [65, 66]}, {"ent_type": "GENE", "char_span": [296, 322], "name": "aspartate aminotransferase", "tok_span": [64, 68], "new_tok_span": [68, 72]}], "relation_list": [{"subject": "quercetin", "sbj_char_span": [47, 56], "object": "low-density lipoprotein", "obj_char_span": [216, 239], "rel_type": "regulator", "sbj_tok_span": [7, 10], "obj_tok_span": [46, 50], "new_sbj_tok_span": [8, 11], "new_obj_tok_span": [50, 54]}, {"subject": "quercetin", "sbj_char_span": [47, 56], "object": "LDL", "obj_char_span": [253, 256], "rel_type": "regulator", "sbj_tok_span": [7, 10], "obj_tok_span": [52, 53], "new_sbj_tok_span": [8, 11], "new_obj_tok_span": [56, 57]}, {"subject": "quercetin", "sbj_char_span": [47, 56], "object": "alanine aminotransferase", "obj_char_span": [261, 285], "rel_type": "regulator", "sbj_tok_span": [7, 10], "obj_tok_span": [57, 60], "new_sbj_tok_span": [8, 11], "new_obj_tok_span": [61, 64]}, {"subject": "quercetin", "sbj_char_span": [47, 56], "object": "ALT", "obj_char_span": [287, 290], "rel_type": "regulator", "sbj_tok_span": [7, 10], "obj_tok_span": [61, 62], "new_sbj_tok_span": [8, 11], "new_obj_tok_span": [65, 66]}, {"subject": "quercetin", "sbj_char_span": [47, 56], "object": "aspartate aminotransferase", "obj_char_span": [296, 322], "rel_type": "regulator", "sbj_tok_span": [7, 10], "obj_tok_span": [64, 68], "new_sbj_tok_span": [8, 11], "new_obj_tok_span": [68, 72]}, {"subject": "quercetin", "sbj_char_span": [47, 56], "object": "AST", "obj_char_span": [324, 327], "rel_type": "regulator", "sbj_tok_span": [7, 10], "obj_tok_span": [69, 70], "new_sbj_tok_span": [8, 11], "new_obj_tok_span": [74, 75]}], "umls_entity_list": [{"mention": "quercetin", "char_span": [47, 56], "sem_type": "Pharmacologic Substance", "tok_span": [7, 10], "new_tok_span": [8, 11]}, {"mention": "quercetin", "char_span": [531, 540], "sem_type": "Pharmacologic Substance", "tok_span": [118, 121], "new_tok_span": [131, 134]}, {"mention": "triglycerides", "char_span": [196, 209], "sem_type": "Organic Chemical", "tok_span": [41, 42], "new_tok_span": [44, 45]}, {"mention": "AST", "char_span": [324, 327], "sem_type": "Gene or Genome", "tok_span": [69, 70], "new_tok_span": [74, 75]}, {"mention": "cytokines", "char_span": [431, 440], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [89, 90], "new_tok_span": [96, 97]}, {"mention": "Sirt1", "char_span": [490, 495], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [102, 105], "new_tok_span": [112, 115]}, {"mention": "Sirt1", "char_span": [490, 495], "sem_type": "Gene or Genome", "tok_span": [102, 105], "new_tok_span": [112, 115]}], "new_text": "The results showed that oral administration of <START=Pharmacologic Substance> quercetin <END=Pharmacologic Substance> at doses of 30 - 60 mg / kg to hyperlipidemia rats for 14 days were highly effective in decreasing the levels of serum total cholesterol ( TC ), <START=Organic Chemical> triglycerides <END=Organic Chemical> ( TG ), low - density lipoprotein cholesterol ( LDL - C ), alanine aminotransferase ( ALT ) and aspartate aminotransferase ( <START=Gene or Genome> AST <END=Gene or Genome> ). It could decrease lipid accumulation in the hepatocytes, and reduce serum levels of pro - inflammatory <START=Amino Acid, Peptide, or Protein> cytokines <END=Amino Acid, Peptide, or Protein> TNF - α and IL - 6 via regulating the expressions of <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> Sirt1 <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome>, NF - κB p65 and iNOS. Thus, dietary <START=Pharmacologic Substance> quercetin <END=Pharmacologic Substance> had significant therapeutic benefits and could be explored as a potential promising candidate for the prevention of NASH."}, {"PMID": 17434872, "id": 11, "text": "Taken together with a recent crystal structure of a lumiracoxib-COX-2 complex, the kinetic analyses presented herein of the inhibition of mutant COX-2s by lumiracoxib allows the definition of the molecular basis of COX-2 inhibition.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [52, 63], "name": "lumiracoxib", "tok_span": [9, 13], "new_tok_span": [10, 14]}, {"ent_type": "CHEMICAL", "char_span": [155, 166], "name": "lumiracoxib", "tok_span": [34, 38], "new_tok_span": [45, 49]}, {"ent_type": "GENE", "char_span": [64, 69], "name": "COX-2", "tok_span": [14, 17], "new_tok_span": [18, 21]}, {"ent_type": "GENE", "char_span": [145, 151], "name": "COX-2s", "tok_span": [29, 33], "new_tok_span": [37, 41]}, {"ent_type": "GENE", "char_span": [215, 220], "name": "COX-2", "tok_span": [46, 49], "new_tok_span": [60, 63]}], "relation_list": [{"subject": "lumiracoxib", "sbj_char_span": [52, 63], "object": "COX-2", "obj_char_span": [64, 69], "rel_type": "regulator", "sbj_tok_span": [9, 13], "obj_tok_span": [14, 17], "new_sbj_tok_span": [10, 14], "new_obj_tok_span": [18, 21]}, {"subject": "lumiracoxib", "sbj_char_span": [155, 166], "object": "COX-2s", "obj_char_span": [145, 151], "rel_type": "inhibitor", "sbj_tok_span": [34, 38], "obj_tok_span": [29, 33], "new_sbj_tok_span": [45, 49], "new_obj_tok_span": [37, 41]}], "umls_entity_list": [{"mention": "lumiracoxib", "char_span": [52, 63], "sem_type": "Pharmacologic Substance", "tok_span": [9, 13], "new_tok_span": [10, 14]}, {"mention": "lumiracoxib", "char_span": [155, 166], "sem_type": "Pharmacologic Substance", "tok_span": [34, 38], "new_tok_span": [45, 49]}, {"mention": "COX-2", "char_span": [64, 69], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [14, 17], "new_tok_span": [18, 21]}, {"mention": "COX-2", "char_span": [145, 150], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [29, 32], "new_tok_span": [37, 40]}, {"mention": "COX-2", "char_span": [215, 220], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [46, 49], "new_tok_span": [60, 63]}, {"mention": "COX-2", "char_span": [64, 69], "sem_type": "Gene or Genome", "tok_span": [14, 17], "new_tok_span": [18, 21]}, {"mention": "COX-2", "char_span": [145, 150], "sem_type": "Gene or Genome", "tok_span": [29, 32], "new_tok_span": [37, 40]}, {"mention": "COX-2", "char_span": [215, 220], "sem_type": "Gene or Genome", "tok_span": [46, 49], "new_tok_span": [60, 63]}], "new_text": "Taken together with a recent crystal structure of a <START=Pharmacologic Substance> lumiracoxib <END=Pharmacologic Substance> - <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> COX - 2 <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> complex, the kinetic analyses presented herein of the inhibition of mutant <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> COX - 2 <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome>s by <START=Pharmacologic Substance> lumiracoxib <END=Pharmacologic Substance> allows the definition of the molecular basis of <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> COX - 2 <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> inhibition."}, {"PMID": 17620346, "id": 3, "text": "The in vitro covalent binding was inhibited in the presence of beta-aminopropionitrile, D-penicillamine, and hydralazine, which suggested that the aldehyde group of allysine in human elastin was relevant to the covalent binding.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [63, 86], "name": "beta-aminopropionitrile", "tok_span": [11, 18], "new_tok_span": [12, 19]}, {"ent_type": "CHEMICAL", "char_span": [88, 103], "name": "D-penicillamine", "tok_span": [19, 26], "new_tok_span": [21, 28]}, {"ent_type": "CHEMICAL", "char_span": [109, 120], "name": "hydralazine", "tok_span": [28, 32], "new_tok_span": [32, 36]}, {"ent_type": "CHEMICAL", "char_span": [147, 155], "name": "aldehyde", "tok_span": [37, 41], "new_tok_span": [42, 46]}, {"ent_type": "CHEMICAL", "char_span": [165, 173], "name": "allysine", "tok_span": [43, 46], "new_tok_span": [50, 53]}, {"ent_type": "GENE", "char_span": [177, 190], "name": "human elastin", "tok_span": [47, 50], "new_tok_span": [55, 58]}], "relation_list": [{"subject": "beta-aminopropionitrile", "sbj_char_span": [63, 86], "object": "human elastin", "obj_char_span": [177, 190], "rel_type": "inhibitor", "sbj_tok_span": [11, 18], "obj_tok_span": [47, 50], "new_sbj_tok_span": [12, 19], "new_obj_tok_span": [55, 58]}, {"subject": "aldehyde", "sbj_char_span": [147, 155], "object": "human elastin", "obj_char_span": [177, 190], "rel_type": "part of", "sbj_tok_span": [37, 41], "obj_tok_span": [47, 50], "new_sbj_tok_span": [42, 46], "new_obj_tok_span": [55, 58]}, {"subject": "allysine", "sbj_char_span": [165, 173], "object": "human elastin", "obj_char_span": [177, 190], "rel_type": "part of", "sbj_tok_span": [43, 46], "obj_tok_span": [47, 50], "new_sbj_tok_span": [50, 53], "new_obj_tok_span": [55, 58]}, {"subject": "D-penicillamine", "sbj_char_span": [88, 103], "object": "human elastin", "obj_char_span": [177, 190], "rel_type": "inhibitor", "sbj_tok_span": [19, 26], "obj_tok_span": [47, 50], "new_sbj_tok_span": [21, 28], "new_obj_tok_span": [55, 58]}, {"subject": "hydralazine", "sbj_char_span": [109, 120], "object": "human elastin", "obj_char_span": [177, 190], "rel_type": "inhibitor", "sbj_tok_span": [28, 32], "obj_tok_span": [47, 50], "new_sbj_tok_span": [32, 36], "new_obj_tok_span": [55, 58]}], "umls_entity_list": [{"mention": "beta-aminopropionitrile", "char_span": [63, 86], "sem_type": "Organic Chemical", "tok_span": [11, 18], "new_tok_span": [12, 19]}, {"mention": "penicillamine", "char_span": [90, 103], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [21, 26], "new_tok_span": [24, 29]}, {"mention": "aldehyde", "char_span": [147, 155], "sem_type": "Organic Chemical", "tok_span": [37, 41], "new_tok_span": [42, 46]}, {"mention": "allysine", "char_span": [165, 173], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [43, 46], "new_tok_span": [50, 53]}, {"mention": "lastin", "char_span": [184, 190], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [48, 50], "new_tok_span": [57, 59]}], "new_text": "The in vitro covalent binding was inhibited in the presence of <START=Organic Chemical> beta - aminopropionitrile <END=Organic Chemical>, D - <START=Amino Acid, Peptide, or Protein> penicillamine <END=Amino Acid, Peptide, or Protein>, and hydralazine, which suggested that the <START=Organic Chemical> aldehyde <END=Organic Chemical> group of <START=Amino Acid, Peptide, or Protein> allysine <END=Amino Acid, Peptide, or Protein> in human <START=Amino Acid, Peptide, or Protein> elastin <END=Amino Acid, Peptide, or Protein> was relevant to the covalent binding."}, {"PMID": 20573261, "id": 5, "text": "METHODS: Mice were sensitized to ovalbumin (OVA) followed by repeated airway challenge with OVA. After inflammation was established mice were dosed with the H4R antagonist, JNJ 7777120, or anti-IL-13 antibody for comparison.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [173, 184], "name": "JNJ 7777120", "tok_span": [35, 40], "new_tok_span": [37, 42]}, {"ent_type": "GENE", "char_span": [33, 42], "name": "ovalbumin", "tok_span": [7, 9], "new_tok_span": [8, 10]}, {"ent_type": "GENE", "char_span": [44, 47], "name": "OVA", "tok_span": [10, 11], "new_tok_span": [12, 13]}, {"ent_type": "GENE", "char_span": [92, 95], "name": "OVA", "tok_span": [18, 19], "new_tok_span": [20, 21]}, {"ent_type": "GENE", "char_span": [157, 160], "name": "H4R", "tok_span": [30, 33], "new_tok_span": [32, 35]}, {"ent_type": "GENE", "char_span": [194, 199], "name": "IL-13", "tok_span": [44, 47], "new_tok_span": [46, 49]}], "relation_list": [{"subject": "JNJ 7777120", "sbj_char_span": [173, 184], "object": "H4R", "obj_char_span": [157, 160], "rel_type": "agonist or antagonist", "sbj_tok_span": [35, 40], "obj_tok_span": [30, 33], "new_sbj_tok_span": [37, 42], "new_obj_tok_span": [32, 35]}], "umls_entity_list": [{"mention": "ovalbumin", "char_span": [33, 42], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [7, 9], "new_tok_span": [8, 10]}], "new_text": "METHODS : Mice were sensitized to <START=Amino Acid, Peptide, or Protein> ovalbumin <END=Amino Acid, Peptide, or Protein> ( OVA ) followed by repeated airway challenge with OVA. After inflammation was established mice were dosed with the H4R antagonist, JNJ 7777120, or anti - IL - 13 antibody for comparison."}, {"PMID": 7995016, "id": 7, "text": "Selegiline is metabolized into l-(-)-desmethylselegiline, l-(-)-methamphetamine, and l-(-)-amphetamine mainly in the liver through the microsomal P-450 system.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [31, 56], "name": "l-(-)-desmethylselegiline", "tok_span": [8, 20], "new_tok_span": [8, 20]}, {"ent_type": "CHEMICAL", "char_span": [58, 79], "name": "l-(-)-methamphetamine", "tok_span": [21, 30], "new_tok_span": [23, 32]}, {"ent_type": "CHEMICAL", "char_span": [85, 102], "name": "l-(-)-amphetamine", "tok_span": [32, 42], "new_tok_span": [36, 46]}, {"ent_type": "CHEMICAL", "char_span": [0, 10], "name": "Selegiline", "tok_span": [0, 4], "new_tok_span": [0, 4]}, {"ent_type": "GENE", "char_span": [146, 151], "name": "P-450", "tok_span": [50, 53], "new_tok_span": [56, 59]}], "relation_list": [{"subject": "Selegiline", "sbj_char_span": [0, 10], "object": "P-450", "obj_char_span": [146, 151], "rel_type": "product or substrate", "sbj_tok_span": [0, 4], "obj_tok_span": [50, 53], "new_sbj_tok_span": [0, 4], "new_obj_tok_span": [56, 59]}, {"subject": "l-(-)-desmethylselegiline", "sbj_char_span": [31, 56], "object": "P-450", "obj_char_span": [146, 151], "rel_type": "product or substrate", "sbj_tok_span": [8, 20], "obj_tok_span": [50, 53], "new_sbj_tok_span": [8, 20], "new_obj_tok_span": [56, 59]}, {"subject": "l-(-)-methamphetamine", "sbj_char_span": [58, 79], "object": "P-450", "obj_char_span": [146, 151], "rel_type": "product or substrate", "sbj_tok_span": [21, 30], "obj_tok_span": [50, 53], "new_sbj_tok_span": [23, 32], "new_obj_tok_span": [56, 59]}, {"subject": "l-(-)-amphetamine", "sbj_char_span": [85, 102], "object": "P-450", "obj_char_span": [146, 151], "rel_type": "product or substrate", "sbj_tok_span": [32, 42], "obj_tok_span": [50, 53], "new_sbj_tok_span": [36, 46], "new_obj_tok_span": [56, 59]}], "umls_entity_list": [{"mention": "desmethylselegiline", "char_span": [37, 56], "sem_type": "Organic Chemical", "tok_span": [14, 20], "new_tok_span": [15, 21]}, {"mention": "methamphetamine", "char_span": [64, 79], "sem_type": "Pharmacologic Substance", "tok_span": [27, 30], "new_tok_span": [30, 33]}, {"mention": "-amphetamin", "char_span": [90, 101], "sem_type": "Pharmacologic Substance", "tok_span": [37, 41], "new_tok_span": [42, 46]}], "new_text": "Selegiline is metabolized into l - ( - ) - <START=Organic Chemical> desmethylselegiline <END=Organic Chemical>, l - ( - ) - <START=Pharmacologic Substance> methamphetamine <END=Pharmacologic Substance>, and l - ( - ) <START=Pharmacologic Substance> - amphetamin <END=Pharmacologic Substance>e mainly in the liver through the microsomal P - 450 system."}, {"PMID": 9374794, "id": 11, "text": "We conclude that cisapride is a potent blocker of HERG channels expressed in HEK293 cells.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [17, 26], "name": "cisapride", "tok_span": [3, 7], "new_tok_span": [3, 7]}, {"ent_type": "GENE", "char_span": [50, 54], "name": "HERG", "tok_span": [12, 14], "new_tok_span": [13, 15]}], "relation_list": [{"subject": "cisapride", "sbj_char_span": [17, 26], "object": "HERG", "obj_char_span": [50, 54], "rel_type": "inhibitor", "sbj_tok_span": [3, 7], "obj_tok_span": [12, 14], "new_sbj_tok_span": [3, 7], "new_obj_tok_span": [13, 15]}], "umls_entity_list": [{"mention": "HERG", "char_span": [50, 54], "sem_type": "Gene or Genome", "tok_span": [12, 14], "new_tok_span": [13, 15]}], "new_text": "We conclude that cisapride is a potent blocker of <START=Gene or Genome> HERG <END=Gene or Genome> channels expressed in HEK293 cells."}, {"PMID": 23117207, "id": 6, "text": "Keap1 is expressed in differentiating osteoclast-like cells and the S349T mutation selectively impairs the SQSTM1-Keap1 interaction in co-immunoprecipitations, which molecular modelling indicates results from effects on critical hydrogen bonds required to stabilise the KIR-Keap1 complex.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [229, 237], "name": "hydrogen", "tok_span": [44, 45], "new_tok_span": [54, 55]}, {"ent_type": "GENE", "char_span": [0, 5], "name": "Keap1", "tok_span": [0, 3], "new_tok_span": [2, 5]}, {"ent_type": "GENE", "char_span": [68, 73], "name": "S349T", "tok_span": [13, 17], "new_tok_span": [17, 21]}, {"ent_type": "GENE", "char_span": [107, 113], "name": "SQSTM1", "tok_span": [21, 24], "new_tok_span": [26, 29]}, {"ent_type": "GENE", "char_span": [114, 119], "name": "Keap1", "tok_span": [25, 28], "new_tok_span": [33, 36]}, {"ent_type": "GENE", "char_span": [270, 273], "name": "KIR", "tok_span": [51, 53], "new_tok_span": [63, 65]}, {"ent_type": "GENE", "char_span": [274, 279], "name": "Keap1", "tok_span": [54, 57], "new_tok_span": [70, 73]}], "relation_list": [{"subject": "hydrogen", "sbj_char_span": [229, 237], "object": "KIR", "obj_char_span": [270, 273], "rel_type": "part of", "sbj_tok_span": [44, 45], "obj_tok_span": [51, 53], "new_sbj_tok_span": [54, 55], "new_obj_tok_span": [63, 65]}, {"subject": "hydrogen", "sbj_char_span": [229, 237], "object": "Keap1", "obj_char_span": [274, 279], "rel_type": "part of", "sbj_tok_span": [44, 45], "obj_tok_span": [54, 57], "new_sbj_tok_span": [54, 55], "new_obj_tok_span": [70, 73]}], "umls_entity_list": [{"mention": "Keap1", "char_span": [0, 5], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [0, 3], "new_tok_span": [2, 5]}, {"mention": "Keap1", "char_span": [114, 119], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [25, 28], "new_tok_span": [33, 36]}, {"mention": "Keap1", "char_span": [274, 279], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [54, 57], "new_tok_span": [70, 73]}, {"mention": "Keap1", "char_span": [0, 5], "sem_type": "Gene or Genome", "tok_span": [0, 3], "new_tok_span": [2, 5]}, {"mention": "Keap1", "char_span": [114, 119], "sem_type": "Gene or Genome", "tok_span": [25, 28], "new_tok_span": [33, 36]}, {"mention": "Keap1", "char_span": [274, 279], "sem_type": "Gene or Genome", "tok_span": [54, 57], "new_tok_span": [70, 73]}, {"mention": "SQSTM1", "char_span": [107, 113], "sem_type": "Gene or Genome", "tok_span": [21, 24], "new_tok_span": [26, 29]}, {"mention": "KIR", "char_span": [270, 273], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [51, 53], "new_tok_span": [63, 65]}, {"mention": "KIR", "char_span": [270, 273], "sem_type": "Gene or Genome", "tok_span": [51, 53], "new_tok_span": [63, 65]}], "new_text": "<START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> Keap1 <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> is expressed in differentiating osteoclast - like cells and the S349T mutation selectively impairs the <START=Gene or Genome> SQSTM1 <END=Gene or Genome> - <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> Keap1 <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> interaction in co - immunoprecipitations, which molecular modelling indicates results from effects on critical hydrogen bonds required to stabilise the <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> KIR <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> - <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> Keap1 <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> complex."}, {"PMID": 23435615, "id": 6, "text": "Additionally, there was a significant difference in plasma concentrations of (R)-5-hydroxyomeprazole among CYP2C19 genotype groups, whereas no significant differences were observed in that of (S)-5-hydroxyomeprazole.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [77, 100], "name": "(R)-5-hydroxyomeprazole", "tok_span": [11, 21], "new_tok_span": [11, 21]}, {"ent_type": "CHEMICAL", "char_span": [192, 215], "name": "(S)-5-hydroxyomeprazole", "tok_span": [38, 48], "new_tok_span": [40, 50]}, {"ent_type": "GENE", "char_span": [107, 114], "name": "CYP2C19", "tok_span": [22, 26], "new_tok_span": [24, 28]}], "relation_list": [{"subject": "(R)-5-hydroxyomeprazole", "sbj_char_span": [77, 100], "object": "CYP2C19", "obj_char_span": [107, 114], "rel_type": "product or substrate", "sbj_tok_span": [11, 21], "obj_tok_span": [22, 26], "new_sbj_tok_span": [11, 21], "new_obj_tok_span": [24, 28]}, {"subject": "(S)-5-hydroxyomeprazole", "sbj_char_span": [192, 215], "object": "CYP2C19", "obj_char_span": [107, 114], "rel_type": "product or substrate", "sbj_tok_span": [38, 48], "obj_tok_span": [22, 26], "new_sbj_tok_span": [40, 50], "new_obj_tok_span": [24, 28]}], "umls_entity_list": [{"mention": "hydroxyomeprazole", "char_span": [83, 100], "sem_type": "Organic Chemical", "tok_span": [17, 21], "new_tok_span": [18, 22]}, {"mention": "hydroxyomeprazole", "char_span": [198, 215], "sem_type": "Organic Chemical", "tok_span": [44, 48], "new_tok_span": [47, 51]}], "new_text": "Additionally, there was a significant difference in plasma concentrations of ( R ) - 5 - <START=Organic Chemical> hydroxyomeprazole <END=Organic Chemical> among CYP2C19 genotype groups, whereas no significant differences were observed in that of ( S ) - 5 - <START=Organic Chemical> hydroxyomeprazole <END=Organic Chemical>."}, {"PMID": 10665814, "id": 2, "text": "Mibefradil (Ro 40-5967) belongs to a new chemical class of these molecules which differs from other Ca2+ antagonists by its ability to potently block T-type Ca2+ channels.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [12, 22], "name": "Ro 40-5967", "tok_span": [6, 11], "new_tok_span": [9, 14]}, {"ent_type": "CHEMICAL", "char_span": [100, 104], "name": "Ca2+", "tok_span": [25, 28], "new_tok_span": [30, 33]}, {"ent_type": "CHEMICAL", "char_span": [157, 161], "name": "Ca2+", "tok_span": [39, 42], "new_tok_span": [46, 49]}, {"ent_type": "CHEMICAL", "char_span": [0, 10], "name": "Mibefradil", "tok_span": [0, 5], "new_tok_span": [1, 6]}, {"ent_type": "GENE", "char_span": [150, 170], "name": "T-type Ca2+ channels", "tok_span": [36, 43], "new_tok_span": [42, 49]}], "relation_list": [{"subject": "Ro 40-5967", "sbj_char_span": [12, 22], "object": "T-type Ca2+ channels", "obj_char_span": [150, 170], "rel_type": "inhibitor", "sbj_tok_span": [6, 11], "obj_tok_span": [36, 43], "new_sbj_tok_span": [9, 14], "new_obj_tok_span": [42, 49]}, {"subject": "Mibefradil", "sbj_char_span": [0, 10], "object": "T-type Ca2+ channels", "obj_char_span": [150, 170], "rel_type": "inhibitor", "sbj_tok_span": [0, 5], "obj_tok_span": [36, 43], "new_sbj_tok_span": [1, 6], "new_obj_tok_span": [42, 49]}], "umls_entity_list": [{"mention": "Mibefradil", "char_span": [0, 10], "sem_type": "Pharmacologic Substance", "tok_span": [0, 5], "new_tok_span": [1, 6]}, {"mention": "Ro 40-5967", "char_span": [12, 22], "sem_type": "Pharmacologic Substance", "tok_span": [6, 11], "new_tok_span": [9, 14]}, {"mention": "Ca2+", "char_span": [100, 104], "sem_type": "Pharmacologic Substance", "tok_span": [25, 28], "new_tok_span": [30, 33]}, {"mention": "Ca2+", "char_span": [157, 161], "sem_type": "Pharmacologic Substance", "tok_span": [39, 42], "new_tok_span": [46, 49]}], "new_text": "<START=Pharmacologic Substance> Mibefradil <END=Pharmacologic Substance> ( <START=Pharmacologic Substance> Ro 40 - 5967 <END=Pharmacologic Substance> ) belongs to a new chemical class of these molecules which differs from other <START=Pharmacologic Substance> Ca2 + <END=Pharmacologic Substance> antagonists by its ability to potently block T - type <START=Pharmacologic Substance> Ca2 + <END=Pharmacologic Substance> channels."}, {"PMID": 17409318, "id": 1, "text": "The use of Delta 6 desaturase (D6D) twice in the conversion of alpha-linolenic acid (ALA; 18:3n-3) to docosahexaenoic acid (DHA; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of DHA from ALA. We examined this using an in vitro model of fatty acid metabolism to measure the accumulation of the long-chain metabolites of ALA in HepG2 cell phospholipids.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [102, 122], "name": "docosahexaenoic acid", "tok_span": [36, 43], "new_tok_span": [41, 48]}, {"ent_type": "CHEMICAL", "char_span": [124, 127], "name": "DHA", "tok_span": [44, 45], "new_tok_span": [51, 52]}, {"ent_type": "CHEMICAL", "char_span": [232, 235], "name": "DHA", "tok_span": [69, 70], "new_tok_span": [78, 79]}, {"ent_type": "CHEMICAL", "char_span": [241, 244], "name": "ALA", "tok_span": [71, 73], "new_tok_span": [81, 83]}, {"ent_type": "CHEMICAL", "char_span": [290, 300], "name": "fatty acid", "tok_span": [83, 85], "new_tok_span": [93, 95]}, {"ent_type": "CHEMICAL", "char_span": [373, 376], "name": "ALA", "tok_span": [97, 99], "new_tok_span": [107, 109]}, {"ent_type": "CHEMICAL", "char_span": [63, 83], "name": "alpha-linolenic acid", "tok_span": [18, 24], "new_tok_span": [21, 27]}, {"ent_type": "CHEMICAL", "char_span": [85, 88], "name": "ALA", "tok_span": [25, 27], "new_tok_span": [29, 31]}, {"ent_type": "GENE", "char_span": [11, 29], "name": "Delta 6 desaturase", "tok_span": [3, 8], "new_tok_span": [3, 8]}, {"ent_type": "GENE", "char_span": [31, 34], "name": "D6D", "tok_span": [9, 12], "new_tok_span": [10, 13]}], "relation_list": [{"subject": "alpha-linolenic acid", "sbj_char_span": [63, 83], "object": "D6D", "obj_char_span": [31, 34], "rel_type": "product or substrate", "sbj_tok_span": [18, 24], "obj_tok_span": [9, 12], "new_sbj_tok_span": [21, 27], "new_obj_tok_span": [10, 13]}, {"subject": "alpha-linolenic acid", "sbj_char_span": [63, 83], "object": "Delta 6 desaturase", "obj_char_span": [11, 29], "rel_type": "product or substrate", "sbj_tok_span": [18, 24], "obj_tok_span": [3, 8], "new_sbj_tok_span": [21, 27], "new_obj_tok_span": [3, 8]}, {"subject": "ALA", "sbj_char_span": [85, 88], "object": "D6D", "obj_char_span": [31, 34], "rel_type": "product or substrate", "sbj_tok_span": [25, 27], "obj_tok_span": [9, 12], "new_sbj_tok_span": [29, 31], "new_obj_tok_span": [10, 13]}, {"subject": "ALA", "sbj_char_span": [85, 88], "object": "Delta 6 desaturase", "obj_char_span": [11, 29], "rel_type": "product or substrate", "sbj_tok_span": [25, 27], "obj_tok_span": [3, 8], "new_sbj_tok_span": [29, 31], "new_obj_tok_span": [3, 8]}, {"subject": "docosahexaenoic acid", "sbj_char_span": [102, 122], "object": "D6D", "obj_char_span": [31, 34], "rel_type": "product or substrate", "sbj_tok_span": [36, 43], "obj_tok_span": [9, 12], "new_sbj_tok_span": [41, 48], "new_obj_tok_span": [10, 13]}, {"subject": "docosahexaenoic acid", "sbj_char_span": [102, 122], "object": "Delta 6 desaturase", "obj_char_span": [11, 29], "rel_type": "product or substrate", "sbj_tok_span": [36, 43], "obj_tok_span": [3, 8], "new_sbj_tok_span": [41, 48], "new_obj_tok_span": [3, 8]}, {"subject": "DHA", "sbj_char_span": [124, 127], "object": "D6D", "obj_char_span": [31, 34], "rel_type": "product or substrate", "sbj_tok_span": [44, 45], "obj_tok_span": [9, 12], "new_sbj_tok_span": [51, 52], "new_obj_tok_span": [10, 13]}, {"subject": "DHA", "sbj_char_span": [124, 127], "object": "Delta 6 desaturase", "obj_char_span": [11, 29], "rel_type": "product or substrate", "sbj_tok_span": [44, 45], "obj_tok_span": [3, 8], "new_sbj_tok_span": [51, 52], "new_obj_tok_span": [3, 8]}, {"subject": "DHA", "sbj_char_span": [232, 235], "object": "Delta 6 desaturase", "obj_char_span": [11, 29], "rel_type": "product or substrate", "sbj_tok_span": [69, 70], "obj_tok_span": [3, 8], "new_sbj_tok_span": [78, 79], "new_obj_tok_span": [3, 8]}, {"subject": "ALA", "sbj_char_span": [241, 244], "object": "Delta 6 desaturase", "obj_char_span": [11, 29], "rel_type": "product or substrate", "sbj_tok_span": [71, 73], "obj_tok_span": [3, 8], "new_sbj_tok_span": [81, 83], "new_obj_tok_span": [3, 8]}, {"subject": "DHA", "sbj_char_span": [232, 235], "object": "D6D", "obj_char_span": [31, 34], "rel_type": "product or substrate", "sbj_tok_span": [69, 70], "obj_tok_span": [9, 12], "new_sbj_tok_span": [78, 79], "new_obj_tok_span": [10, 13]}, {"subject": "ALA", "sbj_char_span": [241, 244], "object": "D6D", "obj_char_span": [31, 34], "rel_type": "product or substrate", "sbj_tok_span": [71, 73], "obj_tok_span": [9, 12], "new_sbj_tok_span": [81, 83], "new_obj_tok_span": [10, 13]}], "umls_entity_list": [{"mention": "D6D", "char_span": [31, 34], "sem_type": "Gene or Genome", "tok_span": [9, 12], "new_tok_span": [10, 13]}, {"mention": "alpha-linolenic acid", "char_span": [63, 83], "sem_type": "Organic Chemical", "tok_span": [18, 24], "new_tok_span": [21, 27]}, {"mention": "docosahexaenoic acid", "char_span": [102, 122], "sem_type": "Pharmacologic Substance", "tok_span": [36, 43], "new_tok_span": [41, 48]}, {"mention": "DHA", "char_span": [124, 127], "sem_type": "Pharmacologic Substance", "tok_span": [44, 45], "new_tok_span": [51, 52]}, {"mention": "DHA", "char_span": [232, 235], "sem_type": "Pharmacologic Substance", "tok_span": [69, 70], "new_tok_span": [78, 79]}, {"mention": "phospholipids", "char_span": [391, 404], "sem_type": "Organic Chemical", "tok_span": [103, 104], "new_tok_span": [114, 115]}], "new_text": "The use of Delta 6 desaturase ( <START=Gene or Genome> D6D <END=Gene or Genome> ) twice in the conversion of <START=Organic Chemical> alpha - linolenic acid <END=Organic Chemical> ( ALA ; 18 : 3n - 3 ) to <START=Pharmacologic Substance> docosahexaenoic acid <END=Pharmacologic Substance> ( <START=Pharmacologic Substance> DHA <END=Pharmacologic Substance> ; 22 : 6n - 3 ) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of <START=Pharmacologic Substance> DHA <END=Pharmacologic Substance> from ALA. We examined this using an in vitro model of fatty acid metabolism to measure the accumulation of the long - chain metabolites of ALA in HepG2 cell <START=Organic Chemical> phospholipids <END=Organic Chemical>."}, {"PMID": 11470741, "id": 1, "text": "Cerivastatin is used in the treatment of hypercholesterolemia to inhibit 3-hydroxy 3-methylglutaryl coenzyme A reductase and thus prevent the synthesis of cholesterol precursors, such as farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP), responsible, respectively, for translocation of Ras and Rho to the cell membrane, a step required for their cell signaling, leading to cell proliferation and migration.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 12], "name": "Cerivastatin", "tok_span": [0, 4], "new_tok_span": [0, 4]}, {"ent_type": "CHEMICAL", "char_span": [155, 166], "name": "cholesterol", "tok_span": [34, 35], "new_tok_span": [34, 35]}, {"ent_type": "CHEMICAL", "char_span": [187, 209], "name": "farnesyl pyrophosphate", "tok_span": [39, 44], "new_tok_span": [40, 45]}, {"ent_type": "CHEMICAL", "char_span": [211, 214], "name": "FPP", "tok_span": [45, 47], "new_tok_span": [47, 49]}, {"ent_type": "CHEMICAL", "char_span": [220, 248], "name": "geranylgeranyl pyrophosphate", "tok_span": [49, 55], "new_tok_span": [52, 58]}, {"ent_type": "CHEMICAL", "char_span": [250, 254], "name": "GGPP", "tok_span": [56, 58], "new_tok_span": [60, 62]}, {"ent_type": "CHEMICAL", "char_span": [73, 110], "name": "3-hydroxy 3-methylglutaryl coenzyme A", "tok_span": [15, 27], "new_tok_span": [15, 27]}, {"ent_type": "GENE", "char_span": [305, 308], "name": "Ras", "tok_span": [67, 68], "new_tok_span": [73, 74]}, {"ent_type": "GENE", "char_span": [313, 316], "name": "Rho", "tok_span": [69, 70], "new_tok_span": [77, 78]}, {"ent_type": "GENE", "char_span": [73, 120], "name": "3-hydroxy 3-methylglutaryl coenzyme A reductase", "tok_span": [15, 28], "new_tok_span": [15, 28]}], "relation_list": [{"subject": "Cerivastatin", "sbj_char_span": [0, 12], "object": "3-hydroxy 3-methylglutaryl coenzyme A reductase", "obj_char_span": [73, 120], "rel_type": "inhibitor", "sbj_tok_span": [0, 4], "obj_tok_span": [15, 28], "new_sbj_tok_span": [0, 4], "new_obj_tok_span": [15, 28]}, {"subject": "cholesterol", "sbj_char_span": [155, 166], "object": "3-hydroxy 3-methylglutaryl coenzyme A reductase", "obj_char_span": [73, 120], "rel_type": "product or substrate", "sbj_tok_span": [34, 35], "obj_tok_span": [15, 28], "new_sbj_tok_span": [34, 35], "new_obj_tok_span": [15, 28]}, {"subject": "farnesyl pyrophosphate", "sbj_char_span": [187, 209], "object": "3-hydroxy 3-methylglutaryl coenzyme A reductase", "obj_char_span": [73, 120], "rel_type": "product or substrate", "sbj_tok_span": [39, 44], "obj_tok_span": [15, 28], "new_sbj_tok_span": [40, 45], "new_obj_tok_span": [15, 28]}, {"subject": "FPP", "sbj_char_span": [211, 214], "object": "3-hydroxy 3-methylglutaryl coenzyme A reductase", "obj_char_span": [73, 120], "rel_type": "product or substrate", "sbj_tok_span": [45, 47], "obj_tok_span": [15, 28], "new_sbj_tok_span": [47, 49], "new_obj_tok_span": [15, 28]}, {"subject": "geranylgeranyl pyrophosphate", "sbj_char_span": [220, 248], "object": "3-hydroxy 3-methylglutaryl coenzyme A reductase", "obj_char_span": [73, 120], "rel_type": "product or substrate", "sbj_tok_span": [49, 55], "obj_tok_span": [15, 28], "new_sbj_tok_span": [52, 58], "new_obj_tok_span": [15, 28]}, {"subject": "GGPP", "sbj_char_span": [250, 254], "object": "3-hydroxy 3-methylglutaryl coenzyme A reductase", "obj_char_span": [73, 120], "rel_type": "product or substrate", "sbj_tok_span": [56, 58], "obj_tok_span": [15, 28], "new_sbj_tok_span": [60, 62], "new_obj_tok_span": [15, 28]}], "umls_entity_list": [{"mention": "farnesyl pyrophosphate", "char_span": [187, 209], "sem_type": "Organic Chemical", "tok_span": [39, 44], "new_tok_span": [40, 45]}, {"mention": "geranylgeranyl", "char_span": [220, 234], "sem_type": "Pharmacologic Substance", "tok_span": [49, 53], "new_tok_span": [52, 56]}, {"mention": "Ras", "char_span": [305, 308], "sem_type": "Gene or Genome", "tok_span": [67, 68], "new_tok_span": [73, 74]}, {"mention": "Ras", "char_span": [305, 308], "sem_type": "Pharmacologic Substance", "tok_span": [67, 68], "new_tok_span": [73, 74]}], "new_text": "Cerivastatin is used in the treatment of hypercholesterolemia to inhibit 3 - hydroxy 3 - methylglutaryl coenzyme A reductase and thus prevent the synthesis of cholesterol precursors, such as <START=Organic Chemical> farnesyl pyrophosphate <END=Organic Chemical> ( FPP ) and <START=Pharmacologic Substance> geranylgeranyl <END=Pharmacologic Substance> pyrophosphate ( GGPP ), responsible, respectively, for translocation of <START=Gene or Genome> <START=Pharmacologic Substance> Ras <END=Gene or Genome> <END=Pharmacologic Substance> and Rho to the cell membrane, a step required for their cell signaling, leading to cell proliferation and migration."}, {"PMID": 23562928, "id": 1, "text": "The purpose of this study is to investigate the effects of n-hexane extracts from bones and internal organs of Japanese eel, Anguilla japonica (HEE), on cyclooxygenase-2 (COX-2)-dependent prostaglandin D2 (PGD2) generation in stem cell factor (SCF), IL-10, plus LPS-induced mouse bone marrow-derived mast cells (BMMCs) and on passive cutaneous anaphylaxis (PCA) in mice.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [188, 204], "name": "prostaglandin D2", "tok_span": [48, 51], "new_tok_span": [48, 51]}, {"ent_type": "CHEMICAL", "char_span": [206, 210], "name": "PGD2", "tok_span": [52, 55], "new_tok_span": [54, 57]}, {"ent_type": "CHEMICAL", "char_span": [59, 67], "name": "n-hexane", "tok_span": [11, 15], "new_tok_span": [11, 15]}, {"ent_type": "GENE", "char_span": [153, 169], "name": "cyclooxygenase-2", "tok_span": [37, 41], "new_tok_span": [37, 41]}, {"ent_type": "GENE", "char_span": [171, 176], "name": "COX-2", "tok_span": [42, 45], "new_tok_span": [42, 45]}, {"ent_type": "GENE", "char_span": [226, 242], "name": "stem cell factor", "tok_span": [58, 61], "new_tok_span": [64, 67]}, {"ent_type": "GENE", "char_span": [244, 247], "name": "SCF", "tok_span": [62, 64], "new_tok_span": [70, 72]}, {"ent_type": "GENE", "char_span": [250, 255], "name": "IL-10", "tok_span": [66, 69], "new_tok_span": [74, 77]}], "relation_list": [{"subject": "prostaglandin D2", "sbj_char_span": [188, 204], "object": "cyclooxygenase-2", "obj_char_span": [153, 169], "rel_type": "product or substrate", "sbj_tok_span": [48, 51], "obj_tok_span": [37, 41], "new_sbj_tok_span": [48, 51], "new_obj_tok_span": [37, 41]}, {"subject": "prostaglandin D2", "sbj_char_span": [188, 204], "object": "COX-2", "obj_char_span": [171, 176], "rel_type": "product or substrate", "sbj_tok_span": [48, 51], "obj_tok_span": [42, 45], "new_sbj_tok_span": [48, 51], "new_obj_tok_span": [42, 45]}, {"subject": "PGD2", "sbj_char_span": [206, 210], "object": "cyclooxygenase-2", "obj_char_span": [153, 169], "rel_type": "product or substrate", "sbj_tok_span": [52, 55], "obj_tok_span": [37, 41], "new_sbj_tok_span": [54, 57], "new_obj_tok_span": [37, 41]}, {"subject": "PGD2", "sbj_char_span": [206, 210], "object": "COX-2", "obj_char_span": [171, 176], "rel_type": "product or substrate", "sbj_tok_span": [52, 55], "obj_tok_span": [42, 45], "new_sbj_tok_span": [54, 57], "new_obj_tok_span": [42, 45]}], "umls_entity_list": [{"mention": "D2", "char_span": [202, 204], "sem_type": "Gene or Genome", "tok_span": [49, 51], "new_tok_span": [50, 52]}, {"mention": "D2", "char_span": [208, 210], "sem_type": "Gene or Genome", "tok_span": [53, 55], "new_tok_span": [56, 58]}, {"mention": "stem", "char_span": [226, 230], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [58, 59], "new_tok_span": [64, 65]}, {"mention": "stem cell factor", "char_span": [226, 242], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [58, 61], "new_tok_span": [64, 67]}, {"mention": "LPS", "char_span": [262, 265], "sem_type": "Organic Chemical", "tok_span": [71, 72], "new_tok_span": [81, 82]}, {"mention": "mast", "char_span": [300, 304], "sem_type": "Gene or Genome", "tok_span": [79, 80], "new_tok_span": [92, 93]}, {"mention": "LPS", "char_span": [262, 265], "sem_type": "Gene or Genome", "tok_span": [71, 72], "new_tok_span": [81, 82]}], "new_text": "The purpose of this study is to investigate the effects of n - hexane extracts from bones and internal organs of Japanese eel, Anguilla japonica ( HEE ), on cyclooxygenase - 2 ( COX - 2 ) - dependent prostaglandin <START=Gene or Genome> D2 <END=Gene or Genome> ( PG <START=Gene or Genome>D2 <END=Gene or Genome> ) generation in <START=Amino Acid, Peptide, or Protein> <START=Amino Acid, Peptide, or Protein> stem <END=Amino Acid, Peptide, or Protein> cell factor <END=Amino Acid, Peptide, or Protein> ( SCF ), IL - 10, plus <START=Organic Chemical> <START=Gene or Genome> LPS <END=Organic Chemical> <END=Gene or Genome> - induced mouse bone marrow - derived <START=Gene or Genome> mast <END=Gene or Genome> cells ( BMMCs ) and on passive cutaneous anaphylaxis ( PCA ) in mice."}, {"PMID": 10224140, "id": 2, "text": "Degenerate primers were designed based on the sequences conserved among OAT1, OAT2, and organic cation transporter 1 (OCT1), and reverse transcription-polymerase chain reaction was performed using rat brain poly(A)+ RNA. The 536-amino acid protein sequence encoded by OAT3 showed 49, 39, and 36% identity to those of OAT1, OAT2, and OCT1, respectively.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [229, 239], "name": "amino acid", "tok_span": [53, 55], "new_tok_span": [66, 68]}, {"ent_type": "GENE", "char_span": [72, 76], "name": "OAT1", "tok_span": [12, 15], "new_tok_span": [13, 16]}, {"ent_type": "GENE", "char_span": [78, 82], "name": "OAT2", "tok_span": [16, 19], "new_tok_span": [19, 22]}, {"ent_type": "GENE", "char_span": [88, 116], "name": "organic cation transporter 1", "tok_span": [21, 25], "new_tok_span": [28, 32]}, {"ent_type": "GENE", "char_span": [118, 122], "name": "OCT1", "tok_span": [26, 28], "new_tok_span": [37, 39]}, {"ent_type": "GENE", "char_span": [268, 272], "name": "OAT3", "tok_span": [59, 62], "new_tok_span": [76, 79]}, {"ent_type": "GENE", "char_span": [317, 321], "name": "OAT1", "tok_span": [74, 77], "new_tok_span": [93, 96]}, {"ent_type": "GENE", "char_span": [323, 327], "name": "OAT2", "tok_span": [78, 81], "new_tok_span": [99, 102]}, {"ent_type": "GENE", "char_span": [333, 337], "name": "OCT1", "tok_span": [83, 85], "new_tok_span": [106, 108]}], "relation_list": [{"subject": "amino acid", "sbj_char_span": [229, 239], "object": "OAT3", "obj_char_span": [268, 272], "rel_type": "part of", "sbj_tok_span": [53, 55], "obj_tok_span": [59, 62], "new_sbj_tok_span": [66, 68], "new_obj_tok_span": [76, 79]}, {"subject": "amino acid", "sbj_char_span": [229, 239], "object": "OAT1", "obj_char_span": [317, 321], "rel_type": "part of", "sbj_tok_span": [53, 55], "obj_tok_span": [74, 77], "new_sbj_tok_span": [66, 68], "new_obj_tok_span": [93, 96]}, {"subject": "amino acid", "sbj_char_span": [229, 239], "object": "OAT2", "obj_char_span": [323, 327], "rel_type": "part of", "sbj_tok_span": [53, 55], "obj_tok_span": [78, 81], "new_sbj_tok_span": [66, 68], "new_obj_tok_span": [99, 102]}, {"subject": "amino acid", "sbj_char_span": [229, 239], "object": "OCT1", "obj_char_span": [333, 337], "rel_type": "part of", "sbj_tok_span": [53, 55], "obj_tok_span": [83, 85], "new_sbj_tok_span": [66, 68], "new_obj_tok_span": [106, 108]}], "umls_entity_list": [{"mention": "OAT1", "char_span": [72, 76], "sem_type": "Gene or Genome", "tok_span": [12, 15], "new_tok_span": [13, 16]}, {"mention": "OAT1", "char_span": [317, 321], "sem_type": "Gene or Genome", "tok_span": [74, 77], "new_tok_span": [93, 96]}, {"mention": "OAT2", "char_span": [78, 82], "sem_type": "Gene or Genome", "tok_span": [16, 19], "new_tok_span": [19, 22]}, {"mention": "OAT2", "char_span": [323, 327], "sem_type": "Gene or Genome", "tok_span": [78, 81], "new_tok_span": [99, 102]}, {"mention": "organic", "char_span": [88, 95], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [21, 22], "new_tok_span": [28, 29]}, {"mention": "organic cation transporter 1", "char_span": [88, 116], "sem_type": "Gene or Genome", "tok_span": [21, 25], "new_tok_span": [28, 32]}, {"mention": "organic cation transporter 1", "char_span": [88, 116], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [21, 25], "new_tok_span": [28, 32]}, {"mention": "OCT1", "char_span": [118, 122], "sem_type": "Gene or Genome", "tok_span": [26, 28], "new_tok_span": [37, 39]}, {"mention": "OCT1", "char_span": [333, 337], "sem_type": "Gene or Genome", "tok_span": [83, 85], "new_tok_span": [106, 108]}, {"mention": "protein", "char_span": [240, 247], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [55, 56], "new_tok_span": [69, 70]}, {"mention": "amino acid protein", "char_span": [229, 247], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [53, 56], "new_tok_span": [66, 69]}, {"mention": "OAT3", "char_span": [268, 272], "sem_type": "Gene or Genome", "tok_span": [59, 62], "new_tok_span": [76, 79]}], "new_text": "Degenerate primers were designed based on the sequences conserved among <START=Gene or Genome> OAT1 <END=Gene or Genome>, <START=Gene or Genome> OAT2 <END=Gene or Genome>, and <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> organic <END=Amino Acid, Peptide, or Protein> cation transporter 1 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> ( <START=Gene or Genome> OCT1 <END=Gene or Genome> ), and reverse transcription - polymerase chain reaction was performed using rat brain poly ( A ) + RNA. The 536 - <START=Amino Acid, Peptide, or Protein> amino acid <START=Amino Acid, Peptide, or Protein> protein <END=Amino Acid, Peptide, or Protein> <END=Amino Acid, Peptide, or Protein> sequence encoded by <START=Gene or Genome> OAT3 <END=Gene or Genome> showed 49, 39, and 36 % identity to those of <START=Gene or Genome> OAT1 <END=Gene or Genome>, <START=Gene or Genome> OAT2 <END=Gene or Genome>, and <START=Gene or Genome> OCT1 <END=Gene or Genome>, respectively."}, {"PMID": 23297412, "id": 2, "text": "Here, we show that oral administration of resveratrol, which leads to activation of an NAD(+)-dependent protein deacetylase SIRT1, suppresses cardiac hypertrophy and fibrosis and restores cardiac diastolic function in dystrophin-deficient mdx mice.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [42, 53], "name": "resveratrol", "tok_span": [8, 10], "new_tok_span": [9, 11]}, {"ent_type": "CHEMICAL", "char_span": [87, 93], "name": "NAD(+)", "tok_span": [17, 21], "new_tok_span": [19, 23]}, {"ent_type": "GENE", "char_span": [87, 129], "name": "NAD(+)-dependent protein deacetylase SIRT1", "tok_span": [17, 29], "new_tok_span": [19, 31]}, {"ent_type": "GENE", "char_span": [218, 228], "name": "dystrophin", "tok_span": [42, 45], "new_tok_span": [50, 53]}], "relation_list": [{"subject": "resveratrol", "sbj_char_span": [42, 53], "object": "NAD(+)-dependent protein deacetylase SIRT1", "obj_char_span": [87, 129], "rel_type": "activator", "sbj_tok_span": [8, 10], "obj_tok_span": [17, 29], "new_sbj_tok_span": [9, 11], "new_obj_tok_span": [19, 31]}], "umls_entity_list": [{"mention": "resveratrol", "char_span": [42, 53], "sem_type": "Pharmacologic Substance", "tok_span": [8, 10], "new_tok_span": [9, 11]}, {"mention": "SIRT1", "char_span": [124, 129], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [27, 29], "new_tok_span": [31, 33]}, {"mention": "SIRT1", "char_span": [124, 129], "sem_type": "Gene or Genome", "tok_span": [27, 29], "new_tok_span": [31, 33]}, {"mention": "dystrophin", "char_span": [218, 228], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [42, 45], "new_tok_span": [50, 53]}, {"mention": "dystrophin", "char_span": [218, 228], "sem_type": "Gene or Genome", "tok_span": [42, 45], "new_tok_span": [50, 53]}], "new_text": "Here, we show that oral administration of <START=Pharmacologic Substance> resveratrol <END=Pharmacologic Substance>, which leads to activation of an NAD ( + ) - dependent protein deacetylase <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> SIRT1 <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome>, suppresses cardiac hypertrophy and fibrosis and restores cardiac diastolic function in <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> dystrophin <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> - deficient mdx mice."}, {"PMID": 23265191, "id": 3, "text": "In the mammalian ISC machinery, preassembly of the Fe-S cluster on the scaffold protein (ISCU) involves a cysteine desulfurase complex (NFS1/ISD11) and frataxin (FXN), the protein deficient in Friedreich's ataxia.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [51, 55], "name": "Fe-S", "tok_span": [11, 14], "new_tok_span": [11, 14]}, {"ent_type": "CHEMICAL", "char_span": [106, 114], "name": "cysteine", "tok_span": [26, 27], "new_tok_span": [34, 35]}, {"ent_type": "GENE", "char_span": [7, 20], "name": "mammalian ISC", "tok_span": [2, 5], "new_tok_span": [2, 5]}, {"ent_type": "GENE", "char_span": [89, 93], "name": "ISCU", "tok_span": [20, 23], "new_tok_span": [24, 27]}, {"ent_type": "GENE", "char_span": [106, 134], "name": "cysteine desulfurase complex", "tok_span": [26, 32], "new_tok_span": [34, 40]}, {"ent_type": "GENE", "char_span": [136, 140], "name": "NFS1", "tok_span": [33, 36], "new_tok_span": [44, 47]}, {"ent_type": "GENE", "char_span": [141, 146], "name": "ISD11", "tok_span": [37, 40], "new_tok_span": [50, 53]}, {"ent_type": "GENE", "char_span": [152, 160], "name": "frataxin", "tok_span": [42, 45], "new_tok_span": [58, 61]}, {"ent_type": "GENE", "char_span": [162, 165], "name": "FXN", "tok_span": [46, 48], "new_tok_span": [64, 66]}], "relation_list": [{"subject": "Fe-S", "sbj_char_span": [51, 55], "object": "ISCU", "obj_char_span": [89, 93], "rel_type": "regulator", "sbj_tok_span": [11, 14], "obj_tok_span": [20, 23], "new_sbj_tok_span": [11, 14], "new_obj_tok_span": [24, 27]}, {"subject": "Fe-S", "sbj_char_span": [51, 55], "object": "mammalian ISC", "obj_char_span": [7, 20], "rel_type": "product or substrate", "sbj_tok_span": [11, 14], "obj_tok_span": [2, 5], "new_sbj_tok_span": [11, 14], "new_obj_tok_span": [2, 5]}], "umls_entity_list": [{"mention": "scaffold", "char_span": [71, 79], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [17, 18], "new_tok_span": [18, 19]}, {"mention": "ISCU", "char_span": [89, 93], "sem_type": "Pharmacologic Substance", "tok_span": [20, 23], "new_tok_span": [24, 27]}, {"mention": "ISCU", "char_span": [89, 93], "sem_type": "Gene or Genome", "tok_span": [20, 23], "new_tok_span": [24, 27]}, {"mention": "cysteine", "char_span": [106, 114], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [26, 27], "new_tok_span": [34, 35]}, {"mention": "cysteine desulfurase", "char_span": [106, 126], "sem_type": "Gene or Genome", "tok_span": [26, 31], "new_tok_span": [34, 39]}, {"mention": "NFS1", "char_span": [136, 140], "sem_type": "Gene or Genome", "tok_span": [33, 36], "new_tok_span": [44, 47]}, {"mention": "ISD11", "char_span": [141, 146], "sem_type": "Gene or Genome", "tok_span": [37, 40], "new_tok_span": [50, 53]}, {"mention": "frataxin", "char_span": [152, 160], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [42, 45], "new_tok_span": [58, 61]}, {"mention": "frataxin", "char_span": [152, 160], "sem_type": "Gene or Genome", "tok_span": [42, 45], "new_tok_span": [58, 61]}], "new_text": "In the mammalian ISC machinery, preassembly of the Fe - S cluster on the <START=Amino Acid, Peptide, or Protein> scaffold <END=Amino Acid, Peptide, or Protein> protein ( <START=Pharmacologic Substance> <START=Gene or Genome> ISCU <END=Pharmacologic Substance> <END=Gene or Genome> ) involves a <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> cysteine <END=Amino Acid, Peptide, or Protein> desulfurase <END=Gene or Genome> complex ( <START=Gene or Genome> NFS1 <END=Gene or Genome> / <START=Gene or Genome> ISD11 <END=Gene or Genome> ) and <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> frataxin <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> ( FXN ), the protein deficient in Friedreich's ataxia."}, {"PMID": 10683249, "id": 7, "text": "The mNQO activity was insensitive to dicoumarol, a potent inhibitor of cytosolic NQO1. Western analysis of microsomal proteins revealed 29- and 18-kDa bands that cross-reacted with polyclonal antibodies raised against cytosolic NQO1. The mNQO activity was partially purified by solubilization of microsomes with detergent Chaps, ammonium sulfate fractionation, and DEAE-Sephacel column chromatography.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [329, 345], "name": "ammonium sulfate", "tok_span": [73, 75], "new_tok_span": [85, 87]}, {"ent_type": "CHEMICAL", "char_span": [365, 369], "name": "DEAE", "tok_span": [78, 80], "new_tok_span": [91, 93]}, {"ent_type": "CHEMICAL", "char_span": [37, 47], "name": "dicoumarol", "tok_span": [9, 13], "new_tok_span": [10, 14]}, {"ent_type": "GENE", "char_span": [228, 232], "name": "NQO1", "tok_span": [48, 52], "new_tok_span": [56, 60]}, {"ent_type": "GENE", "char_span": [238, 242], "name": "mNQO", "tok_span": [54, 58], "new_tok_span": [64, 68]}, {"ent_type": "GENE", "char_span": [4, 8], "name": "mNQO", "tok_span": [1, 5], "new_tok_span": [1, 5]}, {"ent_type": "GENE", "char_span": [81, 85], "name": "NQO1", "tok_span": [19, 23], "new_tok_span": [23, 27]}], "relation_list": [{"subject": "dicoumarol", "sbj_char_span": [37, 47], "object": "NQO1", "obj_char_span": [81, 85], "rel_type": "inhibitor", "sbj_tok_span": [9, 13], "obj_tok_span": [19, 23], "new_sbj_tok_span": [10, 14], "new_obj_tok_span": [23, 27]}], "umls_entity_list": [{"mention": "dicoumarol", "char_span": [37, 47], "sem_type": "Pharmacologic Substance", "tok_span": [9, 13], "new_tok_span": [10, 14]}, {"mention": "NQO1", "char_span": [81, 85], "sem_type": "Gene or Genome", "tok_span": [19, 23], "new_tok_span": [23, 27]}, {"mention": "NQO1", "char_span": [228, 232], "sem_type": "Gene or Genome", "tok_span": [48, 52], "new_tok_span": [56, 60]}, {"mention": "NQO1", "char_span": [81, 85], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [19, 23], "new_tok_span": [23, 27]}, {"mention": "NQO1", "char_span": [228, 232], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [48, 52], "new_tok_span": [56, 60]}, {"mention": "Chaps", "char_span": [322, 327], "sem_type": "Pharmacologic Substance", "tok_span": [70, 72], "new_tok_span": [81, 83]}, {"mention": "DEAE", "char_span": [365, 369], "sem_type": "Pharmacologic Substance", "tok_span": [78, 80], "new_tok_span": [91, 93]}], "new_text": "The mNQO activity was insensitive to <START=Pharmacologic Substance> dicoumarol <END=Pharmacologic Substance>, a potent inhibitor of cytosolic <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> NQO1 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein>. Western analysis of microsomal proteins revealed 29 - and 18 - kDa bands that cross - reacted with polyclonal antibodies raised against cytosolic <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> NQO1 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein>. The mNQO activity was partially purified by solubilization of microsomes with detergent <START=Pharmacologic Substance> Chaps <END=Pharmacologic Substance>, ammonium sulfate fractionation, and <START=Pharmacologic Substance> DEAE <END=Pharmacologic Substance> - Sephacel column chromatography."}, {"PMID": 17604186, "id": 2, "text": "Previous studies have explored the protective effect of naproxen (non-selective COX-inhibitor) or rofecoxib (selective COX-2 inhibitor) against chemical kindling in mice.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [56, 64], "name": "naproxen", "tok_span": [8, 12], "new_tok_span": [9, 13]}, {"ent_type": "CHEMICAL", "char_span": [98, 107], "name": "rofecoxib", "tok_span": [21, 25], "new_tok_span": [23, 27]}, {"ent_type": "GENE", "char_span": [80, 83], "name": "COX", "tok_span": [16, 17], "new_tok_span": [18, 19]}, {"ent_type": "GENE", "char_span": [119, 124], "name": "COX-2", "tok_span": [27, 30], "new_tok_span": [29, 32]}], "relation_list": [{"subject": "naproxen", "sbj_char_span": [56, 64], "object": "COX", "obj_char_span": [80, 83], "rel_type": "inhibitor", "sbj_tok_span": [8, 12], "obj_tok_span": [16, 17], "new_sbj_tok_span": [9, 13], "new_obj_tok_span": [18, 19]}, {"subject": "rofecoxib", "sbj_char_span": [98, 107], "object": "COX-2", "obj_char_span": [119, 124], "rel_type": "inhibitor", "sbj_tok_span": [21, 25], "obj_tok_span": [27, 30], "new_sbj_tok_span": [23, 27], "new_obj_tok_span": [29, 32]}], "umls_entity_list": [{"mention": "naproxen", "char_span": [56, 64], "sem_type": "Pharmacologic Substance", "tok_span": [8, 12], "new_tok_span": [9, 13]}], "new_text": "Previous studies have explored the protective effect of <START=Pharmacologic Substance> naproxen <END=Pharmacologic Substance> ( non - selective COX - inhibitor ) or rofecoxib ( selective COX - 2 inhibitor ) against chemical kindling in mice."}, {"PMID": 10200266, "id": 1, "text": "The MWFE polypeptide of mammalian complex I (the proton-translocating NADH-quinone oxidoreductase) is 70 amino acids long, and it is predicted to be a membrane protein.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [105, 116], "name": "amino acids", "tok_span": [25, 27], "new_tok_span": [33, 35]}, {"ent_type": "CHEMICAL", "char_span": [70, 82], "name": "NADH-quinone", "tok_span": [14, 18], "new_tok_span": [21, 25]}, {"ent_type": "GENE", "char_span": [24, 43], "name": "mammalian complex I", "tok_span": [5, 8], "new_tok_span": [9, 12]}, {"ent_type": "GENE", "char_span": [4, 8], "name": "MWFE", "tok_span": [1, 3], "new_tok_span": [2, 4]}, {"ent_type": "GENE", "char_span": [70, 97], "name": "NADH-quinone oxidoreductase", "tok_span": [14, 22], "new_tok_span": [21, 29]}], "relation_list": [{"subject": "amino acids", "sbj_char_span": [105, 116], "object": "MWFE", "obj_char_span": [4, 8], "rel_type": "part of", "sbj_tok_span": [25, 27], "obj_tok_span": [1, 3], "new_sbj_tok_span": [33, 35], "new_obj_tok_span": [2, 4]}, {"subject": "amino acids", "sbj_char_span": [105, 116], "object": "mammalian complex I", "obj_char_span": [24, 43], "rel_type": "part of", "sbj_tok_span": [25, 27], "obj_tok_span": [5, 8], "new_sbj_tok_span": [33, 35], "new_obj_tok_span": [9, 12]}, {"subject": "amino acids", "sbj_char_span": [105, 116], "object": "NADH-quinone oxidoreductase", "obj_char_span": [70, 97], "rel_type": "part of", "sbj_tok_span": [25, 27], "obj_tok_span": [14, 22], "new_sbj_tok_span": [33, 35], "new_obj_tok_span": [21, 29]}], "umls_entity_list": [{"mention": "MWFE", "char_span": [4, 8], "sem_type": "Gene or Genome", "tok_span": [1, 3], "new_tok_span": [2, 4]}, {"mention": "polypeptide", "char_span": [9, 20], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [3, 4], "new_tok_span": [6, 7]}, {"mention": "complex I", "char_span": [34, 43], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [6, 8], "new_tok_span": [11, 13]}, {"mention": "proton-translocating NADH-quinone oxidoreductase", "char_span": [49, 97], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [10, 22], "new_tok_span": [17, 29]}, {"mention": "membrane protein", "char_span": [151, 167], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [36, 38], "new_tok_span": [45, 47]}], "new_text": "The <START=Gene or Genome> MWFE <END=Gene or Genome> <START=Amino Acid, Peptide, or Protein> polypeptide <END=Amino Acid, Peptide, or Protein> of mammalian <START=Amino Acid, Peptide, or Protein> complex I <END=Amino Acid, Peptide, or Protein> ( the <START=Amino Acid, Peptide, or Protein> proton - translocating NADH - quinone oxidoreductase <END=Amino Acid, Peptide, or Protein> ) is 70 amino acids long, and it is predicted to be a <START=Amino Acid, Peptide, or Protein> membrane protein <END=Amino Acid, Peptide, or Protein>."}, {"PMID": 10823899, "id": 7, "text": "The reductions of [(3)H]DA uptake and AMPH-induced DAT internalization also were inhibited by coexpression of a dominant negative mutant of dynamin I (K44A), indicating that endocytosis modulates transport capacity, likely through a clathrin-mediated pathway.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [18, 26], "name": "[(3)H]DA", "tok_span": [3, 10], "new_tok_span": [3, 10]}, {"ent_type": "CHEMICAL", "char_span": [38, 42], "name": "AMPH", "tok_span": [12, 14], "new_tok_span": [12, 14]}, {"ent_type": "GENE", "char_span": [140, 149], "name": "dynamin I", "tok_span": [30, 33], "new_tok_span": [35, 38]}, {"ent_type": "GENE", "char_span": [151, 155], "name": "K44A", "tok_span": [34, 37], "new_tok_span": [40, 43]}, {"ent_type": "GENE", "char_span": [233, 241], "name": "clathrin", "tok_span": [49, 52], "new_tok_span": [56, 59]}, {"ent_type": "GENE", "char_span": [51, 54], "name": "DAT", "tok_span": [16, 17], "new_tok_span": [18, 19]}], "relation_list": [{"subject": "[(3)H]DA", "sbj_char_span": [18, 26], "object": "DAT", "obj_char_span": [51, 54], "rel_type": "product or substrate", "sbj_tok_span": [3, 10], "obj_tok_span": [16, 17], "new_sbj_tok_span": [3, 10], "new_obj_tok_span": [18, 19]}], "umls_entity_list": [{"mention": "DAT", "char_span": [51, 54], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [16, 17], "new_tok_span": [18, 19]}, {"mention": "DAT", "char_span": [51, 54], "sem_type": "Gene or Genome", "tok_span": [16, 17], "new_tok_span": [18, 19]}, {"mention": "dynamin", "char_span": [140, 147], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [30, 32], "new_tok_span": [35, 37]}, {"mention": "clathrin", "char_span": [233, 241], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [49, 52], "new_tok_span": [56, 59]}], "new_text": "The reductions of [ ( 3 ) H ] DA uptake and AMPH - induced <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> DAT <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> internalization also were inhibited by coexpression of a dominant negative mutant of <START=Amino Acid, Peptide, or Protein> dynamin <END=Amino Acid, Peptide, or Protein> I ( K44A ), indicating that endocytosis modulates transport capacity, likely through a <START=Amino Acid, Peptide, or Protein> clathrin <END=Amino Acid, Peptide, or Protein> - mediated pathway."}, {"PMID": 17664139, "id": 1, "text": "Two sodium-dependent vitamin C transporter isoforms (SVCT1 and SVCT2) were identified as ascorbic acid transporters, but their roles in skin have, as yet, not been elucidated.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [21, 30], "name": "vitamin C", "tok_span": [4, 6], "new_tok_span": [5, 7]}, {"ent_type": "CHEMICAL", "char_span": [4, 10], "name": "sodium", "tok_span": [1, 2], "new_tok_span": [2, 3]}, {"ent_type": "CHEMICAL", "char_span": [89, 102], "name": "ascorbic acid", "tok_span": [20, 23], "new_tok_span": [26, 29]}, {"ent_type": "GENE", "char_span": [4, 42], "name": "sodium-dependent vitamin C transporter", "tok_span": [1, 7], "new_tok_span": [2, 8]}, {"ent_type": "GENE", "char_span": [53, 58], "name": "SVCT1", "tok_span": [9, 12], "new_tok_span": [14, 17]}, {"ent_type": "GENE", "char_span": [63, 68], "name": "SVCT2", "tok_span": [13, 16], "new_tok_span": [19, 22]}], "relation_list": [{"subject": "ascorbic acid", "sbj_char_span": [89, 102], "object": "sodium-dependent vitamin C transporter", "obj_char_span": [4, 42], "rel_type": "product or substrate", "sbj_tok_span": [20, 23], "obj_tok_span": [1, 7], "new_sbj_tok_span": [26, 29], "new_obj_tok_span": [2, 8]}, {"subject": "ascorbic acid", "sbj_char_span": [89, 102], "object": "SVCT1", "obj_char_span": [53, 58], "rel_type": "product or substrate", "sbj_tok_span": [20, 23], "obj_tok_span": [9, 12], "new_sbj_tok_span": [26, 29], "new_obj_tok_span": [14, 17]}, {"subject": "ascorbic acid", "sbj_char_span": [89, 102], "object": "SVCT2", "obj_char_span": [63, 68], "rel_type": "product or substrate", "sbj_tok_span": [20, 23], "obj_tok_span": [13, 16], "new_sbj_tok_span": [26, 29], "new_obj_tok_span": [19, 22]}], "umls_entity_list": [{"mention": "sodium-dependent vitamin C transporter", "char_span": [4, 42], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [1, 7], "new_tok_span": [2, 8]}, {"mention": "isoforms", "char_span": [43, 51], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [7, 8], "new_tok_span": [10, 11]}, {"mention": "SVCT1", "char_span": [53, 58], "sem_type": "Gene or Genome", "tok_span": [9, 12], "new_tok_span": [14, 17]}], "new_text": "Two <START=Amino Acid, Peptide, or Protein> sodium - dependent vitamin C transporter <END=Amino Acid, Peptide, or Protein> <START=Amino Acid, Peptide, or Protein> isoforms <END=Amino Acid, Peptide, or Protein> ( <START=Gene or Genome> SVCT1 <END=Gene or Genome> and SVCT2 ) were identified as ascorbic acid transporters, but their roles in skin have, as yet, not been elucidated."}, {"PMID": 17664139, "id": 4, "text": "Uptake experiments revealed that ascorbic acid affinity of SVCT1 was lower than SVCT2 (K(m)=75 muM and K(m)=44 muM, respectively), but maximal velocity was 9-times higher (36 nmol/min/well).", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [33, 46], "name": "ascorbic acid", "tok_span": [5, 8], "new_tok_span": [6, 9]}, {"ent_type": "GENE", "char_span": [59, 64], "name": "SVCT1", "tok_span": [10, 13], "new_tok_span": [13, 16]}, {"ent_type": "GENE", "char_span": [80, 85], "name": "SVCT2", "tok_span": [16, 19], "new_tok_span": [21, 24]}], "relation_list": [{"subject": "ascorbic acid", "sbj_char_span": [33, 46], "object": "SVCT1", "obj_char_span": [59, 64], "rel_type": "regulator", "sbj_tok_span": [5, 8], "obj_tok_span": [10, 13], "new_sbj_tok_span": [6, 9], "new_obj_tok_span": [13, 16]}], "umls_entity_list": [{"mention": "ascorbic acid", "char_span": [33, 46], "sem_type": "Pharmacologic Substance", "tok_span": [5, 8], "new_tok_span": [6, 9]}, {"mention": "SVCT1", "char_span": [59, 64], "sem_type": "Gene or Genome", "tok_span": [10, 13], "new_tok_span": [13, 16]}, {"mention": "SVCT2", "char_span": [80, 85], "sem_type": "Gene or Genome", "tok_span": [16, 19], "new_tok_span": [21, 24]}], "new_text": "Uptake experiments revealed that <START=Pharmacologic Substance> ascorbic acid <END=Pharmacologic Substance> affinity of <START=Gene or Genome> SVCT1 <END=Gene or Genome> was lower than <START=Gene or Genome> SVCT2 <END=Gene or Genome> ( K ( m ) = 75 muM and K ( m ) = 44 muM, respectively ), but maximal velocity was 9 - times higher ( 36 nmol / min / well )."}, {"PMID": 23220742, "id": 0, "text": "The selective SYK inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [137, 148], "name": "fludarabine", "tok_span": [34, 38], "new_tok_span": [39, 43]}, {"ent_type": "CHEMICAL", "char_span": [28, 35], "name": "P505-15", "tok_span": [5, 10], "new_tok_span": [6, 11]}, {"ent_type": "CHEMICAL", "char_span": [37, 46], "name": "PRT062607", "tok_span": [11, 16], "new_tok_span": [14, 19]}, {"ent_type": "GENE", "char_span": [14, 17], "name": "SYK", "tok_span": [2, 4], "new_tok_span": [2, 4]}], "relation_list": [{"subject": "P505-15", "sbj_char_span": [28, 35], "object": "SYK", "obj_char_span": [14, 17], "rel_type": "inhibitor", "sbj_tok_span": [5, 10], "obj_tok_span": [2, 4], "new_sbj_tok_span": [6, 11], "new_obj_tok_span": [2, 4]}, {"subject": "PRT062607", "sbj_char_span": [37, 46], "object": "SYK", "obj_char_span": [14, 17], "rel_type": "inhibitor", "sbj_tok_span": [11, 16], "obj_tok_span": [2, 4], "new_sbj_tok_span": [14, 19], "new_obj_tok_span": [2, 4]}], "umls_entity_list": [{"mention": "P505-15", "char_span": [28, 35], "sem_type": "Pharmacologic Substance", "tok_span": [5, 10], "new_tok_span": [6, 11]}, {"mention": "PRT062607", "char_span": [37, 46], "sem_type": "Pharmacologic Substance", "tok_span": [11, 16], "new_tok_span": [14, 19]}, {"mention": "fludarabine", "char_span": [137, 148], "sem_type": "Pharmacologic Substance", "tok_span": [34, 38], "new_tok_span": [39, 43]}], "new_text": "The selective SYK inhibitor <START=Pharmacologic Substance> P505 - 15 <END=Pharmacologic Substance> ( <START=Pharmacologic Substance> PRT062607 <END=Pharmacologic Substance> ) inhibits B cell signaling and function in vitro and in vivo and augments the activity of <START=Pharmacologic Substance> fludarabine <END=Pharmacologic Substance> in chronic lymphocytic leukemia."}, {"PMID": 20083608, "id": 3, "text": "Cyan fluorescent protein was fused to the C terminus of the M(2) muscarinic receptor, and a specific binding sequence for the small fluorescent compound fluorescein arsenical hairpin binder, FlAsH, was inserted into the third intracellular loop; the latter site was labeled in intact cells by incubation with FlAsH.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [42, 43], "name": "C", "tok_span": [8, 9], "new_tok_span": [12, 13]}, {"ent_type": "CHEMICAL", "char_span": [153, 164], "name": "fluorescein", "tok_span": [31, 32], "new_tok_span": [40, 41]}, {"ent_type": "GENE", "char_span": [60, 84], "name": "M(2) muscarinic receptor", "tok_span": [12, 20], "new_tok_span": [16, 24]}], "relation_list": [{"subject": "C", "sbj_char_span": [42, 43], "object": "M(2) muscarinic receptor", "obj_char_span": [60, 84], "rel_type": "part of", "sbj_tok_span": [8, 9], "obj_tok_span": [12, 20], "new_sbj_tok_span": [12, 13], "new_obj_tok_span": [16, 24]}, {"subject": "fluorescein", "sbj_char_span": [153, 164], "object": "M(2) muscarinic receptor", "obj_char_span": [60, 84], "rel_type": "regulator", "sbj_tok_span": [31, 32], "obj_tok_span": [12, 20], "new_sbj_tok_span": [40, 41], "new_obj_tok_span": [16, 24]}], "umls_entity_list": [{"mention": "Cyan", "char_span": [0, 4], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [0, 2], "new_tok_span": [1, 3]}, {"mention": "muscarinic receptor", "char_span": [65, 84], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [16, 20], "new_tok_span": [21, 25]}, {"mention": "fluorescent", "char_span": [5, 16], "sem_type": "Organic Chemical", "tok_span": [2, 3], "new_tok_span": [5, 6]}, {"mention": "fluorescent", "char_span": [132, 143], "sem_type": "Organic Chemical", "tok_span": [29, 30], "new_tok_span": [36, 37]}, {"mention": "fluorescein", "char_span": [153, 164], "sem_type": "Pharmacologic Substance", "tok_span": [31, 32], "new_tok_span": [40, 41]}, {"mention": "FlAsH", "char_span": [191, 196], "sem_type": "Gene or Genome", "tok_span": [39, 42], "new_tok_span": [50, 53]}, {"mention": "FlAsH", "char_span": [309, 314], "sem_type": "Gene or Genome", "tok_span": [62, 65], "new_tok_span": [75, 78]}], "new_text": "<START=Amino Acid, Peptide, or Protein> Cyan <END=Amino Acid, Peptide, or Protein> <START=Organic Chemical> fluorescent <END=Organic Chemical> protein was fused to the C terminus of the M ( 2 ) <START=Amino Acid, Peptide, or Protein> muscarinic receptor <END=Amino Acid, Peptide, or Protein>, and a specific binding sequence for the small <START=Organic Chemical> fluorescent <END=Organic Chemical> compound <START=Pharmacologic Substance> fluorescein <END=Pharmacologic Substance> arsenical hairpin binder, <START=Gene or Genome> FlAsH <END=Gene or Genome>, was inserted into the third intracellular loop ; the latter site was labeled in intact cells by incubation with <START=Gene or Genome> FlAsH <END=Gene or Genome>."}, {"PMID": 15947036, "id": 0, "text": "Evaluation of histamine H1-, H2-, and H3-receptor ligands at the human histamine H4 receptor: identification of 4-methylhistamine as the first potent and selective H4 receptor agonist.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [112, 129], "name": "4-methylhistamine", "tok_span": [27, 32], "new_tok_span": [39, 44]}, {"ent_type": "CHEMICAL", "char_span": [14, 23], "name": "histamine", "tok_span": [2, 3], "new_tok_span": [3, 4]}, {"ent_type": "CHEMICAL", "char_span": [71, 80], "name": "histamine", "tok_span": [20, 21], "new_tok_span": [29, 30]}, {"ent_type": "GENE", "char_span": [14, 49], "name": "histamine H1-, H2-, and H3-receptor", "tok_span": [2, 16], "new_tok_span": [3, 17]}, {"ent_type": "GENE", "char_span": [164, 175], "name": "H4 receptor", "tok_span": [38, 41], "new_tok_span": [55, 58]}, {"ent_type": "GENE", "char_span": [65, 92], "name": "human histamine H4 receptor", "tok_span": [19, 24], "new_tok_span": [27, 32]}], "relation_list": [{"subject": "4-methylhistamine", "sbj_char_span": [112, 129], "object": "H4 receptor", "obj_char_span": [164, 175], "rel_type": "agonist or antagonist", "sbj_tok_span": [27, 32], "obj_tok_span": [38, 41], "new_sbj_tok_span": [39, 44], "new_obj_tok_span": [55, 58]}], "umls_entity_list": [{"mention": "histamine", "char_span": [14, 23], "sem_type": "Organic Chemical", "tok_span": [2, 3], "new_tok_span": [3, 4]}, {"mention": "histamine", "char_span": [71, 80], "sem_type": "Organic Chemical", "tok_span": [20, 21], "new_tok_span": [29, 30]}, {"mention": "histamine", "char_span": [120, 129], "sem_type": "Organic Chemical", "tok_span": [30, 32], "new_tok_span": [44, 46]}, {"mention": "H1", "char_span": [24, 26], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [3, 5], "new_tok_span": [7, 9]}, {"mention": "H1", "char_span": [24, 26], "sem_type": "Gene or Genome", "tok_span": [3, 5], "new_tok_span": [7, 9]}, {"mention": "H2", "char_span": [29, 31], "sem_type": "Gene or Genome", "tok_span": [7, 9], "new_tok_span": [14, 16]}, {"mention": "methylhistamine", "char_span": [114, 129], "sem_type": "Organic Chemical", "tok_span": [29, 32], "new_tok_span": [42, 45]}, {"mention": "H4", "char_span": [81, 83], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [21, 23], "new_tok_span": [32, 34]}, {"mention": "H4", "char_span": [164, 166], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [38, 40], "new_tok_span": [55, 57]}, {"mention": "receptor agonist", "char_span": [167, 183], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [40, 42], "new_tok_span": [59, 61]}], "new_text": "Evaluation of <START=Organic Chemical> histamine <END=Organic Chemical> <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> H1 <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> -, <START=Gene or Genome> H2 <END=Gene or Genome> -, and H3 - receptor ligands at the human <START=Organic Chemical> histamine <END=Organic Chemical> <START=Amino Acid, Peptide, or Protein> H4 <END=Amino Acid, Peptide, or Protein> receptor : identification of 4 - <START=Organic Chemical> methyl <START=Organic Chemical>histamine <END=Organic Chemical> <END=Organic Chemical> as the first potent and selective <START=Amino Acid, Peptide, or Protein> H4 <END=Amino Acid, Peptide, or Protein> <START=Amino Acid, Peptide, or Protein> receptor agonist <END=Amino Acid, Peptide, or Protein>."}, {"PMID": 22841397, "id": 8, "text": "Consistent with these effects, glucose tolerance improved, and glucose-stimulated serum insulin levels increased in biotin-supplemented mice, without changes in fasting glucose levels or insulin tolerance.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [31, 38], "name": "glucose", "tok_span": [5, 6], "new_tok_span": [6, 7]}, {"ent_type": "CHEMICAL", "char_span": [63, 70], "name": "glucose", "tok_span": [10, 11], "new_tok_span": [13, 14]}, {"ent_type": "CHEMICAL", "char_span": [116, 122], "name": "biotin", "tok_span": [18, 19], "new_tok_span": [22, 23]}, {"ent_type": "CHEMICAL", "char_span": [169, 176], "name": "glucose", "tok_span": [27, 28], "new_tok_span": [32, 33]}, {"ent_type": "GENE", "char_span": [88, 95], "name": "insulin", "tok_span": [14, 15], "new_tok_span": [18, 19]}, {"ent_type": "GENE", "char_span": [187, 194], "name": "insulin", "tok_span": [30, 31], "new_tok_span": [36, 37]}], "relation_list": [{"subject": "glucose", "sbj_char_span": [63, 70], "object": "insulin", "obj_char_span": [88, 95], "rel_type": "regulator", "sbj_tok_span": [10, 11], "obj_tok_span": [14, 15], "new_sbj_tok_span": [13, 14], "new_obj_tok_span": [18, 19]}, {"subject": "biotin", "sbj_char_span": [116, 122], "object": "insulin", "obj_char_span": [88, 95], "rel_type": "regulator", "sbj_tok_span": [18, 19], "obj_tok_span": [14, 15], "new_sbj_tok_span": [22, 23], "new_obj_tok_span": [18, 19]}], "umls_entity_list": [{"mention": "glucose", "char_span": [31, 38], "sem_type": "Pharmacologic Substance", "tok_span": [5, 6], "new_tok_span": [6, 7]}, {"mention": "glucose", "char_span": [63, 70], "sem_type": "Pharmacologic Substance", "tok_span": [10, 11], "new_tok_span": [13, 14]}, {"mention": "glucose", "char_span": [169, 176], "sem_type": "Pharmacologic Substance", "tok_span": [27, 28], "new_tok_span": [32, 33]}], "new_text": "Consistent with these effects, <START=Pharmacologic Substance> glucose <END=Pharmacologic Substance> tolerance improved, and <START=Pharmacologic Substance> glucose <END=Pharmacologic Substance> - stimulated serum insulin levels increased in biotin - supplemented mice, without changes in fasting <START=Pharmacologic Substance> glucose <END=Pharmacologic Substance> levels or insulin tolerance."}, {"PMID": 1744096, "id": 3, "text": "When added to crude tissue homogenates, Me-Cbl stimulates methionine synthase but similar stimulation is observed with hydroxocobalamin, cyanocobalamin (CN-Cbl), and adenosyl-Cbl, although the mechanisms involved are unknown.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [40, 46], "name": "Me-Cbl", "tok_span": [8, 12], "new_tok_span": [8, 12]}, {"ent_type": "CHEMICAL", "char_span": [58, 68], "name": "methionine", "tok_span": [13, 14], "new_tok_span": [15, 16]}, {"ent_type": "CHEMICAL", "char_span": [119, 135], "name": "hydroxocobalamin", "tok_span": [21, 25], "new_tok_span": [24, 28]}, {"ent_type": "CHEMICAL", "char_span": [137, 151], "name": "cyanocobalamin", "tok_span": [26, 30], "new_tok_span": [31, 35]}, {"ent_type": "CHEMICAL", "char_span": [153, 159], "name": "CN-Cbl", "tok_span": [31, 35], "new_tok_span": [37, 41]}, {"ent_type": "CHEMICAL", "char_span": [166, 178], "name": "adenosyl-Cbl", "tok_span": [38, 43], "new_tok_span": [46, 51]}, {"ent_type": "GENE", "char_span": [58, 77], "name": "methionine synthase", "tok_span": [13, 15], "new_tok_span": [15, 17]}], "relation_list": [{"subject": "Me-Cbl", "sbj_char_span": [40, 46], "object": "methionine synthase", "obj_char_span": [58, 77], "rel_type": "activator", "sbj_tok_span": [8, 12], "obj_tok_span": [13, 15], "new_sbj_tok_span": [8, 12], "new_obj_tok_span": [15, 17]}, {"subject": "hydroxocobalamin", "sbj_char_span": [119, 135], "object": "methionine synthase", "obj_char_span": [58, 77], "rel_type": "activator", "sbj_tok_span": [21, 25], "obj_tok_span": [13, 15], "new_sbj_tok_span": [24, 28], "new_obj_tok_span": [15, 17]}, {"subject": "cyanocobalamin", "sbj_char_span": [137, 151], "object": "methionine synthase", "obj_char_span": [58, 77], "rel_type": "activator", "sbj_tok_span": [26, 30], "obj_tok_span": [13, 15], "new_sbj_tok_span": [31, 35], "new_obj_tok_span": [15, 17]}, {"subject": "CN-Cbl", "sbj_char_span": [153, 159], "object": "methionine synthase", "obj_char_span": [58, 77], "rel_type": "activator", "sbj_tok_span": [31, 35], "obj_tok_span": [13, 15], "new_sbj_tok_span": [37, 41], "new_obj_tok_span": [15, 17]}, {"subject": "adenosyl-Cbl", "sbj_char_span": [166, 178], "object": "methionine synthase", "obj_char_span": [58, 77], "rel_type": "activator", "sbj_tok_span": [38, 43], "obj_tok_span": [13, 15], "new_sbj_tok_span": [46, 51], "new_obj_tok_span": [15, 17]}], "umls_entity_list": [{"mention": "hydroxocobalamin", "char_span": [119, 135], "sem_type": "Pharmacologic Substance", "tok_span": [21, 25], "new_tok_span": [24, 28]}, {"mention": "cyanocobalamin", "char_span": [137, 151], "sem_type": "Pharmacologic Substance", "tok_span": [26, 30], "new_tok_span": [31, 35]}, {"mention": "Cbl", "char_span": [43, 46], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [10, 12], "new_tok_span": [11, 13]}, {"mention": "Cbl", "char_span": [156, 159], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [33, 35], "new_tok_span": [40, 42]}, {"mention": "Cbl", "char_span": [175, 178], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [41, 43], "new_tok_span": [50, 52]}], "new_text": "When added to crude tissue homogenates, Me - <START=Amino Acid, Peptide, or Protein> Cbl <END=Amino Acid, Peptide, or Protein> stimulates methionine synthase but similar stimulation is observed with <START=Pharmacologic Substance> hydroxocobalamin <END=Pharmacologic Substance>, <START=Pharmacologic Substance> cyanocobalamin <END=Pharmacologic Substance> ( CN - <START=Amino Acid, Peptide, or Protein> Cbl <END=Amino Acid, Peptide, or Protein> ), and adenosyl - <START=Amino Acid, Peptide, or Protein> Cbl <END=Amino Acid, Peptide, or Protein>, although the mechanisms involved are unknown."}, {"PMID": 9581512, "id": 5, "text": "Interaction with calmodulin may contribute to the inhibition of MLCK and CDPK by piceatannol.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [81, 92], "name": "piceatannol", "tok_span": [17, 22], "new_tok_span": [20, 25]}, {"ent_type": "GENE", "char_span": [64, 68], "name": "MLCK", "tok_span": [11, 13], "new_tok_span": [13, 15]}, {"ent_type": "GENE", "char_span": [73, 77], "name": "CDPK", "tok_span": [14, 16], "new_tok_span": [16, 18]}, {"ent_type": "GENE", "char_span": [17, 27], "name": "calmodulin", "tok_span": [2, 5], "new_tok_span": [3, 6]}], "relation_list": [{"subject": "piceatannol", "sbj_char_span": [81, 92], "object": "MLCK", "obj_char_span": [64, 68], "rel_type": "inhibitor", "sbj_tok_span": [17, 22], "obj_tok_span": [11, 13], "new_sbj_tok_span": [20, 25], "new_obj_tok_span": [13, 15]}, {"subject": "piceatannol", "sbj_char_span": [81, 92], "object": "CDPK", "obj_char_span": [73, 77], "rel_type": "inhibitor", "sbj_tok_span": [17, 22], "obj_tok_span": [14, 16], "new_sbj_tok_span": [20, 25], "new_obj_tok_span": [16, 18]}], "umls_entity_list": [{"mention": "calmodulin", "char_span": [17, 27], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [2, 5], "new_tok_span": [3, 6]}, {"mention": "piceatannol", "char_span": [81, 92], "sem_type": "Pharmacologic Substance", "tok_span": [17, 22], "new_tok_span": [20, 25]}], "new_text": "Interaction with <START=Amino Acid, Peptide, or Protein> calmodulin <END=Amino Acid, Peptide, or Protein> may contribute to the inhibition of MLCK and CDPK by <START=Pharmacologic Substance> piceatannol <END=Pharmacologic Substance>."}, {"PMID": 16876889, "id": 1, "text": "Serine hydroxymethyltransferase (SHMT) catalyses the reversible conversion of serine and tetrahydrofolate to glycine and methylene-tetrahydrofolate.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 6], "name": "Serine", "tok_span": [0, 2], "new_tok_span": [1, 3]}, {"ent_type": "CHEMICAL", "char_span": [109, 116], "name": "glycine", "tok_span": [22, 23], "new_tok_span": [27, 28]}, {"ent_type": "CHEMICAL", "char_span": [121, 147], "name": "methylene-tetrahydrofolate", "tok_span": [24, 31], "new_tok_span": [31, 38]}, {"ent_type": "CHEMICAL", "char_span": [78, 84], "name": "serine", "tok_span": [15, 16], "new_tok_span": [17, 18]}, {"ent_type": "CHEMICAL", "char_span": [89, 105], "name": "tetrahydrofolate", "tok_span": [17, 21], "new_tok_span": [20, 24]}, {"ent_type": "GENE", "char_span": [0, 31], "name": "Serine hydroxymethyltransferase", "tok_span": [0, 5], "new_tok_span": [1, 6]}, {"ent_type": "GENE", "char_span": [33, 37], "name": "SHMT", "tok_span": [6, 8], "new_tok_span": [8, 10]}], "relation_list": [{"subject": "serine", "sbj_char_span": [78, 84], "object": "Serine hydroxymethyltransferase", "obj_char_span": [0, 31], "rel_type": "product or substrate", "sbj_tok_span": [15, 16], "obj_tok_span": [0, 5], "new_sbj_tok_span": [17, 18], "new_obj_tok_span": [1, 6]}, {"subject": "tetrahydrofolate", "sbj_char_span": [89, 105], "object": "Serine hydroxymethyltransferase", "obj_char_span": [0, 31], "rel_type": "product or substrate", "sbj_tok_span": [17, 21], "obj_tok_span": [0, 5], "new_sbj_tok_span": [20, 24], "new_obj_tok_span": [1, 6]}, {"subject": "glycine", "sbj_char_span": [109, 116], "object": "Serine hydroxymethyltransferase", "obj_char_span": [0, 31], "rel_type": "product or substrate", "sbj_tok_span": [22, 23], "obj_tok_span": [0, 5], "new_sbj_tok_span": [27, 28], "new_obj_tok_span": [1, 6]}, {"subject": "methylene-tetrahydrofolate", "sbj_char_span": [121, 147], "object": "Serine hydroxymethyltransferase", "obj_char_span": [0, 31], "rel_type": "product or substrate", "sbj_tok_span": [24, 31], "obj_tok_span": [0, 5], "new_sbj_tok_span": [31, 38], "new_obj_tok_span": [1, 6]}, {"subject": "serine", "sbj_char_span": [78, 84], "object": "SHMT", "obj_char_span": [33, 37], "rel_type": "product or substrate", "sbj_tok_span": [15, 16], "obj_tok_span": [6, 8], "new_sbj_tok_span": [17, 18], "new_obj_tok_span": [8, 10]}, {"subject": "tetrahydrofolate", "sbj_char_span": [89, 105], "object": "SHMT", "obj_char_span": [33, 37], "rel_type": "product or substrate", "sbj_tok_span": [17, 21], "obj_tok_span": [6, 8], "new_sbj_tok_span": [20, 24], "new_obj_tok_span": [8, 10]}, {"subject": "glycine", "sbj_char_span": [109, 116], "object": "SHMT", "obj_char_span": [33, 37], "rel_type": "product or substrate", "sbj_tok_span": [22, 23], "obj_tok_span": [6, 8], "new_sbj_tok_span": [27, 28], "new_obj_tok_span": [8, 10]}, {"subject": "methylene-tetrahydrofolate", "sbj_char_span": [121, 147], "object": "SHMT", "obj_char_span": [33, 37], "rel_type": "product or substrate", "sbj_tok_span": [24, 31], "obj_tok_span": [6, 8], "new_sbj_tok_span": [31, 38], "new_obj_tok_span": [8, 10]}], "umls_entity_list": [{"mention": "Serine hydroxymethyltransferase", "char_span": [0, 31], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [0, 5], "new_tok_span": [1, 6]}, {"mention": "tetrahydrofolate", "char_span": [89, 105], "sem_type": "Pharmacologic Substance", "tok_span": [17, 21], "new_tok_span": [20, 24]}, {"mention": "tetrahydrofolate", "char_span": [131, 147], "sem_type": "Pharmacologic Substance", "tok_span": [27, 31], "new_tok_span": [36, 40]}, {"mention": "glycine", "char_span": [109, 116], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [22, 23], "new_tok_span": [27, 28]}, {"mention": "methylene", "char_span": [121, 130], "sem_type": "Pharmacologic Substance", "tok_span": [24, 26], "new_tok_span": [31, 33]}], "new_text": "<START=Amino Acid, Peptide, or Protein> Serine hydroxymethyltransferase <END=Amino Acid, Peptide, or Protein> ( SHMT ) catalyses the reversible conversion of serine and <START=Pharmacologic Substance> tetrahydrofolate <END=Pharmacologic Substance> to <START=Amino Acid, Peptide, or Protein> glycine <END=Amino Acid, Peptide, or Protein> and <START=Pharmacologic Substance> methylene <END=Pharmacologic Substance> - <START=Pharmacologic Substance> tetrahydrofolate <END=Pharmacologic Substance>."}, {"PMID": 19427182, "id": 9, "text": "These results strongly suggest that ABCA1 is substantially involved in hepatic alpha-tocopherol secretion.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [79, 95], "name": "alpha-tocopherol", "tok_span": [13, 19], "new_tok_span": [13, 19]}, {"ent_type": "GENE", "char_span": [36, 41], "name": "ABCA1", "tok_span": [5, 8], "new_tok_span": [5, 8]}], "relation_list": [{"subject": "alpha-tocopherol", "sbj_char_span": [79, 95], "object": "ABCA1", "obj_char_span": [36, 41], "rel_type": "product or substrate", "sbj_tok_span": [13, 19], "obj_tok_span": [5, 8], "new_sbj_tok_span": [13, 19], "new_obj_tok_span": [5, 8]}], "umls_entity_list": [], "new_text": "These results strongly suggest that ABCA1 is substantially involved in hepatic alpha - tocopherol secretion."}, {"PMID": 23474389, "id": 3, "text": "Active compounds, such as the nitrobenzyl analogue 6c, were found to exhibit sub-micromolar IC50 values in Bcl-2 expressing human cancer cell lines.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [30, 41], "name": "nitrobenzyl", "tok_span": [6, 9], "new_tok_span": [6, 9]}, {"ent_type": "GENE", "char_span": [107, 112], "name": "Bcl-2", "tok_span": [25, 28], "new_tok_span": [25, 28]}], "relation_list": [{"subject": "nitrobenzyl", "sbj_char_span": [30, 41], "object": "Bcl-2", "obj_char_span": [107, 112], "rel_type": "inhibitor", "sbj_tok_span": [6, 9], "obj_tok_span": [25, 28], "new_sbj_tok_span": [6, 9], "new_obj_tok_span": [25, 28]}], "umls_entity_list": [], "new_text": "Active compounds, such as the nitrobenzyl analogue 6c, were found to exhibit sub - micromolar IC50 values in Bcl - 2 expressing human cancer cell lines."}, {"PMID": 23435915, "id": 7, "text": "Genistin decreased myosin light chain kinase (MLCK) protein contents and MLCK mRNA expression in IJS, and inhibited both phosphorylation and Mg(2+)-ATPase activity of purified myosin, implicating that the decrease of MLCK contents and inhibition of MLCK activity are involved in the genistin-induced inhibitory effects.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 8], "name": "Genistin", "tok_span": [0, 3], "new_tok_span": [1, 4]}, {"ent_type": "CHEMICAL", "char_span": [141, 147], "name": "Mg(2+)", "tok_span": [28, 33], "new_tok_span": [40, 45]}, {"ent_type": "CHEMICAL", "char_span": [283, 291], "name": "genistin", "tok_span": [59, 62], "new_tok_span": [74, 77]}, {"ent_type": "GENE", "char_span": [19, 44], "name": "myosin light chain kinase", "tok_span": [4, 8], "new_tok_span": [10, 14]}, {"ent_type": "GENE", "char_span": [46, 50], "name": "MLCK", "tok_span": [9, 11], "new_tok_span": [19, 21]}, {"ent_type": "GENE", "char_span": [73, 77], "name": "MLCK", "tok_span": [15, 17], "new_tok_span": [27, 29]}, {"ent_type": "GENE", "char_span": [148, 154], "name": "ATPase", "tok_span": [34, 35], "new_tok_span": [46, 47]}, {"ent_type": "GENE", "char_span": [217, 221], "name": "MLCK", "tok_span": [46, 48], "new_tok_span": [60, 62]}, {"ent_type": "GENE", "char_span": [249, 253], "name": "MLCK", "tok_span": [52, 54], "new_tok_span": [66, 68]}], "relation_list": [{"subject": "Genistin", "sbj_char_span": [0, 8], "object": "myosin light chain kinase", "obj_char_span": [19, 44], "rel_type": "regulator", "sbj_tok_span": [0, 3], "obj_tok_span": [4, 8], "new_sbj_tok_span": [1, 4], "new_obj_tok_span": [10, 14]}, {"subject": "Genistin", "sbj_char_span": [0, 8], "object": "MLCK", "obj_char_span": [46, 50], "rel_type": "regulator", "sbj_tok_span": [0, 3], "obj_tok_span": [9, 11], "new_sbj_tok_span": [1, 4], "new_obj_tok_span": [19, 21]}, {"subject": "Genistin", "sbj_char_span": [0, 8], "object": "MLCK", "obj_char_span": [73, 77], "rel_type": "regulator", "sbj_tok_span": [0, 3], "obj_tok_span": [15, 17], "new_sbj_tok_span": [1, 4], "new_obj_tok_span": [27, 29]}, {"subject": "Genistin", "sbj_char_span": [0, 8], "object": "ATPase", "obj_char_span": [148, 154], "rel_type": "inhibitor", "sbj_tok_span": [0, 3], "obj_tok_span": [34, 35], "new_sbj_tok_span": [1, 4], "new_obj_tok_span": [46, 47]}, {"subject": "genistin", "sbj_char_span": [283, 291], "object": "MLCK", "obj_char_span": [217, 221], "rel_type": "regulator", "sbj_tok_span": [59, 62], "obj_tok_span": [46, 48], "new_sbj_tok_span": [74, 77], "new_obj_tok_span": [60, 62]}, {"subject": "genistin", "sbj_char_span": [283, 291], "object": "MLCK", "obj_char_span": [249, 253], "rel_type": "inhibitor", "sbj_tok_span": [59, 62], "obj_tok_span": [52, 54], "new_sbj_tok_span": [74, 77], "new_obj_tok_span": [66, 68]}], "umls_entity_list": [{"mention": "Genistin", "char_span": [0, 8], "sem_type": "Organic Chemical", "tok_span": [0, 3], "new_tok_span": [1, 4]}, {"mention": "genistin", "char_span": [283, 291], "sem_type": "Organic Chemical", "tok_span": [59, 62], "new_tok_span": [74, 77]}, {"mention": "myosin", "char_span": [19, 25], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [4, 5], "new_tok_span": [10, 11]}, {"mention": "myosin", "char_span": [176, 182], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [38, 39], "new_tok_span": [51, 52]}, {"mention": "protein", "char_span": [52, 59], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [12, 13], "new_tok_span": [23, 24]}, {"mention": "myosin light chain kinase", "char_span": [19, 44], "sem_type": "Gene or Genome", "tok_span": [4, 8], "new_tok_span": [10, 14]}, {"mention": "myosin light chain kinase", "char_span": [19, 44], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [4, 8], "new_tok_span": [10, 14]}, {"mention": "myosin light chain", "char_span": [19, 37], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [4, 7], "new_tok_span": [10, 13]}], "new_text": "<START=Organic Chemical> Genistin <END=Organic Chemical> decreased <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> <START=Amino Acid, Peptide, or Protein> myosin <END=Amino Acid, Peptide, or Protein> light chain <END=Amino Acid, Peptide, or Protein> kinase <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> ( MLCK ) <START=Amino Acid, Peptide, or Protein> protein <END=Amino Acid, Peptide, or Protein> contents and MLCK mRNA expression in IJS, and inhibited both phosphorylation and Mg ( 2 + ) - ATPase activity of purified <START=Amino Acid, Peptide, or Protein> myosin <END=Amino Acid, Peptide, or Protein>, implicating that the decrease of MLCK contents and inhibition of MLCK activity are involved in the <START=Organic Chemical> genistin <END=Organic Chemical> - induced inhibitory effects."}, {"PMID": 23371965, "id": 0, "text": "The inactivation of human CYP2E1 by phenethyl isothiocyanate, a naturally occurring chemopreventive agent, and its oxidative bioactivation.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [36, 60], "name": "phenethyl isothiocyanate", "tok_span": [9, 14], "new_tok_span": [14, 19]}, {"ent_type": "GENE", "char_span": [20, 32], "name": "human CYP2E1", "tok_span": [3, 8], "new_tok_span": [3, 8]}], "relation_list": [{"subject": "phenethyl isothiocyanate", "sbj_char_span": [36, 60], "object": "human CYP2E1", "obj_char_span": [20, 32], "rel_type": "inhibitor", "sbj_tok_span": [9, 14], "obj_tok_span": [3, 8], "new_sbj_tok_span": [14, 19], "new_obj_tok_span": [3, 8]}], "umls_entity_list": [{"mention": "CYP2E1", "char_span": [26, 32], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [4, 8], "new_tok_span": [6, 10]}, {"mention": "CYP2E1", "char_span": [26, 32], "sem_type": "Gene or Genome", "tok_span": [4, 8], "new_tok_span": [6, 10]}, {"mention": "phenethyl isothiocyanate", "char_span": [36, 60], "sem_type": "Pharmacologic Substance", "tok_span": [9, 14], "new_tok_span": [14, 19]}, {"mention": "chemopreventive", "char_span": [84, 99], "sem_type": "Pharmacologic Substance", "tok_span": [18, 21], "new_tok_span": [25, 28]}], "new_text": "The inactivation of human <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> CYP2E1 <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> by <START=Pharmacologic Substance> phenethyl isothiocyanate <END=Pharmacologic Substance>, a naturally occurring <START=Pharmacologic Substance> chemopreventive <END=Pharmacologic Substance> agent, and its oxidative bioactivation."}, {"PMID": 22491023, "id": 1, "text": "Xanthurenic acid (XA), a molecule arising from tryptophan metabolism by transamination of 3-hydroxykynurenine, has recently been identified as an endogenous Group II (mGlu2 and mGlu3) metabotropic glutamate (mGlu) receptor ligand in vitro.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 16], "name": "Xanthurenic acid", "tok_span": [0, 5], "new_tok_span": [1, 6]}, {"ent_type": "CHEMICAL", "char_span": [197, 206], "name": "glutamate", "tok_span": [48, 49], "new_tok_span": [54, 55]}, {"ent_type": "CHEMICAL", "char_span": [47, 57], "name": "tryptophan", "tok_span": [14, 15], "new_tok_span": [16, 17]}, {"ent_type": "CHEMICAL", "char_span": [90, 109], "name": "3-hydroxykynurenine", "tok_span": [20, 27], "new_tok_span": [22, 29]}, {"ent_type": "GENE", "char_span": [167, 172], "name": "mGlu2", "tok_span": [38, 41], "new_tok_span": [41, 44]}, {"ent_type": "GENE", "char_span": [177, 182], "name": "mGlu3", "tok_span": [42, 45], "new_tok_span": [47, 50]}, {"ent_type": "GENE", "char_span": [184, 222], "name": "metabotropic glutamate (mGlu) receptor", "tok_span": [46, 54], "new_tok_span": [52, 60]}], "relation_list": [{"subject": "Xanthurenic acid", "sbj_char_span": [0, 16], "object": "mGlu2", "obj_char_span": [167, 172], "rel_type": "regulator", "sbj_tok_span": [0, 5], "obj_tok_span": [38, 41], "new_sbj_tok_span": [1, 6], "new_obj_tok_span": [41, 44]}, {"subject": "Xanthurenic acid", "sbj_char_span": [0, 16], "object": "mGlu3", "obj_char_span": [177, 182], "rel_type": "regulator", "sbj_tok_span": [0, 5], "obj_tok_span": [42, 45], "new_sbj_tok_span": [1, 6], "new_obj_tok_span": [47, 50]}, {"subject": "Xanthurenic acid", "sbj_char_span": [0, 16], "object": "metabotropic glutamate (mGlu) receptor", "obj_char_span": [184, 222], "rel_type": "regulator", "sbj_tok_span": [0, 5], "obj_tok_span": [46, 54], "new_sbj_tok_span": [1, 6], "new_obj_tok_span": [52, 60]}], "umls_entity_list": [{"mention": "Xanthurenic", "char_span": [0, 11], "sem_type": "Organic Chemical", "tok_span": [0, 4], "new_tok_span": [1, 5]}, {"mention": "mGlu2", "char_span": [167, 172], "sem_type": "Gene or Genome", "tok_span": [38, 41], "new_tok_span": [41, 44]}, {"mention": "mGlu3", "char_span": [177, 182], "sem_type": "Gene or Genome", "tok_span": [42, 45], "new_tok_span": [47, 50]}], "new_text": "<START=Organic Chemical> Xanthurenic <END=Organic Chemical> acid ( XA ), a molecule arising from tryptophan metabolism by transamination of 3 - hydroxykynurenine, has recently been identified as an endogenous Group II ( <START=Gene or Genome> mGlu2 <END=Gene or Genome> and <START=Gene or Genome> mGlu3 <END=Gene or Genome> ) metabotropic glutamate ( mGlu ) receptor ligand in vitro."}, {"PMID": 10529655, "id": 0, "text": "Tamsulosin: assessment of affinityof (3)H-P razosin binding to two alpha-1- adrenoceptor subtypes in the canine aorta.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 10], "name": "Tamsulosin", "tok_span": [0, 4], "new_tok_span": [0, 4]}, {"ent_type": "CHEMICAL", "char_span": [37, 51], "name": "(3)H-P razosin", "tok_span": [9, 18], "new_tok_span": [9, 18]}, {"ent_type": "GENE", "char_span": [67, 88], "name": "alpha-1- adrenoceptor", "tok_span": [21, 28], "new_tok_span": [21, 28]}], "relation_list": [{"subject": "(3)H-P razosin", "sbj_char_span": [37, 51], "object": "alpha-1- adrenoceptor", "obj_char_span": [67, 88], "rel_type": "regulator", "sbj_tok_span": [9, 18], "obj_tok_span": [21, 28], "new_sbj_tok_span": [9, 18], "new_obj_tok_span": [21, 28]}], "umls_entity_list": [], "new_text": "Tamsulosin : assessment of affinityof ( 3 ) H - P razosin binding to two alpha - 1 - adrenoceptor subtypes in the canine aorta."}, {"PMID": 1280065, "id": 10, "text": "Inhibition of binding of both plasminogen and plasmin to gp330 by benzamidine was similar, although EACA inhibited the binding of plasmin to gp330 slightly more than the binding of plasminogen to gp330.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [66, 77], "name": "benzamidine", "tok_span": [14, 17], "new_tok_span": [27, 30]}, {"ent_type": "CHEMICAL", "char_span": [100, 104], "name": "EACA", "tok_span": [21, 23], "new_tok_span": [36, 38]}, {"ent_type": "GENE", "char_span": [30, 41], "name": "plasminogen", "tok_span": [5, 7], "new_tok_span": [8, 10]}, {"ent_type": "GENE", "char_span": [46, 53], "name": "plasmin", "tok_span": [8, 9], "new_tok_span": [15, 16]}, {"ent_type": "GENE", "char_span": [57, 62], "name": "gp330", "tok_span": [10, 13], "new_tok_span": [20, 23]}, {"ent_type": "GENE", "char_span": [130, 137], "name": "plasmin", "tok_span": [27, 28], "new_tok_span": [44, 45]}, {"ent_type": "GENE", "char_span": [141, 146], "name": "gp330", "tok_span": [29, 32], "new_tok_span": [49, 52]}, {"ent_type": "GENE", "char_span": [181, 192], "name": "plasminogen", "tok_span": [38, 40], "new_tok_span": [63, 65]}, {"ent_type": "GENE", "char_span": [196, 201], "name": "gp330", "tok_span": [41, 44], "new_tok_span": [71, 74]}], "relation_list": [{"subject": "benzamidine", "sbj_char_span": [66, 77], "object": "plasminogen", "obj_char_span": [30, 41], "rel_type": "inhibitor", "sbj_tok_span": [14, 17], "obj_tok_span": [5, 7], "new_sbj_tok_span": [27, 30], "new_obj_tok_span": [8, 10]}, {"subject": "benzamidine", "sbj_char_span": [66, 77], "object": "plasmin", "obj_char_span": [46, 53], "rel_type": "inhibitor", "sbj_tok_span": [14, 17], "obj_tok_span": [8, 9], "new_sbj_tok_span": [27, 30], "new_obj_tok_span": [15, 16]}, {"subject": "benzamidine", "sbj_char_span": [66, 77], "object": "gp330", "obj_char_span": [57, 62], "rel_type": "regulator", "sbj_tok_span": [14, 17], "obj_tok_span": [10, 13], "new_sbj_tok_span": [27, 30], "new_obj_tok_span": [20, 23]}, {"subject": "EACA", "sbj_char_span": [100, 104], "object": "plasmin", "obj_char_span": [130, 137], "rel_type": "inhibitor", "sbj_tok_span": [21, 23], "obj_tok_span": [27, 28], "new_sbj_tok_span": [36, 38], "new_obj_tok_span": [44, 45]}, {"subject": "EACA", "sbj_char_span": [100, 104], "object": "gp330", "obj_char_span": [141, 146], "rel_type": "regulator", "sbj_tok_span": [21, 23], "obj_tok_span": [29, 32], "new_sbj_tok_span": [36, 38], "new_obj_tok_span": [49, 52]}, {"subject": "EACA", "sbj_char_span": [100, 104], "object": "plasminogen", "obj_char_span": [181, 192], "rel_type": "inhibitor", "sbj_tok_span": [21, 23], "obj_tok_span": [38, 40], "new_sbj_tok_span": [36, 38], "new_obj_tok_span": [63, 65]}, {"subject": "EACA", "sbj_char_span": [100, 104], "object": "gp330", "obj_char_span": [196, 201], "rel_type": "regulator", "sbj_tok_span": [21, 23], "obj_tok_span": [41, 44], "new_sbj_tok_span": [36, 38], "new_obj_tok_span": [71, 74]}], "umls_entity_list": [{"mention": "plasminogen", "char_span": [30, 41], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [5, 7], "new_tok_span": [8, 10]}, {"mention": "plasminogen", "char_span": [181, 192], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [38, 40], "new_tok_span": [63, 65]}, {"mention": "plasminogen", "char_span": [30, 41], "sem_type": "Gene or Genome", "tok_span": [5, 7], "new_tok_span": [8, 10]}, {"mention": "plasminogen", "char_span": [181, 192], "sem_type": "Gene or Genome", "tok_span": [38, 40], "new_tok_span": [63, 65]}, {"mention": "plasmin", "char_span": [30, 37], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [5, 6], "new_tok_span": [8, 9]}, {"mention": "plasmin", "char_span": [46, 53], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [8, 9], "new_tok_span": [15, 16]}, {"mention": "plasmin", "char_span": [130, 137], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [27, 28], "new_tok_span": [44, 45]}, {"mention": "plasmin", "char_span": [181, 188], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [38, 39], "new_tok_span": [63, 64]}, {"mention": "gp330", "char_span": [57, 62], "sem_type": "Gene or Genome", "tok_span": [10, 13], "new_tok_span": [20, 23]}, {"mention": "gp330", "char_span": [141, 146], "sem_type": "Gene or Genome", "tok_span": [29, 32], "new_tok_span": [49, 52]}, {"mention": "gp330", "char_span": [196, 201], "sem_type": "Gene or Genome", "tok_span": [41, 44], "new_tok_span": [71, 74]}, {"mention": "gp330", "char_span": [57, 62], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [10, 13], "new_tok_span": [20, 23]}, {"mention": "gp330", "char_span": [141, 146], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [29, 32], "new_tok_span": [49, 52]}, {"mention": "gp330", "char_span": [196, 201], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [41, 44], "new_tok_span": [71, 74]}, {"mention": "benzamidine", "char_span": [66, 77], "sem_type": "Pharmacologic Substance", "tok_span": [14, 17], "new_tok_span": [27, 30]}, {"mention": "EACA", "char_span": [100, 104], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [21, 23], "new_tok_span": [36, 38]}], "new_text": "Inhibition of binding of both <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> plasmin <END=Amino Acid, Peptide, or Protein>ogen <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> and <START=Amino Acid, Peptide, or Protein> plasmin <END=Amino Acid, Peptide, or Protein> to <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> gp330 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> by <START=Pharmacologic Substance> benzamidine <END=Pharmacologic Substance> was similar, although <START=Amino Acid, Peptide, or Protein> EACA <END=Amino Acid, Peptide, or Protein> inhibited the binding of <START=Amino Acid, Peptide, or Protein> plasmin <END=Amino Acid, Peptide, or Protein> to <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> gp330 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> slightly more than the binding of <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> plasmin <END=Amino Acid, Peptide, or Protein>ogen <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> to <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> gp330 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein>."}, {"PMID": 11860175, "id": 3, "text": "Mitochondria appear to have a Ca2+-inhibited phosphatase, which dephosphorylates the 18-kDa phosphoprotein.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [30, 34], "name": "Ca2+", "tok_span": [6, 9], "new_tok_span": [6, 9]}, {"ent_type": "GENE", "char_span": [45, 56], "name": "phosphatase", "tok_span": [11, 12], "new_tok_span": [12, 13]}], "relation_list": [{"subject": "Ca2+", "sbj_char_span": [30, 34], "object": "phosphatase", "obj_char_span": [45, 56], "rel_type": "inhibitor", "sbj_tok_span": [6, 9], "obj_tok_span": [11, 12], "new_sbj_tok_span": [6, 9], "new_obj_tok_span": [12, 13]}], "umls_entity_list": [{"mention": "phosphatase", "char_span": [45, 56], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [11, 12], "new_tok_span": [12, 13]}], "new_text": "Mitochondria appear to have a Ca2 + - inhibited <START=Amino Acid, Peptide, or Protein> phosphatase <END=Amino Acid, Peptide, or Protein>, which dephosphorylates the 18 - kDa phosphoprotein."}, {"PMID": 23273517, "id": 4, "text": "Docking of nilotinib and of analogues 2a-c to the binding pocket of Abl and of Kit showed that the lack of shape complementarity in Kit is compensated by the stabilizing effect from its juxtamembrane region.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [11, 20], "name": "nilotinib", "tok_span": [3, 6], "new_tok_span": [4, 7]}, {"ent_type": "GENE", "char_span": [68, 71], "name": "Abl", "tok_span": [18, 20], "new_tok_span": [22, 24]}, {"ent_type": "GENE", "char_span": [79, 82], "name": "Kit", "tok_span": [22, 23], "new_tok_span": [29, 30]}, {"ent_type": "GENE", "char_span": [132, 135], "name": "Kit", "tok_span": [32, 33], "new_tok_span": [41, 42]}], "relation_list": [{"subject": "nilotinib", "sbj_char_span": [11, 20], "object": "Abl", "obj_char_span": [68, 71], "rel_type": "regulator", "sbj_tok_span": [3, 6], "obj_tok_span": [18, 20], "new_sbj_tok_span": [4, 7], "new_obj_tok_span": [22, 24]}, {"subject": "nilotinib", "sbj_char_span": [11, 20], "object": "Kit", "obj_char_span": [79, 82], "rel_type": "regulator", "sbj_tok_span": [3, 6], "obj_tok_span": [22, 23], "new_sbj_tok_span": [4, 7], "new_obj_tok_span": [29, 30]}, {"subject": "nilotinib", "sbj_char_span": [11, 20], "object": "Kit", "obj_char_span": [132, 135], "rel_type": "regulator", "sbj_tok_span": [3, 6], "obj_tok_span": [32, 33], "new_sbj_tok_span": [4, 7], "new_obj_tok_span": [41, 42]}], "umls_entity_list": [{"mention": "nilotinib", "char_span": [11, 20], "sem_type": "Pharmacologic Substance", "tok_span": [3, 6], "new_tok_span": [4, 7]}, {"mention": "Abl", "char_span": [68, 71], "sem_type": "Organic Chemical", "tok_span": [18, 20], "new_tok_span": [22, 24]}, {"mention": "Abl", "char_span": [68, 71], "sem_type": "Gene or Genome", "tok_span": [18, 20], "new_tok_span": [22, 24]}, {"mention": "Kit", "char_span": [79, 82], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [22, 23], "new_tok_span": [29, 30]}, {"mention": "Kit", "char_span": [132, 135], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [32, 33], "new_tok_span": [41, 42]}], "new_text": "Docking of <START=Pharmacologic Substance> nilotinib <END=Pharmacologic Substance> and of analogues 2a - c to the binding pocket of <START=Organic Chemical> <START=Gene or Genome> Abl <END=Organic Chemical> <END=Gene or Genome> and of <START=Amino Acid, Peptide, or Protein> Kit <END=Amino Acid, Peptide, or Protein> showed that the lack of shape complementarity in <START=Amino Acid, Peptide, or Protein> Kit <END=Amino Acid, Peptide, or Protein> is compensated by the stabilizing effect from its juxtamembrane region."}, {"PMID": 7858879, "id": 0, "text": "Role of endogenous endothelin in myocardial and coronary endothelial injury after ischaemia and reperfusion in rats: studies with bosentan, a mixed ETA-ETB antagonist. 1.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [130, 138], "name": "bosentan", "tok_span": [21, 24], "new_tok_span": [24, 27]}, {"ent_type": "GENE", "char_span": [148, 151], "name": "ETA", "tok_span": [27, 29], "new_tok_span": [31, 33]}, {"ent_type": "GENE", "char_span": [152, 155], "name": "ETB", "tok_span": [30, 32], "new_tok_span": [35, 37]}, {"ent_type": "GENE", "char_span": [19, 29], "name": "endothelin", "tok_span": [3, 5], "new_tok_span": [4, 6]}], "relation_list": [{"subject": "bosentan", "sbj_char_span": [130, 138], "object": "ETA", "obj_char_span": [148, 151], "rel_type": "agonist or antagonist", "sbj_tok_span": [21, 24], "obj_tok_span": [27, 29], "new_sbj_tok_span": [24, 27], "new_obj_tok_span": [31, 33]}, {"subject": "bosentan", "sbj_char_span": [130, 138], "object": "ETB", "obj_char_span": [152, 155], "rel_type": "agonist or antagonist", "sbj_tok_span": [21, 24], "obj_tok_span": [30, 32], "new_sbj_tok_span": [24, 27], "new_obj_tok_span": [35, 37]}], "umls_entity_list": [{"mention": "endothelin", "char_span": [19, 29], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [3, 5], "new_tok_span": [4, 6]}, {"mention": "bosentan", "char_span": [130, 138], "sem_type": "Pharmacologic Substance", "tok_span": [21, 24], "new_tok_span": [24, 27]}, {"mention": "ETB", "char_span": [152, 155], "sem_type": "Gene or Genome", "tok_span": [30, 32], "new_tok_span": [35, 37]}], "new_text": "Role of endogenous <START=Amino Acid, Peptide, or Protein> endothelin <END=Amino Acid, Peptide, or Protein> in myocardial and coronary endothelial injury after ischaemia and reperfusion in rats : studies with <START=Pharmacologic Substance> bosentan <END=Pharmacologic Substance>, a mixed ETA - <START=Gene or Genome> ETB <END=Gene or Genome> antagonist. 1."}, {"PMID": 23085085, "id": 1, "text": "Histone deacetylase 3 (Hdac3) is a nuclear enzyme that removes acetyl groups from lysine residues in histones and other proteins to epigenetically regulate gene expression.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [63, 69], "name": "acetyl", "tok_span": [18, 19], "new_tok_span": [24, 25]}, {"ent_type": "CHEMICAL", "char_span": [82, 88], "name": "lysine", "tok_span": [21, 22], "new_tok_span": [28, 29]}, {"ent_type": "GENE", "char_span": [0, 21], "name": "Histone deacetylase 3", "tok_span": [0, 6], "new_tok_span": [3, 9]}, {"ent_type": "GENE", "char_span": [101, 109], "name": "histones", "tok_span": [24, 26], "new_tok_span": [34, 36]}, {"ent_type": "GENE", "char_span": [23, 28], "name": "Hdac3", "tok_span": [7, 11], "new_tok_span": [13, 17]}], "relation_list": [{"subject": "acetyl", "sbj_char_span": [63, 69], "object": "histones", "obj_char_span": [101, 109], "rel_type": "part of", "sbj_tok_span": [18, 19], "obj_tok_span": [24, 26], "new_sbj_tok_span": [24, 25], "new_obj_tok_span": [34, 36]}, {"subject": "lysine", "sbj_char_span": [82, 88], "object": "histones", "obj_char_span": [101, 109], "rel_type": "part of", "sbj_tok_span": [21, 22], "obj_tok_span": [24, 26], "new_sbj_tok_span": [28, 29], "new_obj_tok_span": [34, 36]}], "umls_entity_list": [{"mention": "Histone", "char_span": [0, 7], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [0, 2], "new_tok_span": [3, 5]}, {"mention": "histone", "char_span": [101, 108], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [24, 25], "new_tok_span": [34, 35]}, {"mention": "Histone deacetylase 3", "char_span": [0, 21], "sem_type": "Gene or Genome", "tok_span": [0, 6], "new_tok_span": [3, 9]}, {"mention": "Histone deacetylase 3", "char_span": [0, 21], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [0, 6], "new_tok_span": [3, 9]}, {"mention": "lysine", "char_span": [82, 88], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [21, 22], "new_tok_span": [28, 29]}, {"mention": "histones", "char_span": [101, 109], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [24, 26], "new_tok_span": [34, 36]}], "new_text": "<START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> Histone <END=Amino Acid, Peptide, or Protein> deacetylase 3 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> ( Hdac3 ) is a nuclear enzyme that removes acetyl groups from <START=Amino Acid, Peptide, or Protein> lysine <END=Amino Acid, Peptide, or Protein> residues in <START=Amino Acid, Peptide, or Protein> <START=Amino Acid, Peptide, or Protein> histone <END=Amino Acid, Peptide, or Protein>s <END=Amino Acid, Peptide, or Protein> and other proteins to epigenetically regulate gene expression."}, {"PMID": 23297161, "id": 2, "text": "In the present work, the cynomolgus monkey was evaluated as a potential model for studying OATP-mediated DDIs. Three cynomolgus monkey OATPs (cOATPs), with a high degree of amino acid sequence identity (91.9, 93.5, and 96.6% for OATP1B1, 1B3, and 2B1, respectively) to their human counterparts, were cloned, expressed, and characterized.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [173, 183], "name": "amino acid", "tok_span": [49, 51], "new_tok_span": [63, 65]}, {"ent_type": "GENE", "char_span": [91, 95], "name": "OATP", "tok_span": [20, 22], "new_tok_span": [22, 24]}, {"ent_type": "GENE", "char_span": [117, 140], "name": "cynomolgus monkey OATPs", "tok_span": [28, 37], "new_tok_span": [34, 43]}, {"ent_type": "GENE", "char_span": [142, 148], "name": "cOATPs", "tok_span": [38, 42], "new_tok_span": [48, 52]}, {"ent_type": "GENE", "char_span": [229, 250], "name": "OATP1B1, 1B3, and 2B1", "tok_span": [68, 82], "new_tok_span": [85, 99]}], "relation_list": [{"subject": "amino acid", "sbj_char_span": [173, 183], "object": "cynomolgus monkey OATPs", "obj_char_span": [117, 140], "rel_type": "part of", "sbj_tok_span": [49, 51], "obj_tok_span": [28, 37], "new_sbj_tok_span": [63, 65], "new_obj_tok_span": [34, 43]}, {"subject": "amino acid", "sbj_char_span": [173, 183], "object": "cOATPs", "obj_char_span": [142, 148], "rel_type": "part of", "sbj_tok_span": [49, 51], "obj_tok_span": [38, 42], "new_sbj_tok_span": [63, 65], "new_obj_tok_span": [48, 52]}], "umls_entity_list": [{"mention": "DDI", "char_span": [105, 108], "sem_type": "Pharmacologic Substance", "tok_span": [24, 26], "new_tok_span": [29, 31]}, {"mention": "OATP", "char_span": [91, 95], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [20, 22], "new_tok_span": [22, 24]}, {"mention": "OATP", "char_span": [135, 139], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [34, 36], "new_tok_span": [42, 44]}, {"mention": "OATP", "char_span": [143, 147], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [39, 41], "new_tok_span": [51, 53]}, {"mention": "OATP", "char_span": [229, 233], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [68, 70], "new_tok_span": [85, 87]}, {"mention": "OATP", "char_span": [91, 95], "sem_type": "Gene or Genome", "tok_span": [20, 22], "new_tok_span": [22, 24]}, {"mention": "OATP", "char_span": [135, 139], "sem_type": "Gene or Genome", "tok_span": [34, 36], "new_tok_span": [42, 44]}, {"mention": "OATP", "char_span": [143, 147], "sem_type": "Gene or Genome", "tok_span": [39, 41], "new_tok_span": [51, 53]}, {"mention": "OATP", "char_span": [229, 233], "sem_type": "Gene or Genome", "tok_span": [68, 70], "new_tok_span": [85, 87]}, {"mention": "OATP1B1", "char_span": [229, 236], "sem_type": "Gene or Genome", "tok_span": [68, 73], "new_tok_span": [85, 90]}, {"mention": "2B1", "char_span": [247, 250], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [79, 82], "new_tok_span": [100, 103]}], "new_text": "In the present work, the cynomolgus monkey was evaluated as a potential model for studying <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> OATP <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> - mediated <START=Pharmacologic Substance> DDIs <END=Pharmacologic Substance>. Three cynomolgus monkey <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> OATP <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome>s ( c <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome>OATP <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome>s ), with a high degree of amino acid sequence identity ( 91. 9, 93. 5, and 96. 6 % for <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> <START=Gene or Genome> OATP <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome>1B1 <END=Gene or Genome>, 1B3, and <START=Amino Acid, Peptide, or Protein> 2B1 <END=Amino Acid, Peptide, or Protein>, respectively ) to their human counterparts, were cloned, expressed, and characterized."}, {"PMID": 23430109, "id": 3, "text": "Substitution of the FLT3 \"gatekeeper\" phenylalanine with leucine (F691L) conferred mild resistance to ponatinib, but substitutions at the FLT3 activation loop (AL) residue D835 conferred a high degree of resistance.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [38, 51], "name": "phenylalanine", "tok_span": [12, 14], "new_tok_span": [12, 14]}, {"ent_type": "CHEMICAL", "char_span": [57, 64], "name": "leucine", "tok_span": [15, 16], "new_tok_span": [15, 16]}, {"ent_type": "CHEMICAL", "char_span": [102, 111], "name": "ponatinib", "tok_span": [27, 31], "new_tok_span": [28, 32]}, {"ent_type": "GENE", "char_span": [20, 24], "name": "FLT3", "tok_span": [4, 7], "new_tok_span": [4, 7]}, {"ent_type": "GENE", "char_span": [66, 71], "name": "F691L", "tok_span": [17, 21], "new_tok_span": [17, 21]}, {"ent_type": "GENE", "char_span": [138, 158], "name": "FLT3 activation loop", "tok_span": [36, 41], "new_tok_span": [38, 43]}, {"ent_type": "GENE", "char_span": [160, 162], "name": "AL", "tok_span": [42, 43], "new_tok_span": [44, 45]}], "relation_list": [{"subject": "phenylalanine", "sbj_char_span": [38, 51], "object": "FLT3", "obj_char_span": [20, 24], "rel_type": "part of", "sbj_tok_span": [12, 14], "obj_tok_span": [4, 7], "new_sbj_tok_span": [12, 14], "new_obj_tok_span": [4, 7]}, {"subject": "leucine", "sbj_char_span": [57, 64], "object": "FLT3", "obj_char_span": [20, 24], "rel_type": "part of", "sbj_tok_span": [15, 16], "obj_tok_span": [4, 7], "new_sbj_tok_span": [15, 16], "new_obj_tok_span": [4, 7]}], "umls_entity_list": [{"mention": "ponatinib", "char_span": [102, 111], "sem_type": "Pharmacologic Substance", "tok_span": [27, 31], "new_tok_span": [28, 32]}], "new_text": "Substitution of the FLT3 \" gatekeeper \" phenylalanine with leucine ( F691L ) conferred mild resistance to <START=Pharmacologic Substance> ponatinib <END=Pharmacologic Substance>, but substitutions at the FLT3 activation loop ( AL ) residue D835 conferred a high degree of resistance."}, {"PMID": 23521080, "id": 3, "text": "One exception is tranexamic acid (TXA), which, as a lysine mimetic, inhibits binding of plasminogen to fibrin.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [17, 32], "name": "tranexamic acid", "tok_span": [3, 7], "new_tok_span": [4, 8]}, {"ent_type": "CHEMICAL", "char_span": [34, 37], "name": "TXA", "tok_span": [8, 10], "new_tok_span": [10, 12]}, {"ent_type": "CHEMICAL", "char_span": [52, 58], "name": "lysine", "tok_span": [16, 17], "new_tok_span": [18, 19]}, {"ent_type": "GENE", "char_span": [88, 99], "name": "plasminogen", "tok_span": [24, 26], "new_tok_span": [28, 30]}, {"ent_type": "GENE", "char_span": [103, 109], "name": "fibrin", "tok_span": [27, 28], "new_tok_span": [34, 35]}], "relation_list": [{"subject": "TXA", "sbj_char_span": [34, 37], "object": "plasminogen", "obj_char_span": [88, 99], "rel_type": "inhibitor", "sbj_tok_span": [8, 10], "obj_tok_span": [24, 26], "new_sbj_tok_span": [10, 12], "new_obj_tok_span": [28, 30]}, {"subject": "tranexamic acid", "sbj_char_span": [17, 32], "object": "plasminogen", "obj_char_span": [88, 99], "rel_type": "inhibitor", "sbj_tok_span": [3, 7], "obj_tok_span": [24, 26], "new_sbj_tok_span": [4, 8], "new_obj_tok_span": [28, 30]}, {"subject": "lysine", "sbj_char_span": [52, 58], "object": "plasminogen", "obj_char_span": [88, 99], "rel_type": "inhibitor", "sbj_tok_span": [16, 17], "obj_tok_span": [24, 26], "new_sbj_tok_span": [18, 19], "new_obj_tok_span": [28, 30]}, {"subject": "tranexamic acid", "sbj_char_span": [17, 32], "object": "fibrin", "obj_char_span": [103, 109], "rel_type": "inhibitor", "sbj_tok_span": [3, 7], "obj_tok_span": [27, 28], "new_sbj_tok_span": [4, 8], "new_obj_tok_span": [34, 35]}, {"subject": "TXA", "sbj_char_span": [34, 37], "object": "fibrin", "obj_char_span": [103, 109], "rel_type": "inhibitor", "sbj_tok_span": [8, 10], "obj_tok_span": [27, 28], "new_sbj_tok_span": [10, 12], "new_obj_tok_span": [34, 35]}, {"subject": "lysine", "sbj_char_span": [52, 58], "object": "fibrin", "obj_char_span": [103, 109], "rel_type": "inhibitor", "sbj_tok_span": [16, 17], "obj_tok_span": [27, 28], "new_sbj_tok_span": [18, 19], "new_obj_tok_span": [34, 35]}], "umls_entity_list": [{"mention": "tranexamic acid", "char_span": [17, 32], "sem_type": "Pharmacologic Substance", "tok_span": [3, 7], "new_tok_span": [4, 8]}, {"mention": "plasminogen", "char_span": [88, 99], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [24, 26], "new_tok_span": [28, 30]}, {"mention": "plasminogen", "char_span": [88, 99], "sem_type": "Gene or Genome", "tok_span": [24, 26], "new_tok_span": [28, 30]}, {"mention": "fibrin", "char_span": [103, 109], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [27, 28], "new_tok_span": [34, 35]}], "new_text": "One exception is <START=Pharmacologic Substance> tranexamic acid <END=Pharmacologic Substance> ( TXA ), which, as a lysine mimetic, inhibits binding of <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> plasminogen <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> to <START=Amino Acid, Peptide, or Protein> fibrin <END=Amino Acid, Peptide, or Protein>."}, {"PMID": 23274770, "id": 8, "text": "Thus, mitragynine is a significant in vitro CYP1A2 inducer.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [6, 17], "name": "mitragynine", "tok_span": [2, 6], "new_tok_span": [2, 6]}, {"ent_type": "GENE", "char_span": [44, 50], "name": "CYP1A2", "tok_span": [11, 15], "new_tok_span": [13, 17]}], "relation_list": [{"subject": "mitragynine", "sbj_char_span": [6, 17], "object": "CYP1A2", "obj_char_span": [44, 50], "rel_type": "activator", "sbj_tok_span": [2, 6], "obj_tok_span": [11, 15], "new_sbj_tok_span": [2, 6], "new_obj_tok_span": [13, 17]}], "umls_entity_list": [{"mention": "CYP1A2", "char_span": [44, 50], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [11, 15], "new_tok_span": [13, 17]}, {"mention": "CYP1A2", "char_span": [44, 50], "sem_type": "Gene or Genome", "tok_span": [11, 15], "new_tok_span": [13, 17]}], "new_text": "Thus, mitragynine is a significant in vitro <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> CYP1A2 <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> inducer."}, {"PMID": 16782438, "id": 11, "text": "The concentration of imatinib necessary to inhibit RET in vitro, however, makes it impossible to conclude that imatinib monotherapy will be a good option for systemic therapy of MTC.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [21, 29], "name": "imatinib", "tok_span": [3, 5], "new_tok_span": [4, 6]}, {"ent_type": "CHEMICAL", "char_span": [111, 119], "name": "imatinib", "tok_span": [20, 22], "new_tok_span": [25, 27]}, {"ent_type": "GENE", "char_span": [51, 54], "name": "RET", "tok_span": [8, 9], "new_tok_span": [11, 12]}], "relation_list": [{"subject": "imatinib", "sbj_char_span": [21, 29], "object": "RET", "obj_char_span": [51, 54], "rel_type": "inhibitor", "sbj_tok_span": [3, 5], "obj_tok_span": [8, 9], "new_sbj_tok_span": [4, 6], "new_obj_tok_span": [11, 12]}], "umls_entity_list": [{"mention": "imatinib", "char_span": [21, 29], "sem_type": "Pharmacologic Substance", "tok_span": [3, 5], "new_tok_span": [4, 6]}, {"mention": "imatinib", "char_span": [111, 119], "sem_type": "Pharmacologic Substance", "tok_span": [20, 22], "new_tok_span": [25, 27]}, {"mention": "RET", "char_span": [51, 54], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [8, 9], "new_tok_span": [11, 12]}], "new_text": "The concentration of <START=Pharmacologic Substance> imatinib <END=Pharmacologic Substance> necessary to inhibit <START=Amino Acid, Peptide, or Protein> RET <END=Amino Acid, Peptide, or Protein> in vitro, however, makes it impossible to conclude that <START=Pharmacologic Substance> imatinib <END=Pharmacologic Substance> monotherapy will be a good option for systemic therapy of MTC."}, {"PMID": 23453071, "id": 1, "text": "Previously, we have found that BRN-103, a nicotinamide derivative, inhibits vascular endothelial growth factor (VEGF)-mediated angiogenesis signaling in human endothelial cells.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [31, 38], "name": "BRN-103", "tok_span": [6, 10], "new_tok_span": [7, 11]}, {"ent_type": "CHEMICAL", "char_span": [42, 54], "name": "nicotinamide", "tok_span": [12, 14], "new_tok_span": [15, 17]}, {"ent_type": "GENE", "char_span": [112, 116], "name": "VEGF", "tok_span": [22, 23], "new_tok_span": [26, 27]}, {"ent_type": "GENE", "char_span": [76, 110], "name": "vascular endothelial growth factor", "tok_span": [17, 21], "new_tok_span": [21, 25]}], "relation_list": [{"subject": "BRN-103", "sbj_char_span": [31, 38], "object": "vascular endothelial growth factor", "obj_char_span": [76, 110], "rel_type": "inhibitor", "sbj_tok_span": [6, 10], "obj_tok_span": [17, 21], "new_sbj_tok_span": [7, 11], "new_obj_tok_span": [21, 25]}, {"subject": "BRN-103", "sbj_char_span": [31, 38], "object": "VEGF", "obj_char_span": [112, 116], "rel_type": "inhibitor", "sbj_tok_span": [6, 10], "obj_tok_span": [22, 23], "new_sbj_tok_span": [7, 11], "new_obj_tok_span": [26, 27]}, {"subject": "nicotinamide", "sbj_char_span": [42, 54], "object": "vascular endothelial growth factor", "obj_char_span": [76, 110], "rel_type": "inhibitor", "sbj_tok_span": [12, 14], "obj_tok_span": [17, 21], "new_sbj_tok_span": [15, 17], "new_obj_tok_span": [21, 25]}, {"subject": "nicotinamide", "sbj_char_span": [42, 54], "object": "VEGF", "obj_char_span": [112, 116], "rel_type": "inhibitor", "sbj_tok_span": [12, 14], "obj_tok_span": [22, 23], "new_sbj_tok_span": [15, 17], "new_obj_tok_span": [26, 27]}], "umls_entity_list": [{"mention": "BRN-103", "char_span": [31, 38], "sem_type": "Organic Chemical", "tok_span": [6, 10], "new_tok_span": [7, 11]}, {"mention": "nicotinamide", "char_span": [42, 54], "sem_type": "Pharmacologic Substance", "tok_span": [12, 14], "new_tok_span": [15, 17]}], "new_text": "Previously, we have found that <START=Organic Chemical> BRN - 103 <END=Organic Chemical>, a <START=Pharmacologic Substance> nicotinamide <END=Pharmacologic Substance> derivative, inhibits vascular endothelial growth factor ( VEGF ) - mediated angiogenesis signaling in human endothelial cells."}, {"PMID": 23341458, "id": 6, "text": "Similarly, mature BMP-2 was also cleaved to a truncated peptide within its N-terminal region (Arg(289)↓Lys(290)).", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [75, 76], "name": "N", "tok_span": [15, 16], "new_tok_span": [15, 16]}, {"ent_type": "CHEMICAL", "char_span": [94, 97], "name": "Arg", "tok_span": [20, 21], "new_tok_span": [20, 21]}, {"ent_type": "CHEMICAL", "char_span": [103, 106], "name": "Lys", "tok_span": [26, 27], "new_tok_span": [26, 27]}, {"ent_type": "GENE", "char_span": [18, 23], "name": "BMP-2", "tok_span": [3, 6], "new_tok_span": [3, 6]}], "relation_list": [{"subject": "N", "sbj_char_span": [75, 76], "object": "BMP-2", "obj_char_span": [18, 23], "rel_type": "part of", "sbj_tok_span": [15, 16], "obj_tok_span": [3, 6], "new_sbj_tok_span": [15, 16], "new_obj_tok_span": [3, 6]}, {"subject": "Arg", "sbj_char_span": [94, 97], "object": "BMP-2", "obj_char_span": [18, 23], "rel_type": "part of", "sbj_tok_span": [20, 21], "obj_tok_span": [3, 6], "new_sbj_tok_span": [20, 21], "new_obj_tok_span": [3, 6]}, {"subject": "Lys", "sbj_char_span": [103, 106], "object": "BMP-2", "obj_char_span": [18, 23], "rel_type": "part of", "sbj_tok_span": [26, 27], "obj_tok_span": [3, 6], "new_sbj_tok_span": [26, 27], "new_obj_tok_span": [3, 6]}], "umls_entity_list": [], "new_text": "Similarly, mature BMP - 2 was also cleaved to a truncated peptide within its N - terminal region ( Arg ( 289 ) ↓Lys ( 290 ) )."}, {"PMID": 15353592, "id": 5, "text": "The G protein coupling requires the transmembrane domain of T1R2. Surprisingly, the C-terminal transmembrane domain of T1R3 is required for recognizing sweetener cyclamate and sweet taste inhibitor lactisole.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [84, 85], "name": "C", "tok_span": [17, 18], "new_tok_span": [21, 22]}, {"ent_type": "CHEMICAL", "char_span": [162, 171], "name": "cyclamate", "tok_span": [33, 35], "new_tok_span": [40, 42]}, {"ent_type": "CHEMICAL", "char_span": [198, 207], "name": "lactisole", "tok_span": [39, 42], "new_tok_span": [48, 51]}, {"ent_type": "GENE", "char_span": [4, 13], "name": "G protein", "tok_span": [1, 3], "new_tok_span": [2, 4]}, {"ent_type": "GENE", "char_span": [60, 64], "name": "T1R2", "tok_span": [9, 13], "new_tok_span": [12, 16]}, {"ent_type": "GENE", "char_span": [119, 123], "name": "T1R3", "tok_span": [23, 27], "new_tok_span": [28, 32]}], "relation_list": [{"subject": "C", "sbj_char_span": [84, 85], "object": "T1R3", "obj_char_span": [119, 123], "rel_type": "part of", "sbj_tok_span": [17, 18], "obj_tok_span": [23, 27], "new_sbj_tok_span": [21, 22], "new_obj_tok_span": [28, 32]}], "umls_entity_list": [{"mention": "G protein", "char_span": [4, 13], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [1, 3], "new_tok_span": [2, 4]}, {"mention": "T1R2", "char_span": [60, 64], "sem_type": "Gene or Genome", "tok_span": [9, 13], "new_tok_span": [12, 16]}, {"mention": "T1R3", "char_span": [119, 123], "sem_type": "Gene or Genome", "tok_span": [23, 27], "new_tok_span": [28, 32]}, {"mention": "cyclamate", "char_span": [162, 171], "sem_type": "Organic Chemical", "tok_span": [33, 35], "new_tok_span": [40, 42]}, {"mention": "lactisole", "char_span": [198, 207], "sem_type": "Organic Chemical", "tok_span": [39, 42], "new_tok_span": [48, 51]}], "new_text": "The <START=Amino Acid, Peptide, or Protein> G protein <END=Amino Acid, Peptide, or Protein> coupling requires the transmembrane domain of <START=Gene or Genome> T1R2 <END=Gene or Genome>. Surprisingly, the C - terminal transmembrane domain of <START=Gene or Genome> T1R3 <END=Gene or Genome> is required for recognizing sweetener <START=Organic Chemical> cyclamate <END=Organic Chemical> and sweet taste inhibitor <START=Organic Chemical> lactisole <END=Organic Chemical>."}, {"PMID": 23641955, "id": 2, "text": "In this study, liver and kidney relative activity factors were developed for UGT1A1, 1A9 and 2B7 to allow for in vitro-in vivo extrapolation of intrinsic clearance data to whole organ clearance using recombinant human UGT isoforms applying this to laropiprant as a model substrate. 2.  The total body metabolic clearance of laropiprant determined using this approach (5.0 L/hr) agreed well with the value determined in vivo following intravenous administration to healthy human volunteers (5.1 L/hr). 3.  The results suggest that approximately 36%, 36% and 28% of the hepatic metabolic clearance of laropiprant was mediated by UGT1A1, 1A9 and 2B7, respectively.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [248, 259], "name": "laropiprant", "tok_span": [52, 57], "new_tok_span": [61, 66]}, {"ent_type": "CHEMICAL", "char_span": [324, 335], "name": "laropiprant", "tok_span": [70, 75], "new_tok_span": [81, 86]}, {"ent_type": "CHEMICAL", "char_span": [599, 610], "name": "laropiprant", "tok_span": [132, 137], "new_tok_span": [145, 150]}, {"ent_type": "GENE", "char_span": [77, 96], "name": "UGT1A1, 1A9 and 2B7", "tok_span": [13, 26], "new_tok_span": [16, 29]}, {"ent_type": "GENE", "char_span": [212, 221], "name": "human UGT", "tok_span": [45, 48], "new_tok_span": [51, 54]}, {"ent_type": "GENE", "char_span": [627, 646], "name": "UGT1A1, 1A9 and 2B7", "tok_span": [140, 153], "new_tok_span": [157, 170]}], "relation_list": [{"subject": "laropiprant", "sbj_char_span": [248, 259], "object": "human UGT", "obj_char_span": [212, 221], "rel_type": "product or substrate", "sbj_tok_span": [52, 57], "obj_tok_span": [45, 48], "new_sbj_tok_span": [61, 66], "new_obj_tok_span": [51, 54]}], "umls_entity_list": [{"mention": "UGT1A1", "char_span": [77, 83], "sem_type": "Gene or Genome", "tok_span": [13, 18], "new_tok_span": [16, 21]}, {"mention": "UGT1A1", "char_span": [627, 633], "sem_type": "Gene or Genome", "tok_span": [140, 145], "new_tok_span": [157, 162]}, {"mention": "UGT1A1", "char_span": [77, 83], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [13, 18], "new_tok_span": [16, 21]}, {"mention": "UGT1A1", "char_span": [627, 633], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [140, 145], "new_tok_span": [157, 162]}, {"mention": "UGT", "char_span": [77, 80], "sem_type": "Gene or Genome", "tok_span": [13, 15], "new_tok_span": [16, 18]}, {"mention": "UGT", "char_span": [218, 221], "sem_type": "Gene or Genome", "tok_span": [46, 48], "new_tok_span": [53, 55]}, {"mention": "UGT", "char_span": [627, 630], "sem_type": "Gene or Genome", "tok_span": [140, 142], "new_tok_span": [157, 159]}, {"mention": "laropiprant", "char_span": [248, 259], "sem_type": "Pharmacologic Substance", "tok_span": [52, 57], "new_tok_span": [61, 66]}, {"mention": "laropiprant", "char_span": [324, 335], "sem_type": "Pharmacologic Substance", "tok_span": [70, 75], "new_tok_span": [81, 86]}, {"mention": "laropiprant", "char_span": [599, 610], "sem_type": "Pharmacologic Substance", "tok_span": [132, 137], "new_tok_span": [145, 150]}], "new_text": "In this study, liver and kidney relative activity factors were developed for <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> UGT <END=Gene or Genome>1A1 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein>, 1A9 and 2B7 to allow for in vitro - in vivo extrapolation of intrinsic clearance data to whole organ clearance using recombinant human <START=Gene or Genome> UGT <END=Gene or Genome> isoforms applying this to <START=Pharmacologic Substance> laropiprant <END=Pharmacologic Substance> as a model substrate. 2. The total body metabolic clearance of <START=Pharmacologic Substance> laropiprant <END=Pharmacologic Substance> determined using this approach ( 5. 0 L / hr ) agreed well with the value determined in vivo following intravenous administration to healthy human volunteers ( 5. 1 L / hr ). 3. The results suggest that approximately 36 %, 36 % and 28 % of the hepatic metabolic clearance of <START=Pharmacologic Substance> laropiprant <END=Pharmacologic Substance> was mediated by <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> UGT <END=Gene or Genome>1A1 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein>, 1A9 and 2B7, respectively."}, {"PMID": 15618457, "id": 8, "text": "Isoproterenol rapidly induced phosphorylation of Akt and FKHR in eosinophils in a PI3K-dependent manner.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 13], "name": "Isoproterenol", "tok_span": [0, 4], "new_tok_span": [1, 5]}, {"ent_type": "GENE", "char_span": [49, 52], "name": "Akt", "tok_span": [8, 9], "new_tok_span": [12, 13]}, {"ent_type": "GENE", "char_span": [57, 61], "name": "FKHR", "tok_span": [10, 12], "new_tok_span": [17, 19]}, {"ent_type": "GENE", "char_span": [82, 86], "name": "PI3K", "tok_span": [16, 19], "new_tok_span": [24, 27]}], "relation_list": [{"subject": "Isoproterenol", "sbj_char_span": [0, 13], "object": "Akt", "obj_char_span": [49, 52], "rel_type": "activator", "sbj_tok_span": [0, 4], "obj_tok_span": [8, 9], "new_sbj_tok_span": [1, 5], "new_obj_tok_span": [12, 13]}, {"subject": "Isoproterenol", "sbj_char_span": [0, 13], "object": "FKHR", "obj_char_span": [57, 61], "rel_type": "activator", "sbj_tok_span": [0, 4], "obj_tok_span": [10, 12], "new_sbj_tok_span": [1, 5], "new_obj_tok_span": [17, 19]}, {"subject": "Isoproterenol", "sbj_char_span": [0, 13], "object": "PI3K", "obj_char_span": [82, 86], "rel_type": "activator", "sbj_tok_span": [0, 4], "obj_tok_span": [16, 19], "new_sbj_tok_span": [1, 5], "new_obj_tok_span": [24, 27]}], "umls_entity_list": [{"mention": "Isoproterenol", "char_span": [0, 13], "sem_type": "Pharmacologic Substance", "tok_span": [0, 4], "new_tok_span": [1, 5]}, {"mention": "Akt", "char_span": [49, 52], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [8, 9], "new_tok_span": [12, 13]}, {"mention": "Akt", "char_span": [49, 52], "sem_type": "Gene or Genome", "tok_span": [8, 9], "new_tok_span": [12, 13]}, {"mention": "FKHR", "char_span": [57, 61], "sem_type": "Gene or Genome", "tok_span": [10, 12], "new_tok_span": [17, 19]}], "new_text": "<START=Pharmacologic Substance> Isoproterenol <END=Pharmacologic Substance> rapidly induced phosphorylation of <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> Akt <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> and <START=Gene or Genome> FKHR <END=Gene or Genome> in eosinophils in a PI3K - dependent manner."}, {"PMID": 23077105, "id": 5, "text": "The increase in Mrp3 mRNA by EE was prevented by actinomycin D, indicating transcriptional regulation.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [49, 62], "name": "actinomycin D", "tok_span": [12, 15], "new_tok_span": [15, 18]}, {"ent_type": "GENE", "char_span": [16, 20], "name": "Mrp3", "tok_span": [3, 6], "new_tok_span": [4, 7]}], "relation_list": [{"subject": "actinomycin D", "sbj_char_span": [49, 62], "object": "Mrp3", "obj_char_span": [16, 20], "rel_type": "regulator", "sbj_tok_span": [12, 15], "obj_tok_span": [3, 6], "new_sbj_tok_span": [15, 18], "new_obj_tok_span": [4, 7]}], "umls_entity_list": [{"mention": "Mrp3", "char_span": [16, 20], "sem_type": "Gene or Genome", "tok_span": [3, 6], "new_tok_span": [4, 7]}, {"mention": "actinomycin D", "char_span": [49, 62], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [12, 15], "new_tok_span": [15, 18]}], "new_text": "The increase in <START=Gene or Genome> Mrp3 <END=Gene or Genome> mRNA by EE was prevented by <START=Amino Acid, Peptide, or Protein> actinomycin D <END=Amino Acid, Peptide, or Protein>, indicating transcriptional regulation."}, {"PMID": 23542513, "id": 8, "text": "Taken together, our findings indicate that 5HHMF suppresses NO production through modulation of iNOS, consequently suppressing NF-κB activity and induction of Nrf2-dependent HO-1 activity.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [43, 48], "name": "5HHMF", "tok_span": [7, 10], "new_tok_span": [7, 10]}, {"ent_type": "CHEMICAL", "char_span": [60, 62], "name": "NO", "tok_span": [11, 12], "new_tok_span": [11, 12]}, {"ent_type": "GENE", "char_span": [96, 100], "name": "iNOS", "tok_span": [16, 17], "new_tok_span": [16, 17]}, {"ent_type": "GENE", "char_span": [127, 132], "name": "NF-κB", "tok_span": [20, 24], "new_tok_span": [20, 24]}, {"ent_type": "GENE", "char_span": [159, 163], "name": "Nrf2", "tok_span": [28, 30], "new_tok_span": [30, 32]}, {"ent_type": "GENE", "char_span": [174, 178], "name": "HO-1", "tok_span": [32, 35], "new_tok_span": [36, 39]}], "relation_list": [{"subject": "5HHMF", "sbj_char_span": [43, 48], "object": "NF-κB", "obj_char_span": [127, 132], "rel_type": "inhibitor", "sbj_tok_span": [7, 10], "obj_tok_span": [20, 24], "new_sbj_tok_span": [7, 10], "new_obj_tok_span": [20, 24]}, {"subject": "5HHMF", "sbj_char_span": [43, 48], "object": "HO-1", "obj_char_span": [174, 178], "rel_type": "activator", "sbj_tok_span": [7, 10], "obj_tok_span": [32, 35], "new_sbj_tok_span": [7, 10], "new_obj_tok_span": [36, 39]}, {"subject": "5HHMF", "sbj_char_span": [43, 48], "object": "Nrf2", "obj_char_span": [159, 163], "rel_type": "activator", "sbj_tok_span": [7, 10], "obj_tok_span": [28, 30], "new_sbj_tok_span": [7, 10], "new_obj_tok_span": [30, 32]}], "umls_entity_list": [{"mention": "Nrf2", "char_span": [159, 163], "sem_type": "Gene or Genome", "tok_span": [28, 30], "new_tok_span": [30, 32]}, {"mention": "Nrf2", "char_span": [159, 163], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [28, 30], "new_tok_span": [30, 32]}], "new_text": "Taken together, our findings indicate that 5HHMF suppresses NO production through modulation of iNOS, consequently suppressing NF - κB activity and induction of <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> Nrf2 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> - dependent HO - 1 activity."}, {"PMID": 9398183, "id": 7, "text": "The volume of the butyrylcholinesterase active site gorge is approximately 200 A3 larger than that of the acetylcholinesterase gorge, which allows the accommodation of ethopropazine in two different orientations as demonstrated by rigid-body refinement and molecular dynamics calculations.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [168, 181], "name": "ethopropazine", "tok_span": [37, 40], "new_tok_span": [42, 45]}, {"ent_type": "GENE", "char_span": [18, 39], "name": "butyrylcholinesterase", "tok_span": [4, 10], "new_tok_span": [6, 12]}, {"ent_type": "GENE", "char_span": [106, 126], "name": "acetylcholinesterase", "tok_span": [25, 28], "new_tok_span": [29, 32]}], "relation_list": [{"subject": "ethopropazine", "sbj_char_span": [168, 181], "object": "acetylcholinesterase", "obj_char_span": [106, 126], "rel_type": "regulator", "sbj_tok_span": [37, 40], "obj_tok_span": [25, 28], "new_sbj_tok_span": [42, 45], "new_obj_tok_span": [29, 32]}, {"subject": "ethopropazine", "sbj_char_span": [168, 181], "object": "butyrylcholinesterase", "obj_char_span": [18, 39], "rel_type": "regulator", "sbj_tok_span": [37, 40], "obj_tok_span": [4, 10], "new_sbj_tok_span": [42, 45], "new_obj_tok_span": [6, 12]}], "umls_entity_list": [{"mention": "butyrylcholinesterase", "char_span": [18, 39], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [4, 10], "new_tok_span": [6, 12]}, {"mention": "butyrylcholinesterase", "char_span": [18, 39], "sem_type": "Gene or Genome", "tok_span": [4, 10], "new_tok_span": [6, 12]}, {"mention": "ethopropazine", "char_span": [168, 181], "sem_type": "Pharmacologic Substance", "tok_span": [37, 40], "new_tok_span": [42, 45]}], "new_text": "The volume of the <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> butyrylcholinesterase <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> active site gorge is approximately 200 A3 larger than that of the acetylcholinesterase gorge, which allows the accommodation of <START=Pharmacologic Substance> ethopropazine <END=Pharmacologic Substance> in two different orientations as demonstrated by rigid - body refinement and molecular dynamics calculations."}, {"PMID": 12063169, "id": 8, "text": "These results indicate that hOAT4 mediates the high-affinity transport of OTA on the apical side of the proximal tubule, whereas the transport characteristics of OTA are distinct from those by basolateral OATs.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [74, 77], "name": "OTA", "tok_span": [15, 17], "new_tok_span": [15, 17]}, {"ent_type": "CHEMICAL", "char_span": [162, 165], "name": "OTA", "tok_span": [32, 34], "new_tok_span": [32, 34]}, {"ent_type": "GENE", "char_span": [28, 33], "name": "hOAT4", "tok_span": [4, 8], "new_tok_span": [4, 8]}], "relation_list": [{"subject": "OTA", "sbj_char_span": [74, 77], "object": "hOAT4", "obj_char_span": [28, 33], "rel_type": "product or substrate", "sbj_tok_span": [15, 17], "obj_tok_span": [4, 8], "new_sbj_tok_span": [15, 17], "new_obj_tok_span": [4, 8]}, {"subject": "OTA", "sbj_char_span": [162, 165], "object": "hOAT4", "obj_char_span": [28, 33], "rel_type": "product or substrate", "sbj_tok_span": [32, 34], "obj_tok_span": [4, 8], "new_sbj_tok_span": [32, 34], "new_obj_tok_span": [4, 8]}], "umls_entity_list": [{"mention": "OATs", "char_span": [205, 209], "sem_type": "Pharmacologic Substance", "tok_span": [41, 43], "new_tok_span": [42, 44]}], "new_text": "These results indicate that hOAT4 mediates the high - affinity transport of OTA on the apical side of the proximal tubule, whereas the transport characteristics of OTA are distinct from those by basolateral <START=Pharmacologic Substance> OATs <END=Pharmacologic Substance>."}, {"PMID": 12181427, "id": 4, "text": "Molecular models show that the PDE3 inhibitors cilostazol and milrinone share some of common residues but interact with distinct residues at the active site, suggesting that selective inhibitors can be designed with flexible size against PDE3 active site.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [47, 57], "name": "cilostazol", "tok_span": [8, 12], "new_tok_span": [11, 15]}, {"ent_type": "CHEMICAL", "char_span": [62, 71], "name": "milrinone", "tok_span": [13, 16], "new_tok_span": [17, 20]}, {"ent_type": "GENE", "char_span": [31, 35], "name": "PDE3", "tok_span": [5, 7], "new_tok_span": [6, 8]}, {"ent_type": "GENE", "char_span": [238, 242], "name": "PDE3", "tok_span": [42, 44], "new_tok_span": [46, 48]}], "relation_list": [{"subject": "cilostazol", "sbj_char_span": [47, 57], "object": "PDE3", "obj_char_span": [31, 35], "rel_type": "inhibitor", "sbj_tok_span": [8, 12], "obj_tok_span": [5, 7], "new_sbj_tok_span": [11, 15], "new_obj_tok_span": [6, 8]}, {"subject": "milrinone", "sbj_char_span": [62, 71], "object": "PDE3", "obj_char_span": [31, 35], "rel_type": "inhibitor", "sbj_tok_span": [13, 16], "obj_tok_span": [5, 7], "new_sbj_tok_span": [17, 20], "new_obj_tok_span": [6, 8]}], "umls_entity_list": [{"mention": "PDE3 inhibitors", "char_span": [31, 46], "sem_type": "Pharmacologic Substance", "tok_span": [5, 8], "new_tok_span": [6, 9]}, {"mention": "cilostazol", "char_span": [47, 57], "sem_type": "Pharmacologic Substance", "tok_span": [8, 12], "new_tok_span": [11, 15]}], "new_text": "Molecular models show that the <START=Pharmacologic Substance> PDE3 inhibitors <END=Pharmacologic Substance> <START=Pharmacologic Substance> cilostazol <END=Pharmacologic Substance> and milrinone share some of common residues but interact with distinct residues at the active site, suggesting that selective inhibitors can be designed with flexible size against PDE3 active site."}, {"PMID": 11502876, "id": 0, "text": "A Na(+)/Cl(-)-dependent transporter for catecholamines, identified as a norepinephrine transporter, is expressed in the brain of the teleost fish medaka (Oryzias latipes).", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [2, 7], "name": "Na(+)", "tok_span": [1, 5], "new_tok_span": [1, 5]}, {"ent_type": "CHEMICAL", "char_span": [40, 54], "name": "catecholamines", "tok_span": [14, 16], "new_tok_span": [14, 16]}, {"ent_type": "CHEMICAL", "char_span": [72, 86], "name": "norepinephrine", "tok_span": [20, 21], "new_tok_span": [20, 21]}, {"ent_type": "CHEMICAL", "char_span": [8, 13], "name": "Cl(-)", "tok_span": [6, 10], "new_tok_span": [6, 10]}, {"ent_type": "GENE", "char_span": [2, 35], "name": "Na(+)/Cl(-)-dependent transporter", "tok_span": [1, 13], "new_tok_span": [1, 13]}, {"ent_type": "GENE", "char_span": [72, 98], "name": "norepinephrine transporter", "tok_span": [20, 22], "new_tok_span": [20, 22]}], "relation_list": [{"subject": "catecholamines", "sbj_char_span": [40, 54], "object": "norepinephrine transporter", "obj_char_span": [72, 98], "rel_type": "product or substrate", "sbj_tok_span": [14, 16], "obj_tok_span": [20, 22], "new_sbj_tok_span": [14, 16], "new_obj_tok_span": [20, 22]}, {"subject": "catecholamines", "sbj_char_span": [40, 54], "object": "Na(+)/Cl(-)-dependent transporter", "obj_char_span": [2, 35], "rel_type": "product or substrate", "sbj_tok_span": [14, 16], "obj_tok_span": [1, 13], "new_sbj_tok_span": [14, 16], "new_obj_tok_span": [1, 13]}], "umls_entity_list": [], "new_text": "A Na ( + ) / Cl ( - ) - dependent transporter for catecholamines, identified as a norepinephrine transporter, is expressed in the brain of the teleost fish medaka ( Oryzias latipes )."}, {"PMID": 23636640, "id": 4, "text": "METHODS: After 1 month of HFD alone, the mice were given the DPP4 inhibitor vildagliptin for a further 11 months.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [76, 88], "name": "vildagliptin", "tok_span": [17, 22], "new_tok_span": [18, 23]}, {"ent_type": "GENE", "char_span": [61, 65], "name": "DPP4", "tok_span": [14, 16], "new_tok_span": [14, 16]}], "relation_list": [{"subject": "vildagliptin", "sbj_char_span": [76, 88], "object": "DPP4", "obj_char_span": [61, 65], "rel_type": "inhibitor", "sbj_tok_span": [17, 22], "obj_tok_span": [14, 16], "new_sbj_tok_span": [18, 23], "new_obj_tok_span": [14, 16]}], "umls_entity_list": [{"mention": "vildagliptin", "char_span": [76, 88], "sem_type": "Pharmacologic Substance", "tok_span": [17, 22], "new_tok_span": [18, 23]}], "new_text": "METHODS : After 1 month of HFD alone, the mice were given the DPP4 inhibitor <START=Pharmacologic Substance> vildagliptin <END=Pharmacologic Substance> for a further 11 months."}, {"PMID": 17308037, "id": 7, "text": "Administration of a concentration (100 microM) of dipyridamole that blocks PDE8 inhibited ecto-phosphodiesterase activity (by 44%).", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [50, 62], "name": "dipyridamole", "tok_span": [10, 15], "new_tok_span": [10, 15]}, {"ent_type": "GENE", "char_span": [75, 79], "name": "PDE8", "tok_span": [17, 19], "new_tok_span": [17, 19]}, {"ent_type": "GENE", "char_span": [95, 112], "name": "phosphodiesterase", "tok_span": [23, 27], "new_tok_span": [23, 27]}], "relation_list": [{"subject": "dipyridamole", "sbj_char_span": [50, 62], "object": "PDE8", "obj_char_span": [75, 79], "rel_type": "inhibitor", "sbj_tok_span": [10, 15], "obj_tok_span": [17, 19], "new_sbj_tok_span": [10, 15], "new_obj_tok_span": [17, 19]}, {"subject": "dipyridamole", "sbj_char_span": [50, 62], "object": "phosphodiesterase", "obj_char_span": [95, 112], "rel_type": "inhibitor", "sbj_tok_span": [10, 15], "obj_tok_span": [23, 27], "new_sbj_tok_span": [10, 15], "new_obj_tok_span": [23, 27]}], "umls_entity_list": [], "new_text": "Administration of a concentration ( 100 microM ) of dipyridamole that blocks PDE8 inhibited ecto - phosphodiesterase activity ( by 44 % )."}, {"PMID": 23263989, "id": 3, "text": "AF10 has mostly been studied in the context of the leukemic MLL-AF10 fusion protein, which lacks the N-terminal PHD fingers of AF10.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [101, 102], "name": "N", "tok_span": [24, 25], "new_tok_span": [30, 31]}, {"ent_type": "GENE", "char_span": [0, 4], "name": "AF10", "tok_span": [0, 2], "new_tok_span": [1, 3]}, {"ent_type": "GENE", "char_span": [60, 63], "name": "MLL", "tok_span": [13, 15], "new_tok_span": [16, 18]}, {"ent_type": "GENE", "char_span": [64, 68], "name": "AF10", "tok_span": [16, 18], "new_tok_span": [20, 22]}, {"ent_type": "GENE", "char_span": [101, 123], "name": "N-terminal PHD fingers", "tok_span": [24, 30], "new_tok_span": [30, 36]}, {"ent_type": "GENE", "char_span": [127, 131], "name": "AF10", "tok_span": [31, 33], "new_tok_span": [38, 40]}], "relation_list": [{"subject": "N", "sbj_char_span": [101, 102], "object": "AF10", "obj_char_span": [127, 131], "rel_type": "part of", "sbj_tok_span": [24, 25], "obj_tok_span": [31, 33], "new_sbj_tok_span": [30, 31], "new_obj_tok_span": [38, 40]}], "umls_entity_list": [{"mention": "AF10", "char_span": [0, 4], "sem_type": "Gene or Genome", "tok_span": [0, 2], "new_tok_span": [1, 3]}, {"mention": "AF10", "char_span": [64, 68], "sem_type": "Gene or Genome", "tok_span": [16, 18], "new_tok_span": [20, 22]}, {"mention": "AF10", "char_span": [127, 131], "sem_type": "Gene or Genome", "tok_span": [31, 33], "new_tok_span": [38, 40]}, {"mention": "MLL-AF10 fusion protein", "char_span": [60, 83], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [13, 20], "new_tok_span": [16, 23]}], "new_text": "<START=Gene or Genome> AF10 <END=Gene or Genome> has mostly been studied in the context of the leukemic <START=Amino Acid, Peptide, or Protein> MLL - <START=Gene or Genome> AF10 <END=Gene or Genome> fusion protein <END=Amino Acid, Peptide, or Protein>, which lacks the N - terminal PHD fingers of <START=Gene or Genome> AF10 <END=Gene or Genome>."}, {"PMID": 23249624, "id": 2, "text": "Dabrafenib is a BRAF (gene encoding serine/threonine-protein kinase B-Raf) inhibitor that has been developed to selectively target the valine 600 to glutamic acid substitution (BRAF(V600E)), which is commonly found in metastatic melanoma.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [36, 42], "name": "serine", "tok_span": [10, 11], "new_tok_span": [26, 27]}, {"ent_type": "CHEMICAL", "char_span": [43, 52], "name": "threonine", "tok_span": [12, 14], "new_tok_span": [28, 30]}, {"ent_type": "CHEMICAL", "char_span": [135, 141], "name": "valine", "tok_span": [30, 32], "new_tok_span": [49, 51]}, {"ent_type": "CHEMICAL", "char_span": [149, 162], "name": "glutamic acid", "tok_span": [34, 37], "new_tok_span": [55, 58]}, {"ent_type": "GENE", "char_span": [36, 73], "name": "serine/threonine-protein kinase B-Raf", "tok_span": [10, 20], "new_tok_span": [26, 36]}, {"ent_type": "GENE", "char_span": [135, 162], "name": "valine 600 to glutamic acid", "tok_span": [30, 37], "new_tok_span": [49, 56]}, {"ent_type": "GENE", "char_span": [177, 181], "name": "BRAF", "tok_span": [39, 40], "new_tok_span": [64, 65]}, {"ent_type": "GENE", "char_span": [182, 187], "name": "V600E", "tok_span": [41, 44], "new_tok_span": [69, 72]}, {"ent_type": "GENE", "char_span": [16, 20], "name": "BRAF", "tok_span": [6, 7], "new_tok_span": [17, 18]}], "relation_list": [{"subject": "valine", "sbj_char_span": [135, 141], "object": "BRAF", "obj_char_span": [177, 181], "rel_type": "part of", "sbj_tok_span": [30, 32], "obj_tok_span": [39, 40], "new_sbj_tok_span": [49, 51], "new_obj_tok_span": [64, 65]}, {"subject": "glutamic acid", "sbj_char_span": [149, 162], "object": "BRAF", "obj_char_span": [177, 181], "rel_type": "part of", "sbj_tok_span": [34, 37], "obj_tok_span": [39, 40], "new_sbj_tok_span": [55, 58], "new_obj_tok_span": [64, 65]}], "umls_entity_list": [{"mention": "Dabrafenib", "char_span": [0, 10], "sem_type": "Pharmacologic Substance", "tok_span": [0, 4], "new_tok_span": [1, 5]}, {"mention": "gene", "char_span": [22, 26], "sem_type": "Gene or Genome", "tok_span": [8, 9], "new_tok_span": [23, 24]}, {"mention": "raf", "char_span": [3, 6], "sem_type": "Gene or Genome", "tok_span": [1, 3], "new_tok_span": [5, 7]}, {"mention": "RAF", "char_span": [17, 20], "sem_type": "Gene or Genome", "tok_span": [6, 7], "new_tok_span": [17, 18]}, {"mention": "Raf", "char_span": [70, 73], "sem_type": "Gene or Genome", "tok_span": [19, 20], "new_tok_span": [36, 37]}, {"mention": "RAF", "char_span": [178, 181], "sem_type": "Gene or Genome", "tok_span": [39, 40], "new_tok_span": [64, 65]}, {"mention": "valine", "char_span": [135, 141], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [30, 32], "new_tok_span": [49, 51]}, {"mention": "glutamic acid", "char_span": [149, 162], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [34, 37], "new_tok_span": [55, 58]}, {"mention": "braf", "char_span": [2, 6], "sem_type": "Gene or Genome", "tok_span": [1, 3], "new_tok_span": [5, 7]}, {"mention": "BRAF", "char_span": [16, 20], "sem_type": "Gene or Genome", "tok_span": [6, 7], "new_tok_span": [17, 18]}, {"mention": "BRAF", "char_span": [177, 181], "sem_type": "Gene or Genome", "tok_span": [39, 40], "new_tok_span": [64, 65]}, {"mention": "braf", "char_span": [2, 6], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [1, 3], "new_tok_span": [5, 7]}, {"mention": "BRAF", "char_span": [16, 20], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [6, 7], "new_tok_span": [17, 18]}, {"mention": "BRAF", "char_span": [177, 181], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [39, 40], "new_tok_span": [64, 65]}], "new_text": "<START=Pharmacologic Substance> Da <START=Gene or Genome> <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein>brafen <END=Gene or Genome> <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein>ib <END=Pharmacologic Substance> is a <START=Gene or Genome> <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> BRAF <END=Gene or Genome> <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> ( <START=Gene or Genome> gene <END=Gene or Genome> encoding serine / threonine - protein kinase B - <START=Gene or Genome> Raf <END=Gene or Genome> ) inhibitor that has been developed to selectively target the <START=Amino Acid, Peptide, or Protein> valine <END=Amino Acid, Peptide, or Protein> 600 to <START=Amino Acid, Peptide, or Protein> glutamic acid <END=Amino Acid, Peptide, or Protein> substitution ( <START=Gene or Genome> <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> BRAF <END=Gene or Genome> <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> ( V600E ) ), which is commonly found in metastatic melanoma."}, {"PMID": 23249624, "id": 4, "text": "Thus, the objective of the current study was to evaluate the brain distribution of dabrafenib in mice, and to see whether active efflux by P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) restricts its delivery across the blood-brain barrier (BBB). In vitro accumulation studies conducted in Madin-Darby canine kidney II cells indicate that dabrafenib is an avid substrate for both P-gp and BCRP. Directional flux studies revealed greater transport in the basolateral to apical direction with corrected efflux ratios greater than 2 for both P-gp and Bcrp1 transfected cell lines.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [83, 93], "name": "dabrafenib", "tok_span": [15, 19], "new_tok_span": [16, 20]}, {"ent_type": "CHEMICAL", "char_span": [358, 368], "name": "dabrafenib", "tok_span": [76, 80], "new_tok_span": [85, 89]}, {"ent_type": "GENE", "char_span": [558, 562], "name": "P-gp", "tok_span": [117, 120], "new_tok_span": [129, 132]}, {"ent_type": "GENE", "char_span": [567, 572], "name": "Bcrp1", "tok_span": [121, 125], "new_tok_span": [134, 138]}, {"ent_type": "GENE", "char_span": [139, 153], "name": "P-glycoprotein", "tok_span": [29, 32], "new_tok_span": [32, 35]}, {"ent_type": "GENE", "char_span": [155, 159], "name": "P-gp", "tok_span": [33, 36], "new_tok_span": [37, 40]}, {"ent_type": "GENE", "char_span": [165, 197], "name": "breast cancer resistance protein", "tok_span": [38, 42], "new_tok_span": [42, 46]}, {"ent_type": "GENE", "char_span": [199, 203], "name": "BCRP", "tok_span": [43, 45], "new_tok_span": [47, 49]}, {"ent_type": "GENE", "char_span": [399, 403], "name": "P-gp", "tok_span": [87, 90], "new_tok_span": [99, 102]}, {"ent_type": "GENE", "char_span": [408, 412], "name": "BCRP", "tok_span": [91, 93], "new_tok_span": [103, 105]}], "relation_list": [{"subject": "dabrafenib", "sbj_char_span": [358, 368], "object": "P-gp", "obj_char_span": [399, 403], "rel_type": "product or substrate", "sbj_tok_span": [76, 80], "obj_tok_span": [87, 90], "new_sbj_tok_span": [85, 89], "new_obj_tok_span": [99, 102]}, {"subject": "dabrafenib", "sbj_char_span": [358, 368], "object": "BCRP", "obj_char_span": [408, 412], "rel_type": "product or substrate", "sbj_tok_span": [76, 80], "obj_tok_span": [91, 93], "new_sbj_tok_span": [85, 89], "new_obj_tok_span": [103, 105]}], "umls_entity_list": [{"mention": "dabrafenib", "char_span": [83, 93], "sem_type": "Pharmacologic Substance", "tok_span": [15, 19], "new_tok_span": [16, 20]}, {"mention": "dabrafenib", "char_span": [358, 368], "sem_type": "Pharmacologic Substance", "tok_span": [76, 80], "new_tok_span": [85, 89]}, {"mention": "P-glycoprotein", "char_span": [139, 153], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [29, 32], "new_tok_span": [32, 35]}, {"mention": "II", "char_span": [335, 337], "sem_type": "Gene or Genome", "tok_span": [72, 73], "new_tok_span": [78, 79]}, {"mention": "II", "char_span": [335, 337], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [72, 73], "new_tok_span": [78, 79]}, {"mention": "avid", "char_span": [375, 379], "sem_type": "Pharmacologic Substance", "tok_span": [82, 84], "new_tok_span": [93, 95]}, {"mention": "Bcrp1", "char_span": [567, 572], "sem_type": "Gene or Genome", "tok_span": [121, 125], "new_tok_span": [134, 138]}], "new_text": "Thus, the objective of the current study was to evaluate the brain distribution of <START=Pharmacologic Substance> dabrafenib <END=Pharmacologic Substance> in mice, and to see whether active efflux by <START=Amino Acid, Peptide, or Protein> P - glycoprotein <END=Amino Acid, Peptide, or Protein> ( P - gp ) and breast cancer resistance protein ( BCRP ) restricts its delivery across the blood - brain barrier ( BBB ). In vitro accumulation studies conducted in Madin - Darby canine kidney <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> II <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> cells indicate that <START=Pharmacologic Substance> dabrafenib <END=Pharmacologic Substance> is an <START=Pharmacologic Substance> avid <END=Pharmacologic Substance> substrate for both P - gp and BCRP. Directional flux studies revealed greater transport in the basolateral to apical direction with corrected efflux ratios greater than 2 for both P - gp and <START=Gene or Genome> Bcrp1 <END=Gene or Genome> transfected cell lines."}, {"PMID": 10449190, "id": 8, "text": "Our studies demonstrated that (a) stereoselective and rank order differences exist among the direct effects of ephedrine isomers; (b) 1R,2S-ephedrine is the most potent of the four ephedrine isomers on all three human beta-AR; and (c) 1R,2S- ephedrine was nearly equipotent as a beta1-/beta2-AR agonist and the only isomer possessing weak partial agonist activity on beta3-AR.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [111, 120], "name": "ephedrine", "tok_span": [19, 22], "new_tok_span": [20, 23]}, {"ent_type": "CHEMICAL", "char_span": [134, 149], "name": "1R,2S-ephedrine", "tok_span": [27, 36], "new_tok_span": [29, 38]}, {"ent_type": "CHEMICAL", "char_span": [181, 190], "name": "ephedrine", "tok_span": [43, 46], "new_tok_span": [48, 51]}, {"ent_type": "CHEMICAL", "char_span": [235, 251], "name": "1R,2S- ephedrine", "tok_span": [59, 68], "new_tok_span": [65, 74]}, {"ent_type": "GENE", "char_span": [212, 225], "name": "human beta-AR", "tok_span": [50, 54], "new_tok_span": [56, 60]}, {"ent_type": "GENE", "char_span": [279, 294], "name": "beta1-/beta2-AR", "tok_span": [75, 83], "new_tok_span": [83, 91]}, {"ent_type": "GENE", "char_span": [367, 375], "name": "beta3-AR", "tok_span": [94, 98], "new_tok_span": [104, 108]}], "relation_list": [{"subject": "ephedrine", "sbj_char_span": [111, 120], "object": "human beta-AR", "obj_char_span": [212, 225], "rel_type": "agonist or antagonist", "sbj_tok_span": [19, 22], "obj_tok_span": [50, 54], "new_sbj_tok_span": [20, 23], "new_obj_tok_span": [56, 60]}, {"subject": "1R,2S-ephedrine", "sbj_char_span": [134, 149], "object": "human beta-AR", "obj_char_span": [212, 225], "rel_type": "agonist or antagonist", "sbj_tok_span": [27, 36], "obj_tok_span": [50, 54], "new_sbj_tok_span": [29, 38], "new_obj_tok_span": [56, 60]}, {"subject": "ephedrine", "sbj_char_span": [181, 190], "object": "human beta-AR", "obj_char_span": [212, 225], "rel_type": "agonist or antagonist", "sbj_tok_span": [43, 46], "obj_tok_span": [50, 54], "new_sbj_tok_span": [48, 51], "new_obj_tok_span": [56, 60]}, {"subject": "1R,2S- ephedrine", "sbj_char_span": [235, 251], "object": "beta3-AR", "obj_char_span": [367, 375], "rel_type": "agonist or antagonist", "sbj_tok_span": [59, 68], "obj_tok_span": [94, 98], "new_sbj_tok_span": [65, 74], "new_obj_tok_span": [104, 108]}], "umls_entity_list": [{"mention": "ephedrine", "char_span": [111, 120], "sem_type": "Pharmacologic Substance", "tok_span": [19, 22], "new_tok_span": [20, 23]}, {"mention": "ephedrine", "char_span": [140, 149], "sem_type": "Pharmacologic Substance", "tok_span": [33, 36], "new_tok_span": [36, 39]}, {"mention": "ephedrine", "char_span": [181, 190], "sem_type": "Pharmacologic Substance", "tok_span": [43, 46], "new_tok_span": [48, 51]}, {"mention": "ephedrine", "char_span": [242, 251], "sem_type": "Pharmacologic Substance", "tok_span": [65, 68], "new_tok_span": [72, 75]}, {"mention": "beta2", "char_span": [286, 291], "sem_type": "Gene or Genome", "tok_span": [79, 81], "new_tok_span": [88, 90]}], "new_text": "Our studies demonstrated that ( a ) stereoselective and rank order differences exist among the direct effects of <START=Pharmacologic Substance> ephedrine <END=Pharmacologic Substance> isomers ; ( b ) 1R, 2S - <START=Pharmacologic Substance> ephedrine <END=Pharmacologic Substance> is the most potent of the four <START=Pharmacologic Substance> ephedrine <END=Pharmacologic Substance> isomers on all three human beta - AR ; and ( c ) 1R, 2S - <START=Pharmacologic Substance> ephedrine <END=Pharmacologic Substance> was nearly equipotent as a beta1 - / <START=Gene or Genome> beta2 <END=Gene or Genome> - AR agonist and the only isomer possessing weak partial agonist activity on beta3 - AR."}, {"PMID": 23293300, "id": 5, "text": "The inhibitory potency of BOC was lower than known inhibitors of CYP3A (ketoconazole), OATP1B (rifampin), or both (telaprevir).", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [95, 103], "name": "rifampin", "tok_span": [26, 29], "new_tok_span": [27, 30]}, {"ent_type": "CHEMICAL", "char_span": [115, 125], "name": "telaprevir", "tok_span": [34, 38], "new_tok_span": [37, 41]}, {"ent_type": "CHEMICAL", "char_span": [26, 29], "name": "BOC", "tok_span": [4, 6], "new_tok_span": [4, 6]}, {"ent_type": "CHEMICAL", "char_span": [72, 84], "name": "ketoconazole", "tok_span": [16, 19], "new_tok_span": [16, 19]}, {"ent_type": "GENE", "char_span": [87, 93], "name": "OATP1B", "tok_span": [21, 25], "new_tok_span": [21, 25]}, {"ent_type": "GENE", "char_span": [65, 70], "name": "CYP3A", "tok_span": [12, 15], "new_tok_span": [12, 15]}], "relation_list": [{"subject": "ketoconazole", "sbj_char_span": [72, 84], "object": "CYP3A", "obj_char_span": [65, 70], "rel_type": "inhibitor", "sbj_tok_span": [16, 19], "obj_tok_span": [12, 15], "new_sbj_tok_span": [16, 19], "new_obj_tok_span": [12, 15]}, {"subject": "rifampin", "sbj_char_span": [95, 103], "object": "OATP1B", "obj_char_span": [87, 93], "rel_type": "inhibitor", "sbj_tok_span": [26, 29], "obj_tok_span": [21, 25], "new_sbj_tok_span": [27, 30], "new_obj_tok_span": [21, 25]}, {"subject": "telaprevir", "sbj_char_span": [115, 125], "object": "CYP3A", "obj_char_span": [65, 70], "rel_type": "inhibitor", "sbj_tok_span": [34, 38], "obj_tok_span": [12, 15], "new_sbj_tok_span": [37, 41], "new_obj_tok_span": [12, 15]}, {"subject": "telaprevir", "sbj_char_span": [115, 125], "object": "OATP1B", "obj_char_span": [87, 93], "rel_type": "inhibitor", "sbj_tok_span": [34, 38], "obj_tok_span": [21, 25], "new_sbj_tok_span": [37, 41], "new_obj_tok_span": [21, 25]}], "umls_entity_list": [{"mention": "rifampin", "char_span": [95, 103], "sem_type": "Organic Chemical", "tok_span": [26, 29], "new_tok_span": [27, 30]}, {"mention": "telaprevir", "char_span": [115, 125], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [34, 38], "new_tok_span": [37, 41]}], "new_text": "The inhibitory potency of BOC was lower than known inhibitors of CYP3A ( ketoconazole ), OATP1B ( <START=Organic Chemical> rifampin <END=Organic Chemical> ), or both ( <START=Amino Acid, Peptide, or Protein> telaprevir <END=Amino Acid, Peptide, or Protein> )."}, {"PMID": 17673606, "id": 0, "text": "Desvenlafaxine succinate identifies novel antagonist binding determinants in the human norepinephrine transporter.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 24], "name": "Desvenlafaxine succinate", "tok_span": [0, 8], "new_tok_span": [1, 9]}, {"ent_type": "CHEMICAL", "char_span": [87, 101], "name": "norepinephrine", "tok_span": [16, 17], "new_tok_span": [20, 21]}, {"ent_type": "GENE", "char_span": [81, 113], "name": "human norepinephrine transporter", "tok_span": [15, 18], "new_tok_span": [17, 20]}], "relation_list": [{"subject": "Desvenlafaxine succinate", "sbj_char_span": [0, 24], "object": "human norepinephrine transporter", "obj_char_span": [81, 113], "rel_type": "agonist or antagonist", "sbj_tok_span": [0, 8], "obj_tok_span": [15, 18], "new_sbj_tok_span": [1, 9], "new_obj_tok_span": [17, 20]}], "umls_entity_list": [{"mention": "Desvenlafaxine succinate", "char_span": [0, 24], "sem_type": "Pharmacologic Substance", "tok_span": [0, 8], "new_tok_span": [1, 9]}, {"mention": "norepinephrine transporter", "char_span": [87, 113], "sem_type": "Gene or Genome", "tok_span": [16, 18], "new_tok_span": [20, 22]}, {"mention": "norepinephrine transporter", "char_span": [87, 113], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [16, 18], "new_tok_span": [20, 22]}], "new_text": "<START=Pharmacologic Substance> Desvenlafaxine succinate <END=Pharmacologic Substance> identifies novel antagonist binding determinants in the human <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> norepinephrine transporter <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein>."}, {"PMID": 23444386, "id": 0, "text": "Modification of the Catalytic Function of Human Hydroxysteroid Sulfotransferase hSULT2A1 by Formation of Disulfide Bonds.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [105, 114], "name": "Disulfide", "tok_span": [24, 26], "new_tok_span": [24, 26]}, {"ent_type": "CHEMICAL", "char_span": [48, 62], "name": "Hydroxysteroid", "tok_span": [9, 13], "new_tok_span": [9, 13]}, {"ent_type": "GENE", "char_span": [42, 88], "name": "Human Hydroxysteroid Sulfotransferase hSULT2A1", "tok_span": [8, 21], "new_tok_span": [8, 21]}], "relation_list": [{"subject": "Disulfide", "sbj_char_span": [105, 114], "object": "Human Hydroxysteroid Sulfotransferase hSULT2A1", "obj_char_span": [42, 88], "rel_type": "part of", "sbj_tok_span": [24, 26], "obj_tok_span": [8, 21], "new_sbj_tok_span": [24, 26], "new_obj_tok_span": [8, 21]}], "umls_entity_list": [], "new_text": "Modification of the Catalytic Function of Human Hydroxysteroid Sulfotransferase hSULT2A1 by Formation of Disulfide Bonds."}, {"PMID": 23239555, "id": 3, "text": "Here we present boronic and borinic acid derivatives as a new class of potent and nontoxic APT inhibitors.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [16, 23], "name": "boronic", "tok_span": [3, 5], "new_tok_span": [3, 5]}, {"ent_type": "CHEMICAL", "char_span": [28, 40], "name": "borinic acid", "tok_span": [6, 10], "new_tok_span": [6, 10]}, {"ent_type": "GENE", "char_span": [91, 94], "name": "APT", "tok_span": [22, 24], "new_tok_span": [24, 26]}], "relation_list": [{"subject": "boronic", "sbj_char_span": [16, 23], "object": "APT", "obj_char_span": [91, 94], "rel_type": "inhibitor", "sbj_tok_span": [3, 5], "obj_tok_span": [22, 24], "new_sbj_tok_span": [3, 5], "new_obj_tok_span": [24, 26]}, {"subject": "borinic acid", "sbj_char_span": [28, 40], "object": "APT", "obj_char_span": [91, 94], "rel_type": "inhibitor", "sbj_tok_span": [6, 10], "obj_tok_span": [22, 24], "new_sbj_tok_span": [6, 10], "new_obj_tok_span": [24, 26]}], "umls_entity_list": [{"mention": "APT", "char_span": [91, 94], "sem_type": "Pharmacologic Substance", "tok_span": [22, 24], "new_tok_span": [24, 26]}, {"mention": "APT", "char_span": [91, 94], "sem_type": "Gene or Genome", "tok_span": [22, 24], "new_tok_span": [24, 26]}], "new_text": "Here we present boronic and borinic acid derivatives as a new class of potent and nontoxic <START=Pharmacologic Substance> <START=Gene or Genome> APT <END=Pharmacologic Substance> <END=Gene or Genome> inhibitors."}, {"PMID": 23337530, "id": 0, "text": "Anagliptin, a DPP-4 inhibitor, suppresses proliferation of vascular smooth muscles and monocyte inflammatory reaction and attenuates atherosclerosis in male apo E-deficient mice.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 10], "name": "Anagliptin", "tok_span": [0, 4], "new_tok_span": [0, 4]}, {"ent_type": "GENE", "char_span": [14, 19], "name": "DPP-4", "tok_span": [6, 9], "new_tok_span": [7, 10]}, {"ent_type": "GENE", "char_span": [157, 162], "name": "apo E", "tok_span": [27, 29], "new_tok_span": [29, 31]}], "relation_list": [{"subject": "Anagliptin", "sbj_char_span": [0, 10], "object": "DPP-4", "obj_char_span": [14, 19], "rel_type": "inhibitor", "sbj_tok_span": [0, 4], "obj_tok_span": [6, 9], "new_sbj_tok_span": [0, 4], "new_obj_tok_span": [7, 10]}], "umls_entity_list": [{"mention": "DPP-4 inhibitor", "char_span": [14, 29], "sem_type": "Pharmacologic Substance", "tok_span": [6, 10], "new_tok_span": [7, 11]}], "new_text": "Anagliptin, a <START=Pharmacologic Substance> DPP - 4 inhibitor <END=Pharmacologic Substance>, suppresses proliferation of vascular smooth muscles and monocyte inflammatory reaction and attenuates atherosclerosis in male apo E - deficient mice."}, {"PMID": 17367165, "id": 9, "text": "In principle, C2 domain-directed intracellular targeting, which requires coincidence detection of multiple signals (Ca2+ and one or more target lipids), can exhibit two different mechanisms: messenger-activated target affinity (MATA) and target-activated messenger affinity (TAMA). The C2 domains studied here both utilize the TAMA mechanism, in which the C2 domain Ca2+ affinity is too low to be activated by physiological Ca2+ signals in most regions of the cell.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [116, 120], "name": "Ca2+", "tok_span": [19, 22], "new_tok_span": [21, 24]}, {"ent_type": "CHEMICAL", "char_span": [366, 370], "name": "Ca2+", "tok_span": [75, 78], "new_tok_span": [81, 84]}, {"ent_type": "CHEMICAL", "char_span": [424, 428], "name": "Ca2+", "tok_span": [87, 90], "new_tok_span": [93, 96]}, {"ent_type": "GENE", "char_span": [14, 23], "name": "C2 domain", "tok_span": [3, 6], "new_tok_span": [3, 6]}, {"ent_type": "GENE", "char_span": [286, 296], "name": "C2 domains", "tok_span": [57, 60], "new_tok_span": [63, 66]}, {"ent_type": "GENE", "char_span": [356, 365], "name": "C2 domain", "tok_span": [72, 75], "new_tok_span": [78, 81]}], "relation_list": [{"subject": "Ca2+", "sbj_char_span": [366, 370], "object": "C2 domain", "obj_char_span": [356, 365], "rel_type": "regulator", "sbj_tok_span": [75, 78], "obj_tok_span": [72, 75], "new_sbj_tok_span": [81, 84], "new_obj_tok_span": [78, 81]}], "umls_entity_list": [{"mention": "directed", "char_span": [24, 32], "sem_type": "Pharmacologic Substance", "tok_span": [7, 8], "new_tok_span": [8, 9]}, {"mention": "messenger", "char_span": [191, 200], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [36, 37], "new_tok_span": [39, 40]}, {"mention": "messenger", "char_span": [255, 264], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [49, 50], "new_tok_span": [54, 55]}], "new_text": "In principle, C2 domain - <START=Pharmacologic Substance> directed <END=Pharmacologic Substance> intracellular targeting, which requires coincidence detection of multiple signals ( Ca2 + and one or more target lipids ), can exhibit two different mechanisms : <START=Amino Acid, Peptide, or Protein> messenger <END=Amino Acid, Peptide, or Protein> - activated target affinity ( MATA ) and target - activated <START=Amino Acid, Peptide, or Protein> messenger <END=Amino Acid, Peptide, or Protein> affinity ( TAMA ). The C2 domains studied here both utilize the TAMA mechanism, in which the C2 domain Ca2 + affinity is too low to be activated by physiological Ca2 + signals in most regions of the cell."}, {"PMID": 23411241, "id": 2, "text": "Oral administration of APP at 250 and 500 mg/kg bw in mice was shown to be as effective as AFP in lowering the CCl(4)-caused increases of serum alanine aminotransferase, aspartate aminotransferase and lactic dehydrogenase activities, and hepatic malondialdehyde level, and antagonising the decreases in antioxidant superoxide dismutase and glutathione peroxidase activities caused by CCl(4) (p<0.05).", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [111, 117], "name": "CCl(4)", "tok_span": [27, 32], "new_tok_span": [31, 36]}, {"ent_type": "CHEMICAL", "char_span": [144, 151], "name": "alanine", "tok_span": [37, 38], "new_tok_span": [44, 45]}, {"ent_type": "CHEMICAL", "char_span": [170, 179], "name": "aspartate", "tok_span": [41, 43], "new_tok_span": [49, 51]}, {"ent_type": "CHEMICAL", "char_span": [246, 261], "name": "malondialdehyde", "tok_span": [52, 56], "new_tok_span": [61, 65]}, {"ent_type": "CHEMICAL", "char_span": [315, 325], "name": "superoxide", "tok_span": [65, 66], "new_tok_span": [78, 79]}, {"ent_type": "CHEMICAL", "char_span": [340, 351], "name": "glutathione", "tok_span": [68, 69], "new_tok_span": [82, 83]}, {"ent_type": "CHEMICAL", "char_span": [384, 390], "name": "CCl(4)", "tok_span": [73, 78], "new_tok_span": [89, 94]}, {"ent_type": "GENE", "char_span": [138, 168], "name": "serum alanine aminotransferase", "tok_span": [36, 40], "new_tok_span": [43, 47]}, {"ent_type": "GENE", "char_span": [170, 196], "name": "aspartate aminotransferase", "tok_span": [41, 45], "new_tok_span": [49, 53]}, {"ent_type": "GENE", "char_span": [201, 221], "name": "lactic dehydrogenase", "tok_span": [46, 48], "new_tok_span": [54, 56]}, {"ent_type": "GENE", "char_span": [315, 335], "name": "superoxide dismutase", "tok_span": [65, 67], "new_tok_span": [78, 80]}, {"ent_type": "GENE", "char_span": [340, 362], "name": "glutathione peroxidase", "tok_span": [68, 70], "new_tok_span": [82, 84]}], "relation_list": [{"subject": "CCl(4)", "sbj_char_span": [111, 117], "object": "serum alanine aminotransferase", "obj_char_span": [138, 168], "rel_type": "activator", "sbj_tok_span": [27, 32], "obj_tok_span": [36, 40], "new_sbj_tok_span": [31, 36], "new_obj_tok_span": [43, 47]}, {"subject": "CCl(4)", "sbj_char_span": [111, 117], "object": "aspartate aminotransferase", "obj_char_span": [170, 196], "rel_type": "activator", "sbj_tok_span": [27, 32], "obj_tok_span": [41, 45], "new_sbj_tok_span": [31, 36], "new_obj_tok_span": [49, 53]}, {"subject": "CCl(4)", "sbj_char_span": [111, 117], "object": "lactic dehydrogenase", "obj_char_span": [201, 221], "rel_type": "activator", "sbj_tok_span": [27, 32], "obj_tok_span": [46, 48], "new_sbj_tok_span": [31, 36], "new_obj_tok_span": [54, 56]}, {"subject": "CCl(4)", "sbj_char_span": [384, 390], "object": "superoxide dismutase", "obj_char_span": [315, 335], "rel_type": "inhibitor", "sbj_tok_span": [73, 78], "obj_tok_span": [65, 67], "new_sbj_tok_span": [89, 94], "new_obj_tok_span": [78, 80]}, {"subject": "CCl(4)", "sbj_char_span": [384, 390], "object": "glutathione peroxidase", "obj_char_span": [340, 362], "rel_type": "inhibitor", "sbj_tok_span": [73, 78], "obj_tok_span": [68, 70], "new_sbj_tok_span": [89, 94], "new_obj_tok_span": [82, 84]}], "umls_entity_list": [{"mention": "AFP", "char_span": [91, 94], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [22, 24], "new_tok_span": [23, 25]}, {"mention": "CCl", "char_span": [111, 114], "sem_type": "Organic Chemical", "tok_span": [27, 29], "new_tok_span": [31, 33]}, {"mention": "CCl", "char_span": [384, 387], "sem_type": "Organic Chemical", "tok_span": [73, 75], "new_tok_span": [89, 91]}, {"mention": "serum alanine aminotransferase", "char_span": [138, 168], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [36, 40], "new_tok_span": [43, 47]}, {"mention": "CCl", "char_span": [111, 114], "sem_type": "Gene or Genome", "tok_span": [27, 29], "new_tok_span": [31, 33]}, {"mention": "CCl", "char_span": [384, 387], "sem_type": "Gene or Genome", "tok_span": [73, 75], "new_tok_span": [89, 91]}, {"mention": "malondialdehyde", "char_span": [246, 261], "sem_type": "Organic Chemical", "tok_span": [52, 56], "new_tok_span": [61, 65]}, {"mention": "antioxidant", "char_span": [303, 314], "sem_type": "Pharmacologic Substance", "tok_span": [64, 65], "new_tok_span": [75, 76]}, {"mention": "superoxide dismutase", "char_span": [315, 335], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [65, 67], "new_tok_span": [78, 80]}], "new_text": "Oral administration of APP at 250 and 500 mg / kg bw in mice was shown to be as effective as <START=Amino Acid, Peptide, or Protein> AFP <END=Amino Acid, Peptide, or Protein> in lowering the <START=Organic Chemical> <START=Gene or Genome> CCl <END=Organic Chemical> <END=Gene or Genome> ( 4 ) - caused increases of <START=Amino Acid, Peptide, or Protein> serum alanine aminotransferase <END=Amino Acid, Peptide, or Protein>, aspartate aminotransferase and lactic dehydrogenase activities, and hepatic <START=Organic Chemical> malondialdehyde <END=Organic Chemical> level, and antagonising the decreases in <START=Pharmacologic Substance> antioxidant <END=Pharmacologic Substance> <START=Amino Acid, Peptide, or Protein> superoxide dismutase <END=Amino Acid, Peptide, or Protein> and glutathione peroxidase activities caused by <START=Organic Chemical> <START=Gene or Genome> CCl <END=Organic Chemical> <END=Gene or Genome> ( 4 ) ( p < 0. 05 )."}, {"PMID": 23404505, "id": 6, "text": "We also show that removal of either the N- or C-terminal propeptide is required for VEGF-D to drive formation of VEGFR-2/VEGFR-3 heterodimers which have recently been shown to positively regulate angiogenic sprouting.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [40, 41], "name": "N", "tok_span": [8, 9], "new_tok_span": [8, 9]}, {"ent_type": "CHEMICAL", "char_span": [46, 47], "name": "C", "tok_span": [11, 12], "new_tok_span": [11, 12]}, {"ent_type": "GENE", "char_span": [113, 120], "name": "VEGFR-2", "tok_span": [26, 30], "new_tok_span": [31, 35]}, {"ent_type": "GENE", "char_span": [121, 128], "name": "VEGFR-3", "tok_span": [31, 35], "new_tok_span": [37, 41]}, {"ent_type": "GENE", "char_span": [84, 90], "name": "VEGF-D", "tok_span": [19, 22], "new_tok_span": [21, 24]}], "relation_list": [{"subject": "N", "sbj_char_span": [40, 41], "object": "VEGF-D", "obj_char_span": [84, 90], "rel_type": "part of", "sbj_tok_span": [8, 9], "obj_tok_span": [19, 22], "new_sbj_tok_span": [8, 9], "new_obj_tok_span": [21, 24]}, {"subject": "C", "sbj_char_span": [46, 47], "object": "VEGF-D", "obj_char_span": [84, 90], "rel_type": "part of", "sbj_tok_span": [11, 12], "obj_tok_span": [19, 22], "new_sbj_tok_span": [11, 12], "new_obj_tok_span": [21, 24]}], "umls_entity_list": [{"mention": "VEGF-D", "char_span": [84, 90], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [19, 22], "new_tok_span": [21, 24]}, {"mention": "VEGF-D", "char_span": [84, 90], "sem_type": "Gene or Genome", "tok_span": [19, 22], "new_tok_span": [21, 24]}, {"mention": "VEGFR-2", "char_span": [113, 120], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [26, 30], "new_tok_span": [31, 35]}], "new_text": "We also show that removal of either the N - or C - terminal propeptide is required for <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> VEGF - D <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> to drive formation of <START=Amino Acid, Peptide, or Protein> VEGFR - 2 <END=Amino Acid, Peptide, or Protein> / VEGFR - 3 heterodimers which have recently been shown to positively regulate angiogenic sprouting."}, {"PMID": 23074021, "id": 6, "text": "In addition, the number and area of glutathione S-transferase placental form (GST-P) positive foci and proliferating cell nuclear antigen (PCNA) positive cell ratios in the hepatocytes were significantly increased in the male and female rats that were administered 100mg/kg MEG compared with the control animals.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [274, 277], "name": "MEG", "tok_span": [53, 55], "new_tok_span": [61, 63]}, {"ent_type": "CHEMICAL", "char_span": [36, 47], "name": "glutathione", "tok_span": [8, 9], "new_tok_span": [9, 10]}, {"ent_type": "CHEMICAL", "char_span": [48, 49], "name": "S", "tok_span": [9, 10], "new_tok_span": [10, 11]}, {"ent_type": "GENE", "char_span": [36, 76], "name": "glutathione S-transferase placental form", "tok_span": [8, 15], "new_tok_span": [9, 16]}, {"ent_type": "GENE", "char_span": [78, 83], "name": "GST-P", "tok_span": [16, 19], "new_tok_span": [18, 21]}, {"ent_type": "GENE", "char_span": [103, 137], "name": "proliferating cell nuclear antigen", "tok_span": [23, 27], "new_tok_span": [28, 32]}, {"ent_type": "GENE", "char_span": [139, 143], "name": "PCNA", "tok_span": [28, 30], "new_tok_span": [36, 38]}], "relation_list": [{"subject": "MEG", "sbj_char_span": [274, 277], "object": "glutathione S-transferase placental form", "obj_char_span": [36, 76], "rel_type": "regulator", "sbj_tok_span": [53, 55], "obj_tok_span": [8, 15], "new_sbj_tok_span": [61, 63], "new_obj_tok_span": [9, 16]}, {"subject": "MEG", "sbj_char_span": [274, 277], "object": "GST-P", "obj_char_span": [78, 83], "rel_type": "regulator", "sbj_tok_span": [53, 55], "obj_tok_span": [16, 19], "new_sbj_tok_span": [61, 63], "new_obj_tok_span": [18, 21]}, {"subject": "MEG", "sbj_char_span": [274, 277], "object": "proliferating cell nuclear antigen", "obj_char_span": [103, 137], "rel_type": "regulator", "sbj_tok_span": [53, 55], "obj_tok_span": [23, 27], "new_sbj_tok_span": [61, 63], "new_obj_tok_span": [28, 32]}, {"subject": "MEG", "sbj_char_span": [274, 277], "object": "PCNA", "obj_char_span": [139, 143], "rel_type": "regulator", "sbj_tok_span": [53, 55], "obj_tok_span": [28, 30], "new_sbj_tok_span": [61, 63], "new_obj_tok_span": [36, 38]}], "umls_entity_list": [{"mention": "glutathione S-transferase", "char_span": [36, 61], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [8, 13], "new_tok_span": [9, 14]}, {"mention": "proliferating", "char_span": [103, 116], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [23, 24], "new_tok_span": [28, 29]}, {"mention": "proliferating cell nuclear antigen", "char_span": [103, 137], "sem_type": "Gene or Genome", "tok_span": [23, 27], "new_tok_span": [28, 32]}, {"mention": "proliferating cell nuclear antigen", "char_span": [103, 137], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [23, 27], "new_tok_span": [28, 32]}], "new_text": "In addition, the number and area of <START=Amino Acid, Peptide, or Protein> glutathione S - transferase <END=Amino Acid, Peptide, or Protein> placental form ( GST - P ) positive foci and <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> proliferating <END=Amino Acid, Peptide, or Protein> cell nuclear antigen <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> ( PCNA ) positive cell ratios in the hepatocytes were significantly increased in the male and female rats that were administered 100mg / kg MEG compared with the control animals."}, {"PMID": 17369473, "id": 0, "text": "Metformin and phenformin activate AMP-activated protein kinase in the heart by increasing cytosolic AMP concentration.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 9], "name": "Metformin", "tok_span": [0, 2], "new_tok_span": [0, 2]}, {"ent_type": "CHEMICAL", "char_span": [100, 103], "name": "AMP", "tok_span": [17, 18], "new_tok_span": [27, 28]}, {"ent_type": "CHEMICAL", "char_span": [14, 24], "name": "phenformin", "tok_span": [3, 5], "new_tok_span": [4, 6]}, {"ent_type": "CHEMICAL", "char_span": [34, 37], "name": "AMP", "tok_span": [6, 7], "new_tok_span": [11, 12]}, {"ent_type": "GENE", "char_span": [34, 62], "name": "AMP-activated protein kinase", "tok_span": [6, 11], "new_tok_span": [11, 16]}], "relation_list": [{"subject": "Metformin", "sbj_char_span": [0, 9], "object": "AMP-activated protein kinase", "obj_char_span": [34, 62], "rel_type": "activator", "sbj_tok_span": [0, 2], "obj_tok_span": [6, 11], "new_sbj_tok_span": [0, 2], "new_obj_tok_span": [11, 16]}, {"subject": "phenformin", "sbj_char_span": [14, 24], "object": "AMP-activated protein kinase", "obj_char_span": [34, 62], "rel_type": "activator", "sbj_tok_span": [3, 5], "obj_tok_span": [6, 11], "new_sbj_tok_span": [4, 6], "new_obj_tok_span": [11, 16]}], "umls_entity_list": [{"mention": "phenformin", "char_span": [14, 24], "sem_type": "Pharmacologic Substance", "tok_span": [3, 5], "new_tok_span": [4, 6]}, {"mention": "AMP-activated protein kinase", "char_span": [34, 62], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [6, 11], "new_tok_span": [11, 16]}, {"mention": "AMP", "char_span": [34, 37], "sem_type": "Gene or Genome", "tok_span": [6, 7], "new_tok_span": [11, 12]}, {"mention": "AMP", "char_span": [100, 103], "sem_type": "Gene or Genome", "tok_span": [17, 18], "new_tok_span": [27, 28]}, {"mention": "AMP", "char_span": [34, 37], "sem_type": "Pharmacologic Substance", "tok_span": [6, 7], "new_tok_span": [11, 12]}, {"mention": "AMP", "char_span": [100, 103], "sem_type": "Pharmacologic Substance", "tok_span": [17, 18], "new_tok_span": [27, 28]}], "new_text": "Metformin and <START=Pharmacologic Substance> phenformin <END=Pharmacologic Substance> activate <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> <START=Pharmacologic Substance> AMP <END=Gene or Genome> <END=Pharmacologic Substance> - activated protein kinase <END=Amino Acid, Peptide, or Protein> in the heart by increasing cytosolic <START=Gene or Genome> <START=Pharmacologic Substance> AMP <END=Gene or Genome> <END=Pharmacologic Substance> concentration."}, {"PMID": 17369473, "id": 2, "text": "In hearts treated with phenformin for 18 min and then perfused for 20 min with Krebs-Henseleit buffer, [AMP] began to increase at 26 min and AMPK activity was elevated at 36 min.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [23, 33], "name": "phenformin", "tok_span": [4, 6], "new_tok_span": [5, 7]}, {"ent_type": "CHEMICAL", "char_span": [104, 107], "name": "AMP", "tok_span": [24, 25], "new_tok_span": [28, 29]}, {"ent_type": "GENE", "char_span": [141, 145], "name": "AMPK", "tok_span": [33, 34], "new_tok_span": [37, 38]}], "relation_list": [{"subject": "phenformin", "sbj_char_span": [23, 33], "object": "AMPK", "obj_char_span": [141, 145], "rel_type": "activator", "sbj_tok_span": [4, 6], "obj_tok_span": [33, 34], "new_sbj_tok_span": [5, 7], "new_obj_tok_span": [37, 38]}], "umls_entity_list": [{"mention": "phenformin", "char_span": [23, 33], "sem_type": "Pharmacologic Substance", "tok_span": [4, 6], "new_tok_span": [5, 7]}, {"mention": "Krebs-Henseleit buffer", "char_span": [79, 101], "sem_type": "Organic Chemical", "tok_span": [16, 22], "new_tok_span": [19, 25]}], "new_text": "In hearts treated with <START=Pharmacologic Substance> phenformin <END=Pharmacologic Substance> for 18 min and then perfused for 20 min with <START=Organic Chemical> Krebs - Henseleit buffer <END=Organic Chemical>, [ AMP ] began to increase at 26 min and AMPK activity was elevated at 36 min."}, {"PMID": 17602574, "id": 9, "text": "The unusual {FeNO}7 (S = 1/2) electronic configuration adopted by the substrate-bound iron-nitrosyl CDO (termed {ES-NO}7) is a result of the bidentate thiol/amine coordination of l-cysteine in the NO-bound CDO active site.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [13, 17], "name": "FeNO", "tok_span": [3, 5], "new_tok_span": [3, 5]}, {"ent_type": "CHEMICAL", "char_span": [86, 99], "name": "iron-nitrosyl", "tok_span": [22, 27], "new_tok_span": [22, 27]}, {"ent_type": "CHEMICAL", "char_span": [116, 118], "name": "NO", "tok_span": [34, 35], "new_tok_span": [34, 35]}, {"ent_type": "CHEMICAL", "char_span": [141, 162], "name": "bidentate thiol/amine", "tok_span": [43, 49], "new_tok_span": [43, 49]}, {"ent_type": "CHEMICAL", "char_span": [179, 189], "name": "l-cysteine", "tok_span": [51, 54], "new_tok_span": [55, 58]}, {"ent_type": "CHEMICAL", "char_span": [197, 199], "name": "NO", "tok_span": [56, 57], "new_tok_span": [62, 63]}, {"ent_type": "GENE", "char_span": [100, 103], "name": "CDO", "tok_span": [27, 29], "new_tok_span": [27, 29]}, {"ent_type": "GENE", "char_span": [206, 209], "name": "CDO", "tok_span": [59, 61], "new_tok_span": [65, 67]}], "relation_list": [{"subject": "NO", "sbj_char_span": [197, 199], "object": "CDO", "obj_char_span": [206, 209], "rel_type": "regulator", "sbj_tok_span": [56, 57], "obj_tok_span": [59, 61], "new_sbj_tok_span": [62, 63], "new_obj_tok_span": [65, 67]}], "umls_entity_list": [{"mention": "thiol", "char_span": [151, 156], "sem_type": "Organic Chemical", "tok_span": [46, 47], "new_tok_span": [47, 48]}, {"mention": "amine", "char_span": [157, 162], "sem_type": "Organic Chemical", "tok_span": [48, 49], "new_tok_span": [51, 52]}, {"mention": "cysteine", "char_span": [181, 189], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [53, 54], "new_tok_span": [58, 59]}], "new_text": "The unusual { FeNO } 7 ( S = 1 / 2 ) electronic configuration adopted by the substrate - bound iron - nitrosyl CDO ( termed { ES - NO } 7 ) is a result of the bidentate <START=Organic Chemical> thiol <END=Organic Chemical> / <START=Organic Chemical> amine <END=Organic Chemical> coordination of l - <START=Amino Acid, Peptide, or Protein> cysteine <END=Amino Acid, Peptide, or Protein> in the NO - bound CDO active site."}, {"PMID": 10365684, "id": 0, "text": "Methimazole and propylthiouracil increase cellular thyroid peroxidase activity and thyroid peroxidase mRNA in cultured porcine thyroid follicles.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 11], "name": "Methimazole", "tok_span": [0, 4], "new_tok_span": [0, 4]}, {"ent_type": "CHEMICAL", "char_span": [16, 32], "name": "propylthiouracil", "tok_span": [5, 10], "new_tok_span": [6, 11]}, {"ent_type": "GENE", "char_span": [51, 69], "name": "thyroid peroxidase", "tok_span": [12, 14], "new_tok_span": [16, 18]}, {"ent_type": "GENE", "char_span": [83, 101], "name": "thyroid peroxidase", "tok_span": [16, 18], "new_tok_span": [26, 28]}], "relation_list": [{"subject": "Methimazole", "sbj_char_span": [0, 11], "object": "thyroid peroxidase", "obj_char_span": [51, 69], "rel_type": "activator", "sbj_tok_span": [0, 4], "obj_tok_span": [12, 14], "new_sbj_tok_span": [0, 4], "new_obj_tok_span": [16, 18]}, {"subject": "propylthiouracil", "sbj_char_span": [16, 32], "object": "thyroid peroxidase", "obj_char_span": [51, 69], "rel_type": "activator", "sbj_tok_span": [5, 10], "obj_tok_span": [12, 14], "new_sbj_tok_span": [6, 11], "new_obj_tok_span": [16, 18]}, {"subject": "Methimazole", "sbj_char_span": [0, 11], "object": "thyroid peroxidase", "obj_char_span": [83, 101], "rel_type": "regulator", "sbj_tok_span": [0, 4], "obj_tok_span": [16, 18], "new_sbj_tok_span": [0, 4], "new_obj_tok_span": [26, 28]}, {"subject": "propylthiouracil", "sbj_char_span": [16, 32], "object": "thyroid peroxidase", "obj_char_span": [83, 101], "rel_type": "regulator", "sbj_tok_span": [5, 10], "obj_tok_span": [16, 18], "new_sbj_tok_span": [6, 11], "new_obj_tok_span": [26, 28]}], "umls_entity_list": [{"mention": "propylthiouracil", "char_span": [16, 32], "sem_type": "Pharmacologic Substance", "tok_span": [5, 10], "new_tok_span": [6, 11]}, {"mention": "thyroid peroxidase", "char_span": [51, 69], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [12, 14], "new_tok_span": [16, 18]}, {"mention": "thyroid peroxidase", "char_span": [83, 101], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [16, 18], "new_tok_span": [26, 28]}, {"mention": "thyroid peroxidase", "char_span": [51, 69], "sem_type": "Gene or Genome", "tok_span": [12, 14], "new_tok_span": [16, 18]}, {"mention": "thyroid peroxidase", "char_span": [83, 101], "sem_type": "Gene or Genome", "tok_span": [16, 18], "new_tok_span": [26, 28]}, {"mention": "peroxidase", "char_span": [59, 69], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [13, 14], "new_tok_span": [18, 19]}, {"mention": "peroxidase", "char_span": [91, 101], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [17, 18], "new_tok_span": [28, 29]}], "new_text": "Methimazole and <START=Pharmacologic Substance> propylthiouracil <END=Pharmacologic Substance> increase cellular <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> thyroid <START=Amino Acid, Peptide, or Protein> peroxidase <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> activity and <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> thyroid <START=Amino Acid, Peptide, or Protein> peroxidase <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> mRNA in cultured porcine thyroid follicles."}, {"PMID": 2248058, "id": 1, "text": "Inhibition of MAO activity was measured in rat brain homogenates using 5-HT as MAO-A substrate and phenylethylamine as MAO-B substrate.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [71, 75], "name": "5-HT", "tok_span": [13, 16], "new_tok_span": [13, 16]}, {"ent_type": "CHEMICAL", "char_span": [99, 115], "name": "phenylethylamine", "tok_span": [23, 26], "new_tok_span": [28, 31]}, {"ent_type": "GENE", "char_span": [119, 124], "name": "MAO-B", "tok_span": [27, 31], "new_tok_span": [35, 39]}, {"ent_type": "GENE", "char_span": [14, 17], "name": "MAO", "tok_span": [2, 4], "new_tok_span": [2, 4]}, {"ent_type": "GENE", "char_span": [79, 84], "name": "MAO-A", "tok_span": [17, 21], "new_tok_span": [19, 23]}], "relation_list": [{"subject": "5-HT", "sbj_char_span": [71, 75], "object": "MAO-A", "obj_char_span": [79, 84], "rel_type": "product or substrate", "sbj_tok_span": [13, 16], "obj_tok_span": [17, 21], "new_sbj_tok_span": [13, 16], "new_obj_tok_span": [19, 23]}, {"subject": "phenylethylamine", "sbj_char_span": [99, 115], "object": "MAO-B", "obj_char_span": [119, 124], "rel_type": "product or substrate", "sbj_tok_span": [23, 26], "obj_tok_span": [27, 31], "new_sbj_tok_span": [28, 31], "new_obj_tok_span": [35, 39]}], "umls_entity_list": [{"mention": "MAO-A", "char_span": [79, 84], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [17, 21], "new_tok_span": [19, 23]}, {"mention": "MAO-A", "char_span": [79, 84], "sem_type": "Gene or Genome", "tok_span": [17, 21], "new_tok_span": [19, 23]}, {"mention": "phenylethylamine", "char_span": [99, 115], "sem_type": "Pharmacologic Substance", "tok_span": [23, 26], "new_tok_span": [28, 31]}, {"mention": "MAO-B", "char_span": [119, 124], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [27, 31], "new_tok_span": [35, 39]}, {"mention": "MAO-B", "char_span": [119, 124], "sem_type": "Gene or Genome", "tok_span": [27, 31], "new_tok_span": [35, 39]}], "new_text": "Inhibition of MAO activity was measured in rat brain homogenates using 5 - HT as <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> MAO - A <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> substrate and <START=Pharmacologic Substance> phenylethylamine <END=Pharmacologic Substance> as <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> MAO - B <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> substrate."}, {"PMID": 2248058, "id": 4, "text": "Phenelzine, isocarboxazid and tranylcypromine were nonspecific, inhibiting MAO-A and MAO-B to about the same extent.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 10], "name": "Phenelzine", "tok_span": [0, 4], "new_tok_span": [0, 4]}, {"ent_type": "CHEMICAL", "char_span": [12, 25], "name": "isocarboxazid", "tok_span": [5, 10], "new_tok_span": [6, 11]}, {"ent_type": "CHEMICAL", "char_span": [30, 45], "name": "tranylcypromine", "tok_span": [11, 16], "new_tok_span": [13, 18]}, {"ent_type": "GENE", "char_span": [75, 80], "name": "MAO-A", "tok_span": [20, 24], "new_tok_span": [22, 26]}, {"ent_type": "GENE", "char_span": [85, 90], "name": "MAO-B", "tok_span": [25, 29], "new_tok_span": [29, 33]}], "relation_list": [{"subject": "Phenelzine", "sbj_char_span": [0, 10], "object": "MAO-A", "obj_char_span": [75, 80], "rel_type": "inhibitor", "sbj_tok_span": [0, 4], "obj_tok_span": [20, 24], "new_sbj_tok_span": [0, 4], "new_obj_tok_span": [22, 26]}, {"subject": "isocarboxazid", "sbj_char_span": [12, 25], "object": "MAO-A", "obj_char_span": [75, 80], "rel_type": "inhibitor", "sbj_tok_span": [5, 10], "obj_tok_span": [20, 24], "new_sbj_tok_span": [6, 11], "new_obj_tok_span": [22, 26]}, {"subject": "tranylcypromine", "sbj_char_span": [30, 45], "object": "MAO-A", "obj_char_span": [75, 80], "rel_type": "inhibitor", "sbj_tok_span": [11, 16], "obj_tok_span": [20, 24], "new_sbj_tok_span": [13, 18], "new_obj_tok_span": [22, 26]}, {"subject": "Phenelzine", "sbj_char_span": [0, 10], "object": "MAO-B", "obj_char_span": [85, 90], "rel_type": "inhibitor", "sbj_tok_span": [0, 4], "obj_tok_span": [25, 29], "new_sbj_tok_span": [0, 4], "new_obj_tok_span": [29, 33]}, {"subject": "isocarboxazid", "sbj_char_span": [12, 25], "object": "MAO-B", "obj_char_span": [85, 90], "rel_type": "inhibitor", "sbj_tok_span": [5, 10], "obj_tok_span": [25, 29], "new_sbj_tok_span": [6, 11], "new_obj_tok_span": [29, 33]}, {"subject": "tranylcypromine", "sbj_char_span": [30, 45], "object": "MAO-B", "obj_char_span": [85, 90], "rel_type": "inhibitor", "sbj_tok_span": [11, 16], "obj_tok_span": [25, 29], "new_sbj_tok_span": [13, 18], "new_obj_tok_span": [29, 33]}], "umls_entity_list": [{"mention": "isocarboxazid", "char_span": [12, 25], "sem_type": "Pharmacologic Substance", "tok_span": [5, 10], "new_tok_span": [6, 11]}, {"mention": "MAO-B", "char_span": [85, 90], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [25, 29], "new_tok_span": [29, 33]}, {"mention": "MAO-B", "char_span": [85, 90], "sem_type": "Gene or Genome", "tok_span": [25, 29], "new_tok_span": [29, 33]}], "new_text": "Phenelzine, <START=Pharmacologic Substance> isocarboxazid <END=Pharmacologic Substance> and tranylcypromine were nonspecific, inhibiting MAO - A and <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> MAO - B <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> to about the same extent."}, {"PMID": 23210774, "id": 2, "text": "In the last decade, several inhibitors of CK2, have been discovered and characterized to be ATP-competitive compounds.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [92, 95], "name": "ATP", "tok_span": [18, 19], "new_tok_span": [20, 21]}, {"ent_type": "GENE", "char_span": [42, 45], "name": "CK2", "tok_span": [8, 10], "new_tok_span": [9, 11]}], "relation_list": [{"subject": "ATP", "sbj_char_span": [92, 95], "object": "CK2", "obj_char_span": [42, 45], "rel_type": "regulator", "sbj_tok_span": [18, 19], "obj_tok_span": [8, 10], "new_sbj_tok_span": [20, 21], "new_obj_tok_span": [9, 11]}], "umls_entity_list": [{"mention": "CK2", "char_span": [42, 45], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [8, 10], "new_tok_span": [9, 11]}], "new_text": "In the last decade, several inhibitors of <START=Amino Acid, Peptide, or Protein> CK2 <END=Amino Acid, Peptide, or Protein>, have been discovered and characterized to be ATP - competitive compounds."}, {"PMID": 18593822, "id": 0, "text": "Identification of N-terminal receptor activity-modifying protein residues important for calcitonin gene-related peptide, adrenomedullin, and amylin receptor function.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [18, 19], "name": "N", "tok_span": [2, 3], "new_tok_span": [2, 3]}, {"ent_type": "GENE", "char_span": [121, 135], "name": "adrenomedullin", "tok_span": [21, 25], "new_tok_span": [29, 33]}, {"ent_type": "GENE", "char_span": [141, 156], "name": "amylin receptor", "tok_span": [27, 30], "new_tok_span": [37, 40]}, {"ent_type": "GENE", "char_span": [88, 119], "name": "calcitonin gene-related peptide", "tok_span": [13, 20], "new_tok_span": [18, 25]}], "relation_list": [{"subject": "N", "sbj_char_span": [18, 19], "object": "calcitonin gene-related peptide", "obj_char_span": [88, 119], "rel_type": "part of", "sbj_tok_span": [2, 3], "obj_tok_span": [13, 20], "new_sbj_tok_span": [2, 3], "new_obj_tok_span": [18, 25]}, {"subject": "N", "sbj_char_span": [18, 19], "object": "adrenomedullin", "obj_char_span": [121, 135], "rel_type": "part of", "sbj_tok_span": [2, 3], "obj_tok_span": [21, 25], "new_sbj_tok_span": [2, 3], "new_obj_tok_span": [29, 33]}, {"subject": "N", "sbj_char_span": [18, 19], "object": "amylin receptor", "obj_char_span": [141, 156], "rel_type": "part of", "sbj_tok_span": [2, 3], "obj_tok_span": [27, 30], "new_sbj_tok_span": [2, 3], "new_obj_tok_span": [37, 40]}], "umls_entity_list": [{"mention": "receptor activity-modifying protein", "char_span": [29, 64], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [5, 10], "new_tok_span": [6, 11]}, {"mention": "calcitonin", "char_span": [88, 98], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [13, 16], "new_tok_span": [18, 21]}, {"mention": "calcitonin gene-related peptide", "char_span": [88, 119], "sem_type": "Gene or Genome", "tok_span": [13, 20], "new_tok_span": [18, 25]}, {"mention": "calcitonin gene-related peptide", "char_span": [88, 119], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [13, 20], "new_tok_span": [18, 25]}, {"mention": "amylin", "char_span": [141, 147], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [27, 29], "new_tok_span": [37, 39]}, {"mention": "amylin", "char_span": [141, 147], "sem_type": "Gene or Genome", "tok_span": [27, 29], "new_tok_span": [37, 39]}], "new_text": "Identification of N - terminal <START=Amino Acid, Peptide, or Protein> receptor activity - modifying protein <END=Amino Acid, Peptide, or Protein> residues important for <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> calcitonin <END=Amino Acid, Peptide, or Protein> gene - related peptide <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein>, adrenomedullin, and <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> amylin <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> receptor function."}, {"PMID": 11106255, "id": 7, "text": "To assess the feasibility of targeting these high AAAD levels for chemotherapy, AAAD inhibitors carbidopa (alpha-methyl-dopahydrazine), alpha-monofluoromethyldopa (MFMD), and 3-hydroxybenzylhydrazine (NSD-1015) were incubated (72 h) with NCI-H727 human lung carcinoid cells.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [96, 105], "name": "carbidopa", "tok_span": [17, 20], "new_tok_span": [18, 21]}, {"ent_type": "CHEMICAL", "char_span": [107, 133], "name": "alpha-methyl-dopahydrazine", "tok_span": [21, 30], "new_tok_span": [23, 32]}, {"ent_type": "CHEMICAL", "char_span": [136, 162], "name": "alpha-monofluoromethyldopa", "tok_span": [32, 39], "new_tok_span": [35, 42]}, {"ent_type": "CHEMICAL", "char_span": [164, 168], "name": "MFMD", "tok_span": [40, 42], "new_tok_span": [44, 46]}, {"ent_type": "CHEMICAL", "char_span": [175, 199], "name": "3-hydroxybenzylhydrazine", "tok_span": [45, 52], "new_tok_span": [50, 57]}, {"ent_type": "CHEMICAL", "char_span": [201, 209], "name": "NSD-1015", "tok_span": [53, 58], "new_tok_span": [60, 65]}, {"ent_type": "GENE", "char_span": [50, 54], "name": "AAAD", "tok_span": [8, 10], "new_tok_span": [8, 10]}, {"ent_type": "GENE", "char_span": [80, 84], "name": "AAAD", "tok_span": [14, 16], "new_tok_span": [14, 16]}], "relation_list": [{"subject": "carbidopa", "sbj_char_span": [96, 105], "object": "AAAD", "obj_char_span": [80, 84], "rel_type": "inhibitor", "sbj_tok_span": [17, 20], "obj_tok_span": [14, 16], "new_sbj_tok_span": [18, 21], "new_obj_tok_span": [14, 16]}, {"subject": "alpha-methyl-dopahydrazine", "sbj_char_span": [107, 133], "object": "AAAD", "obj_char_span": [80, 84], "rel_type": "inhibitor", "sbj_tok_span": [21, 30], "obj_tok_span": [14, 16], "new_sbj_tok_span": [23, 32], "new_obj_tok_span": [14, 16]}, {"subject": "alpha-monofluoromethyldopa", "sbj_char_span": [136, 162], "object": "AAAD", "obj_char_span": [80, 84], "rel_type": "inhibitor", "sbj_tok_span": [32, 39], "obj_tok_span": [14, 16], "new_sbj_tok_span": [35, 42], "new_obj_tok_span": [14, 16]}, {"subject": "MFMD", "sbj_char_span": [164, 168], "object": "AAAD", "obj_char_span": [80, 84], "rel_type": "inhibitor", "sbj_tok_span": [40, 42], "obj_tok_span": [14, 16], "new_sbj_tok_span": [44, 46], "new_obj_tok_span": [14, 16]}, {"subject": "3-hydroxybenzylhydrazine", "sbj_char_span": [175, 199], "object": "AAAD", "obj_char_span": [80, 84], "rel_type": "inhibitor", "sbj_tok_span": [45, 52], "obj_tok_span": [14, 16], "new_sbj_tok_span": [50, 57], "new_obj_tok_span": [14, 16]}, {"subject": "NSD-1015", "sbj_char_span": [201, 209], "object": "AAAD", "obj_char_span": [80, 84], "rel_type": "inhibitor", "sbj_tok_span": [53, 58], "obj_tok_span": [14, 16], "new_sbj_tok_span": [60, 65], "new_obj_tok_span": [14, 16]}], "umls_entity_list": [{"mention": "carbidopa", "char_span": [96, 105], "sem_type": "Pharmacologic Substance", "tok_span": [17, 20], "new_tok_span": [18, 21]}, {"mention": "alpha-monofluoromethyldopa", "char_span": [136, 162], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [32, 39], "new_tok_span": [35, 42]}, {"mention": "3-hydroxybenzylhydrazine", "char_span": [175, 199], "sem_type": "Pharmacologic Substance", "tok_span": [45, 52], "new_tok_span": [50, 57]}, {"mention": "NSD", "char_span": [201, 204], "sem_type": "Pharmacologic Substance", "tok_span": [53, 55], "new_tok_span": [60, 62]}], "new_text": "To assess the feasibility of targeting these high AAAD levels for chemotherapy, AAAD inhibitors <START=Pharmacologic Substance> carbidopa <END=Pharmacologic Substance> ( alpha - methyl - dopahydrazine ), <START=Amino Acid, Peptide, or Protein> alpha - monofluoromethyldopa <END=Amino Acid, Peptide, or Protein> ( MFMD ), and <START=Pharmacologic Substance> 3 - hydroxybenzylhydrazine <END=Pharmacologic Substance> ( <START=Pharmacologic Substance> NSD <END=Pharmacologic Substance> - 1015 ) were incubated ( 72 h ) with NCI - H727 human lung carcinoid cells."}, {"PMID": 15292070, "id": 6, "text": "Acarbose served as inhibitor of an interfering acid alpha-glucosidase present in neutrophils, which allowed the lysosomal enzyme implicated in Pompe disease to be selectively analyzed.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 8], "name": "Acarbose", "tok_span": [0, 3], "new_tok_span": [0, 3]}, {"ent_type": "GENE", "char_span": [47, 69], "name": "acid alpha-glucosidase", "tok_span": [9, 14], "new_tok_span": [9, 14]}], "relation_list": [{"subject": "Acarbose", "sbj_char_span": [0, 8], "object": "acid alpha-glucosidase", "obj_char_span": [47, 69], "rel_type": "inhibitor", "sbj_tok_span": [0, 3], "obj_tok_span": [9, 14], "new_sbj_tok_span": [0, 3], "new_obj_tok_span": [9, 14]}], "umls_entity_list": [{"mention": "lysosomal", "char_span": [112, 121], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [21, 22], "new_tok_span": [22, 23]}, {"mention": "Pompe disease", "char_span": [143, 156], "sem_type": "Gene or Genome", "tok_span": [25, 29], "new_tok_span": [28, 32]}], "new_text": "Acarbose served as inhibitor of an interfering acid alpha - glucosidase present in neutrophils, which allowed the <START=Amino Acid, Peptide, or Protein> lysosomal <END=Amino Acid, Peptide, or Protein> enzyme implicated in <START=Gene or Genome> Pompe disease <END=Gene or Genome> to be selectively analyzed."}, {"PMID": 10518812, "id": 5, "text": "Mometasone furoate also has strong anti-inflammatory activity, with IL-4 and IL-5 inhibition activities equivalent to those of fluticasone propionate.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 18], "name": "Mometasone furoate", "tok_span": [0, 7], "new_tok_span": [0, 7]}, {"ent_type": "CHEMICAL", "char_span": [127, 149], "name": "fluticasone propionate", "tok_span": [29, 35], "new_tok_span": [32, 38]}, {"ent_type": "GENE", "char_span": [68, 72], "name": "IL-4", "tok_span": [16, 19], "new_tok_span": [16, 19]}, {"ent_type": "GENE", "char_span": [77, 81], "name": "IL-5", "tok_span": [20, 23], "new_tok_span": [21, 24]}], "relation_list": [{"subject": "Mometasone furoate", "sbj_char_span": [0, 18], "object": "IL-4", "obj_char_span": [68, 72], "rel_type": "inhibitor", "sbj_tok_span": [0, 7], "obj_tok_span": [16, 19], "new_sbj_tok_span": [0, 7], "new_obj_tok_span": [16, 19]}, {"subject": "Mometasone furoate", "sbj_char_span": [0, 18], "object": "IL-5", "obj_char_span": [77, 81], "rel_type": "inhibitor", "sbj_tok_span": [0, 7], "obj_tok_span": [20, 23], "new_sbj_tok_span": [0, 7], "new_obj_tok_span": [21, 24]}, {"subject": "fluticasone propionate", "sbj_char_span": [127, 149], "object": "IL-4", "obj_char_span": [68, 72], "rel_type": "inhibitor", "sbj_tok_span": [29, 35], "obj_tok_span": [16, 19], "new_sbj_tok_span": [32, 38], "new_obj_tok_span": [16, 19]}, {"subject": "fluticasone propionate", "sbj_char_span": [127, 149], "object": "IL-5", "obj_char_span": [77, 81], "rel_type": "inhibitor", "sbj_tok_span": [29, 35], "obj_tok_span": [20, 23], "new_sbj_tok_span": [32, 38], "new_obj_tok_span": [21, 24]}], "umls_entity_list": [{"mention": "IL-5", "char_span": [77, 81], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [20, 23], "new_tok_span": [21, 24]}, {"mention": "fluticasone propionate", "char_span": [127, 149], "sem_type": "Pharmacologic Substance", "tok_span": [29, 35], "new_tok_span": [32, 38]}], "new_text": "Mometasone furoate also has strong anti - inflammatory activity, with IL - 4 and <START=Amino Acid, Peptide, or Protein> IL - 5 <END=Amino Acid, Peptide, or Protein> inhibition activities equivalent to those of <START=Pharmacologic Substance> fluticasone propionate <END=Pharmacologic Substance>."}, {"PMID": 15755483, "id": 1, "text": "Besides aspirin several new drugs for inhibition of platelet aggregation and 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibition are used in secondary stroke prevention.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [116, 123], "name": "HMG-CoA", "tok_span": [26, 31], "new_tok_span": [30, 35]}, {"ent_type": "CHEMICAL", "char_span": [77, 114], "name": "3-hydroxy-3-methylglutaryl-coenzyme A", "tok_span": [11, 25], "new_tok_span": [15, 29]}, {"ent_type": "CHEMICAL", "char_span": [8, 15], "name": "aspirin", "tok_span": [1, 2], "new_tok_span": [2, 3]}, {"ent_type": "GENE", "char_span": [77, 134], "name": "3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase", "tok_span": [11, 33], "new_tok_span": [15, 37]}], "relation_list": [{"subject": "aspirin", "sbj_char_span": [8, 15], "object": "3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase", "obj_char_span": [77, 134], "rel_type": "inhibitor", "sbj_tok_span": [1, 2], "obj_tok_span": [11, 33], "new_sbj_tok_span": [2, 3], "new_obj_tok_span": [15, 37]}], "umls_entity_list": [{"mention": "aspirin", "char_span": [8, 15], "sem_type": "Pharmacologic Substance", "tok_span": [1, 2], "new_tok_span": [2, 3]}, {"mention": "new drugs", "char_span": [24, 33], "sem_type": "Pharmacologic Substance", "tok_span": [3, 5], "new_tok_span": [6, 8]}], "new_text": "Besides <START=Pharmacologic Substance> aspirin <END=Pharmacologic Substance> several <START=Pharmacologic Substance> new drugs <END=Pharmacologic Substance> for inhibition of platelet aggregation and 3 - hydroxy - 3 - methylglutaryl - coenzyme A ( HMG - CoA ) reductase inhibition are used in secondary stroke prevention."}, {"PMID": 10460702, "id": 4, "text": "We found that 5-HT stimulated the conversion of [3H]L-arginine ([3H]L-Arg) to [3H]L-Cit, indicating eNOS activation.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [14, 18], "name": "5-HT", "tok_span": [3, 6], "new_tok_span": [3, 6]}, {"ent_type": "CHEMICAL", "char_span": [48, 62], "name": "[3H]L-arginine", "tok_span": [10, 17], "new_tok_span": [10, 17]}, {"ent_type": "CHEMICAL", "char_span": [64, 73], "name": "[3H]L-Arg", "tok_span": [18, 25], "new_tok_span": [20, 27]}, {"ent_type": "CHEMICAL", "char_span": [78, 87], "name": "[3H]L-Cit", "tok_span": [27, 35], "new_tok_span": [31, 39]}, {"ent_type": "GENE", "char_span": [100, 104], "name": "eNOS", "tok_span": [37, 38], "new_tok_span": [41, 42]}], "relation_list": [{"subject": "5-HT", "sbj_char_span": [14, 18], "object": "eNOS", "obj_char_span": [100, 104], "rel_type": "activator", "sbj_tok_span": [3, 6], "obj_tok_span": [37, 38], "new_sbj_tok_span": [3, 6], "new_obj_tok_span": [41, 42]}, {"subject": "[3H]L-arginine", "sbj_char_span": [48, 62], "object": "eNOS", "obj_char_span": [100, 104], "rel_type": "product or substrate", "sbj_tok_span": [10, 17], "obj_tok_span": [37, 38], "new_sbj_tok_span": [10, 17], "new_obj_tok_span": [41, 42]}, {"subject": "[3H]L-Arg", "sbj_char_span": [64, 73], "object": "eNOS", "obj_char_span": [100, 104], "rel_type": "product or substrate", "sbj_tok_span": [18, 25], "obj_tok_span": [37, 38], "new_sbj_tok_span": [20, 27], "new_obj_tok_span": [41, 42]}, {"subject": "[3H]L-Cit", "sbj_char_span": [78, 87], "object": "eNOS", "obj_char_span": [100, 104], "rel_type": "product or substrate", "sbj_tok_span": [27, 35], "obj_tok_span": [37, 38], "new_sbj_tok_span": [31, 39], "new_obj_tok_span": [41, 42]}], "umls_entity_list": [{"mention": "L-arg", "char_span": [52, 57], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [14, 17], "new_tok_span": [15, 18]}, {"mention": "L-Arg", "char_span": [68, 73], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [22, 25], "new_tok_span": [25, 28]}], "new_text": "We found that 5 - HT stimulated the conversion of [ 3H ] <START=Amino Acid, Peptide, or Protein> L - arginine <END=Amino Acid, Peptide, or Protein> ( [ 3H ] <START=Amino Acid, Peptide, or Protein> L - Arg <END=Amino Acid, Peptide, or Protein> ) to [ 3H ] L - Cit, indicating eNOS activation."}, {"PMID": 14672731, "id": 12, "text": "Data from this study have demonstrated that NOMAC is a progestin that has greater steroid receptor selectivity compared to MPA or some other synthetic progestins.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [44, 49], "name": "NOMAC", "tok_span": [7, 9], "new_tok_span": [7, 9]}, {"ent_type": "CHEMICAL", "char_span": [55, 64], "name": "progestin", "tok_span": [11, 14], "new_tok_span": [11, 14]}, {"ent_type": "CHEMICAL", "char_span": [82, 89], "name": "steroid", "tok_span": [17, 18], "new_tok_span": [18, 19]}, {"ent_type": "CHEMICAL", "char_span": [123, 126], "name": "MPA", "tok_span": [22, 24], "new_tok_span": [24, 26]}, {"ent_type": "CHEMICAL", "char_span": [151, 161], "name": "progestins", "tok_span": [28, 31], "new_tok_span": [30, 33]}, {"ent_type": "GENE", "char_span": [82, 98], "name": "steroid receptor", "tok_span": [17, 19], "new_tok_span": [18, 20]}], "relation_list": [{"subject": "NOMAC", "sbj_char_span": [44, 49], "object": "steroid receptor", "obj_char_span": [82, 98], "rel_type": "regulator", "sbj_tok_span": [7, 9], "obj_tok_span": [17, 19], "new_sbj_tok_span": [7, 9], "new_obj_tok_span": [18, 20]}, {"subject": "progestin", "sbj_char_span": [55, 64], "object": "steroid receptor", "obj_char_span": [82, 98], "rel_type": "regulator", "sbj_tok_span": [11, 14], "obj_tok_span": [17, 19], "new_sbj_tok_span": [11, 14], "new_obj_tok_span": [18, 20]}], "umls_entity_list": [{"mention": "steroid receptor", "char_span": [82, 98], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [17, 19], "new_tok_span": [18, 20]}], "new_text": "Data from this study have demonstrated that NOMAC is a progestin that has greater <START=Amino Acid, Peptide, or Protein> steroid receptor <END=Amino Acid, Peptide, or Protein> selectivity compared to MPA or some other synthetic progestins."}, {"PMID": 23103613, "id": 8, "text": "Pretreatment with NAC and specific p38-MAPK inhibitor (SB203580), but not JNK inhibitor (SP600125) effectively abrogated the phosphorylation of p38-MAPK and attenuated the apoptotic signals (including: decrease in cytotoxicity, caspase-3/-7 activation, the cytosolic cytochrome c release, and the reversed alteration of Bcl-2 and Bax mRNA) in CA-treated Neuro-2a cells.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [18, 21], "name": "NAC", "tok_span": [3, 4], "new_tok_span": [4, 5]}, {"ent_type": "CHEMICAL", "char_span": [55, 63], "name": "SB203580", "tok_span": [12, 16], "new_tok_span": [15, 19]}, {"ent_type": "CHEMICAL", "char_span": [89, 97], "name": "SP600125", "tok_span": [23, 26], "new_tok_span": [29, 32]}, {"ent_type": "GENE", "char_span": [35, 38], "name": "p38", "tok_span": [6, 8], "new_tok_span": [8, 10]}, {"ent_type": "GENE", "char_span": [39, 43], "name": "MAPK", "tok_span": [9, 10], "new_tok_span": [11, 12]}, {"ent_type": "GENE", "char_span": [74, 77], "name": "JNK", "tok_span": [20, 21], "new_tok_span": [25, 26]}, {"ent_type": "GENE", "char_span": [144, 147], "name": "p38", "tok_span": [34, 36], "new_tok_span": [40, 42]}, {"ent_type": "GENE", "char_span": [148, 152], "name": "MAPK", "tok_span": [37, 38], "new_tok_span": [43, 44]}, {"ent_type": "GENE", "char_span": [228, 240], "name": "caspase-3/-7", "tok_span": [50, 56], "new_tok_span": [56, 62]}, {"ent_type": "GENE", "char_span": [267, 279], "name": "cytochrome c", "tok_span": [60, 62], "new_tok_span": [68, 70]}, {"ent_type": "GENE", "char_span": [320, 325], "name": "Bcl-2", "tok_span": [69, 72], "new_tok_span": [80, 83]}, {"ent_type": "GENE", "char_span": [330, 333], "name": "Bax", "tok_span": [73, 74], "new_tok_span": [87, 88]}], "relation_list": [{"subject": "SB203580", "sbj_char_span": [55, 63], "object": "MAPK", "obj_char_span": [39, 43], "rel_type": "inhibitor", "sbj_tok_span": [12, 16], "obj_tok_span": [9, 10], "new_sbj_tok_span": [15, 19], "new_obj_tok_span": [11, 12]}, {"subject": "SB203580", "sbj_char_span": [55, 63], "object": "p38", "obj_char_span": [35, 38], "rel_type": "inhibitor", "sbj_tok_span": [12, 16], "obj_tok_span": [6, 8], "new_sbj_tok_span": [15, 19], "new_obj_tok_span": [8, 10]}, {"subject": "SP600125", "sbj_char_span": [89, 97], "object": "JNK", "obj_char_span": [74, 77], "rel_type": "inhibitor", "sbj_tok_span": [23, 26], "obj_tok_span": [20, 21], "new_sbj_tok_span": [29, 32], "new_obj_tok_span": [25, 26]}, {"subject": "NAC", "sbj_char_span": [18, 21], "object": "MAPK", "obj_char_span": [148, 152], "rel_type": "inhibitor", "sbj_tok_span": [3, 4], "obj_tok_span": [37, 38], "new_sbj_tok_span": [4, 5], "new_obj_tok_span": [43, 44]}, {"subject": "NAC", "sbj_char_span": [18, 21], "object": "p38", "obj_char_span": [144, 147], "rel_type": "inhibitor", "sbj_tok_span": [3, 4], "obj_tok_span": [34, 36], "new_sbj_tok_span": [4, 5], "new_obj_tok_span": [40, 42]}, {"subject": "SB203580", "sbj_char_span": [55, 63], "object": "p38", "obj_char_span": [144, 147], "rel_type": "inhibitor", "sbj_tok_span": [12, 16], "obj_tok_span": [34, 36], "new_sbj_tok_span": [15, 19], "new_obj_tok_span": [40, 42]}, {"subject": "SB203580", "sbj_char_span": [55, 63], "object": "MAPK", "obj_char_span": [148, 152], "rel_type": "inhibitor", "sbj_tok_span": [12, 16], "obj_tok_span": [37, 38], "new_sbj_tok_span": [15, 19], "new_obj_tok_span": [43, 44]}], "umls_entity_list": [{"mention": "NAC", "char_span": [18, 21], "sem_type": "Gene or Genome", "tok_span": [3, 4], "new_tok_span": [4, 5]}, {"mention": "SB203580", "char_span": [55, 63], "sem_type": "Pharmacologic Substance", "tok_span": [12, 16], "new_tok_span": [15, 19]}, {"mention": "JNK", "char_span": [74, 77], "sem_type": "Gene or Genome", "tok_span": [20, 21], "new_tok_span": [25, 26]}, {"mention": "cytochrome c", "char_span": [267, 279], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [60, 62], "new_tok_span": [68, 70]}, {"mention": "cytochrome c", "char_span": [267, 279], "sem_type": "Gene or Genome", "tok_span": [60, 62], "new_tok_span": [68, 70]}, {"mention": "Bcl-2", "char_span": [320, 325], "sem_type": "Gene or Genome", "tok_span": [69, 72], "new_tok_span": [80, 83]}, {"mention": "Bax", "char_span": [330, 333], "sem_type": "Gene or Genome", "tok_span": [73, 74], "new_tok_span": [87, 88]}, {"mention": "Bax", "char_span": [330, 333], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [73, 74], "new_tok_span": [87, 88]}], "new_text": "Pretreatment with <START=Gene or Genome> NAC <END=Gene or Genome> and specific p38 - MAPK inhibitor ( <START=Pharmacologic Substance> SB203580 <END=Pharmacologic Substance> ), but not <START=Gene or Genome> JNK <END=Gene or Genome> inhibitor ( SP600125 ) effectively abrogated the phosphorylation of p38 - MAPK and attenuated the apoptotic signals ( including : decrease in cytotoxicity, caspase - 3 / - 7 activation, the cytosolic <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> cytochrome c <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> release, and the reversed alteration of <START=Gene or Genome> Bcl - 2 <END=Gene or Genome> and <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> Bax <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> mRNA ) in CA - treated Neuro - 2a cells."}, {"PMID": 17034761, "id": 7, "text": "IRF3 activation induced by MyD88-independent signaling components, TRIF and TBK1, was also downregulated by auranofin.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [108, 117], "name": "auranofin", "tok_span": [24, 27], "new_tok_span": [39, 42]}, {"ent_type": "GENE", "char_span": [0, 4], "name": "IRF3", "tok_span": [0, 2], "new_tok_span": [2, 4]}, {"ent_type": "GENE", "char_span": [27, 32], "name": "MyD88", "tok_span": [5, 8], "new_tok_span": [11, 14]}, {"ent_type": "GENE", "char_span": [67, 71], "name": "TRIF", "tok_span": [13, 15], "new_tok_span": [22, 24]}, {"ent_type": "GENE", "char_span": [76, 80], "name": "TBK1", "tok_span": [16, 19], "new_tok_span": [28, 31]}], "relation_list": [{"subject": "auranofin", "sbj_char_span": [108, 117], "object": "TRIF", "obj_char_span": [67, 71], "rel_type": "regulator", "sbj_tok_span": [24, 27], "obj_tok_span": [13, 15], "new_sbj_tok_span": [39, 42], "new_obj_tok_span": [22, 24]}, {"subject": "auranofin", "sbj_char_span": [108, 117], "object": "TBK1", "obj_char_span": [76, 80], "rel_type": "regulator", "sbj_tok_span": [24, 27], "obj_tok_span": [16, 19], "new_sbj_tok_span": [39, 42], "new_obj_tok_span": [28, 31]}], "umls_entity_list": [{"mention": "IRF3", "char_span": [0, 4], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [0, 2], "new_tok_span": [2, 4]}, {"mention": "IRF3", "char_span": [0, 4], "sem_type": "Gene or Genome", "tok_span": [0, 2], "new_tok_span": [2, 4]}, {"mention": "MyD88", "char_span": [27, 32], "sem_type": "Gene or Genome", "tok_span": [5, 8], "new_tok_span": [11, 14]}, {"mention": "MyD88", "char_span": [27, 32], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [5, 8], "new_tok_span": [11, 14]}, {"mention": "TRIF", "char_span": [67, 71], "sem_type": "Gene or Genome", "tok_span": [13, 15], "new_tok_span": [22, 24]}, {"mention": "TBK1", "char_span": [76, 80], "sem_type": "Gene or Genome", "tok_span": [16, 19], "new_tok_span": [28, 31]}, {"mention": "TBK1", "char_span": [76, 80], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [16, 19], "new_tok_span": [28, 31]}, {"mention": "auranofin", "char_span": [108, 117], "sem_type": "Pharmacologic Substance", "tok_span": [24, 27], "new_tok_span": [39, 42]}], "new_text": "<START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> IRF3 <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> activation induced by <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> MyD88 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> - independent signaling components, <START=Gene or Genome> TRIF <END=Gene or Genome> and <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> TBK1 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein>, was also downregulated by <START=Pharmacologic Substance> auranofin <END=Pharmacologic Substance>."}, {"PMID": 1361547, "id": 4, "text": "Labetalol (> or = 3 x 10(-8) M) and dilevalol (> or = 10(-8) M) caused surmountable antagonism of the isoprenaline responses of the atria and the pA2 values were 8.60 and 8.98 at the beta 1-adrenoceptors of the rat left atria and 7.90 and 8.31, respectively, on the guinea-pig left atria which has functional beta 1- and beta 2-adrenoceptors.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 9], "name": "Labetalol", "tok_span": [0, 3], "new_tok_span": [1, 4]}, {"ent_type": "CHEMICAL", "char_span": [36, 45], "name": "dilevalol", "tok_span": [17, 20], "new_tok_span": [20, 23]}, {"ent_type": "CHEMICAL", "char_span": [102, 114], "name": "isoprenaline", "tok_span": [40, 43], "new_tok_span": [44, 47]}, {"ent_type": "GENE", "char_span": [183, 203], "name": "beta 1-adrenoceptors", "tok_span": [63, 70], "new_tok_span": [67, 74]}, {"ent_type": "GENE", "char_span": [309, 341], "name": "beta 1- and beta 2-adrenoceptors", "tok_span": [98, 109], "new_tok_span": [102, 113]}], "relation_list": [{"subject": "Labetalol", "sbj_char_span": [0, 9], "object": "beta 1-adrenoceptors", "obj_char_span": [183, 203], "rel_type": "agonist or antagonist", "sbj_tok_span": [0, 3], "obj_tok_span": [63, 70], "new_sbj_tok_span": [1, 4], "new_obj_tok_span": [67, 74]}, {"subject": "dilevalol", "sbj_char_span": [36, 45], "object": "beta 1-adrenoceptors", "obj_char_span": [183, 203], "rel_type": "agonist or antagonist", "sbj_tok_span": [17, 20], "obj_tok_span": [63, 70], "new_sbj_tok_span": [20, 23], "new_obj_tok_span": [67, 74]}, {"subject": "isoprenaline", "sbj_char_span": [102, 114], "object": "beta 1-adrenoceptors", "obj_char_span": [183, 203], "rel_type": "agonist or antagonist", "sbj_tok_span": [40, 43], "obj_tok_span": [63, 70], "new_sbj_tok_span": [44, 47], "new_obj_tok_span": [67, 74]}], "umls_entity_list": [{"mention": "Labetalol", "char_span": [0, 9], "sem_type": "Pharmacologic Substance", "tok_span": [0, 3], "new_tok_span": [1, 4]}, {"mention": "dilevalol", "char_span": [36, 45], "sem_type": "Pharmacologic Substance", "tok_span": [17, 20], "new_tok_span": [20, 23]}], "new_text": "<START=Pharmacologic Substance> Labetalol <END=Pharmacologic Substance> ( > or = 3 x 10 ( - 8 ) M ) and <START=Pharmacologic Substance> dilevalol <END=Pharmacologic Substance> ( > or = 10 ( - 8 ) M ) caused surmountable antagonism of the isoprenaline responses of the atria and the pA2 values were 8. 60 and 8. 98 at the beta 1 - adrenoceptors of the rat left atria and 7. 90 and 8. 31, respectively, on the guinea - pig left atria which has functional beta 1 - and beta 2 - adrenoceptors."}, {"PMID": 1361547, "id": 7, "text": "It is concluded that labetalol and dilevalol are beta 1-adrenoceptor selective antagonists.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [21, 30], "name": "labetalol", "tok_span": [4, 7], "new_tok_span": [4, 7]}, {"ent_type": "CHEMICAL", "char_span": [35, 44], "name": "dilevalol", "tok_span": [8, 11], "new_tok_span": [8, 11]}, {"ent_type": "GENE", "char_span": [49, 68], "name": "beta 1-adrenoceptor", "tok_span": [12, 18], "new_tok_span": [12, 18]}], "relation_list": [{"subject": "labetalol", "sbj_char_span": [21, 30], "object": "beta 1-adrenoceptor", "obj_char_span": [49, 68], "rel_type": "agonist or antagonist", "sbj_tok_span": [4, 7], "obj_tok_span": [12, 18], "new_sbj_tok_span": [4, 7], "new_obj_tok_span": [12, 18]}, {"subject": "dilevalol", "sbj_char_span": [35, 44], "object": "beta 1-adrenoceptor", "obj_char_span": [49, 68], "rel_type": "agonist or antagonist", "sbj_tok_span": [8, 11], "obj_tok_span": [12, 18], "new_sbj_tok_span": [8, 11], "new_obj_tok_span": [12, 18]}], "umls_entity_list": [], "new_text": "It is concluded that labetalol and dilevalol are beta 1 - adrenoceptor selective antagonists."}, {"PMID": 17403555, "id": 6, "text": "MK-801 ((+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate), a noncompetitive NMDA receptor antagonist, partially prevented the decrease in cell viability and the energy impairment.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 6], "name": "MK-801", "tok_span": [0, 4], "new_tok_span": [0, 4]}, {"ent_type": "CHEMICAL", "char_span": [8, 80], "name": "(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate", "tok_span": [5, 43], "new_tok_span": [5, 43]}, {"ent_type": "CHEMICAL", "char_span": [100, 104], "name": "NMDA", "tok_span": [50, 51], "new_tok_span": [54, 55]}, {"ent_type": "GENE", "char_span": [100, 113], "name": "NMDA receptor", "tok_span": [50, 52], "new_tok_span": [54, 56]}], "relation_list": [{"subject": "(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate", "sbj_char_span": [8, 80], "object": "NMDA receptor", "obj_char_span": [100, 113], "rel_type": "agonist or antagonist", "sbj_tok_span": [5, 43], "obj_tok_span": [50, 52], "new_sbj_tok_span": [5, 43], "new_obj_tok_span": [54, 56]}, {"subject": "MK-801", "sbj_char_span": [0, 6], "object": "NMDA receptor", "obj_char_span": [100, 113], "rel_type": "agonist or antagonist", "sbj_tok_span": [0, 4], "obj_tok_span": [50, 52], "new_sbj_tok_span": [0, 4], "new_obj_tok_span": [54, 56]}], "umls_entity_list": [{"mention": "imine", "char_span": [67, 72], "sem_type": "Organic Chemical", "tok_span": [39, 41], "new_tok_span": [40, 42]}, {"mention": "NMDA", "char_span": [100, 104], "sem_type": "Pharmacologic Substance", "tok_span": [50, 51], "new_tok_span": [54, 55]}, {"mention": "NMDA receptor antagonist", "char_span": [100, 124], "sem_type": "Pharmacologic Substance", "tok_span": [50, 53], "new_tok_span": [54, 57]}], "new_text": "MK - 801 ( ( + ) - 5 - methyl - 10, 11 - dihydro - 5H - dibenzo [ a, d ] cyclohepten - 5, 10 - <START=Organic Chemical> imine <END=Organic Chemical> maleate ), a noncompetitive <START=Pharmacologic Substance> <START=Pharmacologic Substance> NMDA <END=Pharmacologic Substance> receptor antagonist <END=Pharmacologic Substance>, partially prevented the decrease in cell viability and the energy impairment."}, {"PMID": 14626653, "id": 7, "text": "Vardenafil has a more potent inhibitory activity of PDE5 in vitro than sildenafil or tadalafil while its pharmacokinetics in vivo is somewhat more rapid than that of the two other compounds.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 10], "name": "Vardenafil", "tok_span": [0, 3], "new_tok_span": [0, 3]}, {"ent_type": "CHEMICAL", "char_span": [71, 81], "name": "sildenafil", "tok_span": [15, 18], "new_tok_span": [18, 21]}, {"ent_type": "CHEMICAL", "char_span": [85, 94], "name": "tadalafil", "tok_span": [19, 23], "new_tok_span": [23, 27]}, {"ent_type": "GENE", "char_span": [52, 56], "name": "PDE5", "tok_span": [10, 12], "new_tok_span": [11, 13]}], "relation_list": [{"subject": "Vardenafil", "sbj_char_span": [0, 10], "object": "PDE5", "obj_char_span": [52, 56], "rel_type": "inhibitor", "sbj_tok_span": [0, 3], "obj_tok_span": [10, 12], "new_sbj_tok_span": [0, 3], "new_obj_tok_span": [11, 13]}], "umls_entity_list": [{"mention": "PDE5", "char_span": [52, 56], "sem_type": "Gene or Genome", "tok_span": [10, 12], "new_tok_span": [11, 13]}, {"mention": "sildenafil", "char_span": [71, 81], "sem_type": "Pharmacologic Substance", "tok_span": [15, 18], "new_tok_span": [18, 21]}], "new_text": "Vardenafil has a more potent inhibitory activity of <START=Gene or Genome> PDE5 <END=Gene or Genome> in vitro than <START=Pharmacologic Substance> sildenafil <END=Pharmacologic Substance> or tadalafil while its pharmacokinetics in vivo is somewhat more rapid than that of the two other compounds."}, {"PMID": 12470615, "id": 0, "text": "Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [106, 116], "name": "resiquimod", "tok_span": [22, 26], "new_tok_span": [29, 33]}, {"ent_type": "CHEMICAL", "char_span": [92, 101], "name": "imiquimod", "tok_span": [17, 21], "new_tok_span": [22, 26]}, {"ent_type": "GENE", "char_span": [37, 46], "name": "cytokines", "tok_span": [6, 7], "new_tok_span": [7, 8]}, {"ent_type": "GENE", "char_span": [77, 81], "name": "TLR7", "tok_span": [13, 15], "new_tok_span": [16, 18]}], "relation_list": [{"subject": "imiquimod", "sbj_char_span": [92, 101], "object": "TLR7", "obj_char_span": [77, 81], "rel_type": "agonist or antagonist", "sbj_tok_span": [17, 21], "obj_tok_span": [13, 15], "new_sbj_tok_span": [22, 26], "new_obj_tok_span": [16, 18]}, {"subject": "resiquimod", "sbj_char_span": [106, 116], "object": "TLR7", "obj_char_span": [77, 81], "rel_type": "agonist or antagonist", "sbj_tok_span": [22, 26], "obj_tok_span": [13, 15], "new_sbj_tok_span": [29, 33], "new_obj_tok_span": [16, 18]}], "umls_entity_list": [{"mention": "cytokines", "char_span": [37, 46], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [6, 7], "new_tok_span": [7, 8]}, {"mention": "TLR7 agonist", "char_span": [77, 89], "sem_type": "Pharmacologic Substance", "tok_span": [13, 16], "new_tok_span": [16, 19]}, {"mention": "imiquimod", "char_span": [92, 101], "sem_type": "Pharmacologic Substance", "tok_span": [17, 21], "new_tok_span": [22, 26]}, {"mention": "resiquimod", "char_span": [106, 116], "sem_type": "Pharmacologic Substance", "tok_span": [22, 26], "new_tok_span": [29, 33]}], "new_text": "Plasmacytoid dendritic cells produce <START=Amino Acid, Peptide, or Protein> cytokines <END=Amino Acid, Peptide, or Protein> and mature in response to the <START=Pharmacologic Substance> TLR7 agonists <END=Pharmacologic Substance>, <START=Pharmacologic Substance> imiquimod <END=Pharmacologic Substance> and <START=Pharmacologic Substance> resiquimod <END=Pharmacologic Substance>."}, {"PMID": 11688549, "id": 3, "text": "The transport amiloride-sensitive mechanism, that decreased the acidic intracellular pH change occurring in this medium, would correspond to Na+-H+ exchange (NHE1 isoform).", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [14, 23], "name": "amiloride", "tok_span": [2, 6], "new_tok_span": [3, 7]}, {"ent_type": "CHEMICAL", "char_span": [141, 144], "name": "Na+", "tok_span": [25, 27], "new_tok_span": [29, 31]}, {"ent_type": "CHEMICAL", "char_span": [145, 147], "name": "H+", "tok_span": [28, 30], "new_tok_span": [32, 34]}, {"ent_type": "GENE", "char_span": [158, 162], "name": "NHE1", "tok_span": [32, 35], "new_tok_span": [38, 41]}], "relation_list": [{"subject": "Na+", "sbj_char_span": [141, 144], "object": "NHE1", "obj_char_span": [158, 162], "rel_type": "product or substrate", "sbj_tok_span": [25, 27], "obj_tok_span": [32, 35], "new_sbj_tok_span": [29, 31], "new_obj_tok_span": [38, 41]}, {"subject": "H+", "sbj_char_span": [145, 147], "object": "NHE1", "obj_char_span": [158, 162], "rel_type": "product or substrate", "sbj_tok_span": [28, 30], "obj_tok_span": [32, 35], "new_sbj_tok_span": [32, 34], "new_obj_tok_span": [38, 41]}], "umls_entity_list": [{"mention": "amiloride", "char_span": [14, 23], "sem_type": "Pharmacologic Substance", "tok_span": [2, 6], "new_tok_span": [3, 7]}, {"mention": "pH", "char_span": [85, 87], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [15, 16], "new_tok_span": [18, 19]}, {"mention": "NHE1", "char_span": [158, 162], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [32, 35], "new_tok_span": [38, 41]}, {"mention": "isoform", "char_span": [163, 170], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [35, 36], "new_tok_span": [44, 45]}, {"mention": "NHE1", "char_span": [158, 162], "sem_type": "Gene or Genome", "tok_span": [32, 35], "new_tok_span": [38, 41]}], "new_text": "The transport <START=Pharmacologic Substance> amiloride <END=Pharmacologic Substance> - sensitive mechanism, that decreased the acidic intracellular <START=Amino Acid, Peptide, or Protein> pH <END=Amino Acid, Peptide, or Protein> change occurring in this medium, would correspond to Na + - H + exchange ( <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> NHE1 <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> <START=Amino Acid, Peptide, or Protein> isoform <END=Amino Acid, Peptide, or Protein> )."}, {"PMID": 12564662, "id": 3, "text": "Serum thromboxane (TX) B2 and plasma prostaglandin (PG) E2 levels were measured by specific radioimmunoassays as indices of platelet COX-1 and monocyte COX-2 activity, respectively.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [6, 25], "name": "thromboxane (TX) B2", "tok_span": [1, 9], "new_tok_span": [1, 9]}, {"ent_type": "CHEMICAL", "char_span": [37, 58], "name": "prostaglandin (PG) E2", "tok_span": [11, 17], "new_tok_span": [11, 17]}, {"ent_type": "GENE", "char_span": [133, 138], "name": "COX-1", "tok_span": [31, 34], "new_tok_span": [31, 34]}, {"ent_type": "GENE", "char_span": [152, 157], "name": "COX-2", "tok_span": [36, 39], "new_tok_span": [36, 39]}], "relation_list": [{"subject": "thromboxane (TX) B2", "sbj_char_span": [6, 25], "object": "COX-1", "obj_char_span": [133, 138], "rel_type": "product or substrate", "sbj_tok_span": [1, 9], "obj_tok_span": [31, 34], "new_sbj_tok_span": [1, 9], "new_obj_tok_span": [31, 34]}, {"subject": "thromboxane (TX) B2", "sbj_char_span": [6, 25], "object": "COX-2", "obj_char_span": [152, 157], "rel_type": "product or substrate", "sbj_tok_span": [1, 9], "obj_tok_span": [36, 39], "new_sbj_tok_span": [1, 9], "new_obj_tok_span": [36, 39]}, {"subject": "prostaglandin (PG) E2", "sbj_char_span": [37, 58], "object": "COX-1", "obj_char_span": [133, 138], "rel_type": "product or substrate", "sbj_tok_span": [11, 17], "obj_tok_span": [31, 34], "new_sbj_tok_span": [11, 17], "new_obj_tok_span": [31, 34]}, {"subject": "prostaglandin (PG) E2", "sbj_char_span": [37, 58], "object": "COX-2", "obj_char_span": [152, 157], "rel_type": "product or substrate", "sbj_tok_span": [11, 17], "obj_tok_span": [36, 39], "new_sbj_tok_span": [11, 17], "new_obj_tok_span": [36, 39]}], "umls_entity_list": [], "new_text": "Serum thromboxane ( TX ) B2 and plasma prostaglandin ( PG ) E2 levels were measured by specific radioimmunoassays as indices of platelet COX - 1 and monocyte COX - 2 activity, respectively."}, {"PMID": 3094574, "id": 0, "text": "Tyrosinase catalyzes an unusual oxidative decarboxylation of 3,4-dihydroxymandelate.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [61, 83], "name": "3,4-dihydroxymandelate", "tok_span": [12, 21], "new_tok_span": [18, 27]}, {"ent_type": "GENE", "char_span": [0, 10], "name": "Tyrosinase", "tok_span": [0, 3], "new_tok_span": [2, 5]}], "relation_list": [{"subject": "3,4-dihydroxymandelate", "sbj_char_span": [61, 83], "object": "Tyrosinase", "obj_char_span": [0, 10], "rel_type": "product or substrate", "sbj_tok_span": [12, 21], "obj_tok_span": [0, 3], "new_sbj_tok_span": [18, 27], "new_obj_tok_span": [2, 5]}], "umls_entity_list": [{"mention": "Tyrosinase", "char_span": [0, 10], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [0, 3], "new_tok_span": [2, 5]}, {"mention": "Tyrosinase", "char_span": [0, 10], "sem_type": "Gene or Genome", "tok_span": [0, 3], "new_tok_span": [2, 5]}, {"mention": "an", "char_span": [21, 23], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [5, 6], "new_tok_span": [10, 11]}, {"mention": "an", "char_span": [75, 77], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [18, 19], "new_tok_span": [25, 26]}], "new_text": "<START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> Tyrosinase <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> catalyzes <START=Amino Acid, Peptide, or Protein> an <END=Amino Acid, Peptide, or Protein> unusual oxidative decarboxylation of 3, 4 - dihydroxy <START=Amino Acid, Peptide, or Protein>man <END=Amino Acid, Peptide, or Protein>delate."}, {"PMID": 23528300, "id": 1, "text": "A series of benzoxazole compounds containing oxamic acid were synthesized and screened for the PTP1B inhibition.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [12, 23], "name": "benzoxazole", "tok_span": [3, 6], "new_tok_span": [4, 7]}, {"ent_type": "CHEMICAL", "char_span": [45, 56], "name": "oxamic acid", "tok_span": [8, 11], "new_tok_span": [11, 14]}, {"ent_type": "GENE", "char_span": [95, 100], "name": "PTP1B", "tok_span": [17, 20], "new_tok_span": [22, 25]}], "relation_list": [{"subject": "oxamic acid", "sbj_char_span": [45, 56], "object": "PTP1B", "obj_char_span": [95, 100], "rel_type": "inhibitor", "sbj_tok_span": [8, 11], "obj_tok_span": [17, 20], "new_sbj_tok_span": [11, 14], "new_obj_tok_span": [22, 25]}, {"subject": "benzoxazole", "sbj_char_span": [12, 23], "object": "PTP1B", "obj_char_span": [95, 100], "rel_type": "inhibitor", "sbj_tok_span": [3, 6], "obj_tok_span": [17, 20], "new_sbj_tok_span": [4, 7], "new_obj_tok_span": [22, 25]}], "umls_entity_list": [{"mention": "benzoxazole", "char_span": [12, 23], "sem_type": "Organic Chemical", "tok_span": [3, 6], "new_tok_span": [4, 7]}, {"mention": "oxamic", "char_span": [45, 51], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [8, 10], "new_tok_span": [11, 13]}, {"mention": "PTP1B", "char_span": [95, 100], "sem_type": "Gene or Genome", "tok_span": [17, 20], "new_tok_span": [22, 25]}], "new_text": "A series of <START=Organic Chemical> benzoxazole <END=Organic Chemical> compounds containing <START=Amino Acid, Peptide, or Protein> oxamic <END=Amino Acid, Peptide, or Protein> acid were synthesized and screened for the <START=Gene or Genome> PTP1B <END=Gene or Genome> inhibition."}, {"PMID": 23376161, "id": 5, "text": "Catalpol also suppressed AGE-induced phosphorylation of mitogen activated protein (MAP) kinases, degradation of IκBα and the nuclear localization of NF-κB.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 8], "name": "Catalpol", "tok_span": [0, 2], "new_tok_span": [1, 3]}, {"ent_type": "GENE", "char_span": [149, 154], "name": "NF-κB", "tok_span": [29, 33], "new_tok_span": [37, 41]}, {"ent_type": "GENE", "char_span": [56, 95], "name": "mitogen activated protein (MAP) kinases", "tok_span": [10, 17], "new_tok_span": [14, 21]}, {"ent_type": "GENE", "char_span": [112, 116], "name": "IκBα", "tok_span": [20, 24], "new_tok_span": [28, 32]}], "relation_list": [{"subject": "Catalpol", "sbj_char_span": [0, 8], "object": "mitogen activated protein (MAP) kinases", "obj_char_span": [56, 95], "rel_type": "inhibitor", "sbj_tok_span": [0, 2], "obj_tok_span": [10, 17], "new_sbj_tok_span": [1, 3], "new_obj_tok_span": [14, 21]}, {"subject": "Catalpol", "sbj_char_span": [0, 8], "object": "IκBα", "obj_char_span": [112, 116], "rel_type": "regulator", "sbj_tok_span": [0, 2], "obj_tok_span": [20, 24], "new_sbj_tok_span": [1, 3], "new_obj_tok_span": [28, 32]}, {"subject": "Catalpol", "sbj_char_span": [0, 8], "object": "NF-κB", "obj_char_span": [149, 154], "rel_type": "regulator", "sbj_tok_span": [0, 2], "obj_tok_span": [29, 33], "new_sbj_tok_span": [1, 3], "new_obj_tok_span": [37, 41]}], "umls_entity_list": [{"mention": "Catalpol", "char_span": [0, 8], "sem_type": "Organic Chemical", "tok_span": [0, 2], "new_tok_span": [1, 3]}, {"mention": "mitogen", "char_span": [56, 63], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [10, 11], "new_tok_span": [14, 15]}, {"mention": "protein", "char_span": [74, 81], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [12, 13], "new_tok_span": [19, 20]}, {"mention": "mitogen", "char_span": [56, 63], "sem_type": "Pharmacologic Substance", "tok_span": [10, 11], "new_tok_span": [14, 15]}], "new_text": "<START=Organic Chemical> Catalpol <END=Organic Chemical> also suppressed AGE - induced phosphorylation of <START=Amino Acid, Peptide, or Protein> <START=Pharmacologic Substance> mitogen <END=Amino Acid, Peptide, or Protein> <END=Pharmacologic Substance> activated <START=Amino Acid, Peptide, or Protein> protein <END=Amino Acid, Peptide, or Protein> ( MAP ) kinases, degradation of IκBα and the nuclear localization of NF - κB."}, {"PMID": 17979301, "id": 0, "text": "Critical amino acids in phosphodiesterase-5 catalytic site that provide for high-affinity interaction with cyclic guanosine monophosphate and inhibitors.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [107, 137], "name": "cyclic guanosine monophosphate", "tok_span": [20, 28], "new_tok_span": [24, 32]}, {"ent_type": "CHEMICAL", "char_span": [9, 20], "name": "amino acids", "tok_span": [1, 3], "new_tok_span": [2, 4]}, {"ent_type": "GENE", "char_span": [24, 43], "name": "phosphodiesterase-5", "tok_span": [4, 10], "new_tok_span": [7, 13]}], "relation_list": [{"subject": "amino acids", "sbj_char_span": [9, 20], "object": "phosphodiesterase-5", "obj_char_span": [24, 43], "rel_type": "part of", "sbj_tok_span": [1, 3], "obj_tok_span": [4, 10], "new_sbj_tok_span": [2, 4], "new_obj_tok_span": [7, 13]}, {"subject": "cyclic guanosine monophosphate", "sbj_char_span": [107, 137], "object": "phosphodiesterase-5", "obj_char_span": [24, 43], "rel_type": "regulator", "sbj_tok_span": [20, 28], "obj_tok_span": [4, 10], "new_sbj_tok_span": [24, 32], "new_obj_tok_span": [7, 13]}], "umls_entity_list": [{"mention": "amino acids", "char_span": [9, 20], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [1, 3], "new_tok_span": [2, 4]}, {"mention": "phosphodiesterase-5", "char_span": [24, 43], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [4, 10], "new_tok_span": [7, 13]}], "new_text": "Critical <START=Amino Acid, Peptide, or Protein> amino acids <END=Amino Acid, Peptide, or Protein> in <START=Amino Acid, Peptide, or Protein> phosphodiesterase - 5 <END=Amino Acid, Peptide, or Protein> catalytic site that provide for high - affinity interaction with cyclic guanosine monophosphate and inhibitors."}, {"PMID": 23531217, "id": 1, "text": "K203 is an experimental bis-pyridinium mono-aldoxime type cholinesterase reactivator of potential use in organophosphate/ organophosphonate poisoning.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [105, 120], "name": "organophosphate", "tok_span": [26, 28], "new_tok_span": [32, 34]}, {"ent_type": "CHEMICAL", "char_span": [122, 139], "name": "organophosphonate", "tok_span": [29, 32], "new_tok_span": [35, 38]}, {"ent_type": "CHEMICAL", "char_span": [24, 52], "name": "bis-pyridinium mono-aldoxime", "tok_span": [5, 15], "new_tok_span": [6, 16]}, {"ent_type": "GENE", "char_span": [58, 72], "name": "cholinesterase", "tok_span": [16, 19], "new_tok_span": [21, 24]}], "relation_list": [{"subject": "bis-pyridinium mono-aldoxime", "sbj_char_span": [24, 52], "object": "cholinesterase", "obj_char_span": [58, 72], "rel_type": "activator", "sbj_tok_span": [5, 15], "obj_tok_span": [16, 19], "new_sbj_tok_span": [6, 16], "new_obj_tok_span": [21, 24]}, {"subject": "organophosphate", "sbj_char_span": [105, 120], "object": "cholinesterase", "obj_char_span": [58, 72], "rel_type": "inhibitor", "sbj_tok_span": [26, 28], "obj_tok_span": [16, 19], "new_sbj_tok_span": [32, 34], "new_obj_tok_span": [21, 24]}, {"subject": "organophosphonate", "sbj_char_span": [122, 139], "object": "cholinesterase", "obj_char_span": [58, 72], "rel_type": "inhibitor", "sbj_tok_span": [29, 32], "obj_tok_span": [16, 19], "new_sbj_tok_span": [35, 38], "new_obj_tok_span": [21, 24]}], "umls_entity_list": [{"mention": "aldoxime", "char_span": [44, 52], "sem_type": "Organic Chemical", "tok_span": [12, 15], "new_tok_span": [15, 18]}, {"mention": "cholinesterase reactivator", "char_span": [58, 84], "sem_type": "Pharmacologic Substance", "tok_span": [16, 22], "new_tok_span": [21, 27]}, {"mention": "bis", "char_span": [24, 27], "sem_type": "Gene or Genome", "tok_span": [5, 6], "new_tok_span": [6, 7]}], "new_text": "K203 is an experimental <START=Gene or Genome> bis <END=Gene or Genome> - pyridinium mono - <START=Organic Chemical> aldoxime <END=Organic Chemical> type <START=Pharmacologic Substance> cholinesterase reactivator <END=Pharmacologic Substance> of potential use in organophosphate / organophosphonate poisoning."}, {"PMID": 16010590, "id": 13, "text": "The drug interaction may partly be dependent on the folate homeostasis since WiDr/F cells growing at low folate conditions show pronounced synergism in growth inhibition, two-sided TS inhibition and DNA damage, especially when TFT is combined with the tight-binding TS inhibitor GW1843.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [52, 58], "name": "folate", "tok_span": [9, 10], "new_tok_span": [10, 11]}, {"ent_type": "CHEMICAL", "char_span": [105, 111], "name": "folate", "tok_span": [20, 21], "new_tok_span": [23, 24]}, {"ent_type": "CHEMICAL", "char_span": [227, 230], "name": "TFT", "tok_span": [42, 44], "new_tok_span": [46, 48]}, {"ent_type": "CHEMICAL", "char_span": [279, 285], "name": "GW1843", "tok_span": [53, 56], "new_tok_span": [58, 61]}, {"ent_type": "GENE", "char_span": [181, 183], "name": "TS", "tok_span": [34, 35], "new_tok_span": [38, 39]}, {"ent_type": "GENE", "char_span": [266, 268], "name": "TS", "tok_span": [51, 52], "new_tok_span": [55, 56]}], "relation_list": [{"subject": "TFT", "sbj_char_span": [227, 230], "object": "TS", "obj_char_span": [181, 183], "rel_type": "inhibitor", "sbj_tok_span": [42, 44], "obj_tok_span": [34, 35], "new_sbj_tok_span": [46, 48], "new_obj_tok_span": [38, 39]}, {"subject": "GW1843", "sbj_char_span": [279, 285], "object": "TS", "obj_char_span": [266, 268], "rel_type": "inhibitor", "sbj_tok_span": [53, 56], "obj_tok_span": [51, 52], "new_sbj_tok_span": [58, 61], "new_obj_tok_span": [55, 56]}, {"subject": "GW1843", "sbj_char_span": [279, 285], "object": "TS", "obj_char_span": [181, 183], "rel_type": "inhibitor", "sbj_tok_span": [53, 56], "obj_tok_span": [34, 35], "new_sbj_tok_span": [58, 61], "new_obj_tok_span": [38, 39]}], "umls_entity_list": [{"mention": "folate", "char_span": [52, 58], "sem_type": "Pharmacologic Substance", "tok_span": [9, 10], "new_tok_span": [10, 11]}, {"mention": "folate", "char_span": [105, 111], "sem_type": "Pharmacologic Substance", "tok_span": [20, 21], "new_tok_span": [23, 24]}, {"mention": "GW1843", "char_span": [279, 285], "sem_type": "Pharmacologic Substance", "tok_span": [53, 56], "new_tok_span": [58, 61]}], "new_text": "The drug interaction may partly be dependent on the <START=Pharmacologic Substance> folate <END=Pharmacologic Substance> homeostasis since WiDr / F cells growing at low <START=Pharmacologic Substance> folate <END=Pharmacologic Substance> conditions show pronounced synergism in growth inhibition, two - sided TS inhibition and DNA damage, especially when TFT is combined with the tight - binding TS inhibitor <START=Pharmacologic Substance> GW1843 <END=Pharmacologic Substance>."}, {"PMID": 23028140, "id": 5, "text": "In vitro, CYP2C8 inhibitors and CYP3A4 inhibitors inhibited the depletion of 0.1 µM imatinib by 45 and 80%, respectively, and the formation of the main metabolite of imatinib, N-desmethylimatinib, by >50%.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [84, 92], "name": "imatinib", "tok_span": [22, 24], "new_tok_span": [23, 25]}, {"ent_type": "CHEMICAL", "char_span": [166, 174], "name": "imatinib", "tok_span": [40, 42], "new_tok_span": [43, 45]}, {"ent_type": "CHEMICAL", "char_span": [176, 195], "name": "N-desmethylimatinib", "tok_span": [43, 50], "new_tok_span": [48, 55]}, {"ent_type": "GENE", "char_span": [10, 16], "name": "CYP2C8", "tok_span": [3, 7], "new_tok_span": [3, 7]}, {"ent_type": "GENE", "char_span": [32, 38], "name": "CYP3A4", "tok_span": [9, 13], "new_tok_span": [9, 13]}], "relation_list": [{"subject": "imatinib", "sbj_char_span": [84, 92], "object": "CYP2C8", "obj_char_span": [10, 16], "rel_type": "product or substrate", "sbj_tok_span": [22, 24], "obj_tok_span": [3, 7], "new_sbj_tok_span": [23, 25], "new_obj_tok_span": [3, 7]}, {"subject": "imatinib", "sbj_char_span": [84, 92], "object": "CYP3A4", "obj_char_span": [32, 38], "rel_type": "product or substrate", "sbj_tok_span": [22, 24], "obj_tok_span": [9, 13], "new_sbj_tok_span": [23, 25], "new_obj_tok_span": [9, 13]}, {"subject": "imatinib", "sbj_char_span": [166, 174], "object": "CYP2C8", "obj_char_span": [10, 16], "rel_type": "product or substrate", "sbj_tok_span": [40, 42], "obj_tok_span": [3, 7], "new_sbj_tok_span": [43, 45], "new_obj_tok_span": [3, 7]}, {"subject": "imatinib", "sbj_char_span": [166, 174], "object": "CYP3A4", "obj_char_span": [32, 38], "rel_type": "product or substrate", "sbj_tok_span": [40, 42], "obj_tok_span": [9, 13], "new_sbj_tok_span": [43, 45], "new_obj_tok_span": [9, 13]}, {"subject": "N-desmethylimatinib", "sbj_char_span": [176, 195], "object": "CYP2C8", "obj_char_span": [10, 16], "rel_type": "product or substrate", "sbj_tok_span": [43, 50], "obj_tok_span": [3, 7], "new_sbj_tok_span": [48, 55], "new_obj_tok_span": [3, 7]}, {"subject": "N-desmethylimatinib", "sbj_char_span": [176, 195], "object": "CYP3A4", "obj_char_span": [32, 38], "rel_type": "product or substrate", "sbj_tok_span": [43, 50], "obj_tok_span": [9, 13], "new_sbj_tok_span": [48, 55], "new_obj_tok_span": [9, 13]}], "umls_entity_list": [{"mention": "imatinib", "char_span": [84, 92], "sem_type": "Pharmacologic Substance", "tok_span": [22, 24], "new_tok_span": [23, 25]}, {"mention": "imatinib", "char_span": [166, 174], "sem_type": "Pharmacologic Substance", "tok_span": [40, 42], "new_tok_span": [43, 45]}, {"mention": "imatinib", "char_span": [187, 195], "sem_type": "Pharmacologic Substance", "tok_span": [47, 50], "new_tok_span": [53, 56]}, {"mention": "N-desmethylimatinib", "char_span": [176, 195], "sem_type": "Pharmacologic Substance", "tok_span": [43, 50], "new_tok_span": [48, 55]}], "new_text": "In vitro, CYP2C8 inhibitors and CYP3A4 inhibitors inhibited the depletion of 0. 1 [UNK] <START=Pharmacologic Substance> imatinib <END=Pharmacologic Substance> by 45 and 80 %, respectively, and the formation of the main metabolite of <START=Pharmacologic Substance> imatinib <END=Pharmacologic Substance>, <START=Pharmacologic Substance> N - desmethyl <START=Pharmacologic Substance>imatinib <END=Pharmacologic Substance> <END=Pharmacologic Substance>, by > 50 %."}, {"PMID": 23028140, "id": 8, "text": "During long-term treatment with imatinib 400 mg once or twice daily, up to 65 or 75% of its hepatic elimination was predicted to occur via CYP2C8, and only about 35 or 25% by CYP3A4, due to dose- and time-dependent autoinactivation of CYP3A4 by imatinib.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [32, 40], "name": "imatinib", "tok_span": [6, 8], "new_tok_span": [6, 8]}, {"ent_type": "CHEMICAL", "char_span": [245, 253], "name": "imatinib", "tok_span": [67, 69], "new_tok_span": [71, 73]}, {"ent_type": "GENE", "char_span": [139, 145], "name": "CYP2C8", "tok_span": [30, 34], "new_tok_span": [30, 34]}, {"ent_type": "GENE", "char_span": [175, 181], "name": "CYP3A4", "tok_span": [43, 47], "new_tok_span": [44, 48]}, {"ent_type": "GENE", "char_span": [235, 241], "name": "CYP3A4", "tok_span": [62, 66], "new_tok_span": [65, 69]}], "relation_list": [{"subject": "imatinib", "sbj_char_span": [32, 40], "object": "CYP2C8", "obj_char_span": [139, 145], "rel_type": "product or substrate", "sbj_tok_span": [6, 8], "obj_tok_span": [30, 34], "new_sbj_tok_span": [6, 8], "new_obj_tok_span": [30, 34]}, {"subject": "imatinib", "sbj_char_span": [32, 40], "object": "CYP3A4", "obj_char_span": [175, 181], "rel_type": "product or substrate", "sbj_tok_span": [6, 8], "obj_tok_span": [43, 47], "new_sbj_tok_span": [6, 8], "new_obj_tok_span": [44, 48]}, {"subject": "imatinib", "sbj_char_span": [245, 253], "object": "CYP3A4", "obj_char_span": [235, 241], "rel_type": "inhibitor", "sbj_tok_span": [67, 69], "obj_tok_span": [62, 66], "new_sbj_tok_span": [71, 73], "new_obj_tok_span": [65, 69]}], "umls_entity_list": [{"mention": "CYP3A4", "char_span": [175, 181], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [43, 47], "new_tok_span": [44, 48]}, {"mention": "CYP3A4", "char_span": [235, 241], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [62, 66], "new_tok_span": [65, 69]}], "new_text": "During long - term treatment with imatinib 400 mg once or twice daily, up to 65 or 75 % of its hepatic elimination was predicted to occur via CYP2C8, and only about 35 or 25 % by <START=Amino Acid, Peptide, or Protein> CYP3A4 <END=Amino Acid, Peptide, or Protein>, due to dose - and time - dependent autoinactivation of <START=Amino Acid, Peptide, or Protein> CYP3A4 <END=Amino Acid, Peptide, or Protein> by imatinib."}, {"PMID": 10690753, "id": 5, "text": "We conclude that felbamate exhibits modest selectivity for NMDA receptors composed of NR1a/NR2B subunits.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [17, 26], "name": "felbamate", "tok_span": [3, 8], "new_tok_span": [3, 8]}, {"ent_type": "CHEMICAL", "char_span": [59, 63], "name": "NMDA", "tok_span": [12, 13], "new_tok_span": [12, 13]}, {"ent_type": "GENE", "char_span": [59, 73], "name": "NMDA receptors", "tok_span": [12, 14], "new_tok_span": [12, 14]}, {"ent_type": "GENE", "char_span": [86, 90], "name": "NR1a", "tok_span": [16, 19], "new_tok_span": [18, 21]}, {"ent_type": "GENE", "char_span": [91, 95], "name": "NR2B", "tok_span": [20, 23], "new_tok_span": [24, 27]}], "relation_list": [{"subject": "felbamate", "sbj_char_span": [17, 26], "object": "NMDA receptors", "obj_char_span": [59, 73], "rel_type": "inhibitor", "sbj_tok_span": [3, 8], "obj_tok_span": [12, 14], "new_sbj_tok_span": [3, 8], "new_obj_tok_span": [12, 14]}, {"subject": "felbamate", "sbj_char_span": [17, 26], "object": "NR2B", "obj_char_span": [91, 95], "rel_type": "inhibitor", "sbj_tok_span": [3, 8], "obj_tok_span": [20, 23], "new_sbj_tok_span": [3, 8], "new_obj_tok_span": [24, 27]}, {"subject": "felbamate", "sbj_char_span": [17, 26], "object": "NR1a", "obj_char_span": [86, 90], "rel_type": "inhibitor", "sbj_tok_span": [3, 8], "obj_tok_span": [16, 19], "new_sbj_tok_span": [3, 8], "new_obj_tok_span": [18, 21]}], "umls_entity_list": [{"mention": "receptors", "char_span": [64, 73], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [13, 14], "new_tok_span": [14, 15]}, {"mention": "NR2B", "char_span": [91, 95], "sem_type": "Gene or Genome", "tok_span": [20, 23], "new_tok_span": [24, 27]}, {"mention": "subunit", "char_span": [96, 103], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [23, 24], "new_tok_span": [30, 31]}, {"mention": "NR2B", "char_span": [91, 95], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [20, 23], "new_tok_span": [24, 27]}], "new_text": "We conclude that felbamate exhibits modest selectivity for NMDA <START=Amino Acid, Peptide, or Protein> receptors <END=Amino Acid, Peptide, or Protein> composed of NR1a / <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> NR2B <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> <START=Amino Acid, Peptide, or Protein> subunits <END=Amino Acid, Peptide, or Protein>."}, {"PMID": 23281044, "id": 0, "text": "Hydrosoluble benzo[e]pyridoindolones as potent inhibitors of aurora kinases.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [13, 36], "name": "benzo[e]pyridoindolones", "tok_span": [2, 12], "new_tok_span": [2, 12]}, {"ent_type": "GENE", "char_span": [61, 75], "name": "aurora kinases", "tok_span": [16, 19], "new_tok_span": [17, 20]}], "relation_list": [{"subject": "benzo[e]pyridoindolones", "sbj_char_span": [13, 36], "object": "aurora kinases", "obj_char_span": [61, 75], "rel_type": "inhibitor", "sbj_tok_span": [2, 12], "obj_tok_span": [16, 19], "new_sbj_tok_span": [2, 12], "new_obj_tok_span": [17, 20]}], "umls_entity_list": [{"mention": "aurora", "char_span": [61, 67], "sem_type": "Pharmacologic Substance", "tok_span": [16, 18], "new_tok_span": [17, 19]}], "new_text": "Hydrosoluble benzo [ e ] pyridoindolones as potent inhibitors of <START=Pharmacologic Substance> aurora <END=Pharmacologic Substance> kinases."}, {"PMID": 11488610, "id": 7, "text": "Changes in the accessibility of Trp residues upon pyridoxal-P binding strongly supported a significant conformational change in GAD. Fluorescence intensity measurements were also carried out to investigate the unfolding of GAD using guanidine hydrochloride (GdnHCl) as the denaturant.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [233, 256], "name": "guanidine hydrochloride", "tok_span": [38, 41], "new_tok_span": [41, 44]}, {"ent_type": "CHEMICAL", "char_span": [258, 264], "name": "GdnHCl", "tok_span": [42, 45], "new_tok_span": [46, 49]}, {"ent_type": "CHEMICAL", "char_span": [32, 35], "name": "Trp", "tok_span": [5, 6], "new_tok_span": [6, 7]}, {"ent_type": "CHEMICAL", "char_span": [50, 61], "name": "pyridoxal-P", "tok_span": [8, 14], "new_tok_span": [10, 16]}, {"ent_type": "GENE", "char_span": [128, 131], "name": "GAD", "tok_span": [22, 23], "new_tok_span": [24, 25]}, {"ent_type": "GENE", "char_span": [223, 226], "name": "GAD", "tok_span": [36, 37], "new_tok_span": [38, 39]}], "relation_list": [{"subject": "Trp", "sbj_char_span": [32, 35], "object": "GAD", "obj_char_span": [128, 131], "rel_type": "part of", "sbj_tok_span": [5, 6], "obj_tok_span": [22, 23], "new_sbj_tok_span": [6, 7], "new_obj_tok_span": [24, 25]}, {"subject": "pyridoxal-P", "sbj_char_span": [50, 61], "object": "GAD", "obj_char_span": [128, 131], "rel_type": "regulator", "sbj_tok_span": [8, 14], "obj_tok_span": [22, 23], "new_sbj_tok_span": [10, 16], "new_obj_tok_span": [24, 25]}], "umls_entity_list": [{"mention": "Trp", "char_span": [32, 35], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [5, 6], "new_tok_span": [6, 7]}, {"mention": "guanidine hydrochloride", "char_span": [233, 256], "sem_type": "Pharmacologic Substance", "tok_span": [38, 41], "new_tok_span": [41, 44]}], "new_text": "Changes in the accessibility of <START=Amino Acid, Peptide, or Protein> Trp <END=Amino Acid, Peptide, or Protein> residues upon pyridoxal - P binding strongly supported a significant conformational change in GAD. Fluorescence intensity measurements were also carried out to investigate the unfolding of GAD using <START=Pharmacologic Substance> guanidine hydrochloride <END=Pharmacologic Substance> ( GdnHCl ) as the denaturant."}, {"PMID": 23597507, "id": 5, "text": "Intraplantar or intrathecal administered Phα1β reduced both nocifensive behavior and mechanical hypersensitivity induced by capsaicin similarly to that observed with SB366791, a specific TRPV1 antagonist.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [124, 133], "name": "capsaicin", "tok_span": [24, 27], "new_tok_span": [25, 28]}, {"ent_type": "CHEMICAL", "char_span": [166, 174], "name": "SB366791", "tok_span": [32, 36], "new_tok_span": [35, 39]}, {"ent_type": "GENE", "char_span": [187, 192], "name": "TRPV1", "tok_span": [39, 42], "new_tok_span": [44, 47]}], "relation_list": [{"subject": "SB366791", "sbj_char_span": [166, 174], "object": "TRPV1", "obj_char_span": [187, 192], "rel_type": "agonist or antagonist", "sbj_tok_span": [32, 36], "obj_tok_span": [39, 42], "new_sbj_tok_span": [35, 39], "new_obj_tok_span": [44, 47]}], "umls_entity_list": [{"mention": "capsaicin", "char_span": [124, 133], "sem_type": "Pharmacologic Substance", "tok_span": [24, 27], "new_tok_span": [25, 28]}, {"mention": "SB366791", "char_span": [166, 174], "sem_type": "Pharmacologic Substance", "tok_span": [32, 36], "new_tok_span": [35, 39]}, {"mention": "TRPV1", "char_span": [187, 192], "sem_type": "Gene or Genome", "tok_span": [39, 42], "new_tok_span": [44, 47]}], "new_text": "Intraplantar or intrathecal administered Phα1β reduced both nocifensive behavior and mechanical hypersensitivity induced by <START=Pharmacologic Substance> capsaicin <END=Pharmacologic Substance> similarly to that observed with <START=Pharmacologic Substance> SB366791 <END=Pharmacologic Substance>, a specific <START=Gene or Genome> TRPV1 <END=Gene or Genome> antagonist."}, {"PMID": 14757700, "id": 9, "text": "In contrast, menthol- and icilin-activated TRPM8 currents were suppressed by low pH. 6.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [13, 20], "name": "menthol", "tok_span": [3, 5], "new_tok_span": [3, 5]}, {"ent_type": "CHEMICAL", "char_span": [26, 32], "name": "icilin", "tok_span": [7, 9], "new_tok_span": [8, 10]}, {"ent_type": "GENE", "char_span": [43, 48], "name": "TRPM8", "tok_span": [11, 14], "new_tok_span": [14, 17]}], "relation_list": [{"subject": "menthol", "sbj_char_span": [13, 20], "object": "TRPM8", "obj_char_span": [43, 48], "rel_type": "activator", "sbj_tok_span": [3, 5], "obj_tok_span": [11, 14], "new_sbj_tok_span": [3, 5], "new_obj_tok_span": [14, 17]}, {"subject": "icilin", "sbj_char_span": [26, 32], "object": "TRPM8", "obj_char_span": [43, 48], "rel_type": "activator", "sbj_tok_span": [7, 9], "obj_tok_span": [11, 14], "new_sbj_tok_span": [8, 10], "new_obj_tok_span": [14, 17]}], "umls_entity_list": [{"mention": "icilin", "char_span": [26, 32], "sem_type": "Organic Chemical", "tok_span": [7, 9], "new_tok_span": [8, 10]}, {"mention": "TRPM8", "char_span": [43, 48], "sem_type": "Gene or Genome", "tok_span": [11, 14], "new_tok_span": [14, 17]}], "new_text": "In contrast, menthol - and <START=Organic Chemical> icilin <END=Organic Chemical> - activated <START=Gene or Genome> TRPM8 <END=Gene or Genome> currents were suppressed by low pH. 6."}, {"PMID": 23179349, "id": 14, "text": "The decrease in insulin and nitric oxide in rats fed the diet high in iron, fat, fructose, and salt was associated with disorders of zinc, copper, and calcium status, as well as with an increase in the relative mass of the gonads.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [28, 40], "name": "nitric oxide", "tok_span": [5, 7], "new_tok_span": [6, 8]}, {"ent_type": "CHEMICAL", "char_span": [70, 74], "name": "iron", "tok_span": [14, 15], "new_tok_span": [16, 17]}, {"ent_type": "CHEMICAL", "char_span": [81, 89], "name": "fructose", "tok_span": [18, 19], "new_tok_span": [21, 22]}, {"ent_type": "CHEMICAL", "char_span": [133, 137], "name": "zinc", "tok_span": [27, 28], "new_tok_span": [31, 32]}, {"ent_type": "CHEMICAL", "char_span": [139, 145], "name": "copper", "tok_span": [29, 30], "new_tok_span": [34, 35]}, {"ent_type": "CHEMICAL", "char_span": [151, 158], "name": "calcium", "tok_span": [32, 33], "new_tok_span": [39, 40]}, {"ent_type": "GENE", "char_span": [16, 23], "name": "insulin", "tok_span": [3, 4], "new_tok_span": [3, 4]}], "relation_list": [{"subject": "iron", "sbj_char_span": [70, 74], "object": "insulin", "obj_char_span": [16, 23], "rel_type": "regulator", "sbj_tok_span": [14, 15], "obj_tok_span": [3, 4], "new_sbj_tok_span": [16, 17], "new_obj_tok_span": [3, 4]}, {"subject": "fructose", "sbj_char_span": [81, 89], "object": "insulin", "obj_char_span": [16, 23], "rel_type": "regulator", "sbj_tok_span": [18, 19], "obj_tok_span": [3, 4], "new_sbj_tok_span": [21, 22], "new_obj_tok_span": [3, 4]}], "umls_entity_list": [{"mention": "nitric oxide", "char_span": [28, 40], "sem_type": "Pharmacologic Substance", "tok_span": [5, 7], "new_tok_span": [6, 8]}, {"mention": "fructose", "char_span": [81, 89], "sem_type": "Pharmacologic Substance", "tok_span": [18, 19], "new_tok_span": [21, 22]}, {"mention": "copper", "char_span": [139, 145], "sem_type": "Pharmacologic Substance", "tok_span": [29, 30], "new_tok_span": [34, 35]}, {"mention": "calcium", "char_span": [151, 158], "sem_type": "Pharmacologic Substance", "tok_span": [32, 33], "new_tok_span": [39, 40]}], "new_text": "The decrease in insulin and <START=Pharmacologic Substance> nitric oxide <END=Pharmacologic Substance> in rats fed the diet high in iron, fat, <START=Pharmacologic Substance> fructose <END=Pharmacologic Substance>, and salt was associated with disorders of zinc, <START=Pharmacologic Substance> copper <END=Pharmacologic Substance>, and <START=Pharmacologic Substance> calcium <END=Pharmacologic Substance> status, as well as with an increase in the relative mass of the gonads."}, {"PMID": 10220509, "id": 3, "text": "The current study evaluates the effects of a selective COX-2 inhibitor (SC-236) on renal function in cirrhotic rats with ascites.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [72, 78], "name": "SC-236", "tok_span": [14, 18], "new_tok_span": [15, 19]}, {"ent_type": "GENE", "char_span": [55, 60], "name": "COX-2", "tok_span": [9, 12], "new_tok_span": [9, 12]}], "relation_list": [{"subject": "SC-236", "sbj_char_span": [72, 78], "object": "COX-2", "obj_char_span": [55, 60], "rel_type": "inhibitor", "sbj_tok_span": [14, 18], "obj_tok_span": [9, 12], "new_sbj_tok_span": [15, 19], "new_obj_tok_span": [9, 12]}], "umls_entity_list": [{"mention": "SC-236", "char_span": [72, 78], "sem_type": "Pharmacologic Substance", "tok_span": [14, 18], "new_tok_span": [15, 19]}], "new_text": "The current study evaluates the effects of a selective COX - 2 inhibitor ( <START=Pharmacologic Substance> SC - 236 <END=Pharmacologic Substance> ) on renal function in cirrhotic rats with ascites."}, {"PMID": 17445089, "id": 4, "text": "Perhexiline reduces fatty acid metabolism through the inhibition of carnitine palmitoyltransferase, the enzyme responsible for mitochondrial uptake of long-chain fatty acids.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 11], "name": "Perhexiline", "tok_span": [0, 4], "new_tok_span": [1, 5]}, {"ent_type": "CHEMICAL", "char_span": [20, 30], "name": "fatty acid", "tok_span": [5, 7], "new_tok_span": [7, 9]}, {"ent_type": "CHEMICAL", "char_span": [68, 77], "name": "carnitine", "tok_span": [12, 15], "new_tok_span": [14, 17]}, {"ent_type": "CHEMICAL", "char_span": [151, 173], "name": "long-chain fatty acids", "tok_span": [27, 32], "new_tok_span": [29, 34]}, {"ent_type": "GENE", "char_span": [68, 98], "name": "carnitine palmitoyltransferase", "tok_span": [12, 19], "new_tok_span": [14, 21]}], "relation_list": [{"subject": "Perhexiline", "sbj_char_span": [0, 11], "object": "carnitine palmitoyltransferase", "obj_char_span": [68, 98], "rel_type": "inhibitor", "sbj_tok_span": [0, 4], "obj_tok_span": [12, 19], "new_sbj_tok_span": [1, 5], "new_obj_tok_span": [14, 21]}, {"subject": "long-chain fatty acids", "sbj_char_span": [151, 173], "object": "carnitine palmitoyltransferase", "obj_char_span": [68, 98], "rel_type": "product or substrate", "sbj_tok_span": [27, 32], "obj_tok_span": [12, 19], "new_sbj_tok_span": [29, 34], "new_obj_tok_span": [14, 21]}, {"subject": "fatty acid", "sbj_char_span": [20, 30], "object": "carnitine palmitoyltransferase", "obj_char_span": [68, 98], "rel_type": "product or substrate", "sbj_tok_span": [5, 7], "obj_tok_span": [12, 19], "new_sbj_tok_span": [7, 9], "new_obj_tok_span": [14, 21]}], "umls_entity_list": [{"mention": "Perhexiline", "char_span": [0, 11], "sem_type": "Pharmacologic Substance", "tok_span": [0, 4], "new_tok_span": [1, 5]}], "new_text": "<START=Pharmacologic Substance> Perhexiline <END=Pharmacologic Substance> reduces fatty acid metabolism through the inhibition of carnitine palmitoyltransferase, the enzyme responsible for mitochondrial uptake of long - chain fatty acids."}, {"PMID": 12601049, "id": 0, "text": "Subconjunctival nano- and microparticles sustain retinal delivery of budesonide, a corticosteroid capable of inhibiting VEGF expression.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [69, 79], "name": "budesonide", "tok_span": [15, 19], "new_tok_span": [18, 22]}, {"ent_type": "CHEMICAL", "char_span": [83, 97], "name": "corticosteroid", "tok_span": [21, 22], "new_tok_span": [26, 27]}, {"ent_type": "GENE", "char_span": [120, 124], "name": "VEGF", "tok_span": [25, 26], "new_tok_span": [31, 32]}], "relation_list": [{"subject": "budesonide", "sbj_char_span": [69, 79], "object": "VEGF", "obj_char_span": [120, 124], "rel_type": "regulator", "sbj_tok_span": [15, 19], "obj_tok_span": [25, 26], "new_sbj_tok_span": [18, 22], "new_obj_tok_span": [31, 32]}, {"subject": "corticosteroid", "sbj_char_span": [83, 97], "object": "VEGF", "obj_char_span": [120, 124], "rel_type": "regulator", "sbj_tok_span": [21, 22], "obj_tok_span": [25, 26], "new_sbj_tok_span": [26, 27], "new_obj_tok_span": [31, 32]}], "umls_entity_list": [{"mention": "sustain", "char_span": [41, 48], "sem_type": "Pharmacologic Substance", "tok_span": [11, 12], "new_tok_span": [12, 13]}, {"mention": "budesonide", "char_span": [69, 79], "sem_type": "Pharmacologic Substance", "tok_span": [15, 19], "new_tok_span": [18, 22]}, {"mention": "corticosteroid", "char_span": [83, 97], "sem_type": "Pharmacologic Substance", "tok_span": [21, 22], "new_tok_span": [26, 27]}], "new_text": "Subconjunctival nano - and microparticles <START=Pharmacologic Substance> sustain <END=Pharmacologic Substance> retinal delivery of <START=Pharmacologic Substance> budesonide <END=Pharmacologic Substance>, a <START=Pharmacologic Substance> corticosteroid <END=Pharmacologic Substance> capable of inhibiting VEGF expression."}, {"PMID": 10405348, "id": 8, "text": "Both paclitaxel and 2-meOE2 also inhibited stimulation of aromatase activity by IL-6 plus its soluble receptor and PGE(2).", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [5, 15], "name": "paclitaxel", "tok_span": [1, 2], "new_tok_span": [1, 2]}, {"ent_type": "CHEMICAL", "char_span": [20, 27], "name": "2-meOE2", "tok_span": [3, 8], "new_tok_span": [3, 8]}, {"ent_type": "CHEMICAL", "char_span": [115, 121], "name": "PGE(2)", "tok_span": [24, 28], "new_tok_span": [24, 28]}, {"ent_type": "GENE", "char_span": [58, 67], "name": "aromatase", "tok_span": [12, 14], "new_tok_span": [12, 14]}, {"ent_type": "GENE", "char_span": [80, 84], "name": "IL-6", "tok_span": [16, 19], "new_tok_span": [16, 19]}], "relation_list": [{"subject": "paclitaxel", "sbj_char_span": [5, 15], "object": "aromatase", "obj_char_span": [58, 67], "rel_type": "inhibitor", "sbj_tok_span": [1, 2], "obj_tok_span": [12, 14], "new_sbj_tok_span": [1, 2], "new_obj_tok_span": [12, 14]}, {"subject": "2-meOE2", "sbj_char_span": [20, 27], "object": "aromatase", "obj_char_span": [58, 67], "rel_type": "inhibitor", "sbj_tok_span": [3, 8], "obj_tok_span": [12, 14], "new_sbj_tok_span": [3, 8], "new_obj_tok_span": [12, 14]}, {"subject": "paclitaxel", "sbj_char_span": [5, 15], "object": "IL-6", "obj_char_span": [80, 84], "rel_type": "inhibitor", "sbj_tok_span": [1, 2], "obj_tok_span": [16, 19], "new_sbj_tok_span": [1, 2], "new_obj_tok_span": [16, 19]}, {"subject": "PGE(2)", "sbj_char_span": [115, 121], "object": "aromatase", "obj_char_span": [58, 67], "rel_type": "activator", "sbj_tok_span": [24, 28], "obj_tok_span": [12, 14], "new_sbj_tok_span": [24, 28], "new_obj_tok_span": [12, 14]}], "umls_entity_list": [], "new_text": "Both paclitaxel and 2 - meOE2 also inhibited stimulation of aromatase activity by IL - 6 plus its soluble receptor and PGE ( 2 )."}, {"PMID": 16298345, "id": 3, "text": "In competition binding studies the affinity of a range of human chemokines for macaque CCR5 was also similar to human CCR5. Maraviroc inhibited binding of [125I]-MIP-1beta to CCR5 from macaque and human with similar potency (IC50 = 17.50 +/- 1.24 nM and 7.18 +/- 0.93 nM, respectively) and antagonised MIP-1beta induced intracellular calcium release mediated through CCR5 from macaque and human with similar potency (IC50 = 17.50 +/- 3.30 nM and 12.07 +/- 1.89, respectively). [3H]-maraviroc bound with high affinity to CCR5 from macaque (K(d) = 1.36+/-0.07 nM) and human (K(d) = 0.86 +/- 0.08 nM), but was found to dissociate approximately 10-fold more quickly from macaque CCR5. However, as with the human receptor, maraviroc was shown to be a high affinity, potent functional antagonist of macaque CCR5 thereby indicating that the macaque should be a suitable species in which to evaluate the pharmacology, safety and potential mechanism-related toxicology of novel CCR5 antagonists.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [718, 727], "name": "maraviroc", "tok_span": [211, 214], "new_tok_span": [241, 244]}, {"ent_type": "CHEMICAL", "char_span": [124, 133], "name": "Maraviroc", "tok_span": [25, 28], "new_tok_span": [35, 38]}, {"ent_type": "CHEMICAL", "char_span": [156, 160], "name": "125I", "tok_span": [32, 34], "new_tok_span": [42, 44]}, {"ent_type": "CHEMICAL", "char_span": [334, 341], "name": "calcium", "tok_span": [88, 89], "new_tok_span": [106, 107]}, {"ent_type": "CHEMICAL", "char_span": [477, 491], "name": "[3H]-maraviroc", "tok_span": [130, 138], "new_tok_span": [152, 160]}, {"ent_type": "GENE", "char_span": [520, 524], "name": "CCR5", "tok_span": [143, 145], "new_tok_span": [167, 169]}, {"ent_type": "GENE", "char_span": [667, 679], "name": "macaque CCR5", "tok_span": [198, 202], "new_tok_span": [224, 228]}, {"ent_type": "GENE", "char_span": [793, 805], "name": "macaque CCR5", "tok_span": [226, 230], "new_tok_span": [256, 260]}, {"ent_type": "GENE", "char_span": [969, 973], "name": "CCR5", "tok_span": [259, 261], "new_tok_span": [295, 297]}, {"ent_type": "GENE", "char_span": [79, 91], "name": "macaque CCR5", "tok_span": [13, 17], "new_tok_span": [15, 19]}, {"ent_type": "GENE", "char_span": [112, 122], "name": "human CCR5", "tok_span": [21, 24], "new_tok_span": [27, 30]}, {"ent_type": "GENE", "char_span": [175, 179], "name": "CCR5", "tok_span": [41, 43], "new_tok_span": [55, 57]}, {"ent_type": "GENE", "char_span": [367, 371], "name": "CCR5", "tok_span": [92, 94], "new_tok_span": [112, 114]}], "relation_list": [{"subject": "125I", "sbj_char_span": [156, 160], "object": "CCR5", "obj_char_span": [175, 179], "rel_type": "regulator", "sbj_tok_span": [32, 34], "obj_tok_span": [41, 43], "new_sbj_tok_span": [42, 44], "new_obj_tok_span": [55, 57]}, {"subject": "Maraviroc", "sbj_char_span": [124, 133], "object": "CCR5", "obj_char_span": [175, 179], "rel_type": "regulator", "sbj_tok_span": [25, 28], "obj_tok_span": [41, 43], "new_sbj_tok_span": [35, 38], "new_obj_tok_span": [55, 57]}, {"subject": "Maraviroc", "sbj_char_span": [124, 133], "object": "CCR5", "obj_char_span": [367, 371], "rel_type": "agonist or antagonist", "sbj_tok_span": [25, 28], "obj_tok_span": [92, 94], "new_sbj_tok_span": [35, 38], "new_obj_tok_span": [112, 114]}, {"subject": "[3H]-maraviroc", "sbj_char_span": [477, 491], "object": "CCR5", "obj_char_span": [520, 524], "rel_type": "regulator", "sbj_tok_span": [130, 138], "obj_tok_span": [143, 145], "new_sbj_tok_span": [152, 160], "new_obj_tok_span": [167, 169]}, {"subject": "[3H]-maraviroc", "sbj_char_span": [477, 491], "object": "macaque CCR5", "obj_char_span": [667, 679], "rel_type": "regulator", "sbj_tok_span": [130, 138], "obj_tok_span": [198, 202], "new_sbj_tok_span": [152, 160], "new_obj_tok_span": [224, 228]}, {"subject": "maraviroc", "sbj_char_span": [718, 727], "object": "macaque CCR5", "obj_char_span": [793, 805], "rel_type": "agonist or antagonist", "sbj_tok_span": [211, 214], "obj_tok_span": [226, 230], "new_sbj_tok_span": [241, 244], "new_obj_tok_span": [256, 260]}, {"subject": "maraviroc", "sbj_char_span": [718, 727], "object": "CCR5", "obj_char_span": [969, 973], "rel_type": "agonist or antagonist", "sbj_tok_span": [211, 214], "obj_tok_span": [259, 261], "new_sbj_tok_span": [241, 244], "new_obj_tok_span": [295, 297]}], "umls_entity_list": [{"mention": "chemokines", "char_span": [64, 74], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [11, 12], "new_tok_span": [12, 13]}, {"mention": "CCR5", "char_span": [87, 91], "sem_type": "Gene or Genome", "tok_span": [15, 17], "new_tok_span": [19, 21]}, {"mention": "CCR5", "char_span": [118, 122], "sem_type": "Gene or Genome", "tok_span": [22, 24], "new_tok_span": [30, 32]}, {"mention": "CCR5", "char_span": [175, 179], "sem_type": "Gene or Genome", "tok_span": [41, 43], "new_tok_span": [55, 57]}, {"mention": "CCR5", "char_span": [367, 371], "sem_type": "Gene or Genome", "tok_span": [92, 94], "new_tok_span": [112, 114]}, {"mention": "CCR5", "char_span": [520, 524], "sem_type": "Gene or Genome", "tok_span": [143, 145], "new_tok_span": [167, 169]}, {"mention": "CCR5", "char_span": [675, 679], "sem_type": "Gene or Genome", "tok_span": [200, 202], "new_tok_span": [228, 230]}, {"mention": "CCR5", "char_span": [801, 805], "sem_type": "Gene or Genome", "tok_span": [228, 230], "new_tok_span": [260, 262]}, {"mention": "CCR5", "char_span": [969, 973], "sem_type": "Gene or Genome", "tok_span": [259, 261], "new_tok_span": [295, 297]}, {"mention": "CCR5", "char_span": [87, 91], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [15, 17], "new_tok_span": [19, 21]}, {"mention": "CCR5", "char_span": [118, 122], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [22, 24], "new_tok_span": [30, 32]}, {"mention": "CCR5", "char_span": [175, 179], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [41, 43], "new_tok_span": [55, 57]}, {"mention": "CCR5", "char_span": [367, 371], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [92, 94], "new_tok_span": [112, 114]}, {"mention": "CCR5", "char_span": [520, 524], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [143, 145], "new_tok_span": [167, 169]}, {"mention": "CCR5", "char_span": [675, 679], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [200, 202], "new_tok_span": [228, 230]}, {"mention": "CCR5", "char_span": [801, 805], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [228, 230], "new_tok_span": [260, 262]}, {"mention": "CCR5", "char_span": [969, 973], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [259, 261], "new_tok_span": [295, 297]}, {"mention": "MIP-1beta", "char_span": [162, 171], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [36, 40], "new_tok_span": [47, 51]}, {"mention": "MIP-1beta", "char_span": [302, 311], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [82, 86], "new_tok_span": [99, 103]}], "new_text": "In competition binding studies the affinity of a range of human <START=Amino Acid, Peptide, or Protein> chemokines <END=Amino Acid, Peptide, or Protein> for macaque <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> CCR5 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> was also similar to human <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> CCR5 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein>. Maraviroc inhibited binding of [ 125I ] - <START=Amino Acid, Peptide, or Protein> MIP - 1beta <END=Amino Acid, Peptide, or Protein> to <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> CCR5 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> from macaque and human with similar potency ( IC50 = 17. 50 + / - 1. 24 nM and 7. 18 + / - 0. 93 nM, respectively ) and antagonised <START=Amino Acid, Peptide, or Protein> MIP - 1beta <END=Amino Acid, Peptide, or Protein> induced intracellular calcium release mediated through <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> CCR5 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> from macaque and human with similar potency ( IC50 = 17. 50 + / - 3. 30 nM and 12. 07 + / - 1. 89, respectively ). [ 3H ] - maraviroc bound with high affinity to <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> CCR5 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> from macaque ( K ( d ) = 1. 36 + / - 0. 07 nM ) and human ( K ( d ) = 0. 86 + / - 0. 08 nM ), but was found to dissociate approximately 10 - fold more quickly from macaque <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> CCR5 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein>. However, as with the human receptor, maraviroc was shown to be a high affinity, potent functional antagonist of macaque <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> CCR5 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> thereby indicating that the macaque should be a suitable species in which to evaluate the pharmacology, safety and potential mechanism - related toxicology of novel <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> CCR5 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> antagonists."}, {"PMID": 10388743, "id": 5, "text": "Removal of the EGF1-bound calcium ion is shown by simulation to lead to minor structural changes within the EGF1 domain, but also leads to substantial relative reorientation of the Gla and EGF1 domains.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [26, 33], "name": "calcium", "tok_span": [8, 9], "new_tok_span": [11, 12]}, {"ent_type": "GENE", "char_span": [15, 19], "name": "EGF1", "tok_span": [4, 6], "new_tok_span": [5, 7]}, {"ent_type": "GENE", "char_span": [108, 119], "name": "EGF1 domain", "tok_span": [22, 25], "new_tok_span": [27, 30]}, {"ent_type": "GENE", "char_span": [181, 201], "name": "Gla and EGF1 domains", "tok_span": [36, 42], "new_tok_span": [44, 50]}], "relation_list": [{"subject": "calcium", "sbj_char_span": [26, 33], "object": "EGF1", "obj_char_span": [15, 19], "rel_type": "regulator", "sbj_tok_span": [8, 9], "obj_tok_span": [4, 6], "new_sbj_tok_span": [11, 12], "new_obj_tok_span": [5, 7]}], "umls_entity_list": [{"mention": "EGF1", "char_span": [15, 19], "sem_type": "Gene or Genome", "tok_span": [4, 6], "new_tok_span": [5, 7]}, {"mention": "EGF1", "char_span": [108, 112], "sem_type": "Gene or Genome", "tok_span": [22, 24], "new_tok_span": [27, 29]}, {"mention": "EGF1", "char_span": [189, 193], "sem_type": "Gene or Genome", "tok_span": [39, 41], "new_tok_span": [50, 52]}, {"mention": "calcium ion", "char_span": [26, 37], "sem_type": "Pharmacologic Substance", "tok_span": [8, 10], "new_tok_span": [11, 13]}, {"mention": "Gla", "char_span": [181, 184], "sem_type": "Pharmacologic Substance", "tok_span": [36, 38], "new_tok_span": [44, 46]}, {"mention": "Gla", "char_span": [181, 184], "sem_type": "Gene or Genome", "tok_span": [36, 38], "new_tok_span": [44, 46]}], "new_text": "Removal of the <START=Gene or Genome> EGF1 <END=Gene or Genome> - bound <START=Pharmacologic Substance> calcium ion <END=Pharmacologic Substance> is shown by simulation to lead to minor structural changes within the <START=Gene or Genome> EGF1 <END=Gene or Genome> domain, but also leads to substantial relative reorientation of the <START=Pharmacologic Substance> <START=Gene or Genome> Gla <END=Pharmacologic Substance> <END=Gene or Genome> and <START=Gene or Genome> EGF1 <END=Gene or Genome> domains."}, {"PMID": 23148920, "id": 8, "text": "NaHS induced phosphorylation of eNOS at the activating phosphoserine residue 1179.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 4], "name": "NaHS", "tok_span": [0, 2], "new_tok_span": [0, 2]}, {"ent_type": "CHEMICAL", "char_span": [55, 68], "name": "phosphoserine", "tok_span": [9, 12], "new_tok_span": [14, 17]}, {"ent_type": "GENE", "char_span": [32, 36], "name": "eNOS", "tok_span": [5, 6], "new_tok_span": [7, 8]}], "relation_list": [{"subject": "NaHS", "sbj_char_span": [0, 4], "object": "eNOS", "obj_char_span": [32, 36], "rel_type": "activator", "sbj_tok_span": [0, 2], "obj_tok_span": [5, 6], "new_sbj_tok_span": [0, 2], "new_obj_tok_span": [7, 8]}, {"subject": "phosphoserine", "sbj_char_span": [55, 68], "object": "eNOS", "obj_char_span": [32, 36], "rel_type": "part of", "sbj_tok_span": [9, 12], "obj_tok_span": [5, 6], "new_sbj_tok_span": [14, 17], "new_obj_tok_span": [7, 8]}], "umls_entity_list": [{"mention": "eNOS", "char_span": [32, 36], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [5, 6], "new_tok_span": [7, 8]}, {"mention": "eNOS", "char_span": [32, 36], "sem_type": "Gene or Genome", "tok_span": [5, 6], "new_tok_span": [7, 8]}, {"mention": "phosphoserine", "char_span": [55, 68], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [9, 12], "new_tok_span": [14, 17]}], "new_text": "NaHS induced phosphorylation of <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> eNOS <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> at the activating <START=Amino Acid, Peptide, or Protein> phosphoserine <END=Amino Acid, Peptide, or Protein> residue 1179."}, {"PMID": 11256847, "id": 0, "text": "Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [41, 53], "name": "Rosuvastatin", "tok_span": [8, 11], "new_tok_span": [9, 12]}, {"ent_type": "CHEMICAL", "char_span": [61, 98], "name": "3-hydroxy-3-methylglutaryl coenzyme A", "tok_span": [14, 27], "new_tok_span": [16, 29]}, {"ent_type": "GENE", "char_span": [61, 108], "name": "3-hydroxy-3-methylglutaryl coenzyme A reductase", "tok_span": [14, 28], "new_tok_span": [16, 30]}], "relation_list": [{"subject": "Rosuvastatin", "sbj_char_span": [41, 53], "object": "3-hydroxy-3-methylglutaryl coenzyme A reductase", "obj_char_span": [61, 108], "rel_type": "inhibitor", "sbj_tok_span": [8, 11], "obj_tok_span": [14, 28], "new_sbj_tok_span": [9, 12], "new_obj_tok_span": [16, 30]}], "umls_entity_list": [{"mention": "Rosuvastatin", "char_span": [41, 53], "sem_type": "Pharmacologic Substance", "tok_span": [8, 11], "new_tok_span": [9, 12]}, {"mention": "reductase inhibitor", "char_span": [99, 118], "sem_type": "Pharmacologic Substance", "tok_span": [27, 29], "new_tok_span": [30, 32]}], "new_text": "Preclinical and clinical pharmacology of <START=Pharmacologic Substance> Rosuvastatin <END=Pharmacologic Substance>, a new 3 - hydroxy - 3 - methylglutaryl coenzyme A <START=Pharmacologic Substance> reductase inhibitor <END=Pharmacologic Substance>."}, {"PMID": 10653606, "id": 12, "text": "Metabolism of arachidonic acid to leukotrienes is not involved in the response to 24R, 25-(OH)(2)D(3) because inhibition of lipoxygenase had no effect.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [14, 30], "name": "arachidonic acid", "tok_span": [2, 6], "new_tok_span": [2, 6]}, {"ent_type": "CHEMICAL", "char_span": [34, 46], "name": "leukotrienes", "tok_span": [7, 10], "new_tok_span": [8, 11]}, {"ent_type": "CHEMICAL", "char_span": [82, 101], "name": "24R, 25-(OH)(2)D(3)", "tok_span": [17, 32], "new_tok_span": [19, 34]}, {"ent_type": "GENE", "char_span": [124, 136], "name": "lipoxygenase", "tok_span": [35, 37], "new_tok_span": [38, 40]}], "relation_list": [{"subject": "arachidonic acid", "sbj_char_span": [14, 30], "object": "lipoxygenase", "obj_char_span": [124, 136], "rel_type": "product or substrate", "sbj_tok_span": [2, 6], "obj_tok_span": [35, 37], "new_sbj_tok_span": [2, 6], "new_obj_tok_span": [38, 40]}, {"subject": "leukotrienes", "sbj_char_span": [34, 46], "object": "lipoxygenase", "obj_char_span": [124, 136], "rel_type": "product or substrate", "sbj_tok_span": [7, 10], "obj_tok_span": [35, 37], "new_sbj_tok_span": [8, 11], "new_obj_tok_span": [38, 40]}], "umls_entity_list": [{"mention": "leukotrienes", "char_span": [34, 46], "sem_type": "Organic Chemical", "tok_span": [7, 10], "new_tok_span": [8, 11]}, {"mention": "lipoxygenase", "char_span": [124, 136], "sem_type": "Pharmacologic Substance", "tok_span": [35, 37], "new_tok_span": [38, 40]}], "new_text": "Metabolism of arachidonic acid to <START=Organic Chemical> leukotrienes <END=Organic Chemical> is not involved in the response to 24R, 25 - ( OH ) ( 2 ) D ( 3 ) because inhibition of <START=Pharmacologic Substance> lipoxygenase <END=Pharmacologic Substance> had no effect."}, {"PMID": 22430206, "id": 5, "text": "To better understand SFK-mediated nuclear translocation of EGFR, we investigated which SFK member(s) controlled this process as well as the EGFR tyrosine residues that are involved.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [145, 153], "name": "tyrosine", "tok_span": [29, 30], "new_tok_span": [34, 35]}, {"ent_type": "GENE", "char_span": [21, 24], "name": "SFK", "tok_span": [3, 5], "new_tok_span": [3, 5]}, {"ent_type": "GENE", "char_span": [59, 63], "name": "EGFR", "tok_span": [10, 11], "new_tok_span": [11, 12]}, {"ent_type": "GENE", "char_span": [87, 90], "name": "SFK", "tok_span": [15, 17], "new_tok_span": [17, 19]}, {"ent_type": "GENE", "char_span": [140, 144], "name": "EGFR", "tok_span": [28, 29], "new_tok_span": [31, 32]}], "relation_list": [{"subject": "tyrosine", "sbj_char_span": [145, 153], "object": "EGFR", "obj_char_span": [140, 144], "rel_type": "part of", "sbj_tok_span": [29, 30], "obj_tok_span": [28, 29], "new_sbj_tok_span": [34, 35], "new_obj_tok_span": [31, 32]}], "umls_entity_list": [{"mention": "EGFR", "char_span": [59, 63], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [10, 11], "new_tok_span": [11, 12]}, {"mention": "EGFR", "char_span": [140, 144], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [28, 29], "new_tok_span": [31, 32]}, {"mention": "tyrosine", "char_span": [145, 153], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [29, 30], "new_tok_span": [34, 35]}], "new_text": "To better understand SFK - mediated nuclear translocation of <START=Amino Acid, Peptide, or Protein> EGFR <END=Amino Acid, Peptide, or Protein>, we investigated which SFK member ( s ) controlled this process as well as the <START=Amino Acid, Peptide, or Protein> EGFR <END=Amino Acid, Peptide, or Protein> <START=Amino Acid, Peptide, or Protein> tyrosine <END=Amino Acid, Peptide, or Protein> residues that are involved."}, {"PMID": 17664022, "id": 1, "text": "The inhibitory effect of clonidine (non-selective alpha2-adrenoceptor agonist) and oxymetazoline (alpha2A-adrenoceptor selective agonist) was compared on basal and stimulated gastric motor activity (gastric tone and contractions) using the balloon method in the rat.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [25, 34], "name": "clonidine", "tok_span": [4, 6], "new_tok_span": [5, 7]}, {"ent_type": "CHEMICAL", "char_span": [83, 96], "name": "oxymetazoline", "tok_span": [19, 24], "new_tok_span": [25, 30]}, {"ent_type": "GENE", "char_span": [50, 69], "name": "alpha2-adrenoceptor", "tok_span": [10, 16], "new_tok_span": [12, 18]}, {"ent_type": "GENE", "char_span": [98, 118], "name": "alpha2A-adrenoceptor", "tok_span": [25, 32], "new_tok_span": [31, 38]}], "relation_list": [{"subject": "clonidine", "sbj_char_span": [25, 34], "object": "alpha2-adrenoceptor", "obj_char_span": [50, 69], "rel_type": "agonist or antagonist", "sbj_tok_span": [4, 6], "obj_tok_span": [10, 16], "new_sbj_tok_span": [5, 7], "new_obj_tok_span": [12, 18]}, {"subject": "oxymetazoline", "sbj_char_span": [83, 96], "object": "alpha2A-adrenoceptor", "obj_char_span": [98, 118], "rel_type": "agonist or antagonist", "sbj_tok_span": [19, 24], "obj_tok_span": [25, 32], "new_sbj_tok_span": [25, 30], "new_obj_tok_span": [31, 38]}], "umls_entity_list": [{"mention": "clonidine", "char_span": [25, 34], "sem_type": "Pharmacologic Substance", "tok_span": [4, 6], "new_tok_span": [5, 7]}, {"mention": "adrenoceptor", "char_span": [57, 69], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [13, 16], "new_tok_span": [17, 20]}, {"mention": "adrenoceptor", "char_span": [106, 118], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [29, 32], "new_tok_span": [36, 39]}, {"mention": "adrenoceptor agonist", "char_span": [57, 77], "sem_type": "Pharmacologic Substance", "tok_span": [13, 17], "new_tok_span": [17, 21]}], "new_text": "The inhibitory effect of <START=Pharmacologic Substance> clonidine <END=Pharmacologic Substance> ( non - selective alpha2 - <START=Amino Acid, Peptide, or Protein> <START=Pharmacologic Substance> adrenoceptor <END=Amino Acid, Peptide, or Protein> agonist <END=Pharmacologic Substance> ) and oxymetazoline ( alpha2A - <START=Amino Acid, Peptide, or Protein> adrenoceptor <END=Amino Acid, Peptide, or Protein> selective agonist ) was compared on basal and stimulated gastric motor activity ( gastric tone and contractions ) using the balloon method in the rat."}, {"PMID": 23354070, "id": 6, "text": "Moreover, molecular dynamics simulations have identified an allosteric mechanism by which binding of palinurin leads to GSK-3β inhibition.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [101, 110], "name": "palinurin", "tok_span": [16, 19], "new_tok_span": [16, 19]}, {"ent_type": "GENE", "char_span": [120, 126], "name": "GSK-3β", "tok_span": [21, 25], "new_tok_span": [21, 25]}], "relation_list": [{"subject": "palinurin", "sbj_char_span": [101, 110], "object": "GSK-3β", "obj_char_span": [120, 126], "rel_type": "inhibitor", "sbj_tok_span": [16, 19], "obj_tok_span": [21, 25], "new_sbj_tok_span": [16, 19], "new_obj_tok_span": [21, 25]}], "umls_entity_list": [], "new_text": "Moreover, molecular dynamics simulations have identified an allosteric mechanism by which binding of palinurin leads to GSK - 3β inhibition."}, {"PMID": 23319419, "id": 7, "text": "ICA is a mixed agonist of mutant EAG and EAG/ERG chimera channels that inactivate by a combination of slow and fast mechanisms.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 3], "name": "ICA", "tok_span": [0, 1], "new_tok_span": [0, 1]}, {"ent_type": "GENE", "char_span": [33, 36], "name": "EAG", "tok_span": [7, 9], "new_tok_span": [8, 10]}, {"ent_type": "GENE", "char_span": [41, 44], "name": "EAG", "tok_span": [10, 12], "new_tok_span": [13, 15]}, {"ent_type": "GENE", "char_span": [45, 48], "name": "ERG", "tok_span": [13, 15], "new_tok_span": [17, 19]}], "relation_list": [{"subject": "ICA", "sbj_char_span": [0, 3], "object": "EAG", "obj_char_span": [33, 36], "rel_type": "agonist or antagonist", "sbj_tok_span": [0, 1], "obj_tok_span": [7, 9], "new_sbj_tok_span": [0, 1], "new_obj_tok_span": [8, 10]}, {"subject": "ICA", "sbj_char_span": [0, 3], "object": "EAG", "obj_char_span": [41, 44], "rel_type": "agonist or antagonist", "sbj_tok_span": [0, 1], "obj_tok_span": [10, 12], "new_sbj_tok_span": [0, 1], "new_obj_tok_span": [13, 15]}, {"subject": "ICA", "sbj_char_span": [0, 3], "object": "ERG", "obj_char_span": [45, 48], "rel_type": "agonist or antagonist", "sbj_tok_span": [0, 1], "obj_tok_span": [13, 15], "new_sbj_tok_span": [0, 1], "new_obj_tok_span": [17, 19]}], "umls_entity_list": [{"mention": "EAG", "char_span": [33, 36], "sem_type": "Gene or Genome", "tok_span": [7, 9], "new_tok_span": [8, 10]}, {"mention": "EAG", "char_span": [41, 44], "sem_type": "Gene or Genome", "tok_span": [10, 12], "new_tok_span": [13, 15]}], "new_text": "ICA is a mixed agonist of mutant <START=Gene or Genome> EAG <END=Gene or Genome> and <START=Gene or Genome> EAG <END=Gene or Genome> / ERG chimera channels that inactivate by a combination of slow and fast mechanisms."}, {"PMID": 12358053, "id": 2, "text": "In addition, we have previously shown an important role for COX-produced prostanoids in recovery of ischaemic-injured equine jejunum.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [73, 84], "name": "prostanoids", "tok_span": [14, 17], "new_tok_span": [14, 17]}, {"ent_type": "GENE", "char_span": [60, 63], "name": "COX", "tok_span": [11, 12], "new_tok_span": [11, 12]}], "relation_list": [{"subject": "prostanoids", "sbj_char_span": [73, 84], "object": "COX", "obj_char_span": [60, 63], "rel_type": "product or substrate", "sbj_tok_span": [14, 17], "obj_tok_span": [11, 12], "new_sbj_tok_span": [14, 17], "new_obj_tok_span": [11, 12]}], "umls_entity_list": [], "new_text": "In addition, we have previously shown an important role for COX - produced prostanoids in recovery of ischaemic - injured equine jejunum."}, {"PMID": 12668769, "id": 3, "text": "An alternative THF-dependent pathway involves the C1-THF synthase/SHMT activities with formate as 1-C source.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [15, 18], "name": "THF", "tok_span": [2, 3], "new_tok_span": [4, 5]}, {"ent_type": "CHEMICAL", "char_span": [50, 52], "name": "C1", "tok_span": [8, 10], "new_tok_span": [10, 12]}, {"ent_type": "CHEMICAL", "char_span": [53, 56], "name": "THF", "tok_span": [11, 12], "new_tok_span": [13, 14]}, {"ent_type": "CHEMICAL", "char_span": [87, 94], "name": "formate", "tok_span": [18, 20], "new_tok_span": [25, 27]}, {"ent_type": "CHEMICAL", "char_span": [98, 101], "name": "1-C", "tok_span": [21, 24], "new_tok_span": [29, 32]}, {"ent_type": "GENE", "char_span": [50, 65], "name": "C1-THF synthase", "tok_span": [8, 13], "new_tok_span": [10, 15]}, {"ent_type": "GENE", "char_span": [66, 70], "name": "SHMT", "tok_span": [14, 16], "new_tok_span": [18, 20]}], "relation_list": [{"subject": "formate", "sbj_char_span": [87, 94], "object": "SHMT", "obj_char_span": [66, 70], "rel_type": "product or substrate", "sbj_tok_span": [18, 20], "obj_tok_span": [14, 16], "new_sbj_tok_span": [25, 27], "new_obj_tok_span": [18, 20]}, {"subject": "formate", "sbj_char_span": [87, 94], "object": "C1-THF synthase", "obj_char_span": [50, 65], "rel_type": "product or substrate", "sbj_tok_span": [18, 20], "obj_tok_span": [8, 13], "new_sbj_tok_span": [25, 27], "new_obj_tok_span": [10, 15]}], "umls_entity_list": [{"mention": "alternative", "char_span": [3, 14], "sem_type": "Gene or Genome", "tok_span": [1, 2], "new_tok_span": [2, 3]}, {"mention": "SHMT", "char_span": [66, 70], "sem_type": "Gene or Genome", "tok_span": [14, 16], "new_tok_span": [18, 20]}, {"mention": "formate", "char_span": [87, 94], "sem_type": "Organic Chemical", "tok_span": [18, 20], "new_tok_span": [25, 27]}, {"mention": "SHMT", "char_span": [66, 70], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [14, 16], "new_tok_span": [18, 20]}], "new_text": "An <START=Gene or Genome> alternative <END=Gene or Genome> THF - dependent pathway involves the C1 - THF synthase / <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> SHMT <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> activities with <START=Organic Chemical> formate <END=Organic Chemical> as 1 - C source."}, {"PMID": 12668769, "id": 14, "text": "On the other hand, the accumulation of Ser through the C1-THF synthase/SHMT pathway in glyD plants was 2.5-fold greater than that in WT plants.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [39, 42], "name": "Ser", "tok_span": [8, 9], "new_tok_span": [8, 9]}, {"ent_type": "CHEMICAL", "char_span": [55, 57], "name": "C1", "tok_span": [11, 13], "new_tok_span": [11, 13]}, {"ent_type": "CHEMICAL", "char_span": [58, 61], "name": "THF", "tok_span": [14, 15], "new_tok_span": [14, 15]}, {"ent_type": "CHEMICAL", "char_span": [87, 91], "name": "glyD", "tok_span": [21, 23], "new_tok_span": [26, 28]}, {"ent_type": "GENE", "char_span": [55, 70], "name": "C1-THF synthase", "tok_span": [11, 16], "new_tok_span": [11, 16]}, {"ent_type": "GENE", "char_span": [71, 75], "name": "SHMT", "tok_span": [17, 19], "new_tok_span": [19, 21]}], "relation_list": [{"subject": "Ser", "sbj_char_span": [39, 42], "object": "SHMT", "obj_char_span": [71, 75], "rel_type": "product or substrate", "sbj_tok_span": [8, 9], "obj_tok_span": [17, 19], "new_sbj_tok_span": [8, 9], "new_obj_tok_span": [19, 21]}], "umls_entity_list": [{"mention": "SHMT", "char_span": [71, 75], "sem_type": "Gene or Genome", "tok_span": [17, 19], "new_tok_span": [19, 21]}, {"mention": "glyD", "char_span": [87, 91], "sem_type": "Gene or Genome", "tok_span": [21, 23], "new_tok_span": [26, 28]}, {"mention": "SHMT", "char_span": [71, 75], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [17, 19], "new_tok_span": [19, 21]}, {"mention": "WT", "char_span": [133, 135], "sem_type": "Gene or Genome", "tok_span": [34, 35], "new_tok_span": [41, 42]}], "new_text": "On the other hand, the accumulation of Ser through the C1 - THF synthase / <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> SHMT <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> pathway in <START=Gene or Genome> glyD <END=Gene or Genome> plants was 2. 5 - fold greater than that in <START=Gene or Genome> WT <END=Gene or Genome> plants."}, {"PMID": 23418859, "id": 2, "text": "Salidroside or salidroside+PI3K inhibitor (LY294002) was administered via intracoronary injections at the onset of reperfusion.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 11], "name": "Salidroside", "tok_span": [0, 4], "new_tok_span": [1, 5]}, {"ent_type": "CHEMICAL", "char_span": [15, 26], "name": "salidroside", "tok_span": [5, 9], "new_tok_span": [8, 12]}, {"ent_type": "CHEMICAL", "char_span": [43, 51], "name": "LY294002", "tok_span": [15, 19], "new_tok_span": [21, 25]}, {"ent_type": "GENE", "char_span": [27, 31], "name": "PI3K", "tok_span": [10, 13], "new_tok_span": [15, 18]}], "relation_list": [{"subject": "LY294002", "sbj_char_span": [43, 51], "object": "PI3K", "obj_char_span": [27, 31], "rel_type": "inhibitor", "sbj_tok_span": [15, 19], "obj_tok_span": [10, 13], "new_sbj_tok_span": [21, 25], "new_obj_tok_span": [15, 18]}], "umls_entity_list": [{"mention": "Salidroside", "char_span": [0, 11], "sem_type": "Pharmacologic Substance", "tok_span": [0, 4], "new_tok_span": [1, 5]}, {"mention": "salidroside", "char_span": [15, 26], "sem_type": "Pharmacologic Substance", "tok_span": [5, 9], "new_tok_span": [8, 12]}, {"mention": "PI3K inhibitor", "char_span": [27, 41], "sem_type": "Pharmacologic Substance", "tok_span": [10, 14], "new_tok_span": [15, 19]}], "new_text": "<START=Pharmacologic Substance> Salidroside <END=Pharmacologic Substance> or <START=Pharmacologic Substance> salidroside <END=Pharmacologic Substance> + <START=Pharmacologic Substance> PI3K inhibitor <END=Pharmacologic Substance> ( LY294002 ) was administered via intracoronary injections at the onset of reperfusion."}, {"PMID": 7678677, "id": 2, "text": "Alprenolol and BAAM at 10(-7), 3 x 10(-7), and 10(-6) M inhibited the cardiac stimulation response slightly, which is indicative of membrane-stabilizing activity independent of beta-adrenoceptor blockade.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [15, 19], "name": "BAAM", "tok_span": [6, 8], "new_tok_span": [7, 9]}, {"ent_type": "CHEMICAL", "char_span": [0, 10], "name": "Alprenolol", "tok_span": [0, 5], "new_tok_span": [0, 5]}, {"ent_type": "GENE", "char_span": [177, 194], "name": "beta-adrenoceptor", "tok_span": [47, 52], "new_tok_span": [49, 54]}], "relation_list": [{"subject": "Alprenolol", "sbj_char_span": [0, 10], "object": "beta-adrenoceptor", "obj_char_span": [177, 194], "rel_type": "inhibitor", "sbj_tok_span": [0, 5], "obj_tok_span": [47, 52], "new_sbj_tok_span": [0, 5], "new_obj_tok_span": [49, 54]}, {"subject": "BAAM", "sbj_char_span": [15, 19], "object": "beta-adrenoceptor", "obj_char_span": [177, 194], "rel_type": "inhibitor", "sbj_tok_span": [6, 8], "obj_tok_span": [47, 52], "new_sbj_tok_span": [7, 9], "new_obj_tok_span": [49, 54]}], "umls_entity_list": [{"mention": "BAAM", "char_span": [15, 19], "sem_type": "Organic Chemical", "tok_span": [6, 8], "new_tok_span": [7, 9]}], "new_text": "Alprenolol and <START=Organic Chemical> BAAM <END=Organic Chemical> at 10 ( - 7 ), 3 x 10 ( - 7 ), and 10 ( - 6 ) M inhibited the cardiac stimulation response slightly, which is indicative of membrane - stabilizing activity independent of beta - adrenoceptor blockade."}, {"PMID": 23742252, "id": 1, "text": "The synthesis, preclinical profile, and in vivo efficacy in rat xenograft models of the novel and selective anaplastic lymphoma kinase inhibitor 15b (LDK378) are described.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [150, 156], "name": "LDK378", "tok_span": [28, 32], "new_tok_span": [31, 35]}, {"ent_type": "GENE", "char_span": [108, 134], "name": "anaplastic lymphoma kinase", "tok_span": [20, 24], "new_tok_span": [21, 25]}], "relation_list": [{"subject": "LDK378", "sbj_char_span": [150, 156], "object": "anaplastic lymphoma kinase", "obj_char_span": [108, 134], "rel_type": "inhibitor", "sbj_tok_span": [28, 32], "obj_tok_span": [20, 24], "new_sbj_tok_span": [31, 35], "new_obj_tok_span": [21, 25]}], "umls_entity_list": [{"mention": "anaplastic lymphoma kinase inhibitor", "char_span": [108, 144], "sem_type": "Pharmacologic Substance", "tok_span": [20, 25], "new_tok_span": [21, 26]}, {"mention": "LDK378", "char_span": [150, 156], "sem_type": "Pharmacologic Substance", "tok_span": [28, 32], "new_tok_span": [31, 35]}], "new_text": "The synthesis, preclinical profile, and in vivo efficacy in rat xenograft models of the novel and selective <START=Pharmacologic Substance> anaplastic lymphoma kinase inhibitor <END=Pharmacologic Substance> 15b ( <START=Pharmacologic Substance> LDK378 <END=Pharmacologic Substance> ) are described."}, {"PMID": 23388095, "id": 12, "text": "Inducible heme-oxygenase 1 mRNA expressions were significantly higher in the DMOG group.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [10, 14], "name": "heme", "tok_span": [3, 4], "new_tok_span": [3, 4]}, {"ent_type": "CHEMICAL", "char_span": [77, 81], "name": "DMOG", "tok_span": [15, 17], "new_tok_span": [15, 17]}, {"ent_type": "GENE", "char_span": [10, 26], "name": "heme-oxygenase 1", "tok_span": [3, 8], "new_tok_span": [3, 8]}], "relation_list": [{"subject": "DMOG", "sbj_char_span": [77, 81], "object": "heme-oxygenase 1", "obj_char_span": [10, 26], "rel_type": "regulator", "sbj_tok_span": [15, 17], "obj_tok_span": [3, 8], "new_sbj_tok_span": [15, 17], "new_obj_tok_span": [3, 8]}], "umls_entity_list": [], "new_text": "Inducible heme - oxygenase 1 mRNA expressions were significantly higher in the DMOG group."}, {"PMID": 10898598, "id": 9, "text": "POCl(3) on reaction with water and HOP(O)Cl(2) have the same potency for inhibition of AChE from either electric eel or housefly head as well as the same toxicity for mice.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 7], "name": "POCl(3)", "tok_span": [0, 5], "new_tok_span": [0, 5]}, {"ent_type": "CHEMICAL", "char_span": [35, 46], "name": "HOP(O)Cl(2)", "tok_span": [10, 19], "new_tok_span": [11, 20]}, {"ent_type": "GENE", "char_span": [87, 91], "name": "AChE", "tok_span": [26, 28], "new_tok_span": [28, 30]}], "relation_list": [{"subject": "POCl(3)", "sbj_char_span": [0, 7], "object": "AChE", "obj_char_span": [87, 91], "rel_type": "inhibitor", "sbj_tok_span": [0, 5], "obj_tok_span": [26, 28], "new_sbj_tok_span": [0, 5], "new_obj_tok_span": [28, 30]}, {"subject": "HOP(O)Cl(2)", "sbj_char_span": [35, 46], "object": "AChE", "obj_char_span": [87, 91], "rel_type": "inhibitor", "sbj_tok_span": [10, 19], "obj_tok_span": [26, 28], "new_sbj_tok_span": [11, 20], "new_obj_tok_span": [28, 30]}], "umls_entity_list": [{"mention": "HOP", "char_span": [35, 38], "sem_type": "Gene or Genome", "tok_span": [10, 12], "new_tok_span": [11, 13]}], "new_text": "POCl ( 3 ) on reaction with water and <START=Gene or Genome> HOP <END=Gene or Genome> ( O ) Cl ( 2 ) have the same potency for inhibition of AChE from either electric eel or housefly head as well as the same toxicity for mice."}, {"PMID": 23386702, "id": 2, "text": "Uridine 5'-diphosphate- glucuronosyltransferases are colocalized with carboxylesterases and have the potential to further metabolize carboxylic acids to acyl glucuronides, but it is currently unknown if acyl glucuronides, being esters, also interact with carboxylesterases.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 22], "name": "Uridine 5'-diphosphate", "tok_span": [0, 7], "new_tok_span": [0, 7]}, {"ent_type": "CHEMICAL", "char_span": [133, 149], "name": "carboxylic acids", "tok_span": [28, 31], "new_tok_span": [31, 34]}, {"ent_type": "CHEMICAL", "char_span": [153, 170], "name": "acyl glucuronides", "tok_span": [32, 36], "new_tok_span": [36, 40]}, {"ent_type": "CHEMICAL", "char_span": [203, 220], "name": "acyl glucuronides", "tok_span": [43, 47], "new_tok_span": [51, 55]}, {"ent_type": "CHEMICAL", "char_span": [228, 234], "name": "esters", "tok_span": [49, 50], "new_tok_span": [59, 60]}, {"ent_type": "GENE", "char_span": [0, 48], "name": "Uridine 5'-diphosphate- glucuronosyltransferases", "tok_span": [0, 13], "new_tok_span": [0, 13]}, {"ent_type": "GENE", "char_span": [70, 87], "name": "carboxylesterases", "tok_span": [17, 20], "new_tok_span": [19, 22]}, {"ent_type": "GENE", "char_span": [255, 272], "name": "carboxylesterases", "tok_span": [54, 57], "new_tok_span": [64, 67]}], "relation_list": [{"subject": "carboxylic acids", "sbj_char_span": [133, 149], "object": "Uridine 5'-diphosphate- glucuronosyltransferases", "obj_char_span": [0, 48], "rel_type": "product or substrate", "sbj_tok_span": [28, 31], "obj_tok_span": [0, 13], "new_sbj_tok_span": [31, 34], "new_obj_tok_span": [0, 13]}, {"subject": "acyl glucuronides", "sbj_char_span": [153, 170], "object": "Uridine 5'-diphosphate- glucuronosyltransferases", "obj_char_span": [0, 48], "rel_type": "product or substrate", "sbj_tok_span": [32, 36], "obj_tok_span": [0, 13], "new_sbj_tok_span": [36, 40], "new_obj_tok_span": [0, 13]}, {"subject": "carboxylic acids", "sbj_char_span": [133, 149], "object": "carboxylesterases", "obj_char_span": [70, 87], "rel_type": "product or substrate", "sbj_tok_span": [28, 31], "obj_tok_span": [17, 20], "new_sbj_tok_span": [31, 34], "new_obj_tok_span": [19, 22]}, {"subject": "acyl glucuronides", "sbj_char_span": [153, 170], "object": "carboxylesterases", "obj_char_span": [70, 87], "rel_type": "product or substrate", "sbj_tok_span": [32, 36], "obj_tok_span": [17, 20], "new_sbj_tok_span": [36, 40], "new_obj_tok_span": [19, 22]}], "umls_entity_list": [{"mention": "glucuronosyltransferase", "char_span": [24, 47], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [8, 12], "new_tok_span": [9, 13]}, {"mention": "carboxylic", "char_span": [133, 143], "sem_type": "Organic Chemical", "tok_span": [28, 30], "new_tok_span": [31, 33]}, {"mention": "glucuronides", "char_span": [158, 170], "sem_type": "Organic Chemical", "tok_span": [33, 36], "new_tok_span": [38, 41]}, {"mention": "glucuronides", "char_span": [208, 220], "sem_type": "Organic Chemical", "tok_span": [44, 47], "new_tok_span": [53, 56]}, {"mention": "unknown", "char_span": [192, 199], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [41, 42], "new_tok_span": [48, 49]}], "new_text": "Uridine 5'- diphosphate - <START=Amino Acid, Peptide, or Protein> glucuronosyltransferase <END=Amino Acid, Peptide, or Protein>s are colocalized with carboxylesterases and have the potential to further metabolize <START=Organic Chemical> carboxylic <END=Organic Chemical> acids to acyl <START=Organic Chemical> glucuronides <END=Organic Chemical>, but it is currently <START=Amino Acid, Peptide, or Protein> unknown <END=Amino Acid, Peptide, or Protein> if acyl <START=Organic Chemical> glucuronides <END=Organic Chemical>, being esters, also interact with carboxylesterases."}, {"PMID": 23386702, "id": 4, "text": "Methods: The stability of six acyl glucuronides in the presence of hCES1, hCES2, and buffer alone (100 mM potassium phosphate, pH 7.4, 37°C) were investigated.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [30, 47], "name": "acyl glucuronides", "tok_span": [6, 10], "new_tok_span": [6, 10]}, {"ent_type": "CHEMICAL", "char_span": [106, 125], "name": "potassium phosphate", "tok_span": [28, 30], "new_tok_span": [33, 35]}, {"ent_type": "GENE", "char_span": [67, 72], "name": "hCES1", "tok_span": [14, 17], "new_tok_span": [16, 19]}, {"ent_type": "GENE", "char_span": [74, 79], "name": "hCES2", "tok_span": [18, 21], "new_tok_span": [20, 23]}], "relation_list": [{"subject": "acyl glucuronides", "sbj_char_span": [30, 47], "object": "hCES1", "obj_char_span": [67, 72], "rel_type": "product or substrate", "sbj_tok_span": [6, 10], "obj_tok_span": [14, 17], "new_sbj_tok_span": [6, 10], "new_obj_tok_span": [16, 19]}, {"subject": "acyl glucuronides", "sbj_char_span": [30, 47], "object": "hCES2", "obj_char_span": [74, 79], "rel_type": "product or substrate", "sbj_tok_span": [6, 10], "obj_tok_span": [18, 21], "new_sbj_tok_span": [6, 10], "new_obj_tok_span": [20, 23]}], "umls_entity_list": [{"mention": "glucuronides", "char_span": [35, 47], "sem_type": "Organic Chemical", "tok_span": [7, 10], "new_tok_span": [8, 11]}, {"mention": "buffer", "char_span": [85, 91], "sem_type": "Pharmacologic Substance", "tok_span": [23, 24], "new_tok_span": [26, 27]}, {"mention": "potassium phosphate", "char_span": [106, 125], "sem_type": "Pharmacologic Substance", "tok_span": [28, 30], "new_tok_span": [33, 35]}], "new_text": "Methods : The stability of six acyl <START=Organic Chemical> glucuronides <END=Organic Chemical> in the presence of hCES1, hCES2, and <START=Pharmacologic Substance> buffer <END=Pharmacologic Substance> alone ( 100 mM <START=Pharmacologic Substance> potassium phosphate <END=Pharmacologic Substance>, pH 7. 4, 37°C ) were investigated."}, {"PMID": 23645249, "id": 4, "text": "Herein, we report that post-weaning dietary exposure to soy protein isolate and its bioactive isoflavone genistein lowered mammary adiposity and increased mammary tumor suppressor PTEN and E-cadherin expression in female mice, relative to control casein diet.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [94, 104], "name": "isoflavone", "tok_span": [17, 20], "new_tok_span": [22, 25]}, {"ent_type": "CHEMICAL", "char_span": [105, 114], "name": "genistein", "tok_span": [20, 23], "new_tok_span": [27, 30]}, {"ent_type": "GENE", "char_span": [180, 184], "name": "PTEN", "tok_span": [32, 33], "new_tok_span": [46, 47]}, {"ent_type": "GENE", "char_span": [189, 199], "name": "E-cadherin", "tok_span": [34, 39], "new_tok_span": [52, 57]}], "relation_list": [{"subject": "isoflavone", "sbj_char_span": [94, 104], "object": "PTEN", "obj_char_span": [180, 184], "rel_type": "regulator", "sbj_tok_span": [17, 20], "obj_tok_span": [32, 33], "new_sbj_tok_span": [22, 25], "new_obj_tok_span": [46, 47]}, {"subject": "genistein", "sbj_char_span": [105, 114], "object": "PTEN", "obj_char_span": [180, 184], "rel_type": "regulator", "sbj_tok_span": [20, 23], "obj_tok_span": [32, 33], "new_sbj_tok_span": [27, 30], "new_obj_tok_span": [46, 47]}, {"subject": "isoflavone", "sbj_char_span": [94, 104], "object": "E-cadherin", "obj_char_span": [189, 199], "rel_type": "regulator", "sbj_tok_span": [17, 20], "obj_tok_span": [34, 39], "new_sbj_tok_span": [22, 25], "new_obj_tok_span": [52, 57]}, {"subject": "genistein", "sbj_char_span": [105, 114], "object": "E-cadherin", "obj_char_span": [189, 199], "rel_type": "regulator", "sbj_tok_span": [20, 23], "obj_tok_span": [34, 39], "new_sbj_tok_span": [27, 30], "new_obj_tok_span": [52, 57]}], "umls_entity_list": [{"mention": "soy protein isolate", "char_span": [56, 75], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [11, 14], "new_tok_span": [13, 16]}, {"mention": "soy protein isolate", "char_span": [56, 75], "sem_type": "Organic Chemical", "tok_span": [11, 14], "new_tok_span": [13, 16]}, {"mention": "isoflavone", "char_span": [94, 104], "sem_type": "Pharmacologic Substance", "tok_span": [17, 20], "new_tok_span": [22, 25]}, {"mention": "genistein", "char_span": [105, 114], "sem_type": "Pharmacologic Substance", "tok_span": [20, 23], "new_tok_span": [27, 30]}, {"mention": "PTEN", "char_span": [180, 184], "sem_type": "Gene or Genome", "tok_span": [32, 33], "new_tok_span": [46, 47]}, {"mention": "PTEN", "char_span": [180, 184], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [32, 33], "new_tok_span": [46, 47]}, {"mention": "suppressor", "char_span": [169, 179], "sem_type": "Pharmacologic Substance", "tok_span": [31, 32], "new_tok_span": [41, 42]}, {"mention": "tumor suppressor", "char_span": [163, 179], "sem_type": "Gene or Genome", "tok_span": [30, 32], "new_tok_span": [39, 41]}, {"mention": "E-cadherin", "char_span": [189, 199], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [34, 39], "new_tok_span": [52, 57]}, {"mention": "E-cadherin", "char_span": [189, 199], "sem_type": "Gene or Genome", "tok_span": [34, 39], "new_tok_span": [52, 57]}, {"mention": "casein", "char_span": [247, 253], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [47, 49], "new_tok_span": [68, 70]}], "new_text": "Herein, we report that post - weaning dietary exposure to <START=Amino Acid, Peptide, or Protein> <START=Organic Chemical> soy protein isolate <END=Amino Acid, Peptide, or Protein> <END=Organic Chemical> and its bioactive <START=Pharmacologic Substance> isoflavone <END=Pharmacologic Substance> <START=Pharmacologic Substance> genistein <END=Pharmacologic Substance> lowered mammary adiposity and increased mammary <START=Gene or Genome> tumor <START=Pharmacologic Substance> suppressor <END=Pharmacologic Substance> <END=Gene or Genome> <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> PTEN <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> and <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> E - cadherin <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> expression in female mice, relative to control <START=Amino Acid, Peptide, or Protein> casein <END=Amino Acid, Peptide, or Protein> diet."}, {"PMID": 10909982, "id": 8, "text": "Treatment of lactating mice with a single injection of bezafibrate, an activator of the peroxisome proliferator-activated receptor (PPAR), raises UCP-3 mRNA in skeletal muscle to levels similar to those in virgin mice. 4-chloro-6-[(2,3-xylidine)-pirimidinylthio] acetic acid (WY-14,643), a specific ligand of the PPAR-alpha subtype, causes the most dramatic increase in UCP-3 mRNA, whereas troglitazone, a specific activator of PPAR-gamma, also significantly increases UCP-3 mRNA abundance in skeletal muscle of lactating mice.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [55, 66], "name": "bezafibrate", "tok_span": [10, 14], "new_tok_span": [11, 15]}, {"ent_type": "CHEMICAL", "char_span": [219, 274], "name": "4-chloro-6-[(2,3-xylidine)-pirimidinylthio] acetic acid", "tok_span": [49, 75], "new_tok_span": [53, 79]}, {"ent_type": "CHEMICAL", "char_span": [276, 285], "name": "WY-14,643", "tok_span": [76, 83], "new_tok_span": [83, 90]}, {"ent_type": "CHEMICAL", "char_span": [390, 402], "name": "troglitazone", "tok_span": [108, 112], "new_tok_span": [118, 122]}, {"ent_type": "GENE", "char_span": [88, 130], "name": "peroxisome proliferator-activated receptor", "tok_span": [19, 26], "new_tok_span": [21, 28]}, {"ent_type": "GENE", "char_span": [132, 136], "name": "PPAR", "tok_span": [27, 28], "new_tok_span": [29, 30]}, {"ent_type": "GENE", "char_span": [146, 151], "name": "UCP-3", "tok_span": [31, 35], "new_tok_span": [34, 38]}, {"ent_type": "GENE", "char_span": [313, 323], "name": "PPAR-alpha", "tok_span": [90, 93], "new_tok_span": [98, 101]}, {"ent_type": "GENE", "char_span": [370, 375], "name": "UCP-3", "tok_span": [101, 105], "new_tok_span": [110, 114]}, {"ent_type": "GENE", "char_span": [428, 438], "name": "PPAR-gamma", "tok_span": [117, 120], "new_tok_span": [127, 130]}, {"ent_type": "GENE", "char_span": [469, 474], "name": "UCP-3", "tok_span": [124, 128], "new_tok_span": [135, 139]}], "relation_list": [{"subject": "bezafibrate", "sbj_char_span": [55, 66], "object": "peroxisome proliferator-activated receptor", "obj_char_span": [88, 130], "rel_type": "activator", "sbj_tok_span": [10, 14], "obj_tok_span": [19, 26], "new_sbj_tok_span": [11, 15], "new_obj_tok_span": [21, 28]}, {"subject": "bezafibrate", "sbj_char_span": [55, 66], "object": "PPAR", "obj_char_span": [132, 136], "rel_type": "activator", "sbj_tok_span": [10, 14], "obj_tok_span": [27, 28], "new_sbj_tok_span": [11, 15], "new_obj_tok_span": [29, 30]}, {"subject": "bezafibrate", "sbj_char_span": [55, 66], "object": "UCP-3", "obj_char_span": [146, 151], "rel_type": "regulator", "sbj_tok_span": [10, 14], "obj_tok_span": [31, 35], "new_sbj_tok_span": [11, 15], "new_obj_tok_span": [34, 38]}, {"subject": "troglitazone", "sbj_char_span": [390, 402], "object": "PPAR-gamma", "obj_char_span": [428, 438], "rel_type": "activator", "sbj_tok_span": [108, 112], "obj_tok_span": [117, 120], "new_sbj_tok_span": [118, 122], "new_obj_tok_span": [127, 130]}, {"subject": "troglitazone", "sbj_char_span": [390, 402], "object": "UCP-3", "obj_char_span": [469, 474], "rel_type": "regulator", "sbj_tok_span": [108, 112], "obj_tok_span": [124, 128], "new_sbj_tok_span": [118, 122], "new_obj_tok_span": [135, 139]}, {"subject": "WY-14,643", "sbj_char_span": [276, 285], "object": "PPAR-alpha", "obj_char_span": [313, 323], "rel_type": "regulator", "sbj_tok_span": [76, 83], "obj_tok_span": [90, 93], "new_sbj_tok_span": [83, 90], "new_obj_tok_span": [98, 101]}, {"subject": "4-chloro-6-[(2,3-xylidine)-pirimidinylthio] acetic acid", "sbj_char_span": [219, 274], "object": "PPAR-alpha", "obj_char_span": [313, 323], "rel_type": "regulator", "sbj_tok_span": [49, 75], "obj_tok_span": [90, 93], "new_sbj_tok_span": [53, 79], "new_obj_tok_span": [98, 101]}, {"subject": "4-chloro-6-[(2,3-xylidine)-pirimidinylthio] acetic acid", "sbj_char_span": [219, 274], "object": "UCP-3", "obj_char_span": [370, 375], "rel_type": "regulator", "sbj_tok_span": [49, 75], "obj_tok_span": [101, 105], "new_sbj_tok_span": [53, 79], "new_obj_tok_span": [110, 114]}, {"subject": "WY-14,643", "sbj_char_span": [276, 285], "object": "UCP-3", "obj_char_span": [370, 375], "rel_type": "regulator", "sbj_tok_span": [76, 83], "obj_tok_span": [101, 105], "new_sbj_tok_span": [83, 90], "new_obj_tok_span": [110, 114]}], "umls_entity_list": [{"mention": "bezafibrate", "char_span": [55, 66], "sem_type": "Pharmacologic Substance", "tok_span": [10, 14], "new_tok_span": [11, 15]}, {"mention": "UCP", "char_span": [146, 149], "sem_type": "Gene or Genome", "tok_span": [31, 33], "new_tok_span": [34, 36]}, {"mention": "UCP", "char_span": [370, 373], "sem_type": "Gene or Genome", "tok_span": [101, 103], "new_tok_span": [110, 112]}, {"mention": "UCP", "char_span": [469, 472], "sem_type": "Gene or Genome", "tok_span": [124, 126], "new_tok_span": [135, 137]}, {"mention": "xylidine", "char_span": [236, 244], "sem_type": "Organic Chemical", "tok_span": [62, 64], "new_tok_span": [67, 69]}, {"mention": "WY", "char_span": [276, 278], "sem_type": "Pharmacologic Substance", "tok_span": [76, 78], "new_tok_span": [83, 85]}], "new_text": "Treatment of lactating mice with a single injection of <START=Pharmacologic Substance> bezafibrate <END=Pharmacologic Substance>, an activator of the peroxisome proliferator - activated receptor ( PPAR ), raises <START=Gene or Genome> UCP <END=Gene or Genome> - 3 mRNA in skeletal muscle to levels similar to those in virgin mice. 4 - chloro - 6 - [ ( 2, 3 - <START=Organic Chemical> xylidine <END=Organic Chemical> ) - pirimidinylthio ] acetic acid ( <START=Pharmacologic Substance> WY <END=Pharmacologic Substance> - 14, 643 ), a specific ligand of the PPAR - alpha subtype, causes the most dramatic increase in <START=Gene or Genome> UCP <END=Gene or Genome> - 3 mRNA, whereas troglitazone, a specific activator of PPAR - gamma, also significantly increases <START=Gene or Genome> UCP <END=Gene or Genome> - 3 mRNA abundance in skeletal muscle of lactating mice."}, {"PMID": 14596599, "id": 5, "text": "The holo-SDH crystallized with O-methylserine (OMS) was also determined at 2.6 A resolution by molecular replacement.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [31, 45], "name": "O-methylserine", "tok_span": [9, 14], "new_tok_span": [10, 15]}, {"ent_type": "CHEMICAL", "char_span": [47, 50], "name": "OMS", "tok_span": [15, 17], "new_tok_span": [17, 19]}, {"ent_type": "GENE", "char_span": [4, 12], "name": "holo-SDH", "tok_span": [1, 6], "new_tok_span": [1, 6]}], "relation_list": [{"subject": "O-methylserine", "sbj_char_span": [31, 45], "object": "holo-SDH", "obj_char_span": [4, 12], "rel_type": "regulator", "sbj_tok_span": [9, 14], "obj_tok_span": [1, 6], "new_sbj_tok_span": [10, 15], "new_obj_tok_span": [1, 6]}, {"subject": "OMS", "sbj_char_span": [47, 50], "object": "holo-SDH", "obj_char_span": [4, 12], "rel_type": "regulator", "sbj_tok_span": [15, 17], "obj_tok_span": [1, 6], "new_sbj_tok_span": [17, 19], "new_obj_tok_span": [1, 6]}], "umls_entity_list": [{"mention": "O-methylserine", "char_span": [31, 45], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [9, 14], "new_tok_span": [10, 15]}], "new_text": "The holo - SDH crystallized with <START=Amino Acid, Peptide, or Protein> O - methylserine <END=Amino Acid, Peptide, or Protein> ( OMS ) was also determined at 2. 6 A resolution by molecular replacement."}, {"PMID": 23142789, "id": 6, "text": "Transient receptor potential cation channel, subfamily V, member 6 (TRPV6) and transient receptor potential cation channel, subfamily V, member 5 (TRPV5) are Ca entry channels responsible for Ca absorption in the kidney and intestine, respectively.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [158, 160], "name": "Ca", "tok_span": [35, 36], "new_tok_span": [45, 46]}, {"ent_type": "CHEMICAL", "char_span": [192, 194], "name": "Ca", "tok_span": [40, 41], "new_tok_span": [50, 51]}, {"ent_type": "GENE", "char_span": [0, 66], "name": "Transient receptor potential cation channel, subfamily V, member 6", "tok_span": [0, 12], "new_tok_span": [1, 13]}, {"ent_type": "GENE", "char_span": [68, 73], "name": "TRPV6", "tok_span": [13, 16], "new_tok_span": [17, 20]}, {"ent_type": "GENE", "char_span": [79, 145], "name": "transient receptor potential cation channel, subfamily V, member 5", "tok_span": [18, 29], "new_tok_span": [25, 36]}, {"ent_type": "GENE", "char_span": [147, 152], "name": "TRPV5", "tok_span": [30, 33], "new_tok_span": [39, 42]}, {"ent_type": "GENE", "char_span": [158, 175], "name": "Ca entry channels", "tok_span": [35, 38], "new_tok_span": [45, 48]}], "relation_list": [{"subject": "Ca", "sbj_char_span": [192, 194], "object": "Transient receptor potential cation channel, subfamily V, member 6", "obj_char_span": [0, 66], "rel_type": "product or substrate", "sbj_tok_span": [40, 41], "obj_tok_span": [0, 12], "new_sbj_tok_span": [50, 51], "new_obj_tok_span": [1, 13]}, {"subject": "Ca", "sbj_char_span": [192, 194], "object": "TRPV6", "obj_char_span": [68, 73], "rel_type": "product or substrate", "sbj_tok_span": [40, 41], "obj_tok_span": [13, 16], "new_sbj_tok_span": [50, 51], "new_obj_tok_span": [17, 20]}, {"subject": "Ca", "sbj_char_span": [192, 194], "object": "Ca entry channels", "obj_char_span": [158, 175], "rel_type": "product or substrate", "sbj_tok_span": [40, 41], "obj_tok_span": [35, 38], "new_sbj_tok_span": [50, 51], "new_obj_tok_span": [45, 48]}], "umls_entity_list": [{"mention": "Transient receptor potential cation channel", "char_span": [0, 43], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [0, 6], "new_tok_span": [1, 7]}, {"mention": "transient receptor potential cation channel", "char_span": [79, 122], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [18, 23], "new_tok_span": [25, 30]}, {"mention": "TRPV6", "char_span": [68, 73], "sem_type": "Gene or Genome", "tok_span": [13, 16], "new_tok_span": [17, 20]}, {"mention": "TRPV6", "char_span": [68, 73], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [13, 16], "new_tok_span": [17, 20]}, {"mention": "TRPV5", "char_span": [147, 152], "sem_type": "Gene or Genome", "tok_span": [30, 33], "new_tok_span": [39, 42]}], "new_text": "<START=Amino Acid, Peptide, or Protein> Transient receptor potential cation channel <END=Amino Acid, Peptide, or Protein>, subfamily V, member 6 ( <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> TRPV6 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> ) and <START=Amino Acid, Peptide, or Protein> transient receptor potential cation channel <END=Amino Acid, Peptide, or Protein>, subfamily V, member 5 ( <START=Gene or Genome> TRPV5 <END=Gene or Genome> ) are Ca entry channels responsible for Ca absorption in the kidney and intestine, respectively."}, {"PMID": 23435916, "id": 4, "text": "Similarly, pristimerin inhibited the release of pro-inflammatory cytokines, namely, tumor necrosis factor-α and interleukin-6, induced by LPS. The underlying mechanism of the anti-inflammatory action of pristimerin was correlated with down-regulation of nuclear factor-κB and the mitogen-activated protein kinase signal pathway.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [11, 22], "name": "pristimerin", "tok_span": [2, 6], "new_tok_span": [3, 7]}, {"ent_type": "CHEMICAL", "char_span": [203, 214], "name": "pristimerin", "tok_span": [41, 45], "new_tok_span": [44, 48]}, {"ent_type": "GENE", "char_span": [65, 74], "name": "cytokines", "tok_span": [13, 14], "new_tok_span": [15, 16]}, {"ent_type": "GENE", "char_span": [84, 107], "name": "tumor necrosis factor-α", "tok_span": [17, 22], "new_tok_span": [19, 24]}, {"ent_type": "GENE", "char_span": [112, 125], "name": "interleukin-6", "tok_span": [23, 26], "new_tok_span": [25, 28]}, {"ent_type": "GENE", "char_span": [254, 271], "name": "nuclear factor-κB", "tok_span": [52, 57], "new_tok_span": [56, 61]}, {"ent_type": "GENE", "char_span": [280, 312], "name": "mitogen-activated protein kinase", "tok_span": [59, 64], "new_tok_span": [64, 69]}], "relation_list": [{"subject": "pristimerin", "sbj_char_span": [11, 22], "object": "cytokines", "obj_char_span": [65, 74], "rel_type": "regulator", "sbj_tok_span": [2, 6], "obj_tok_span": [13, 14], "new_sbj_tok_span": [3, 7], "new_obj_tok_span": [15, 16]}, {"subject": "pristimerin", "sbj_char_span": [11, 22], "object": "tumor necrosis factor-α", "obj_char_span": [84, 107], "rel_type": "regulator", "sbj_tok_span": [2, 6], "obj_tok_span": [17, 22], "new_sbj_tok_span": [3, 7], "new_obj_tok_span": [19, 24]}, {"subject": "pristimerin", "sbj_char_span": [11, 22], "object": "interleukin-6", "obj_char_span": [112, 125], "rel_type": "regulator", "sbj_tok_span": [2, 6], "obj_tok_span": [23, 26], "new_sbj_tok_span": [3, 7], "new_obj_tok_span": [25, 28]}, {"subject": "pristimerin", "sbj_char_span": [203, 214], "object": "nuclear factor-κB", "obj_char_span": [254, 271], "rel_type": "inhibitor", "sbj_tok_span": [41, 45], "obj_tok_span": [52, 57], "new_sbj_tok_span": [44, 48], "new_obj_tok_span": [56, 61]}, {"subject": "pristimerin", "sbj_char_span": [203, 214], "object": "mitogen-activated protein kinase", "obj_char_span": [280, 312], "rel_type": "inhibitor", "sbj_tok_span": [41, 45], "obj_tok_span": [59, 64], "new_sbj_tok_span": [44, 48], "new_obj_tok_span": [64, 69]}], "umls_entity_list": [{"mention": "pristimerin", "char_span": [11, 22], "sem_type": "Pharmacologic Substance", "tok_span": [2, 6], "new_tok_span": [3, 7]}, {"mention": "pristimerin", "char_span": [203, 214], "sem_type": "Pharmacologic Substance", "tok_span": [41, 45], "new_tok_span": [44, 48]}, {"mention": "mitogen-activated protein kinase", "char_span": [280, 312], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [59, 64], "new_tok_span": [64, 69]}], "new_text": "Similarly, <START=Pharmacologic Substance> pristimerin <END=Pharmacologic Substance> inhibited the release of pro - inflammatory cytokines, namely, tumor necrosis factor - α and interleukin - 6, induced by LPS. The underlying mechanism of the anti - inflammatory action of <START=Pharmacologic Substance> pristimerin <END=Pharmacologic Substance> was correlated with down - regulation of nuclear factor - κB and the <START=Amino Acid, Peptide, or Protein> mitogen - activated protein kinase <END=Amino Acid, Peptide, or Protein> signal pathway."}, {"PMID": 13679187, "id": 1, "text": "Ambenonium (1), an old AChE inhibitor, is endowed with an outstanding affinity and a peculiar mechanism of action that, taken together, make it a very promising pharmacological tool for the treatment of Alzheimer's disease (AD). Unfortunately, the bisquaternary structure of 1 prevents its passage through the blood brain barrier.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 10], "name": "Ambenonium", "tok_span": [0, 3], "new_tok_span": [1, 4]}, {"ent_type": "GENE", "char_span": [23, 27], "name": "AChE", "tok_span": [9, 11], "new_tok_span": [11, 13]}], "relation_list": [{"subject": "Ambenonium", "sbj_char_span": [0, 10], "object": "AChE", "obj_char_span": [23, 27], "rel_type": "inhibitor", "sbj_tok_span": [0, 3], "obj_tok_span": [9, 11], "new_sbj_tok_span": [1, 4], "new_obj_tok_span": [11, 13]}], "umls_entity_list": [{"mention": "Ambenonium", "char_span": [0, 10], "sem_type": "Pharmacologic Substance", "tok_span": [0, 3], "new_tok_span": [1, 4]}], "new_text": "<START=Pharmacologic Substance> Ambenonium <END=Pharmacologic Substance> ( 1 ), an old AChE inhibitor, is endowed with an outstanding affinity and a peculiar mechanism of action that, taken together, make it a very promising pharmacological tool for the treatment of Alzheimer's disease ( AD ). Unfortunately, the bisquaternary structure of 1 prevents its passage through the blood brain barrier."}, {"PMID": 17899080, "id": 3, "text": "Examination of the glycosylation pattern of the NH(2) terminus of FV and FVIII revealed N-glycans at positions 23 and 27 in FV and at position 41 in FVIII. To improve FVIII secretion, a 14-amino-acid-long polypeptide with (G3) or without (G0; control) three N-linked glycosylation consensus sites was inserted upstream of the NH(2) terminus of a B-domain deleted FVIII protein.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [48, 53], "name": "NH(2)", "tok_span": [7, 11], "new_tok_span": [7, 11]}, {"ent_type": "CHEMICAL", "char_span": [88, 89], "name": "N", "tok_span": [18, 19], "new_tok_span": [18, 19]}, {"ent_type": "CHEMICAL", "char_span": [189, 199], "name": "amino-acid", "tok_span": [46, 49], "new_tok_span": [48, 51]}, {"ent_type": "CHEMICAL", "char_span": [258, 259], "name": "N", "tok_span": [66, 67], "new_tok_span": [68, 69]}, {"ent_type": "CHEMICAL", "char_span": [326, 331], "name": "NH(2)", "tok_span": [77, 81], "new_tok_span": [79, 83]}, {"ent_type": "GENE", "char_span": [66, 68], "name": "FV", "tok_span": [13, 14], "new_tok_span": [13, 14]}, {"ent_type": "GENE", "char_span": [73, 78], "name": "FVIII", "tok_span": [15, 17], "new_tok_span": [15, 17]}, {"ent_type": "GENE", "char_span": [124, 126], "name": "FV", "tok_span": [28, 29], "new_tok_span": [30, 31]}, {"ent_type": "GENE", "char_span": [149, 154], "name": "FVIII", "tok_span": [34, 36], "new_tok_span": [36, 38]}, {"ent_type": "GENE", "char_span": [167, 172], "name": "FVIII", "tok_span": [39, 41], "new_tok_span": [41, 43]}, {"ent_type": "GENE", "char_span": [346, 354], "name": "B-domain", "tok_span": [84, 87], "new_tok_span": [86, 89]}, {"ent_type": "GENE", "char_span": [363, 368], "name": "FVIII", "tok_span": [88, 90], "new_tok_span": [90, 92]}], "relation_list": [{"subject": "NH(2)", "sbj_char_span": [48, 53], "object": "FV", "obj_char_span": [66, 68], "rel_type": "part of", "sbj_tok_span": [7, 11], "obj_tok_span": [13, 14], "new_sbj_tok_span": [7, 11], "new_obj_tok_span": [13, 14]}, {"subject": "NH(2)", "sbj_char_span": [48, 53], "object": "FVIII", "obj_char_span": [73, 78], "rel_type": "part of", "sbj_tok_span": [7, 11], "obj_tok_span": [15, 17], "new_sbj_tok_span": [7, 11], "new_obj_tok_span": [15, 17]}, {"subject": "N", "sbj_char_span": [88, 89], "object": "FV", "obj_char_span": [124, 126], "rel_type": "part of", "sbj_tok_span": [18, 19], "obj_tok_span": [28, 29], "new_sbj_tok_span": [18, 19], "new_obj_tok_span": [30, 31]}, {"subject": "N", "sbj_char_span": [88, 89], "object": "FVIII", "obj_char_span": [149, 154], "rel_type": "part of", "sbj_tok_span": [18, 19], "obj_tok_span": [34, 36], "new_sbj_tok_span": [18, 19], "new_obj_tok_span": [36, 38]}, {"subject": "NH(2)", "sbj_char_span": [326, 331], "object": "B-domain", "obj_char_span": [346, 354], "rel_type": "part of", "sbj_tok_span": [77, 81], "obj_tok_span": [84, 87], "new_sbj_tok_span": [79, 83], "new_obj_tok_span": [86, 89]}, {"subject": "NH(2)", "sbj_char_span": [326, 331], "object": "FVIII", "obj_char_span": [363, 368], "rel_type": "part of", "sbj_tok_span": [77, 81], "obj_tok_span": [88, 90], "new_sbj_tok_span": [79, 83], "new_obj_tok_span": [90, 92]}], "umls_entity_list": [{"mention": "glycans", "char_span": [90, 97], "sem_type": "Pharmacologic Substance", "tok_span": [20, 22], "new_tok_span": [21, 23]}], "new_text": "Examination of the glycosylation pattern of the NH ( 2 ) terminus of FV and FVIII revealed N - <START=Pharmacologic Substance> glycans <END=Pharmacologic Substance> at positions 23 and 27 in FV and at position 41 in FVIII. To improve FVIII secretion, a 14 - amino - acid - long polypeptide with ( G3 ) or without ( G0 ; control ) three N - linked glycosylation consensus sites was inserted upstream of the NH ( 2 ) terminus of a B - domain deleted FVIII protein."}, {"PMID": 1611705, "id": 8, "text": "Abrupt removal of amrinone or pentoxifylline from the culture medium prior to LPS stimulation, however, caused significantly augmented TNF production.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [18, 26], "name": "amrinone", "tok_span": [4, 7], "new_tok_span": [5, 8]}, {"ent_type": "CHEMICAL", "char_span": [30, 44], "name": "pentoxifylline", "tok_span": [8, 13], "new_tok_span": [11, 16]}, {"ent_type": "GENE", "char_span": [135, 138], "name": "TNF", "tok_span": [27, 28], "new_tok_span": [35, 36]}], "relation_list": [{"subject": "amrinone", "sbj_char_span": [18, 26], "object": "TNF", "obj_char_span": [135, 138], "rel_type": "regulator", "sbj_tok_span": [4, 7], "obj_tok_span": [27, 28], "new_sbj_tok_span": [5, 8], "new_obj_tok_span": [35, 36]}, {"subject": "pentoxifylline", "sbj_char_span": [30, 44], "object": "TNF", "obj_char_span": [135, 138], "rel_type": "regulator", "sbj_tok_span": [8, 13], "obj_tok_span": [27, 28], "new_sbj_tok_span": [11, 16], "new_obj_tok_span": [35, 36]}], "umls_entity_list": [{"mention": "amrinone", "char_span": [18, 26], "sem_type": "Pharmacologic Substance", "tok_span": [4, 7], "new_tok_span": [5, 8]}, {"mention": "pentoxifylline", "char_span": [30, 44], "sem_type": "Pharmacologic Substance", "tok_span": [8, 13], "new_tok_span": [11, 16]}, {"mention": "LPS", "char_span": [78, 81], "sem_type": "Organic Chemical", "tok_span": [19, 20], "new_tok_span": [25, 26]}, {"mention": "LPS", "char_span": [78, 81], "sem_type": "Gene or Genome", "tok_span": [19, 20], "new_tok_span": [25, 26]}], "new_text": "Abrupt removal of <START=Pharmacologic Substance> amrinone <END=Pharmacologic Substance> or <START=Pharmacologic Substance> pentoxifylline <END=Pharmacologic Substance> from the culture medium prior to <START=Organic Chemical> <START=Gene or Genome> LPS <END=Organic Chemical> <END=Gene or Genome> stimulation, however, caused significantly augmented TNF production."}, {"PMID": 10839989, "id": 8, "text": "N(5)-Substituted H(4)biopterin derivatives were not oxidized to products serving as substrates for dihydropteridine reductase and,depending on the substituent, were competitive inhibitors of phenylalanine hydroxylase: N(5)-methyl- and N(5)-hydroxymethyl H(4)biopterin inhibited phenylalanine hydroxylase, whereas N(5)-formyl- and N(5)-acetyl H(4)biopterin had no effect.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 30], "name": "N(5)-Substituted H(4)biopterin", "tok_span": [0, 14], "new_tok_span": [0, 14]}, {"ent_type": "CHEMICAL", "char_span": [99, 115], "name": "dihydropteridine", "tok_span": [24, 30], "new_tok_span": [28, 34]}, {"ent_type": "CHEMICAL", "char_span": [191, 204], "name": "phenylalanine", "tok_span": [43, 45], "new_tok_span": [51, 53]}, {"ent_type": "CHEMICAL", "char_span": [218, 229], "name": "N(5)-methyl", "tok_span": [48, 54], "new_tok_span": [58, 64]}, {"ent_type": "CHEMICAL", "char_span": [235, 267], "name": "N(5)-hydroxymethyl H(4)biopterin", "tok_span": [56, 70], "new_tok_span": [66, 80]}, {"ent_type": "CHEMICAL", "char_span": [278, 291], "name": "phenylalanine", "tok_span": [71, 73], "new_tok_span": [85, 87]}, {"ent_type": "CHEMICAL", "char_span": [313, 324], "name": "N(5)-formyl", "tok_span": [77, 84], "new_tok_span": [93, 100]}, {"ent_type": "CHEMICAL", "char_span": [330, 355], "name": "N(5)-acetyl H(4)biopterin", "tok_span": [86, 99], "new_tok_span": [102, 115]}, {"ent_type": "GENE", "char_span": [99, 125], "name": "dihydropteridine reductase", "tok_span": [24, 31], "new_tok_span": [28, 35]}, {"ent_type": "GENE", "char_span": [191, 216], "name": "phenylalanine hydroxylase", "tok_span": [43, 47], "new_tok_span": [51, 55]}, {"ent_type": "GENE", "char_span": [278, 303], "name": "phenylalanine hydroxylase", "tok_span": [71, 75], "new_tok_span": [85, 89]}], "relation_list": [{"subject": "N(5)-Substituted H(4)biopterin", "sbj_char_span": [0, 30], "object": "dihydropteridine reductase", "obj_char_span": [99, 125], "rel_type": "product or substrate", "sbj_tok_span": [0, 14], "obj_tok_span": [24, 31], "new_sbj_tok_span": [0, 14], "new_obj_tok_span": [28, 35]}, {"subject": "N(5)-methyl", "sbj_char_span": [218, 229], "object": "phenylalanine hydroxylase", "obj_char_span": [278, 303], "rel_type": "inhibitor", "sbj_tok_span": [48, 54], "obj_tok_span": [71, 75], "new_sbj_tok_span": [58, 64], "new_obj_tok_span": [85, 89]}, {"subject": "N(5)-hydroxymethyl H(4)biopterin", "sbj_char_span": [235, 267], "object": "phenylalanine hydroxylase", "obj_char_span": [278, 303], "rel_type": "inhibitor", "sbj_tok_span": [56, 70], "obj_tok_span": [71, 75], "new_sbj_tok_span": [66, 80], "new_obj_tok_span": [85, 89]}], "umls_entity_list": [{"mention": "biopterin", "char_span": [21, 30], "sem_type": "Organic Chemical", "tok_span": [11, 14], "new_tok_span": [12, 15]}, {"mention": "biopterin", "char_span": [258, 267], "sem_type": "Organic Chemical", "tok_span": [67, 70], "new_tok_span": [78, 81]}, {"mention": "biopterin", "char_span": [346, 355], "sem_type": "Organic Chemical", "tok_span": [96, 99], "new_tok_span": [113, 116]}, {"mention": "dihydropteridine", "char_span": [99, 115], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [24, 30], "new_tok_span": [28, 34]}, {"mention": "dihydropteridine reductase", "char_span": [99, 125], "sem_type": "Gene or Genome", "tok_span": [24, 31], "new_tok_span": [28, 35]}, {"mention": "phenylalanine", "char_span": [191, 204], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [43, 45], "new_tok_span": [51, 53]}, {"mention": "phenylalanine", "char_span": [278, 291], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [71, 73], "new_tok_span": [85, 87]}, {"mention": "phenylalanine hydroxylase", "char_span": [191, 216], "sem_type": "Gene or Genome", "tok_span": [43, 47], "new_tok_span": [51, 55]}, {"mention": "phenylalanine hydroxylase", "char_span": [278, 303], "sem_type": "Gene or Genome", "tok_span": [71, 75], "new_tok_span": [85, 89]}], "new_text": "N ( 5 ) - Substituted H ( 4 ) <START=Organic Chemical> biopterin <END=Organic Chemical> derivatives were not oxidized to products serving as substrates for <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> dihydropteridine <END=Amino Acid, Peptide, or Protein> reductase <END=Gene or Genome> and, depending on the substituent, were competitive inhibitors of <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> phenylalanine <END=Amino Acid, Peptide, or Protein> hydroxylase <END=Gene or Genome> : N ( 5 ) - methyl - and N ( 5 ) - hydroxymethyl H ( 4 ) <START=Organic Chemical> biopterin <END=Organic Chemical> inhibited <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> phenylalanine <END=Amino Acid, Peptide, or Protein> hydroxylase <END=Gene or Genome>, whereas N ( 5 ) - formyl - and N ( 5 ) - acetyl H ( 4 ) <START=Organic Chemical> biopterin <END=Organic Chemical> had no effect."}, {"PMID": 17408613, "id": 6, "text": "In this study, irbesartan was investigated in comparison with fenfluramine, an established satiating drug, and the angiotensin converting enzyme (ACE) inhibitor captopril.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [15, 25], "name": "irbesartan", "tok_span": [4, 7], "new_tok_span": [4, 7]}, {"ent_type": "CHEMICAL", "char_span": [62, 74], "name": "fenfluramine", "tok_span": [12, 18], "new_tok_span": [12, 18]}, {"ent_type": "CHEMICAL", "char_span": [115, 126], "name": "angiotensin", "tok_span": [28, 29], "new_tok_span": [28, 29]}, {"ent_type": "CHEMICAL", "char_span": [161, 170], "name": "captopril", "tok_span": [35, 38], "new_tok_span": [36, 39]}, {"ent_type": "GENE", "char_span": [115, 144], "name": "angiotensin converting enzyme", "tok_span": [28, 31], "new_tok_span": [28, 31]}, {"ent_type": "GENE", "char_span": [146, 149], "name": "ACE", "tok_span": [32, 33], "new_tok_span": [32, 33]}], "relation_list": [{"subject": "captopril", "sbj_char_span": [161, 170], "object": "angiotensin converting enzyme", "obj_char_span": [115, 144], "rel_type": "inhibitor", "sbj_tok_span": [35, 38], "obj_tok_span": [28, 31], "new_sbj_tok_span": [36, 39], "new_obj_tok_span": [28, 31]}, {"subject": "captopril", "sbj_char_span": [161, 170], "object": "ACE", "obj_char_span": [146, 149], "rel_type": "inhibitor", "sbj_tok_span": [35, 38], "obj_tok_span": [32, 33], "new_sbj_tok_span": [36, 39], "new_obj_tok_span": [32, 33]}], "umls_entity_list": [{"mention": "captopril", "char_span": [161, 170], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [35, 38], "new_tok_span": [36, 39]}], "new_text": "In this study, irbesartan was investigated in comparison with fenfluramine, an established satiating drug, and the angiotensin converting enzyme ( ACE ) inhibitor <START=Amino Acid, Peptide, or Protein> captopril <END=Amino Acid, Peptide, or Protein>."}, {"PMID": 23532918, "id": 4, "text": "We had previously reported a fluorescein conjugate that was shown (by confocal microscopy imaging of DS-red-labelled cortical neurons) to bind specifically to GluN2B.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [29, 40], "name": "fluorescein", "tok_span": [5, 6], "new_tok_span": [6, 7]}, {"ent_type": "GENE", "char_span": [159, 165], "name": "GluN2B", "tok_span": [28, 32], "new_tok_span": [32, 36]}], "relation_list": [{"subject": "fluorescein", "sbj_char_span": [29, 40], "object": "GluN2B", "obj_char_span": [159, 165], "rel_type": "regulator", "sbj_tok_span": [5, 6], "obj_tok_span": [28, 32], "new_sbj_tok_span": [6, 7], "new_obj_tok_span": [32, 36]}], "umls_entity_list": [{"mention": "fluorescein", "char_span": [29, 40], "sem_type": "Pharmacologic Substance", "tok_span": [5, 6], "new_tok_span": [6, 7]}, {"mention": "GluN2B", "char_span": [159, 165], "sem_type": "Gene or Genome", "tok_span": [28, 32], "new_tok_span": [32, 36]}, {"mention": "GluN2B", "char_span": [159, 165], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [28, 32], "new_tok_span": [32, 36]}], "new_text": "We had previously reported a <START=Pharmacologic Substance> fluorescein <END=Pharmacologic Substance> conjugate that was shown ( by confocal microscopy imaging of DS - red - labelled cortical neurons ) to bind specifically to <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> GluN2B <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein>."}, {"PMID": 15106733, "id": 9, "text": "The results showed that salicylate inhibited the activation of ERK and IKK, IkappaB degradation and NF-kappaB activation independent of ROS release and suggested that salicylate exerts its anti-inflammatory action in part through inhibition of the ERK, IKK, IkappaB, NF-kappaB and resultant COX-2 expression pathway.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [24, 34], "name": "salicylate", "tok_span": [4, 7], "new_tok_span": [4, 7]}, {"ent_type": "CHEMICAL", "char_span": [167, 177], "name": "salicylate", "tok_span": [33, 36], "new_tok_span": [37, 40]}, {"ent_type": "GENE", "char_span": [63, 66], "name": "ERK", "tok_span": [11, 12], "new_tok_span": [12, 13]}, {"ent_type": "GENE", "char_span": [71, 74], "name": "IKK", "tok_span": [13, 15], "new_tok_span": [15, 17]}, {"ent_type": "GENE", "char_span": [76, 83], "name": "IkappaB", "tok_span": [16, 19], "new_tok_span": [19, 22]}, {"ent_type": "GENE", "char_span": [100, 109], "name": "NF-kappaB", "tok_span": [21, 25], "new_tok_span": [25, 29]}, {"ent_type": "GENE", "char_span": [248, 251], "name": "ERK", "tok_span": [48, 49], "new_tok_span": [53, 54]}, {"ent_type": "GENE", "char_span": [253, 256], "name": "IKK", "tok_span": [50, 52], "new_tok_span": [56, 58]}, {"ent_type": "GENE", "char_span": [258, 265], "name": "IkappaB", "tok_span": [53, 56], "new_tok_span": [60, 63]}, {"ent_type": "GENE", "char_span": [267, 276], "name": "NF-kappaB", "tok_span": [57, 61], "new_tok_span": [65, 69]}, {"ent_type": "GENE", "char_span": [291, 296], "name": "COX-2", "tok_span": [63, 66], "new_tok_span": [71, 74]}], "relation_list": [{"subject": "salicylate", "sbj_char_span": [24, 34], "object": "NF-kappaB", "obj_char_span": [100, 109], "rel_type": "inhibitor", "sbj_tok_span": [4, 7], "obj_tok_span": [21, 25], "new_sbj_tok_span": [4, 7], "new_obj_tok_span": [25, 29]}, {"subject": "salicylate", "sbj_char_span": [167, 177], "object": "ERK", "obj_char_span": [248, 251], "rel_type": "inhibitor", "sbj_tok_span": [33, 36], "obj_tok_span": [48, 49], "new_sbj_tok_span": [37, 40], "new_obj_tok_span": [53, 54]}, {"subject": "salicylate", "sbj_char_span": [167, 177], "object": "IKK", "obj_char_span": [253, 256], "rel_type": "inhibitor", "sbj_tok_span": [33, 36], "obj_tok_span": [50, 52], "new_sbj_tok_span": [37, 40], "new_obj_tok_span": [56, 58]}, {"subject": "salicylate", "sbj_char_span": [167, 177], "object": "IkappaB", "obj_char_span": [258, 265], "rel_type": "inhibitor", "sbj_tok_span": [33, 36], "obj_tok_span": [53, 56], "new_sbj_tok_span": [37, 40], "new_obj_tok_span": [60, 63]}, {"subject": "salicylate", "sbj_char_span": [167, 177], "object": "NF-kappaB", "obj_char_span": [267, 276], "rel_type": "inhibitor", "sbj_tok_span": [33, 36], "obj_tok_span": [57, 61], "new_sbj_tok_span": [37, 40], "new_obj_tok_span": [65, 69]}, {"subject": "salicylate", "sbj_char_span": [167, 177], "object": "COX-2", "obj_char_span": [291, 296], "rel_type": "inhibitor", "sbj_tok_span": [33, 36], "obj_tok_span": [63, 66], "new_sbj_tok_span": [37, 40], "new_obj_tok_span": [71, 74]}], "umls_entity_list": [{"mention": "ERK", "char_span": [63, 66], "sem_type": "Pharmacologic Substance", "tok_span": [11, 12], "new_tok_span": [12, 13]}, {"mention": "ERK", "char_span": [248, 251], "sem_type": "Pharmacologic Substance", "tok_span": [48, 49], "new_tok_span": [53, 54]}, {"mention": "IkappaB", "char_span": [76, 83], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [16, 19], "new_tok_span": [19, 22]}, {"mention": "IkappaB", "char_span": [258, 265], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [53, 56], "new_tok_span": [60, 63]}], "new_text": "The results showed that salicylate inhibited the activation of <START=Pharmacologic Substance> ERK <END=Pharmacologic Substance> and IKK, <START=Amino Acid, Peptide, or Protein> IkappaB <END=Amino Acid, Peptide, or Protein> degradation and NF - kappaB activation independent of ROS release and suggested that salicylate exerts its anti - inflammatory action in part through inhibition of the <START=Pharmacologic Substance> ERK <END=Pharmacologic Substance>, IKK, <START=Amino Acid, Peptide, or Protein> IkappaB <END=Amino Acid, Peptide, or Protein>, NF - kappaB and resultant COX - 2 expression pathway."}, {"PMID": 23462380, "id": 13, "text": "Recommended management may include use of acetylcholinesterase inhibitors (e.g. neostigmine) and wound care on a case-by-case basis.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [80, 91], "name": "neostigmine", "tok_span": [16, 20], "new_tok_span": [19, 23]}, {"ent_type": "GENE", "char_span": [42, 62], "name": "acetylcholinesterase", "tok_span": [7, 10], "new_tok_span": [8, 11]}], "relation_list": [{"subject": "neostigmine", "sbj_char_span": [80, 91], "object": "acetylcholinesterase", "obj_char_span": [42, 62], "rel_type": "inhibitor", "sbj_tok_span": [16, 20], "obj_tok_span": [7, 10], "new_sbj_tok_span": [19, 23], "new_obj_tok_span": [8, 11]}], "umls_entity_list": [{"mention": "acetylcholinesterase", "char_span": [42, 62], "sem_type": "Pharmacologic Substance", "tok_span": [7, 10], "new_tok_span": [8, 11]}, {"mention": "neostigmine", "char_span": [80, 91], "sem_type": "Pharmacologic Substance", "tok_span": [16, 20], "new_tok_span": [19, 23]}], "new_text": "Recommended management may include use of <START=Pharmacologic Substance> acetylcholinesterase <END=Pharmacologic Substance> inhibitors ( e. g. <START=Pharmacologic Substance> neostigmine <END=Pharmacologic Substance> ) and wound care on a case - by - case basis."}, {"PMID": 12110374, "id": 0, "text": "Dopamine D(2) receptor-induced COX-2-mediated production of prostaglandin E(2) in D(2)-transfected Chinese hamster ovary cells without simultaneous administration of a Ca(2+)-mobilizing agent.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 8], "name": "Dopamine", "tok_span": [0, 4], "new_tok_span": [1, 5]}, {"ent_type": "CHEMICAL", "char_span": [168, 174], "name": "Ca(2+)", "tok_span": [40, 45], "new_tok_span": [42, 47]}, {"ent_type": "CHEMICAL", "char_span": [60, 78], "name": "prostaglandin E(2)", "tok_span": [18, 23], "new_tok_span": [20, 25]}, {"ent_type": "GENE", "char_span": [0, 22], "name": "Dopamine D(2) receptor", "tok_span": [0, 9], "new_tok_span": [1, 10]}, {"ent_type": "GENE", "char_span": [31, 36], "name": "COX-2", "tok_span": [11, 14], "new_tok_span": [13, 16]}, {"ent_type": "GENE", "char_span": [82, 86], "name": "D(2)", "tok_span": [24, 28], "new_tok_span": [26, 30]}], "relation_list": [{"subject": "prostaglandin E(2)", "sbj_char_span": [60, 78], "object": "COX-2", "obj_char_span": [31, 36], "rel_type": "product or substrate", "sbj_tok_span": [18, 23], "obj_tok_span": [11, 14], "new_sbj_tok_span": [20, 25], "new_obj_tok_span": [13, 16]}], "umls_entity_list": [{"mention": "Dopamine", "char_span": [0, 8], "sem_type": "Pharmacologic Substance", "tok_span": [0, 4], "new_tok_span": [1, 5]}], "new_text": "<START=Pharmacologic Substance> Dopamine <END=Pharmacologic Substance> D ( 2 ) receptor - induced COX - 2 - mediated production of prostaglandin E ( 2 ) in D ( 2 ) - transfected Chinese hamster ovary cells without simultaneous administration of a Ca ( 2 + ) - mobilizing agent."}, {"PMID": 11772142, "id": 1, "text": "UNLABELLED: Rabeprazole is an inhibitor of the gastric proton pump.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [12, 23], "name": "Rabeprazole", "tok_span": [5, 8], "new_tok_span": [6, 9]}, {"ent_type": "GENE", "char_span": [47, 66], "name": "gastric proton pump", "tok_span": [13, 16], "new_tok_span": [15, 18]}], "relation_list": [{"subject": "Rabeprazole", "sbj_char_span": [12, 23], "object": "gastric proton pump", "obj_char_span": [47, 66], "rel_type": "inhibitor", "sbj_tok_span": [5, 8], "obj_tok_span": [13, 16], "new_sbj_tok_span": [6, 9], "new_obj_tok_span": [15, 18]}], "umls_entity_list": [{"mention": "Rabeprazole", "char_span": [12, 23], "sem_type": "Pharmacologic Substance", "tok_span": [5, 8], "new_tok_span": [6, 9]}], "new_text": "UNLABELLED : <START=Pharmacologic Substance> Rabeprazole <END=Pharmacologic Substance> is an inhibitor of the gastric proton pump."}, {"PMID": 11212269, "id": 4, "text": "We report here that a human degradation-resistant GLP-2 analogue, h[Gly2]-GLP-2 significantly improves survival, reduces bacteremia, attenuates epithelial injury, and inhibits crypt apoptosis in the murine gastrointestinal tract after administration of topoisomerase I inhibitor irinotecan hydrochloride or the antimetabolite 5-fluorouracil. h[Gly2]-GLP-2 significantly improved survival and reduced weight loss but did not impair chemotherapy effectiveness in tumor-bearing mice treated with cyclical irinotecan.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [68, 72], "name": "Gly2", "tok_span": [16, 18], "new_tok_span": [20, 22]}, {"ent_type": "CHEMICAL", "char_span": [279, 303], "name": "irinotecan hydrochloride", "tok_span": [54, 59], "new_tok_span": [66, 71]}, {"ent_type": "CHEMICAL", "char_span": [326, 340], "name": "5-fluorouracil", "tok_span": [65, 70], "new_tok_span": [81, 86]}, {"ent_type": "CHEMICAL", "char_span": [344, 348], "name": "Gly2", "tok_span": [73, 75], "new_tok_span": [91, 93]}, {"ent_type": "GENE", "char_span": [50, 55], "name": "GLP-2", "tok_span": [9, 12], "new_tok_span": [11, 14]}, {"ent_type": "GENE", "char_span": [74, 79], "name": "GLP-2", "tok_span": [20, 23], "new_tok_span": [26, 29]}, {"ent_type": "GENE", "char_span": [253, 268], "name": "topoisomerase I", "tok_span": [49, 53], "new_tok_span": [58, 62]}, {"ent_type": "GENE", "char_span": [350, 355], "name": "GLP-2", "tok_span": [77, 80], "new_tok_span": [97, 100]}], "relation_list": [{"subject": "irinotecan hydrochloride", "sbj_char_span": [279, 303], "object": "topoisomerase I", "obj_char_span": [253, 268], "rel_type": "inhibitor", "sbj_tok_span": [54, 59], "obj_tok_span": [49, 53], "new_sbj_tok_span": [66, 71], "new_obj_tok_span": [58, 62]}], "umls_entity_list": [{"mention": "GLP-2", "char_span": [50, 55], "sem_type": "Pharmacologic Substance", "tok_span": [9, 12], "new_tok_span": [11, 14]}, {"mention": "GLP-2", "char_span": [74, 79], "sem_type": "Pharmacologic Substance", "tok_span": [20, 23], "new_tok_span": [26, 29]}, {"mention": "GLP-2", "char_span": [350, 355], "sem_type": "Pharmacologic Substance", "tok_span": [77, 80], "new_tok_span": [97, 100]}, {"mention": "GLP-2", "char_span": [50, 55], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [9, 12], "new_tok_span": [11, 14]}, {"mention": "GLP-2", "char_span": [74, 79], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [20, 23], "new_tok_span": [26, 29]}, {"mention": "GLP-2", "char_span": [350, 355], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [77, 80], "new_tok_span": [97, 100]}, {"mention": "topoisomerase I inhibitor", "char_span": [253, 278], "sem_type": "Pharmacologic Substance", "tok_span": [49, 54], "new_tok_span": [58, 63]}, {"mention": "irinotecan hydrochloride", "char_span": [279, 303], "sem_type": "Pharmacologic Substance", "tok_span": [54, 59], "new_tok_span": [66, 71]}, {"mention": "antimetabolite", "char_span": [311, 325], "sem_type": "Pharmacologic Substance", "tok_span": [61, 65], "new_tok_span": [76, 80]}, {"mention": "fluorouracil", "char_span": [328, 340], "sem_type": "Pharmacologic Substance", "tok_span": [67, 70], "new_tok_span": [84, 87]}, {"mention": "irinotecan", "char_span": [279, 289], "sem_type": "Pharmacologic Substance", "tok_span": [54, 58], "new_tok_span": [66, 70]}, {"mention": "irinotecan", "char_span": [502, 512], "sem_type": "Pharmacologic Substance", "tok_span": [102, 106], "new_tok_span": [125, 129]}], "new_text": "We report here that a human degradation - resistant <START=Pharmacologic Substance> <START=Amino Acid, Peptide, or Protein> GLP - 2 <END=Pharmacologic Substance> <END=Amino Acid, Peptide, or Protein> analogue, h [ Gly2 ] - <START=Pharmacologic Substance> <START=Amino Acid, Peptide, or Protein> GLP - 2 <END=Pharmacologic Substance> <END=Amino Acid, Peptide, or Protein> significantly improves survival, reduces bacteremia, attenuates epithelial injury, and inhibits crypt apoptosis in the murine gastrointestinal tract after administration of <START=Pharmacologic Substance> topoisomerase I inhibitor <END=Pharmacologic Substance> <START=Pharmacologic Substance> <START=Pharmacologic Substance> irinotecan <END=Pharmacologic Substance> hydrochloride <END=Pharmacologic Substance> or the <START=Pharmacologic Substance> antimetabolite <END=Pharmacologic Substance> 5 - <START=Pharmacologic Substance> fluorouracil <END=Pharmacologic Substance>. h [ Gly2 ] - <START=Pharmacologic Substance> <START=Amino Acid, Peptide, or Protein> GLP - 2 <END=Pharmacologic Substance> <END=Amino Acid, Peptide, or Protein> significantly improved survival and reduced weight loss but did not impair chemotherapy effectiveness in tumor - bearing mice treated with cyclical <START=Pharmacologic Substance> irinotecan <END=Pharmacologic Substance>."}, {"PMID": 23643747, "id": 4, "text": "This effect was prevented by rapamycin, an inhibitor of the mammalian target of rapamycin complex 1 (mTORC1), or by PF470867, a selective inhibitor of the p70 ribosomal S6 kinase 1 (S6K1).", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [29, 38], "name": "rapamycin", "tok_span": [5, 6], "new_tok_span": [5, 6]}, {"ent_type": "CHEMICAL", "char_span": [80, 89], "name": "rapamycin", "tok_span": [14, 15], "new_tok_span": [15, 16]}, {"ent_type": "CHEMICAL", "char_span": [116, 124], "name": "PF470867", "tok_span": [25, 29], "new_tok_span": [27, 31]}, {"ent_type": "GENE", "char_span": [60, 99], "name": "mammalian target of rapamycin complex 1", "tok_span": [11, 17], "new_tok_span": [12, 18]}, {"ent_type": "GENE", "char_span": [101, 107], "name": "mTORC1", "tok_span": [18, 21], "new_tok_span": [20, 23]}, {"ent_type": "GENE", "char_span": [155, 180], "name": "p70 ribosomal S6 kinase 1", "tok_span": [35, 42], "new_tok_span": [39, 46]}, {"ent_type": "GENE", "char_span": [182, 186], "name": "S6K1", "tok_span": [43, 47], "new_tok_span": [53, 57]}], "relation_list": [{"subject": "rapamycin", "sbj_char_span": [29, 38], "object": "mammalian target of rapamycin complex 1", "obj_char_span": [60, 99], "rel_type": "inhibitor", "sbj_tok_span": [5, 6], "obj_tok_span": [11, 17], "new_sbj_tok_span": [5, 6], "new_obj_tok_span": [12, 18]}, {"subject": "rapamycin", "sbj_char_span": [29, 38], "object": "mTORC1", "obj_char_span": [101, 107], "rel_type": "inhibitor", "sbj_tok_span": [5, 6], "obj_tok_span": [18, 21], "new_sbj_tok_span": [5, 6], "new_obj_tok_span": [20, 23]}, {"subject": "PF470867", "sbj_char_span": [116, 124], "object": "p70 ribosomal S6 kinase 1", "obj_char_span": [155, 180], "rel_type": "inhibitor", "sbj_tok_span": [25, 29], "obj_tok_span": [35, 42], "new_sbj_tok_span": [27, 31], "new_obj_tok_span": [39, 46]}, {"subject": "PF470867", "sbj_char_span": [116, 124], "object": "S6K1", "obj_char_span": [182, 186], "rel_type": "inhibitor", "sbj_tok_span": [25, 29], "obj_tok_span": [43, 47], "new_sbj_tok_span": [27, 31], "new_obj_tok_span": [53, 57]}], "umls_entity_list": [{"mention": "mammalian target of rapamycin complex 1", "char_span": [60, 99], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [11, 17], "new_tok_span": [12, 18]}, {"mention": "p70", "char_span": [155, 158], "sem_type": "Gene or Genome", "tok_span": [35, 37], "new_tok_span": [39, 41]}, {"mention": "ribosomal S6 kinase 1", "char_span": [159, 180], "sem_type": "Gene or Genome", "tok_span": [37, 42], "new_tok_span": [45, 50]}, {"mention": "ribosomal S6 kinase 1", "char_span": [159, 180], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [37, 42], "new_tok_span": [45, 50]}, {"mention": "p70", "char_span": [155, 158], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [35, 37], "new_tok_span": [39, 41]}], "new_text": "This effect was prevented by rapamycin, an inhibitor of the <START=Amino Acid, Peptide, or Protein> mammalian target of rapamycin complex 1 <END=Amino Acid, Peptide, or Protein> ( mTORC1 ), or by PF470867, a selective inhibitor of the <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> p70 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> ribosomal S6 kinase 1 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> ( S6K1 )."}, {"PMID": 8740147, "id": 12, "text": "Amezinium is much less potent as a MAO inhibitor in cells with the uptake2 transporter, such as the myocardial cells of the heart.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 9], "name": "Amezinium", "tok_span": [0, 4], "new_tok_span": [0, 4]}, {"ent_type": "GENE", "char_span": [35, 38], "name": "MAO", "tok_span": [10, 12], "new_tok_span": [10, 12]}, {"ent_type": "GENE", "char_span": [67, 86], "name": "uptake2 transporter", "tok_span": [17, 20], "new_tok_span": [17, 20]}], "relation_list": [{"subject": "Amezinium", "sbj_char_span": [0, 9], "object": "MAO", "obj_char_span": [35, 38], "rel_type": "inhibitor", "sbj_tok_span": [0, 4], "obj_tok_span": [10, 12], "new_sbj_tok_span": [0, 4], "new_obj_tok_span": [10, 12]}, {"subject": "Amezinium", "sbj_char_span": [0, 9], "object": "uptake2 transporter", "obj_char_span": [67, 86], "rel_type": "product or substrate", "sbj_tok_span": [0, 4], "obj_tok_span": [17, 20], "new_sbj_tok_span": [0, 4], "new_obj_tok_span": [17, 20]}], "umls_entity_list": [], "new_text": "Amezinium is much less potent as a MAO inhibitor in cells with the uptake2 transporter, such as the myocardial cells of the heart."}, {"PMID": 10566562, "id": 3, "text": "In recent studies, the cyclooxygenase-2 (COX-2) inhibitor rofecoxib demonstrated analgesic effects similar to those of NSAIDs in the treatment of acute pain and primary dysmenorrhea.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [58, 67], "name": "rofecoxib", "tok_span": [15, 19], "new_tok_span": [16, 20]}, {"ent_type": "GENE", "char_span": [23, 39], "name": "cyclooxygenase-2", "tok_span": [5, 9], "new_tok_span": [5, 9]}, {"ent_type": "GENE", "char_span": [41, 46], "name": "COX-2", "tok_span": [10, 13], "new_tok_span": [10, 13]}], "relation_list": [{"subject": "rofecoxib", "sbj_char_span": [58, 67], "object": "cyclooxygenase-2", "obj_char_span": [23, 39], "rel_type": "inhibitor", "sbj_tok_span": [15, 19], "obj_tok_span": [5, 9], "new_sbj_tok_span": [16, 20], "new_obj_tok_span": [5, 9]}, {"subject": "rofecoxib", "sbj_char_span": [58, 67], "object": "COX-2", "obj_char_span": [41, 46], "rel_type": "inhibitor", "sbj_tok_span": [15, 19], "obj_tok_span": [10, 13], "new_sbj_tok_span": [16, 20], "new_obj_tok_span": [10, 13]}], "umls_entity_list": [{"mention": "rofecoxib", "char_span": [58, 67], "sem_type": "Pharmacologic Substance", "tok_span": [15, 19], "new_tok_span": [16, 20]}, {"mention": "NSAIDs", "char_span": [119, 125], "sem_type": "Pharmacologic Substance", "tok_span": [26, 28], "new_tok_span": [29, 31]}], "new_text": "In recent studies, the cyclooxygenase - 2 ( COX - 2 ) inhibitor <START=Pharmacologic Substance> rofecoxib <END=Pharmacologic Substance> demonstrated analgesic effects similar to those of <START=Pharmacologic Substance> NSAIDs <END=Pharmacologic Substance> in the treatment of acute pain and primary dysmenorrhea."}, {"PMID": 23223345, "id": 13, "text": "PROT had no significant effect compared with CARB. CONCLUSIONS A diet that partially replaces carbohydrate with unsaturated fat may improve insulin sensitivity in a population at risk for cardiovascular disease.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [45, 49], "name": "CARB", "tok_span": [8, 10], "new_tok_span": [11, 13]}, {"ent_type": "CHEMICAL", "char_span": [94, 106], "name": "carbohydrate", "tok_span": [17, 18], "new_tok_span": [23, 24]}, {"ent_type": "GENE", "char_span": [140, 147], "name": "insulin", "tok_span": [23, 24], "new_tok_span": [33, 34]}], "relation_list": [{"subject": "carbohydrate", "sbj_char_span": [94, 106], "object": "insulin", "obj_char_span": [140, 147], "rel_type": "regulator", "sbj_tok_span": [17, 18], "obj_tok_span": [23, 24], "new_sbj_tok_span": [23, 24], "new_obj_tok_span": [33, 34]}], "umls_entity_list": [{"mention": "PROT", "char_span": [0, 4], "sem_type": "Gene or Genome", "tok_span": [0, 2], "new_tok_span": [1, 3]}, {"mention": "CARB", "char_span": [45, 49], "sem_type": "Gene or Genome", "tok_span": [8, 10], "new_tok_span": [11, 13]}, {"mention": "carb", "char_span": [94, 98], "sem_type": "Gene or Genome", "tok_span": [17, 18], "new_tok_span": [23, 24]}, {"mention": "carbohydrate", "char_span": [94, 106], "sem_type": "Organic Chemical", "tok_span": [17, 18], "new_tok_span": [23, 24]}, {"mention": "unsaturated fat", "char_span": [112, 127], "sem_type": "Organic Chemical", "tok_span": [19, 21], "new_tok_span": [28, 30]}], "new_text": "<START=Gene or Genome> PROT <END=Gene or Genome> had no significant effect compared with <START=Gene or Genome> CARB <END=Gene or Genome>. CONCLUSIONS A diet that partially replaces <START=Gene or Genome> <START=Organic Chemical> carbohydrate <END=Gene or Genome> <END=Organic Chemical> with <START=Organic Chemical> unsaturated fat <END=Organic Chemical> may improve insulin sensitivity in a population at risk for cardiovascular disease."}, {"PMID": 10939639, "id": 3, "text": "Hepatocytes isolated from Sch B pretreated (a daily dose of 1 mmol/kg for 3 days) rats showed a significant increase (25%) in DTD activity.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [26, 31], "name": "Sch B", "tok_span": [4, 6], "new_tok_span": [4, 6]}, {"ent_type": "GENE", "char_span": [126, 129], "name": "DTD", "tok_span": [30, 32], "new_tok_span": [31, 33]}], "relation_list": [{"subject": "Sch B", "sbj_char_span": [26, 31], "object": "DTD", "obj_char_span": [126, 129], "rel_type": "activator", "sbj_tok_span": [4, 6], "obj_tok_span": [30, 32], "new_sbj_tok_span": [4, 6], "new_obj_tok_span": [31, 33]}], "umls_entity_list": [{"mention": "DTD", "char_span": [126, 129], "sem_type": "Gene or Genome", "tok_span": [30, 32], "new_tok_span": [31, 33]}], "new_text": "Hepatocytes isolated from Sch B pretreated ( a daily dose of 1 mmol / kg for 3 days ) rats showed a significant increase ( 25 % ) in <START=Gene or Genome> DTD <END=Gene or Genome> activity."}, {"PMID": 23349208, "id": 3, "text": "Both fatty acids, but DHA to a lesser extent compared with EPA, selectively and dose-dependently reduced the percentage of cytokine-expressing Th cells in a peroxisome proliferator-activated receptor (PPAR)γ-dependent fashion, whereas the expression of the cell surface marker CD69 was unaltered on activated T cells.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [5, 16], "name": "fatty acids", "tok_span": [1, 3], "new_tok_span": [6, 8]}, {"ent_type": "CHEMICAL", "char_span": [22, 25], "name": "DHA", "tok_span": [5, 6], "new_tok_span": [12, 13]}, {"ent_type": "CHEMICAL", "char_span": [59, 62], "name": "EPA", "tok_span": [12, 13], "new_tok_span": [24, 25]}, {"ent_type": "GENE", "char_span": [123, 131], "name": "cytokine", "tok_span": [24, 25], "new_tok_span": [41, 42]}, {"ent_type": "GENE", "char_span": [157, 207], "name": "peroxisome proliferator-activated receptor (PPAR)γ", "tok_span": [31, 42], "new_tok_span": [54, 65]}, {"ent_type": "GENE", "char_span": [277, 281], "name": "CD69", "tok_span": [54, 56], "new_tok_span": [87, 89]}], "relation_list": [{"subject": "DHA", "sbj_char_span": [22, 25], "object": "cytokine", "obj_char_span": [123, 131], "rel_type": "regulator", "sbj_tok_span": [5, 6], "obj_tok_span": [24, 25], "new_sbj_tok_span": [12, 13], "new_obj_tok_span": [41, 42]}, {"subject": "fatty acids", "sbj_char_span": [5, 16], "object": "cytokine", "obj_char_span": [123, 131], "rel_type": "regulator", "sbj_tok_span": [1, 3], "obj_tok_span": [24, 25], "new_sbj_tok_span": [6, 8], "new_obj_tok_span": [41, 42]}, {"subject": "EPA", "sbj_char_span": [59, 62], "object": "cytokine", "obj_char_span": [123, 131], "rel_type": "regulator", "sbj_tok_span": [12, 13], "obj_tok_span": [24, 25], "new_sbj_tok_span": [24, 25], "new_obj_tok_span": [41, 42]}], "umls_entity_list": [{"mention": "fatty", "char_span": [5, 10], "sem_type": "Organic Chemical", "tok_span": [1, 2], "new_tok_span": [6, 7]}, {"mention": "DHA", "char_span": [22, 25], "sem_type": "Pharmacologic Substance", "tok_span": [5, 6], "new_tok_span": [12, 13]}, {"mention": "cytokine", "char_span": [123, 131], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [24, 25], "new_tok_span": [41, 42]}, {"mention": "th", "char_span": [2, 4], "sem_type": "Gene or Genome", "tok_span": [0, 1], "new_tok_span": [2, 3]}, {"mention": "th", "char_span": [56, 58], "sem_type": "Gene or Genome", "tok_span": [11, 12], "new_tok_span": [21, 22]}, {"mention": "th", "char_span": [105, 107], "sem_type": "Gene or Genome", "tok_span": [21, 22], "new_tok_span": [35, 36]}, {"mention": "Th", "char_span": [143, 145], "sem_type": "Gene or Genome", "tok_span": [27, 28], "new_tok_span": [47, 48]}, {"mention": "th", "char_span": [235, 237], "sem_type": "Gene or Genome", "tok_span": [47, 48], "new_tok_span": [73, 74]}, {"mention": "th", "char_span": [253, 255], "sem_type": "Gene or Genome", "tok_span": [50, 51], "new_tok_span": [80, 81]}, {"mention": "th", "char_span": [2, 4], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [0, 1], "new_tok_span": [2, 3]}, {"mention": "th", "char_span": [56, 58], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [11, 12], "new_tok_span": [21, 22]}, {"mention": "th", "char_span": [105, 107], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [21, 22], "new_tok_span": [35, 36]}, {"mention": "Th", "char_span": [143, 145], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [27, 28], "new_tok_span": [47, 48]}, {"mention": "th", "char_span": [235, 237], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [47, 48], "new_tok_span": [73, 74]}, {"mention": "th", "char_span": [253, 255], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [50, 51], "new_tok_span": [80, 81]}, {"mention": "peroxisome proliferator-activated receptor", "char_span": [157, 199], "sem_type": "Gene or Genome", "tok_span": [31, 38], "new_tok_span": [54, 61]}, {"mention": "CD69", "char_span": [277, 281], "sem_type": "Gene or Genome", "tok_span": [54, 56], "new_tok_span": [87, 89]}], "new_text": "<START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> Both <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> <START=Organic Chemical> fatty <END=Organic Chemical> acids, but <START=Pharmacologic Substance> DHA <END=Pharmacologic Substance> to a lesser extent compared <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> with <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> EPA, selectively and dose - dependently reduced <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> the <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> percentage of <START=Amino Acid, Peptide, or Protein> cytokine <END=Amino Acid, Peptide, or Protein> - expressing <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> Th <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> cells in a <START=Gene or Genome> peroxisome proliferator - activated receptor <END=Gene or Genome> ( PPAR ) γ - dependent fashion, whereas <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> the <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> expression of <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> the <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> cell surface marker <START=Gene or Genome> CD69 <END=Gene or Genome> was unaltered on activated T cells."}, {"PMID": 23157627, "id": 4, "text": "The neural network underlying the ability of 5-HT(1A) agonists to treat cognitive impairments of schizophrenia likely includes dopamine, glutamate, and gamma-aminobutyric acid neurons.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [45, 49], "name": "5-HT", "tok_span": [7, 10], "new_tok_span": [7, 10]}, {"ent_type": "CHEMICAL", "char_span": [127, 135], "name": "dopamine", "tok_span": [23, 24], "new_tok_span": [23, 24]}, {"ent_type": "CHEMICAL", "char_span": [137, 146], "name": "glutamate", "tok_span": [25, 26], "new_tok_span": [25, 26]}, {"ent_type": "CHEMICAL", "char_span": [152, 175], "name": "gamma-aminobutyric acid", "tok_span": [28, 35], "new_tok_span": [29, 36]}, {"ent_type": "GENE", "char_span": [45, 53], "name": "5-HT(1A)", "tok_span": [7, 14], "new_tok_span": [7, 14]}], "relation_list": [{"subject": "dopamine", "sbj_char_span": [127, 135], "object": "5-HT(1A)", "obj_char_span": [45, 53], "rel_type": "agonist or antagonist", "sbj_tok_span": [23, 24], "obj_tok_span": [7, 14], "new_sbj_tok_span": [23, 24], "new_obj_tok_span": [7, 14]}, {"subject": "glutamate", "sbj_char_span": [137, 146], "object": "5-HT(1A)", "obj_char_span": [45, 53], "rel_type": "agonist or antagonist", "sbj_tok_span": [25, 26], "obj_tok_span": [7, 14], "new_sbj_tok_span": [25, 26], "new_obj_tok_span": [7, 14]}, {"subject": "gamma-aminobutyric acid", "sbj_char_span": [152, 175], "object": "5-HT(1A)", "obj_char_span": [45, 53], "rel_type": "agonist or antagonist", "sbj_tok_span": [28, 35], "obj_tok_span": [7, 14], "new_sbj_tok_span": [29, 36], "new_obj_tok_span": [7, 14]}], "umls_entity_list": [{"mention": "gamma-aminobutyric acid", "char_span": [152, 175], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [28, 35], "new_tok_span": [29, 36]}], "new_text": "The neural network underlying the ability of 5 - HT ( 1A ) agonists to treat cognitive impairments of schizophrenia likely includes dopamine, glutamate, and <START=Amino Acid, Peptide, or Protein> gamma - aminobutyric acid <END=Amino Acid, Peptide, or Protein> neurons."}, {"PMID": 23378608, "id": 7, "text": "Moreover, treatment of high-fat-diet-fed apelin-knockout mice with a selective cyclooxygenase-2 inhibitor, celecoxib, improved vascular function, and also attenuated obesity.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [107, 116], "name": "celecoxib", "tok_span": [25, 29], "new_tok_span": [29, 33]}, {"ent_type": "GENE", "char_span": [41, 47], "name": "apelin", "tok_span": [11, 13], "new_tok_span": [13, 15]}, {"ent_type": "GENE", "char_span": [79, 95], "name": "cyclooxygenase-2", "tok_span": [19, 23], "new_tok_span": [23, 27]}], "relation_list": [{"subject": "celecoxib", "sbj_char_span": [107, 116], "object": "cyclooxygenase-2", "obj_char_span": [79, 95], "rel_type": "inhibitor", "sbj_tok_span": [25, 29], "obj_tok_span": [19, 23], "new_sbj_tok_span": [29, 33], "new_obj_tok_span": [23, 27]}], "umls_entity_list": [{"mention": "apelin", "char_span": [41, 47], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [11, 13], "new_tok_span": [13, 15]}, {"mention": "apelin", "char_span": [41, 47], "sem_type": "Gene or Genome", "tok_span": [11, 13], "new_tok_span": [13, 15]}], "new_text": "Moreover, treatment of high - fat - diet - fed <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> apelin <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> - knockout mice with a selective cyclooxygenase - 2 inhibitor, celecoxib, improved vascular function, and also attenuated obesity."}, {"PMID": 16472148, "id": 3, "text": "In this review, the novel action mechanism (s) of cilostazol are overviewed with the focus on the action of cilostazol in in vitro and in vivo studies as a maxi-K channel opener targeting anti-apoptotic signaling pathways.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [50, 60], "name": "cilostazol", "tok_span": [12, 16], "new_tok_span": [13, 17]}, {"ent_type": "CHEMICAL", "char_span": [108, 118], "name": "cilostazol", "tok_span": [26, 30], "new_tok_span": [29, 33]}, {"ent_type": "CHEMICAL", "char_span": [161, 162], "name": "K", "tok_span": [42, 43], "new_tok_span": [46, 47]}, {"ent_type": "GENE", "char_span": [156, 170], "name": "maxi-K channel", "tok_span": [39, 44], "new_tok_span": [43, 48]}], "relation_list": [{"subject": "cilostazol", "sbj_char_span": [108, 118], "object": "maxi-K channel", "obj_char_span": [156, 170], "rel_type": "activator", "sbj_tok_span": [26, 30], "obj_tok_span": [39, 44], "new_sbj_tok_span": [29, 33], "new_obj_tok_span": [43, 48]}], "umls_entity_list": [{"mention": "cilostazol", "char_span": [50, 60], "sem_type": "Pharmacologic Substance", "tok_span": [12, 16], "new_tok_span": [13, 17]}, {"mention": "cilostazol", "char_span": [108, 118], "sem_type": "Pharmacologic Substance", "tok_span": [26, 30], "new_tok_span": [29, 33]}], "new_text": "In this review, the novel action mechanism ( s ) of <START=Pharmacologic Substance> cilostazol <END=Pharmacologic Substance> are overviewed with the focus on the action of <START=Pharmacologic Substance> cilostazol <END=Pharmacologic Substance> in in vitro and in vivo studies as a maxi - K channel opener targeting anti - apoptotic signaling pathways."}, {"PMID": 16472148, "id": 5, "text": "Increase in cyclic AMP and decrease in TNF-alpha levels were identified in the ipsilateral cortex under treatment with cilostazol accompanied by decreased Bax formation and cytochrome c release with increased Bcl-2 production in the penumbral area as well as in the in vitro human umbilical endothelial cells.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [12, 22], "name": "cyclic AMP", "tok_span": [3, 5], "new_tok_span": [4, 6]}, {"ent_type": "CHEMICAL", "char_span": [119, 129], "name": "cilostazol", "tok_span": [21, 25], "new_tok_span": [23, 27]}, {"ent_type": "GENE", "char_span": [39, 48], "name": "TNF-alpha", "tok_span": [8, 11], "new_tok_span": [10, 13]}, {"ent_type": "GENE", "char_span": [155, 158], "name": "Bax", "tok_span": [28, 29], "new_tok_span": [32, 33]}, {"ent_type": "GENE", "char_span": [173, 185], "name": "cytochrome c", "tok_span": [31, 33], "new_tok_span": [37, 39]}, {"ent_type": "GENE", "char_span": [209, 214], "name": "Bcl-2", "tok_span": [36, 39], "new_tok_span": [42, 45]}], "relation_list": [{"subject": "cilostazol", "sbj_char_span": [119, 129], "object": "TNF-alpha", "obj_char_span": [39, 48], "rel_type": "regulator", "sbj_tok_span": [21, 25], "obj_tok_span": [8, 11], "new_sbj_tok_span": [23, 27], "new_obj_tok_span": [10, 13]}, {"subject": "cilostazol", "sbj_char_span": [119, 129], "object": "Bax", "obj_char_span": [155, 158], "rel_type": "regulator", "sbj_tok_span": [21, 25], "obj_tok_span": [28, 29], "new_sbj_tok_span": [23, 27], "new_obj_tok_span": [32, 33]}, {"subject": "cilostazol", "sbj_char_span": [119, 129], "object": "cytochrome c", "obj_char_span": [173, 185], "rel_type": "regulator", "sbj_tok_span": [21, 25], "obj_tok_span": [31, 33], "new_sbj_tok_span": [23, 27], "new_obj_tok_span": [37, 39]}, {"subject": "cilostazol", "sbj_char_span": [119, 129], "object": "Bcl-2", "obj_char_span": [209, 214], "rel_type": "regulator", "sbj_tok_span": [21, 25], "obj_tok_span": [36, 39], "new_sbj_tok_span": [23, 27], "new_obj_tok_span": [42, 45]}], "umls_entity_list": [{"mention": "cyclic AMP", "char_span": [12, 22], "sem_type": "Pharmacologic Substance", "tok_span": [3, 5], "new_tok_span": [4, 6]}, {"mention": "Bax", "char_span": [155, 158], "sem_type": "Gene or Genome", "tok_span": [28, 29], "new_tok_span": [32, 33]}, {"mention": "Bax", "char_span": [155, 158], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [28, 29], "new_tok_span": [32, 33]}, {"mention": "penumbra", "char_span": [233, 241], "sem_type": "Gene or Genome", "tok_span": [42, 45], "new_tok_span": [49, 52]}], "new_text": "Increase in <START=Pharmacologic Substance> cyclic AMP <END=Pharmacologic Substance> and decrease in TNF - alpha levels were identified in the ipsilateral cortex under treatment with cilostazol accompanied by decreased <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> Bax <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> formation and cytochrome c release with increased Bcl - 2 production in the <START=Gene or Genome> penumbral <END=Gene or Genome> area as well as in the in vitro human umbilical endothelial cells."}, {"PMID": 16472148, "id": 7, "text": "Further, cilostazol prevented TNF-alpha-induced PTEN phosphorylation and apoptotic cell death via increased CK2 phosphorylation in the SK-N-SH cells.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [9, 19], "name": "cilostazol", "tok_span": [2, 6], "new_tok_span": [2, 6]}, {"ent_type": "GENE", "char_span": [30, 39], "name": "TNF-alpha", "tok_span": [7, 10], "new_tok_span": [7, 10]}, {"ent_type": "GENE", "char_span": [48, 52], "name": "PTEN", "tok_span": [12, 13], "new_tok_span": [14, 15]}, {"ent_type": "GENE", "char_span": [108, 111], "name": "CK2", "tok_span": [20, 22], "new_tok_span": [25, 27]}], "relation_list": [{"subject": "cilostazol", "sbj_char_span": [9, 19], "object": "TNF-alpha", "obj_char_span": [30, 39], "rel_type": "regulator", "sbj_tok_span": [2, 6], "obj_tok_span": [7, 10], "new_sbj_tok_span": [2, 6], "new_obj_tok_span": [7, 10]}, {"subject": "cilostazol", "sbj_char_span": [9, 19], "object": "PTEN", "obj_char_span": [48, 52], "rel_type": "activator", "sbj_tok_span": [2, 6], "obj_tok_span": [12, 13], "new_sbj_tok_span": [2, 6], "new_obj_tok_span": [14, 15]}, {"subject": "cilostazol", "sbj_char_span": [9, 19], "object": "CK2", "obj_char_span": [108, 111], "rel_type": "activator", "sbj_tok_span": [2, 6], "obj_tok_span": [20, 22], "new_sbj_tok_span": [2, 6], "new_obj_tok_span": [25, 27]}], "umls_entity_list": [{"mention": "PTEN", "char_span": [48, 52], "sem_type": "Gene or Genome", "tok_span": [12, 13], "new_tok_span": [14, 15]}, {"mention": "PTEN", "char_span": [48, 52], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [12, 13], "new_tok_span": [14, 15]}, {"mention": "CK2", "char_span": [108, 111], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [20, 22], "new_tok_span": [25, 27]}], "new_text": "Further, cilostazol prevented TNF - alpha - induced <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> PTEN <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> phosphorylation and apoptotic cell death via increased <START=Amino Acid, Peptide, or Protein> CK2 <END=Amino Acid, Peptide, or Protein> phosphorylation in the SK - N - SH cells."}, {"PMID": 11330337, "id": 8, "text": "Moreover, the rank order for potency in inhibiting acetylcholinesterase (ambenonium>neostigmine=physostigmine =tacrine>pyridostigmine=edrophonium=galanthamine >desoxypeganine>parathion>gramine) indicated that the most effective inhibitors of acetylcholinesterase also displaced [3H]-oxotremorine-M to the greatest extent.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [73, 83], "name": "ambenonium", "tok_span": [13, 16], "new_tok_span": [15, 18]}, {"ent_type": "CHEMICAL", "char_span": [84, 95], "name": "neostigmine", "tok_span": [17, 21], "new_tok_span": [19, 23]}, {"ent_type": "CHEMICAL", "char_span": [96, 109], "name": "physostigmine", "tok_span": [22, 26], "new_tok_span": [24, 28]}, {"ent_type": "CHEMICAL", "char_span": [111, 118], "name": "tacrine", "tok_span": [27, 29], "new_tok_span": [29, 31]}, {"ent_type": "CHEMICAL", "char_span": [119, 133], "name": "pyridostigmine", "tok_span": [30, 35], "new_tok_span": [33, 38]}, {"ent_type": "CHEMICAL", "char_span": [134, 145], "name": "edrophonium", "tok_span": [36, 39], "new_tok_span": [40, 43]}, {"ent_type": "CHEMICAL", "char_span": [146, 158], "name": "galanthamine", "tok_span": [40, 43], "new_tok_span": [44, 47]}, {"ent_type": "CHEMICAL", "char_span": [160, 174], "name": "desoxypeganine", "tok_span": [44, 48], "new_tok_span": [48, 52]}, {"ent_type": "CHEMICAL", "char_span": [175, 184], "name": "parathion", "tok_span": [49, 52], "new_tok_span": [53, 56]}, {"ent_type": "CHEMICAL", "char_span": [185, 192], "name": "gramine", "tok_span": [53, 55], "new_tok_span": [58, 60]}, {"ent_type": "CHEMICAL", "char_span": [278, 297], "name": "[3H]-oxotremorine-M", "tok_span": [68, 80], "new_tok_span": [76, 88]}, {"ent_type": "GENE", "char_span": [51, 71], "name": "acetylcholinesterase", "tok_span": [9, 12], "new_tok_span": [10, 13]}, {"ent_type": "GENE", "char_span": [242, 262], "name": "acetylcholinesterase", "tok_span": [63, 66], "new_tok_span": [70, 73]}], "relation_list": [{"subject": "ambenonium", "sbj_char_span": [73, 83], "object": "acetylcholinesterase", "obj_char_span": [51, 71], "rel_type": "inhibitor", "sbj_tok_span": [13, 16], "obj_tok_span": [9, 12], "new_sbj_tok_span": [15, 18], "new_obj_tok_span": [10, 13]}, {"subject": "neostigmine", "sbj_char_span": [84, 95], "object": "acetylcholinesterase", "obj_char_span": [51, 71], "rel_type": "inhibitor", "sbj_tok_span": [17, 21], "obj_tok_span": [9, 12], "new_sbj_tok_span": [19, 23], "new_obj_tok_span": [10, 13]}, {"subject": "physostigmine", "sbj_char_span": [96, 109], "object": "acetylcholinesterase", "obj_char_span": [51, 71], "rel_type": "inhibitor", "sbj_tok_span": [22, 26], "obj_tok_span": [9, 12], "new_sbj_tok_span": [24, 28], "new_obj_tok_span": [10, 13]}, {"subject": "tacrine", "sbj_char_span": [111, 118], "object": "acetylcholinesterase", "obj_char_span": [51, 71], "rel_type": "inhibitor", "sbj_tok_span": [27, 29], "obj_tok_span": [9, 12], "new_sbj_tok_span": [29, 31], "new_obj_tok_span": [10, 13]}, {"subject": "pyridostigmine", "sbj_char_span": [119, 133], "object": "acetylcholinesterase", "obj_char_span": [51, 71], "rel_type": "inhibitor", "sbj_tok_span": [30, 35], "obj_tok_span": [9, 12], "new_sbj_tok_span": [33, 38], "new_obj_tok_span": [10, 13]}, {"subject": "edrophonium", "sbj_char_span": [134, 145], "object": "acetylcholinesterase", "obj_char_span": [51, 71], "rel_type": "inhibitor", "sbj_tok_span": [36, 39], "obj_tok_span": [9, 12], "new_sbj_tok_span": [40, 43], "new_obj_tok_span": [10, 13]}, {"subject": "galanthamine", "sbj_char_span": [146, 158], "object": "acetylcholinesterase", "obj_char_span": [51, 71], "rel_type": "inhibitor", "sbj_tok_span": [40, 43], "obj_tok_span": [9, 12], "new_sbj_tok_span": [44, 47], "new_obj_tok_span": [10, 13]}, {"subject": "desoxypeganine", "sbj_char_span": [160, 174], "object": "acetylcholinesterase", "obj_char_span": [51, 71], "rel_type": "inhibitor", "sbj_tok_span": [44, 48], "obj_tok_span": [9, 12], "new_sbj_tok_span": [48, 52], "new_obj_tok_span": [10, 13]}, {"subject": "parathion", "sbj_char_span": [175, 184], "object": "acetylcholinesterase", "obj_char_span": [51, 71], "rel_type": "inhibitor", "sbj_tok_span": [49, 52], "obj_tok_span": [9, 12], "new_sbj_tok_span": [53, 56], "new_obj_tok_span": [10, 13]}, {"subject": "gramine", "sbj_char_span": [185, 192], "object": "acetylcholinesterase", "obj_char_span": [51, 71], "rel_type": "inhibitor", "sbj_tok_span": [53, 55], "obj_tok_span": [9, 12], "new_sbj_tok_span": [58, 60], "new_obj_tok_span": [10, 13]}, {"subject": "ambenonium", "sbj_char_span": [73, 83], "object": "acetylcholinesterase", "obj_char_span": [242, 262], "rel_type": "inhibitor", "sbj_tok_span": [13, 16], "obj_tok_span": [63, 66], "new_sbj_tok_span": [15, 18], "new_obj_tok_span": [70, 73]}, {"subject": "neostigmine", "sbj_char_span": [84, 95], "object": "acetylcholinesterase", "obj_char_span": [242, 262], "rel_type": "inhibitor", "sbj_tok_span": [17, 21], "obj_tok_span": [63, 66], "new_sbj_tok_span": [19, 23], "new_obj_tok_span": [70, 73]}, {"subject": "physostigmine", "sbj_char_span": [96, 109], "object": "acetylcholinesterase", "obj_char_span": [242, 262], "rel_type": "inhibitor", "sbj_tok_span": [22, 26], "obj_tok_span": [63, 66], "new_sbj_tok_span": [24, 28], "new_obj_tok_span": [70, 73]}, {"subject": "tacrine", "sbj_char_span": [111, 118], "object": "acetylcholinesterase", "obj_char_span": [242, 262], "rel_type": "inhibitor", "sbj_tok_span": [27, 29], "obj_tok_span": [63, 66], "new_sbj_tok_span": [29, 31], "new_obj_tok_span": [70, 73]}, {"subject": "pyridostigmine", "sbj_char_span": [119, 133], "object": "acetylcholinesterase", "obj_char_span": [242, 262], "rel_type": "inhibitor", "sbj_tok_span": [30, 35], "obj_tok_span": [63, 66], "new_sbj_tok_span": [33, 38], "new_obj_tok_span": [70, 73]}, {"subject": "edrophonium", "sbj_char_span": [134, 145], "object": "acetylcholinesterase", "obj_char_span": [242, 262], "rel_type": "inhibitor", "sbj_tok_span": [36, 39], "obj_tok_span": [63, 66], "new_sbj_tok_span": [40, 43], "new_obj_tok_span": [70, 73]}, {"subject": "galanthamine", "sbj_char_span": [146, 158], "object": "acetylcholinesterase", "obj_char_span": [242, 262], "rel_type": "inhibitor", "sbj_tok_span": [40, 43], "obj_tok_span": [63, 66], "new_sbj_tok_span": [44, 47], "new_obj_tok_span": [70, 73]}, {"subject": "desoxypeganine", "sbj_char_span": [160, 174], "object": "acetylcholinesterase", "obj_char_span": [242, 262], "rel_type": "inhibitor", "sbj_tok_span": [44, 48], "obj_tok_span": [63, 66], "new_sbj_tok_span": [48, 52], "new_obj_tok_span": [70, 73]}, {"subject": "parathion", "sbj_char_span": [175, 184], "object": "acetylcholinesterase", "obj_char_span": [242, 262], "rel_type": "inhibitor", "sbj_tok_span": [49, 52], "obj_tok_span": [63, 66], "new_sbj_tok_span": [53, 56], "new_obj_tok_span": [70, 73]}, {"subject": "gramine", "sbj_char_span": [185, 192], "object": "acetylcholinesterase", "obj_char_span": [242, 262], "rel_type": "inhibitor", "sbj_tok_span": [53, 55], "obj_tok_span": [63, 66], "new_sbj_tok_span": [58, 60], "new_obj_tok_span": [70, 73]}], "umls_entity_list": [{"mention": "pyridostigmine", "char_span": [119, 133], "sem_type": "Pharmacologic Substance", "tok_span": [30, 35], "new_tok_span": [33, 38]}, {"mention": "gramine", "char_span": [185, 192], "sem_type": "Organic Chemical", "tok_span": [53, 55], "new_tok_span": [58, 60]}, {"mention": "acetylcholinesterase", "char_span": [51, 71], "sem_type": "Pharmacologic Substance", "tok_span": [9, 12], "new_tok_span": [10, 13]}, {"mention": "acetylcholinesterase", "char_span": [242, 262], "sem_type": "Pharmacologic Substance", "tok_span": [63, 66], "new_tok_span": [70, 73]}, {"mention": "oxotremorine", "char_span": [283, 295], "sem_type": "Pharmacologic Substance", "tok_span": [73, 78], "new_tok_span": [82, 87]}], "new_text": "Moreover, the rank order for potency in inhibiting <START=Pharmacologic Substance> acetylcholinesterase <END=Pharmacologic Substance> ( ambenonium > neostigmine = physostigmine = tacrine > <START=Pharmacologic Substance> pyridostigmine <END=Pharmacologic Substance> = edrophonium = galanthamine > desoxypeganine > parathion > <START=Organic Chemical> gramine <END=Organic Chemical> ) indicated that the most effective inhibitors of <START=Pharmacologic Substance> acetylcholinesterase <END=Pharmacologic Substance> also displaced [ 3H ] - <START=Pharmacologic Substance> oxotremorine <END=Pharmacologic Substance> - M to the greatest extent."}, {"PMID": 23605695, "id": 1, "text": "Pasireotide (Signifor(®)) is a new subcutaneous somatostatin analogue that acts via somatostatin receptors to inhibit the secretion of corticotropin from the pituitary adenoma in patients with Cushing's disease.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 11], "name": "Pasireotide", "tok_span": [0, 3], "new_tok_span": [1, 4]}, {"ent_type": "CHEMICAL", "char_span": [13, 21], "name": "Signifor", "tok_span": [4, 7], "new_tok_span": [7, 10]}, {"ent_type": "CHEMICAL", "char_span": [48, 60], "name": "somatostatin", "tok_span": [15, 17], "new_tok_span": [22, 24]}, {"ent_type": "CHEMICAL", "char_span": [84, 96], "name": "somatostatin", "tok_span": [21, 23], "new_tok_span": [32, 34]}, {"ent_type": "GENE", "char_span": [135, 148], "name": "corticotropin", "tok_span": [29, 31], "new_tok_span": [41, 43]}, {"ent_type": "GENE", "char_span": [48, 60], "name": "somatostatin", "tok_span": [15, 17], "new_tok_span": [22, 24]}, {"ent_type": "GENE", "char_span": [84, 106], "name": "somatostatin receptors", "tok_span": [21, 24], "new_tok_span": [32, 35]}], "relation_list": [{"subject": "Pasireotide", "sbj_char_span": [0, 11], "object": "somatostatin receptors", "obj_char_span": [84, 106], "rel_type": "regulator", "sbj_tok_span": [0, 3], "obj_tok_span": [21, 24], "new_sbj_tok_span": [1, 4], "new_obj_tok_span": [32, 35]}, {"subject": "Signifor", "sbj_char_span": [13, 21], "object": "somatostatin receptors", "obj_char_span": [84, 106], "rel_type": "regulator", "sbj_tok_span": [4, 7], "obj_tok_span": [21, 24], "new_sbj_tok_span": [7, 10], "new_obj_tok_span": [32, 35]}, {"subject": "Pasireotide", "sbj_char_span": [0, 11], "object": "corticotropin", "obj_char_span": [135, 148], "rel_type": "regulator", "sbj_tok_span": [0, 3], "obj_tok_span": [29, 31], "new_sbj_tok_span": [1, 4], "new_obj_tok_span": [41, 43]}, {"subject": "Signifor", "sbj_char_span": [13, 21], "object": "corticotropin", "obj_char_span": [135, 148], "rel_type": "regulator", "sbj_tok_span": [4, 7], "obj_tok_span": [29, 31], "new_sbj_tok_span": [7, 10], "new_obj_tok_span": [41, 43]}], "umls_entity_list": [{"mention": "Pasireotide", "char_span": [0, 11], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [0, 3], "new_tok_span": [1, 4]}, {"mention": "Signifor", "char_span": [13, 21], "sem_type": "Pharmacologic Substance", "tok_span": [4, 7], "new_tok_span": [7, 10]}, {"mention": "somatostatin analogue", "char_span": [48, 69], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [15, 18], "new_tok_span": [22, 25]}, {"mention": "somatostatin analog", "char_span": [48, 67], "sem_type": "Pharmacologic Substance", "tok_span": [15, 18], "new_tok_span": [22, 25]}, {"mention": "somatostatin analogue", "char_span": [48, 69], "sem_type": "Pharmacologic Substance", "tok_span": [15, 18], "new_tok_span": [22, 25]}, {"mention": "somatostatin receptor", "char_span": [84, 105], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [21, 24], "new_tok_span": [32, 35]}], "new_text": "<START=Amino Acid, Peptide, or Protein> Pasireotide <END=Amino Acid, Peptide, or Protein> ( <START=Pharmacologic Substance> Signifor <END=Pharmacologic Substance> ( ® ) ) is a new subcutaneous <START=Amino Acid, Peptide, or Protein> <START=Pharmacologic Substance> <START=Pharmacologic Substance> somatostatin analogue <END=Amino Acid, Peptide, or Protein> <END=Pharmacologic Substance> <END=Pharmacologic Substance> that acts via <START=Amino Acid, Peptide, or Protein> somatostatin receptors <END=Amino Acid, Peptide, or Protein> to inhibit the secretion of corticotropin from the pituitary adenoma in patients with Cushing's disease."}, {"PMID": 15277241, "id": 1, "text": "Glutathione transferase zeta (GSTZ1-1) is the major enzyme that catalyzes the metabolism of alpha-halo acids such as dichloroacetic acid, a carcinogenic contaminant of chlorinated water.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 11], "name": "Glutathione", "tok_span": [0, 2], "new_tok_span": [1, 3]}, {"ent_type": "CHEMICAL", "char_span": [117, 136], "name": "dichloroacetic acid", "tok_span": [29, 34], "new_tok_span": [36, 41]}, {"ent_type": "CHEMICAL", "char_span": [92, 108], "name": "alpha-halo acids", "tok_span": [23, 27], "new_tok_span": [29, 33]}, {"ent_type": "GENE", "char_span": [0, 28], "name": "Glutathione transferase zeta", "tok_span": [0, 6], "new_tok_span": [1, 7]}, {"ent_type": "GENE", "char_span": [30, 37], "name": "GSTZ1-1", "tok_span": [7, 12], "new_tok_span": [12, 17]}], "relation_list": [{"subject": "alpha-halo acids", "sbj_char_span": [92, 108], "object": "Glutathione transferase zeta", "obj_char_span": [0, 28], "rel_type": "product or substrate", "sbj_tok_span": [23, 27], "obj_tok_span": [0, 6], "new_sbj_tok_span": [29, 33], "new_obj_tok_span": [1, 7]}, {"subject": "alpha-halo acids", "sbj_char_span": [92, 108], "object": "GSTZ1-1", "obj_char_span": [30, 37], "rel_type": "product or substrate", "sbj_tok_span": [23, 27], "obj_tok_span": [7, 12], "new_sbj_tok_span": [29, 33], "new_obj_tok_span": [12, 17]}, {"subject": "dichloroacetic acid", "sbj_char_span": [117, 136], "object": "Glutathione transferase zeta", "obj_char_span": [0, 28], "rel_type": "product or substrate", "sbj_tok_span": [29, 34], "obj_tok_span": [0, 6], "new_sbj_tok_span": [36, 41], "new_obj_tok_span": [1, 7]}, {"subject": "dichloroacetic acid", "sbj_char_span": [117, 136], "object": "GSTZ1-1", "obj_char_span": [30, 37], "rel_type": "product or substrate", "sbj_tok_span": [29, 34], "obj_tok_span": [7, 12], "new_sbj_tok_span": [36, 41], "new_obj_tok_span": [12, 17]}], "umls_entity_list": [{"mention": "Glutathione transferase", "char_span": [0, 23], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [0, 4], "new_tok_span": [1, 5]}, {"mention": "zeta", "char_span": [24, 28], "sem_type": "Gene or Genome", "tok_span": [4, 6], "new_tok_span": [7, 9]}, {"mention": "GSTZ1-1", "char_span": [30, 37], "sem_type": "Gene or Genome", "tok_span": [7, 12], "new_tok_span": [12, 17]}, {"mention": "dichloroacetic acid", "char_span": [117, 136], "sem_type": "Pharmacologic Substance", "tok_span": [29, 34], "new_tok_span": [36, 41]}], "new_text": "<START=Amino Acid, Peptide, or Protein> Glutathione transferase <END=Amino Acid, Peptide, or Protein> <START=Gene or Genome> zeta <END=Gene or Genome> ( <START=Gene or Genome> GSTZ1 - 1 <END=Gene or Genome> ) is the major enzyme that catalyzes the metabolism of alpha - halo acids such as <START=Pharmacologic Substance> dichloroacetic acid <END=Pharmacologic Substance>, a carcinogenic contaminant of chlorinated water."}, {"PMID": 10611634, "id": 6, "text": "In guinea pigs, antagonist actions of yohimbine at 5-HT(1B) receptors are revealed by blockade of hypothermia evoked by the 5-HT(1B) agonist, GR46,611.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [38, 47], "name": "yohimbine", "tok_span": [7, 11], "new_tok_span": [7, 11]}, {"ent_type": "CHEMICAL", "char_span": [51, 55], "name": "5-HT", "tok_span": [12, 15], "new_tok_span": [12, 15]}, {"ent_type": "CHEMICAL", "char_span": [124, 128], "name": "5-HT", "tok_span": [30, 33], "new_tok_span": [30, 33]}, {"ent_type": "CHEMICAL", "char_span": [142, 150], "name": "GR46,611", "tok_span": [39, 44], "new_tok_span": [39, 44]}, {"ent_type": "GENE", "char_span": [51, 59], "name": "5-HT(1B)", "tok_span": [12, 19], "new_tok_span": [12, 19]}, {"ent_type": "GENE", "char_span": [124, 132], "name": "5-HT(1B)", "tok_span": [30, 37], "new_tok_span": [30, 37]}], "relation_list": [{"subject": "yohimbine", "sbj_char_span": [38, 47], "object": "5-HT(1B)", "obj_char_span": [51, 59], "rel_type": "agonist or antagonist", "sbj_tok_span": [7, 11], "obj_tok_span": [12, 19], "new_sbj_tok_span": [7, 11], "new_obj_tok_span": [12, 19]}, {"subject": "GR46,611", "sbj_char_span": [142, 150], "object": "5-HT(1B)", "obj_char_span": [124, 132], "rel_type": "agonist or antagonist", "sbj_tok_span": [39, 44], "obj_tok_span": [30, 37], "new_sbj_tok_span": [39, 44], "new_obj_tok_span": [30, 37]}], "umls_entity_list": [], "new_text": "In guinea pigs, antagonist actions of yohimbine at 5 - HT ( 1B ) receptors are revealed by blockade of hypothermia evoked by the 5 - HT ( 1B ) agonist, GR46, 611."}, {"PMID": 15680478, "id": 7, "text": "We found that Ac-[Ser117]Lep116-140-NH2 (V) differentially activates CART neurons through the rostrocaudal extension of the arcuate nucleus.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [36, 39], "name": "NH2", "tok_span": [15, 17], "new_tok_span": [19, 21]}, {"ent_type": "GENE", "char_span": [69, 73], "name": "CART", "tok_span": [22, 24], "new_tok_span": [32, 34]}], "relation_list": [{"subject": "NH2", "sbj_char_span": [36, 39], "object": "CART", "obj_char_span": [69, 73], "rel_type": "activator", "sbj_tok_span": [15, 17], "obj_tok_span": [22, 24], "new_sbj_tok_span": [19, 21], "new_obj_tok_span": [32, 34]}], "umls_entity_list": [{"mention": "Ac", "char_span": [14, 16], "sem_type": "Gene or Genome", "tok_span": [3, 4], "new_tok_span": [5, 6]}, {"mention": "ac", "char_span": [59, 61], "sem_type": "Gene or Genome", "tok_span": [21, 22], "new_tok_span": [27, 28]}, {"mention": "Ac", "char_span": [14, 16], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [3, 4], "new_tok_span": [5, 6]}, {"mention": "ac", "char_span": [59, 61], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [21, 22], "new_tok_span": [27, 28]}, {"mention": "CART", "char_span": [69, 73], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [22, 24], "new_tok_span": [32, 34]}, {"mention": "CART", "char_span": [69, 73], "sem_type": "Gene or Genome", "tok_span": [22, 24], "new_tok_span": [32, 34]}], "new_text": "We found that <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> Ac <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> - [ Ser117 ] Lep116 - 140 - NH2 ( V ) differentially <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> activates <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> CART <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> neurons through the rostrocaudal extension of the arcuate nucleus."}, {"PMID": 12795776, "id": 18, "text": "Terbutaline alone caused an increase in heart rate, a rise in systolic blood pressure, a fall in serum potassium and a rise in both serum glucose and insulin.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 11], "name": "Terbutaline", "tok_span": [0, 3], "new_tok_span": [0, 3]}, {"ent_type": "CHEMICAL", "char_span": [103, 112], "name": "potassium", "tok_span": [22, 23], "new_tok_span": [22, 23]}, {"ent_type": "CHEMICAL", "char_span": [138, 145], "name": "glucose", "tok_span": [29, 30], "new_tok_span": [29, 30]}, {"ent_type": "GENE", "char_span": [150, 157], "name": "insulin", "tok_span": [31, 32], "new_tok_span": [31, 32]}], "relation_list": [{"subject": "Terbutaline", "sbj_char_span": [0, 11], "object": "insulin", "obj_char_span": [150, 157], "rel_type": "regulator", "sbj_tok_span": [0, 3], "obj_tok_span": [31, 32], "new_sbj_tok_span": [0, 3], "new_obj_tok_span": [31, 32]}], "umls_entity_list": [], "new_text": "Terbutaline alone caused an increase in heart rate, a rise in systolic blood pressure, a fall in serum potassium and a rise in both serum glucose and insulin."}, {"PMID": 20193764, "id": 2, "text": "Of known interventions, psychopharmacology provides readily available options, such as the anti-dementia drugs, e.g. acetylcholinesterase inhibitors (donepezil, galantamine, rivastigmine) and memantine.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [150, 159], "name": "donepezil", "tok_span": [32, 35], "new_tok_span": [36, 39]}, {"ent_type": "CHEMICAL", "char_span": [161, 172], "name": "galantamine", "tok_span": [36, 40], "new_tok_span": [40, 44]}, {"ent_type": "CHEMICAL", "char_span": [174, 186], "name": "rivastigmine", "tok_span": [41, 46], "new_tok_span": [45, 50]}, {"ent_type": "CHEMICAL", "char_span": [192, 201], "name": "memantine", "tok_span": [48, 51], "new_tok_span": [52, 55]}, {"ent_type": "GENE", "char_span": [117, 137], "name": "acetylcholinesterase", "tok_span": [27, 30], "new_tok_span": [30, 33]}], "relation_list": [{"subject": "donepezil", "sbj_char_span": [150, 159], "object": "acetylcholinesterase", "obj_char_span": [117, 137], "rel_type": "inhibitor", "sbj_tok_span": [32, 35], "obj_tok_span": [27, 30], "new_sbj_tok_span": [36, 39], "new_obj_tok_span": [30, 33]}, {"subject": "galantamine", "sbj_char_span": [161, 172], "object": "acetylcholinesterase", "obj_char_span": [117, 137], "rel_type": "inhibitor", "sbj_tok_span": [36, 40], "obj_tok_span": [27, 30], "new_sbj_tok_span": [40, 44], "new_obj_tok_span": [30, 33]}, {"subject": "rivastigmine", "sbj_char_span": [174, 186], "object": "acetylcholinesterase", "obj_char_span": [117, 137], "rel_type": "inhibitor", "sbj_tok_span": [41, 46], "obj_tok_span": [27, 30], "new_sbj_tok_span": [45, 50], "new_obj_tok_span": [30, 33]}], "umls_entity_list": [{"mention": "anti-dementia", "char_span": [91, 104], "sem_type": "Pharmacologic Substance", "tok_span": [18, 21], "new_tok_span": [19, 22]}, {"mention": "acetylcholinesterase", "char_span": [117, 137], "sem_type": "Pharmacologic Substance", "tok_span": [27, 30], "new_tok_span": [30, 33]}], "new_text": "Of known interventions, psychopharmacology provides readily available options, such as the <START=Pharmacologic Substance> anti - dementia <END=Pharmacologic Substance> drugs, e. g. <START=Pharmacologic Substance> acetylcholinesterase <END=Pharmacologic Substance> inhibitors ( donepezil, galantamine, rivastigmine ) and memantine."}, {"PMID": 23581848, "id": 0, "text": "Design and synthesis of a tetrahydroisoquinoline-based hydroxamate derivative (ZYJ-34v), an oral active histone deacetylase inhibitor with potent antitumor activity.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [26, 48], "name": "tetrahydroisoquinoline", "tok_span": [5, 10], "new_tok_span": [6, 11]}, {"ent_type": "CHEMICAL", "char_span": [55, 66], "name": "hydroxamate", "tok_span": [12, 14], "new_tok_span": [15, 17]}, {"ent_type": "CHEMICAL", "char_span": [79, 86], "name": "ZYJ-34v", "tok_span": [16, 22], "new_tok_span": [20, 26]}, {"ent_type": "GENE", "char_span": [104, 123], "name": "histone deacetylase", "tok_span": [27, 31], "new_tok_span": [31, 35]}], "relation_list": [{"subject": "tetrahydroisoquinoline", "sbj_char_span": [26, 48], "object": "histone deacetylase", "obj_char_span": [104, 123], "rel_type": "inhibitor", "sbj_tok_span": [5, 10], "obj_tok_span": [27, 31], "new_sbj_tok_span": [6, 11], "new_obj_tok_span": [31, 35]}, {"subject": "hydroxamate", "sbj_char_span": [55, 66], "object": "histone deacetylase", "obj_char_span": [104, 123], "rel_type": "inhibitor", "sbj_tok_span": [12, 14], "obj_tok_span": [27, 31], "new_sbj_tok_span": [15, 17], "new_obj_tok_span": [31, 35]}, {"subject": "ZYJ-34v", "sbj_char_span": [79, 86], "object": "histone deacetylase", "obj_char_span": [104, 123], "rel_type": "inhibitor", "sbj_tok_span": [16, 22], "obj_tok_span": [27, 31], "new_sbj_tok_span": [20, 26], "new_obj_tok_span": [31, 35]}], "umls_entity_list": [{"mention": "tetrahydroisoquinoline", "char_span": [26, 48], "sem_type": "Organic Chemical", "tok_span": [5, 10], "new_tok_span": [6, 11]}, {"mention": "hydroxamate", "char_span": [55, 66], "sem_type": "Organic Chemical", "tok_span": [12, 14], "new_tok_span": [15, 17]}], "new_text": "Design and synthesis of a <START=Organic Chemical> tetrahydroisoquinoline <END=Organic Chemical> - based <START=Organic Chemical> hydroxamate <END=Organic Chemical> derivative ( ZYJ - 34v ), an oral active histone deacetylase inhibitor with potent antitumor activity."}, {"PMID": 17155857, "id": 2, "text": "The phosphodiesterase 4 (PDE4) enzyme plays a significant role in modulating the activity of cAMP, an important second messenger that mediates the relaxation of airway smooth muscle and suppresses inflammatory cell function, thereby attenuating the inflammatory response.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [93, 97], "name": "cAMP", "tok_span": [20, 21], "new_tok_span": [20, 21]}, {"ent_type": "GENE", "char_span": [4, 23], "name": "phosphodiesterase 4", "tok_span": [1, 6], "new_tok_span": [1, 6]}, {"ent_type": "GENE", "char_span": [25, 29], "name": "PDE4", "tok_span": [7, 9], "new_tok_span": [7, 9]}], "relation_list": [{"subject": "cAMP", "sbj_char_span": [93, 97], "object": "phosphodiesterase 4", "obj_char_span": [4, 23], "rel_type": "product or substrate", "sbj_tok_span": [20, 21], "obj_tok_span": [1, 6], "new_sbj_tok_span": [20, 21], "new_obj_tok_span": [1, 6]}, {"subject": "cAMP", "sbj_char_span": [93, 97], "object": "PDE4", "obj_char_span": [25, 29], "rel_type": "product or substrate", "sbj_tok_span": [20, 21], "obj_tok_span": [7, 9], "new_sbj_tok_span": [20, 21], "new_obj_tok_span": [7, 9]}], "umls_entity_list": [], "new_text": "The phosphodiesterase 4 ( PDE4 ) enzyme plays a significant role in modulating the activity of cAMP, an important second messenger that mediates the relaxation of airway smooth muscle and suppresses inflammatory cell function, thereby attenuating the inflammatory response."}, {"PMID": 17463174, "id": 1, "text": "BACKGROUND: Inosine monophosphate dehydrogenase (IMPDH) catalyzes the rate-limiting step in de novo guanine nucleotide synthesis and is implicated in cell cycle control.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [100, 118], "name": "guanine nucleotide", "tok_span": [24, 27], "new_tok_span": [24, 27]}, {"ent_type": "CHEMICAL", "char_span": [12, 33], "name": "Inosine monophosphate", "tok_span": [2, 9], "new_tok_span": [2, 9]}, {"ent_type": "GENE", "char_span": [12, 47], "name": "Inosine monophosphate dehydrogenase", "tok_span": [2, 10], "new_tok_span": [2, 10]}, {"ent_type": "GENE", "char_span": [49, 54], "name": "IMPDH", "tok_span": [11, 13], "new_tok_span": [11, 13]}], "relation_list": [{"subject": "guanine nucleotide", "sbj_char_span": [100, 118], "object": "Inosine monophosphate dehydrogenase", "obj_char_span": [12, 47], "rel_type": "product or substrate", "sbj_tok_span": [24, 27], "obj_tok_span": [2, 10], "new_sbj_tok_span": [24, 27], "new_obj_tok_span": [2, 10]}, {"subject": "guanine nucleotide", "sbj_char_span": [100, 118], "object": "IMPDH", "obj_char_span": [49, 54], "rel_type": "product or substrate", "sbj_tok_span": [24, 27], "obj_tok_span": [11, 13], "new_sbj_tok_span": [24, 27], "new_obj_tok_span": [11, 13]}], "umls_entity_list": [], "new_text": "BACKGROUND : Inosine monophosphate dehydrogenase ( IMPDH ) catalyzes the rate - limiting step in de novo guanine nucleotide synthesis and is implicated in cell cycle control."}, {"PMID": 23377617, "id": 2, "text": "This work tested the hypothesis that a decreased Zn availability can affect glutathione (GSH) metabolism in the developing rat brain and in neuronal cells in culture, as well as the capacity of human neuroblastoma IMR-32 cells to upregulate GSH when challenged with dopamine (DA). GSH levels were low in the brain of gestation day 19 (GD19) fetuses from dams fed marginal Zn diets throughout gestation and in Zn-deficient IMR-32 cells. γ-Glutamylcysteine synthetase (GCL), the first enzyme in the GSH synthetic pathway, was altered by Zn deficiency (ZD). The protein and mRNA levels of the GCL modifier (GCLM) and catalytic (GCLC) subunits were lower in the Zn-deficient GD19 fetal brain and in IMR-32 cells compared with controls.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [49, 51], "name": "Zn", "tok_span": [8, 9], "new_tok_span": [8, 9]}, {"ent_type": "CHEMICAL", "char_span": [76, 87], "name": "glutathione", "tok_span": [12, 13], "new_tok_span": [12, 13]}, {"ent_type": "CHEMICAL", "char_span": [89, 92], "name": "GSH", "tok_span": [14, 15], "new_tok_span": [15, 16]}, {"ent_type": "CHEMICAL", "char_span": [241, 244], "name": "GSH", "tok_span": [46, 47], "new_tok_span": [49, 50]}, {"ent_type": "CHEMICAL", "char_span": [266, 274], "name": "dopamine", "tok_span": [50, 51], "new_tok_span": [54, 55]}, {"ent_type": "CHEMICAL", "char_span": [281, 284], "name": "GSH", "tok_span": [55, 56], "new_tok_span": [60, 61]}, {"ent_type": "CHEMICAL", "char_span": [372, 374], "name": "Zn", "tok_span": [76, 77], "new_tok_span": [82, 83]}, {"ent_type": "CHEMICAL", "char_span": [409, 411], "name": "Zn", "tok_span": [82, 83], "new_tok_span": [88, 89]}, {"ent_type": "CHEMICAL", "char_span": [436, 454], "name": "γ-Glutamylcysteine", "tok_span": [91, 97], "new_tok_span": [97, 103]}, {"ent_type": "CHEMICAL", "char_span": [497, 500], "name": "GSH", "tok_span": [109, 110], "new_tok_span": [118, 119]}, {"ent_type": "CHEMICAL", "char_span": [535, 537], "name": "Zn", "tok_span": [116, 117], "new_tok_span": [128, 129]}, {"ent_type": "CHEMICAL", "char_span": [658, 660], "name": "Zn", "tok_span": [150, 151], "new_tok_span": [174, 175]}, {"ent_type": "GENE", "char_span": [436, 465], "name": "γ-Glutamylcysteine synthetase", "tok_span": [91, 99], "new_tok_span": [97, 105]}, {"ent_type": "GENE", "char_span": [467, 470], "name": "GCL", "tok_span": [100, 102], "new_tok_span": [107, 109]}, {"ent_type": "GENE", "char_span": [590, 602], "name": "GCL modifier", "tok_span": [130, 135], "new_tok_span": [143, 148]}, {"ent_type": "GENE", "char_span": [604, 608], "name": "GCLM", "tok_span": [136, 138], "new_tok_span": [151, 153]}, {"ent_type": "GENE", "char_span": [625, 629], "name": "GCLC", "tok_span": [142, 144], "new_tok_span": [161, 163]}], "relation_list": [{"subject": "GSH", "sbj_char_span": [497, 500], "object": "γ-Glutamylcysteine synthetase", "obj_char_span": [436, 465], "rel_type": "product or substrate", "sbj_tok_span": [109, 110], "obj_tok_span": [91, 99], "new_sbj_tok_span": [118, 119], "new_obj_tok_span": [97, 105]}, {"subject": "GSH", "sbj_char_span": [497, 500], "object": "GCL", "obj_char_span": [467, 470], "rel_type": "product or substrate", "sbj_tok_span": [109, 110], "obj_tok_span": [100, 102], "new_sbj_tok_span": [118, 119], "new_obj_tok_span": [107, 109]}], "umls_entity_list": [{"mention": "GCL", "char_span": [467, 470], "sem_type": "Gene or Genome", "tok_span": [100, 102], "new_tok_span": [107, 109]}, {"mention": "GCL", "char_span": [590, 593], "sem_type": "Gene or Genome", "tok_span": [130, 132], "new_tok_span": [143, 145]}, {"mention": "GCL", "char_span": [604, 607], "sem_type": "Gene or Genome", "tok_span": [136, 138], "new_tok_span": [151, 153]}, {"mention": "GCL", "char_span": [625, 628], "sem_type": "Gene or Genome", "tok_span": [142, 144], "new_tok_span": [161, 163]}, {"mention": "GSH", "char_span": [89, 92], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [14, 15], "new_tok_span": [15, 16]}, {"mention": "GSH", "char_span": [241, 244], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [46, 47], "new_tok_span": [49, 50]}, {"mention": "GSH", "char_span": [281, 284], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [55, 56], "new_tok_span": [60, 61]}, {"mention": "GSH", "char_span": [497, 500], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [109, 110], "new_tok_span": [118, 119]}, {"mention": "synthetic", "char_span": [501, 510], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [110, 111], "new_tok_span": [121, 122]}, {"mention": "GCLC", "char_span": [625, 629], "sem_type": "Gene or Genome", "tok_span": [142, 144], "new_tok_span": [161, 163]}, {"mention": "GCLC", "char_span": [625, 629], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [142, 144], "new_tok_span": [161, 163]}, {"mention": "subunit", "char_span": [631, 638], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [145, 146], "new_tok_span": [168, 169]}], "new_text": "This work tested the hypothesis that a decreased Zn availability can affect glutathione ( <START=Amino Acid, Peptide, or Protein> GSH <END=Amino Acid, Peptide, or Protein> ) metabolism in the developing rat brain and in neuronal cells in culture, as well as the capacity of human neuroblastoma IMR - 32 cells to upregulate <START=Amino Acid, Peptide, or Protein> GSH <END=Amino Acid, Peptide, or Protein> when challenged with dopamine ( DA ). <START=Amino Acid, Peptide, or Protein> GSH <END=Amino Acid, Peptide, or Protein> levels were low in the brain of gestation day 19 ( GD19 ) fetuses from dams fed marginal Zn diets throughout gestation and in Zn - deficient IMR - 32 cells. γ - Glutamylcysteine synthetase ( <START=Gene or Genome> GCL <END=Gene or Genome> ), the first enzyme in the <START=Amino Acid, Peptide, or Protein> GSH <END=Amino Acid, Peptide, or Protein> <START=Amino Acid, Peptide, or Protein> synthetic <END=Amino Acid, Peptide, or Protein> pathway, was altered by Zn deficiency ( ZD ). The protein and mRNA levels of the <START=Gene or Genome> GCL <END=Gene or Genome> modifier ( <START=Gene or Genome> GCLM <END=Gene or Genome> ) and catalytic ( <START=Gene or Genome> <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> GCLC <END=Gene or Genome> <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> ) <START=Amino Acid, Peptide, or Protein> subunits <END=Amino Acid, Peptide, or Protein> were lower in the Zn - deficient GD19 fetal brain and in IMR - 32 cells compared with controls."}, {"PMID": 2125244, "id": 3, "text": "It is proposed that two molecules of estramustine phosphate interact with each of the three tubulin-binding sites of MAP2 and inhibit the MAP2:tubulin interaction by neutralising two highly conserved basic residues.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [37, 59], "name": "estramustine phosphate", "tok_span": [7, 12], "new_tok_span": [7, 12]}, {"ent_type": "GENE", "char_span": [117, 121], "name": "MAP2", "tok_span": [23, 25], "new_tok_span": [24, 26]}, {"ent_type": "GENE", "char_span": [138, 142], "name": "MAP2", "tok_span": [28, 30], "new_tok_span": [31, 33]}, {"ent_type": "GENE", "char_span": [143, 150], "name": "tubulin", "tok_span": [31, 32], "new_tok_span": [35, 36]}], "relation_list": [{"subject": "estramustine phosphate", "sbj_char_span": [37, 59], "object": "MAP2", "obj_char_span": [117, 121], "rel_type": "regulator", "sbj_tok_span": [7, 12], "obj_tok_span": [23, 25], "new_sbj_tok_span": [7, 12], "new_obj_tok_span": [24, 26]}, {"subject": "estramustine phosphate", "sbj_char_span": [37, 59], "object": "MAP2", "obj_char_span": [138, 142], "rel_type": "inhibitor", "sbj_tok_span": [7, 12], "obj_tok_span": [28, 30], "new_sbj_tok_span": [7, 12], "new_obj_tok_span": [31, 33]}, {"subject": "estramustine phosphate", "sbj_char_span": [37, 59], "object": "tubulin", "obj_char_span": [143, 150], "rel_type": "inhibitor", "sbj_tok_span": [7, 12], "obj_tok_span": [31, 32], "new_sbj_tok_span": [7, 12], "new_obj_tok_span": [35, 36]}], "umls_entity_list": [{"mention": "MAP2", "char_span": [117, 121], "sem_type": "Gene or Genome", "tok_span": [23, 25], "new_tok_span": [24, 26]}, {"mention": "MAP2", "char_span": [138, 142], "sem_type": "Gene or Genome", "tok_span": [28, 30], "new_tok_span": [31, 33]}], "new_text": "It is proposed that two molecules of estramustine phosphate interact with each of the three tubulin - binding sites of <START=Gene or Genome> MAP2 <END=Gene or Genome> and inhibit the <START=Gene or Genome> MAP2 <END=Gene or Genome> : tubulin interaction by neutralising two highly conserved basic residues."}, {"PMID": 1386491, "id": 0, "text": "Effectiveness of endopeptidase inhibition (candoxatril) in congestive heart failure.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [43, 54], "name": "candoxatril", "tok_span": [9, 14], "new_tok_span": [9, 14]}, {"ent_type": "GENE", "char_span": [17, 30], "name": "endopeptidase", "tok_span": [3, 7], "new_tok_span": [3, 7]}], "relation_list": [{"subject": "candoxatril", "sbj_char_span": [43, 54], "object": "endopeptidase", "obj_char_span": [17, 30], "rel_type": "inhibitor", "sbj_tok_span": [9, 14], "obj_tok_span": [3, 7], "new_sbj_tok_span": [9, 14], "new_obj_tok_span": [3, 7]}], "umls_entity_list": [], "new_text": "Effectiveness of endopeptidase inhibition ( candoxatril ) in congestive heart failure."}, {"PMID": 24261583, "id": 1, "text": "INTRODUCTION: Macitentan is a novel dual endothelin receptor antagonist (ERA) showing sustained receptor occupancy.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [14, 24], "name": "Macitentan", "tok_span": [2, 5], "new_tok_span": [3, 6]}, {"ent_type": "GENE", "char_span": [41, 60], "name": "endothelin receptor", "tok_span": [9, 12], "new_tok_span": [12, 15]}], "relation_list": [{"subject": "Macitentan", "sbj_char_span": [14, 24], "object": "endothelin receptor", "obj_char_span": [41, 60], "rel_type": "agonist or antagonist", "sbj_tok_span": [2, 5], "obj_tok_span": [9, 12], "new_sbj_tok_span": [3, 6], "new_obj_tok_span": [12, 15]}], "umls_entity_list": [{"mention": "Macitentan", "char_span": [14, 24], "sem_type": "Pharmacologic Substance", "tok_span": [2, 5], "new_tok_span": [3, 6]}, {"mention": "endothelin receptor antagonist", "char_span": [41, 71], "sem_type": "Pharmacologic Substance", "tok_span": [9, 13], "new_tok_span": [12, 16]}], "new_text": "INTRODUCTION : <START=Pharmacologic Substance> Macitentan <END=Pharmacologic Substance> is a novel dual <START=Pharmacologic Substance> endothelin receptor antagonist <END=Pharmacologic Substance> ( ERA ) showing sustained receptor occupancy."}, {"PMID": 12974388, "id": 1, "text": "S-Adenosylmethionine decarboxylase (AdoMetDC) is a key enzyme in polyamine biosynthesis.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 20], "name": "S-Adenosylmethionine", "tok_span": [0, 6], "new_tok_span": [0, 6]}, {"ent_type": "CHEMICAL", "char_span": [65, 74], "name": "polyamine", "tok_span": [20, 22], "new_tok_span": [20, 22]}, {"ent_type": "GENE", "char_span": [0, 34], "name": "S-Adenosylmethionine decarboxylase", "tok_span": [0, 9], "new_tok_span": [0, 9]}, {"ent_type": "GENE", "char_span": [36, 44], "name": "AdoMetDC", "tok_span": [10, 14], "new_tok_span": [10, 14]}], "relation_list": [{"subject": "polyamine", "sbj_char_span": [65, 74], "object": "S-Adenosylmethionine decarboxylase", "obj_char_span": [0, 34], "rel_type": "product or substrate", "sbj_tok_span": [20, 22], "obj_tok_span": [0, 9], "new_sbj_tok_span": [20, 22], "new_obj_tok_span": [0, 9]}, {"subject": "polyamine", "sbj_char_span": [65, 74], "object": "AdoMetDC", "obj_char_span": [36, 44], "rel_type": "product or substrate", "sbj_tok_span": [20, 22], "obj_tok_span": [10, 14], "new_sbj_tok_span": [20, 22], "new_obj_tok_span": [10, 14]}], "umls_entity_list": [], "new_text": "S - Adenosylmethionine decarboxylase ( AdoMetDC ) is a key enzyme in polyamine biosynthesis."}, {"PMID": 12974388, "id": 9, "text": "Unexpectedly, BW-1 was determined to be a competitive inhibitor with respect to AdoMet, having a Ki value of 310 microM for the putrescine-stimulated human AdoMetDC. Furthermore, we show for the O. volvulus and the human enzyme that the degree of inhibition by BW-1 depends on the actual putrescine concentration.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [128, 138], "name": "putrescine", "tok_span": [32, 35], "new_tok_span": [35, 38]}, {"ent_type": "CHEMICAL", "char_span": [288, 298], "name": "putrescine", "tok_span": [71, 74], "new_tok_span": [82, 85]}, {"ent_type": "GENE", "char_span": [150, 164], "name": "human AdoMetDC", "tok_span": [37, 42], "new_tok_span": [41, 46]}], "relation_list": [{"subject": "putrescine", "sbj_char_span": [128, 138], "object": "human AdoMetDC", "obj_char_span": [150, 164], "rel_type": "activator", "sbj_tok_span": [32, 35], "obj_tok_span": [37, 42], "new_sbj_tok_span": [35, 38], "new_obj_tok_span": [41, 46]}], "umls_entity_list": [{"mention": "AdoMet", "char_span": [80, 86], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [18, 21], "new_tok_span": [19, 22]}, {"mention": "AdoMet", "char_span": [156, 162], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [38, 41], "new_tok_span": [45, 48]}, {"mention": "putrescine", "char_span": [128, 138], "sem_type": "Organic Chemical", "tok_span": [32, 35], "new_tok_span": [35, 38]}, {"mention": "putrescine", "char_span": [288, 298], "sem_type": "Organic Chemical", "tok_span": [71, 74], "new_tok_span": [82, 85]}, {"mention": "AdoMetDC", "char_span": [156, 164], "sem_type": "Gene or Genome", "tok_span": [38, 42], "new_tok_span": [45, 49]}, {"mention": "AdoMetDC", "char_span": [156, 164], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [38, 42], "new_tok_span": [45, 49]}], "new_text": "Unexpectedly, BW - 1 was determined to be a competitive inhibitor with respect to <START=Amino Acid, Peptide, or Protein> AdoMet <END=Amino Acid, Peptide, or Protein>, having a Ki value of 310 microM for the <START=Organic Chemical> putrescine <END=Organic Chemical> - stimulated human <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> AdoMet <END=Amino Acid, Peptide, or Protein>DC <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein>. Furthermore, we show for the O. volvulus and the human enzyme that the degree of inhibition by BW - 1 depends on the actual <START=Organic Chemical> putrescine <END=Organic Chemical> concentration."}, {"PMID": 12063084, "id": 0, "text": "The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [18, 30], "name": "aripiprazole", "tok_span": [3, 7], "new_tok_span": [4, 8]}, {"ent_type": "GENE", "char_span": [67, 88], "name": "human 5-HT1A receptor", "tok_span": [15, 22], "new_tok_span": [17, 24]}], "relation_list": [{"subject": "aripiprazole", "sbj_char_span": [18, 30], "object": "human 5-HT1A receptor", "obj_char_span": [67, 88], "rel_type": "agonist or antagonist", "sbj_tok_span": [3, 7], "obj_tok_span": [15, 22], "new_sbj_tok_span": [4, 8], "new_obj_tok_span": [17, 24]}], "umls_entity_list": [{"mention": "aripiprazole", "char_span": [18, 30], "sem_type": "Pharmacologic Substance", "tok_span": [3, 7], "new_tok_span": [4, 8]}], "new_text": "The antipsychotic <START=Pharmacologic Substance> aripiprazole <END=Pharmacologic Substance> is a potent, partial agonist at the human 5 - HT1A receptor."}, {"PMID": 23471964, "id": 3, "text": "Also, cells containing a triple-cysteine mutant of maspin showed elevated ERK1/2 activity, a downstream target of ROS, and enhanced proliferation and colony formation.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [32, 40], "name": "cysteine", "tok_span": [7, 8], "new_tok_span": [7, 8]}, {"ent_type": "GENE", "char_span": [51, 57], "name": "maspin", "tok_span": [10, 12], "new_tok_span": [12, 14]}, {"ent_type": "GENE", "char_span": [74, 80], "name": "ERK1/2", "tok_span": [14, 18], "new_tok_span": [18, 22]}], "relation_list": [{"subject": "cysteine", "sbj_char_span": [32, 40], "object": "maspin", "obj_char_span": [51, 57], "rel_type": "part of", "sbj_tok_span": [7, 8], "obj_tok_span": [10, 12], "new_sbj_tok_span": [7, 8], "new_obj_tok_span": [12, 14]}], "umls_entity_list": [{"mention": "maspin", "char_span": [51, 57], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [10, 12], "new_tok_span": [12, 14]}, {"mention": "maspin", "char_span": [51, 57], "sem_type": "Gene or Genome", "tok_span": [10, 12], "new_tok_span": [12, 14]}, {"mention": "ROS", "char_span": [114, 117], "sem_type": "Gene or Genome", "tok_span": [24, 25], "new_tok_span": [29, 30]}], "new_text": "Also, cells containing a triple - cysteine mutant of <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> maspin <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> showed elevated ERK1 / 2 activity, a downstream target of <START=Gene or Genome> ROS <END=Gene or Genome>, and enhanced proliferation and colony formation."}, {"PMID": 1975995, "id": 1, "text": "We evaluated the clinical effectiveness of esmolol, an ultra-short-acting beta 1-adrenergic receptor blocking drug, to control the sinus tachycardia and increase in arterial blood pressures induced by electroconvulsive therapy (ECT). Each of 20 patients, ASA physical status I-III, participated in a double-blind, randomized study, involving four match-pair trials (placebo versus esmolol) during ECT. Each patient acted as his or her own control (total number of ECT procedures, 160).", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [381, 388], "name": "esmolol", "tok_span": [79, 82], "new_tok_span": [86, 89]}, {"ent_type": "CHEMICAL", "char_span": [43, 50], "name": "esmolol", "tok_span": [6, 9], "new_tok_span": [7, 10]}, {"ent_type": "GENE", "char_span": [74, 100], "name": "beta 1-adrenergic receptor", "tok_span": [16, 22], "new_tok_span": [18, 24]}], "relation_list": [{"subject": "esmolol", "sbj_char_span": [43, 50], "object": "beta 1-adrenergic receptor", "obj_char_span": [74, 100], "rel_type": "inhibitor", "sbj_tok_span": [6, 9], "obj_tok_span": [16, 22], "new_sbj_tok_span": [7, 10], "new_obj_tok_span": [18, 24]}], "umls_entity_list": [{"mention": "esmolol", "char_span": [43, 50], "sem_type": "Pharmacologic Substance", "tok_span": [6, 9], "new_tok_span": [7, 10]}, {"mention": "esmolol", "char_span": [381, 388], "sem_type": "Pharmacologic Substance", "tok_span": [79, 82], "new_tok_span": [86, 89]}, {"mention": "ASA", "char_span": [255, 258], "sem_type": "Pharmacologic Substance", "tok_span": [53, 54], "new_tok_span": [57, 58]}, {"mention": "ASA", "char_span": [255, 258], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [53, 54], "new_tok_span": [57, 58]}], "new_text": "We evaluated the clinical effectiveness of <START=Pharmacologic Substance> esmolol <END=Pharmacologic Substance>, an ultra - short - acting beta 1 - adrenergic receptor blocking drug, to control the sinus tachycardia and increase in arterial blood pressures induced by electroconvulsive therapy ( ECT ). Each of 20 patients, <START=Pharmacologic Substance> <START=Amino Acid, Peptide, or Protein> ASA <END=Pharmacologic Substance> <END=Amino Acid, Peptide, or Protein> physical status I - III, participated in a double - blind, randomized study, involving four match - pair trials ( placebo versus <START=Pharmacologic Substance> esmolol <END=Pharmacologic Substance> ) during ECT. Each patient acted as his or her own control ( total number of ECT procedures, 160 )."}, {"PMID": 23416002, "id": 4, "text": "This is distinct from Rock inhibitors based on non-amino acid derived quinazolinones, where high selectivity against PKA could be obtained.(22) The inhibitors presented here in some cases possessed sub-nanomolar inhibition of Rock, nanomolar potency in ppMLC cell based assays, low to fair cytochrome P-450 inhibition, and good human microsomal stability.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [51, 61], "name": "amino acid", "tok_span": [10, 12], "new_tok_span": [10, 12]}, {"ent_type": "CHEMICAL", "char_span": [70, 84], "name": "quinazolinones", "tok_span": [13, 17], "new_tok_span": [14, 18]}, {"ent_type": "GENE", "char_span": [22, 26], "name": "Rock", "tok_span": [4, 5], "new_tok_span": [4, 5]}, {"ent_type": "GENE", "char_span": [117, 120], "name": "PKA", "tok_span": [22, 23], "new_tok_span": [24, 25]}, {"ent_type": "GENE", "char_span": [226, 230], "name": "Rock", "tok_span": [44, 45], "new_tok_span": [46, 47]}, {"ent_type": "GENE", "char_span": [290, 306], "name": "cytochrome P-450", "tok_span": [60, 64], "new_tok_span": [62, 66]}], "relation_list": [{"subject": "amino acid", "sbj_char_span": [51, 61], "object": "Rock", "obj_char_span": [22, 26], "rel_type": "inhibitor", "sbj_tok_span": [10, 12], "obj_tok_span": [4, 5], "new_sbj_tok_span": [10, 12], "new_obj_tok_span": [4, 5]}, {"subject": "quinazolinones", "sbj_char_span": [70, 84], "object": "Rock", "obj_char_span": [22, 26], "rel_type": "inhibitor", "sbj_tok_span": [13, 17], "obj_tok_span": [4, 5], "new_sbj_tok_span": [14, 18], "new_obj_tok_span": [4, 5]}, {"subject": "amino acid", "sbj_char_span": [51, 61], "object": "PKA", "obj_char_span": [117, 120], "rel_type": "inhibitor", "sbj_tok_span": [10, 12], "obj_tok_span": [22, 23], "new_sbj_tok_span": [10, 12], "new_obj_tok_span": [24, 25]}, {"subject": "quinazolinones", "sbj_char_span": [70, 84], "object": "PKA", "obj_char_span": [117, 120], "rel_type": "inhibitor", "sbj_tok_span": [13, 17], "obj_tok_span": [22, 23], "new_sbj_tok_span": [14, 18], "new_obj_tok_span": [24, 25]}], "umls_entity_list": [{"mention": "quinazolinones", "char_span": [70, 84], "sem_type": "Organic Chemical", "tok_span": [13, 17], "new_tok_span": [14, 18]}], "new_text": "This is distinct from Rock inhibitors based on non - amino acid derived <START=Organic Chemical> quinazolinones <END=Organic Chemical>, where high selectivity against PKA could be obtained. ( 22 ) The inhibitors presented here in some cases possessed sub - nanomolar inhibition of Rock, nanomolar potency in ppMLC cell based assays, low to fair cytochrome P - 450 inhibition, and good human microsomal stability."}, {"PMID": 16675639, "id": 4, "text": "Inhibition of [3H]5-HT or [3H]NE uptake by DVS for the hSERT or hNET produced IC50 values of 47.3 +/- 19.4 and 531.3 +/- 113.0 nM, respectively.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [14, 22], "name": "[3H]5-HT", "tok_span": [2, 9], "new_tok_span": [2, 9]}, {"ent_type": "CHEMICAL", "char_span": [26, 32], "name": "[3H]NE", "tok_span": [10, 15], "new_tok_span": [10, 15]}, {"ent_type": "CHEMICAL", "char_span": [43, 46], "name": "DVS", "tok_span": [17, 19], "new_tok_span": [17, 19]}, {"ent_type": "GENE", "char_span": [55, 60], "name": "hSERT", "tok_span": [21, 24], "new_tok_span": [21, 24]}, {"ent_type": "GENE", "char_span": [64, 68], "name": "hNET", "tok_span": [25, 27], "new_tok_span": [25, 27]}], "relation_list": [{"subject": "DVS", "sbj_char_span": [43, 46], "object": "hSERT", "obj_char_span": [55, 60], "rel_type": "regulator", "sbj_tok_span": [17, 19], "obj_tok_span": [21, 24], "new_sbj_tok_span": [17, 19], "new_obj_tok_span": [21, 24]}, {"subject": "DVS", "sbj_char_span": [43, 46], "object": "hNET", "obj_char_span": [64, 68], "rel_type": "regulator", "sbj_tok_span": [17, 19], "obj_tok_span": [25, 27], "new_sbj_tok_span": [17, 19], "new_obj_tok_span": [25, 27]}, {"subject": "[3H]5-HT", "sbj_char_span": [14, 22], "object": "hSERT", "obj_char_span": [55, 60], "rel_type": "product or substrate", "sbj_tok_span": [2, 9], "obj_tok_span": [21, 24], "new_sbj_tok_span": [2, 9], "new_obj_tok_span": [21, 24]}, {"subject": "[3H]NE", "sbj_char_span": [26, 32], "object": "hNET", "obj_char_span": [64, 68], "rel_type": "product or substrate", "sbj_tok_span": [10, 15], "obj_tok_span": [25, 27], "new_sbj_tok_span": [10, 15], "new_obj_tok_span": [25, 27]}], "umls_entity_list": [], "new_text": "Inhibition of [ 3H ] 5 - HT or [ 3H ] NE uptake by DVS for the hSERT or hNET produced IC50 values of 47. 3 + / - 19. 4 and 531. 3 + / - 113. 0 nM, respectively."}, {"PMID": 9117115, "id": 3, "text": "At the alpha 1B-adrenoceptor of the rat spleen and rabbit corpus cavernosum penis, tamsulosin again acted as a competitive antagonist but with a significantly lower affinity (pKB = 8.9-9.2). 4.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [83, 93], "name": "tamsulosin", "tok_span": [22, 26], "new_tok_span": [22, 26]}, {"ent_type": "GENE", "char_span": [7, 28], "name": "alpha 1B-adrenoceptor", "tok_span": [2, 9], "new_tok_span": [2, 9]}], "relation_list": [{"subject": "tamsulosin", "sbj_char_span": [83, 93], "object": "alpha 1B-adrenoceptor", "obj_char_span": [7, 28], "rel_type": "agonist or antagonist", "sbj_tok_span": [22, 26], "obj_tok_span": [2, 9], "new_sbj_tok_span": [22, 26], "new_obj_tok_span": [2, 9]}, {"subject": "tamsulosin", "sbj_char_span": [83, 93], "object": "alpha 1B-adrenoceptor", "obj_char_span": [7, 28], "rel_type": "regulator", "sbj_tok_span": [22, 26], "obj_tok_span": [2, 9], "new_sbj_tok_span": [22, 26], "new_obj_tok_span": [2, 9]}], "umls_entity_list": [], "new_text": "At the alpha 1B - adrenoceptor of the rat spleen and rabbit corpus cavernosum penis, tamsulosin again acted as a competitive antagonist but with a significantly lower affinity ( pKB = 8. 9 - 9. 2 ). 4."}, {"PMID": 21838705, "id": 6, "text": "Because clinical studies investigating interactions between garlic and human immunodeficiency virus protease inhibitors saquinavir and ritonavir have already been performed, we used these in vivo data to evaluate the in vitro results and the reliability of the models employed as screening tools for forecasting the potential of first-pass intestinal metabolism changes.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [120, 130], "name": "saquinavir", "tok_span": [15, 18], "new_tok_span": [18, 21]}, {"ent_type": "CHEMICAL", "char_span": [135, 144], "name": "ritonavir", "tok_span": [19, 22], "new_tok_span": [23, 26]}, {"ent_type": "GENE", "char_span": [71, 108], "name": "human immunodeficiency virus protease", "tok_span": [9, 14], "new_tok_span": [11, 16]}], "relation_list": [{"subject": "saquinavir", "sbj_char_span": [120, 130], "object": "human immunodeficiency virus protease", "obj_char_span": [71, 108], "rel_type": "inhibitor", "sbj_tok_span": [15, 18], "obj_tok_span": [9, 14], "new_sbj_tok_span": [18, 21], "new_obj_tok_span": [11, 16]}, {"subject": "ritonavir", "sbj_char_span": [135, 144], "object": "human immunodeficiency virus protease", "obj_char_span": [71, 108], "rel_type": "inhibitor", "sbj_tok_span": [19, 22], "obj_tok_span": [9, 14], "new_sbj_tok_span": [23, 26], "new_obj_tok_span": [11, 16]}], "umls_entity_list": [{"mention": "garlic", "char_span": [60, 66], "sem_type": "Pharmacologic Substance", "tok_span": [6, 8], "new_tok_span": [7, 9]}, {"mention": "saquinavir", "char_span": [120, 130], "sem_type": "Pharmacologic Substance", "tok_span": [15, 18], "new_tok_span": [18, 21]}], "new_text": "Because clinical studies investigating interactions between <START=Pharmacologic Substance> garlic <END=Pharmacologic Substance> and human immunodeficiency virus protease inhibitors <START=Pharmacologic Substance> saquinavir <END=Pharmacologic Substance> and ritonavir have already been performed, we used these in vivo data to evaluate the in vitro results and the reliability of the models employed as screening tools for forecasting the potential of first - pass intestinal metabolism changes."}, {"PMID": 16790533, "id": 2, "text": "Dopamine, DOPA, and DOPAC underwent tyrosinase-catalyzed oxidation to generate aminochrome, dopachrome, and furanoquinone, respectively.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 8], "name": "Dopamine", "tok_span": [0, 4], "new_tok_span": [0, 4]}, {"ent_type": "CHEMICAL", "char_span": [10, 14], "name": "DOPA", "tok_span": [5, 7], "new_tok_span": [5, 7]}, {"ent_type": "CHEMICAL", "char_span": [20, 25], "name": "DOPAC", "tok_span": [9, 12], "new_tok_span": [9, 12]}, {"ent_type": "CHEMICAL", "char_span": [79, 90], "name": "aminochrome", "tok_span": [21, 24], "new_tok_span": [26, 29]}, {"ent_type": "CHEMICAL", "char_span": [92, 102], "name": "dopachrome", "tok_span": [25, 28], "new_tok_span": [32, 35]}, {"ent_type": "CHEMICAL", "char_span": [108, 121], "name": "furanoquinone", "tok_span": [30, 34], "new_tok_span": [38, 42]}, {"ent_type": "GENE", "char_span": [36, 46], "name": "tyrosinase", "tok_span": [13, 16], "new_tok_span": [15, 18]}], "relation_list": [{"subject": "Dopamine", "sbj_char_span": [0, 8], "object": "tyrosinase", "obj_char_span": [36, 46], "rel_type": "product or substrate", "sbj_tok_span": [0, 4], "obj_tok_span": [13, 16], "new_sbj_tok_span": [0, 4], "new_obj_tok_span": [15, 18]}, {"subject": "DOPA", "sbj_char_span": [10, 14], "object": "tyrosinase", "obj_char_span": [36, 46], "rel_type": "product or substrate", "sbj_tok_span": [5, 7], "obj_tok_span": [13, 16], "new_sbj_tok_span": [5, 7], "new_obj_tok_span": [15, 18]}, {"subject": "DOPAC", "sbj_char_span": [20, 25], "object": "tyrosinase", "obj_char_span": [36, 46], "rel_type": "product or substrate", "sbj_tok_span": [9, 12], "obj_tok_span": [13, 16], "new_sbj_tok_span": [9, 12], "new_obj_tok_span": [15, 18]}, {"subject": "aminochrome", "sbj_char_span": [79, 90], "object": "tyrosinase", "obj_char_span": [36, 46], "rel_type": "product or substrate", "sbj_tok_span": [21, 24], "obj_tok_span": [13, 16], "new_sbj_tok_span": [26, 29], "new_obj_tok_span": [15, 18]}, {"subject": "dopachrome", "sbj_char_span": [92, 102], "object": "tyrosinase", "obj_char_span": [36, 46], "rel_type": "product or substrate", "sbj_tok_span": [25, 28], "obj_tok_span": [13, 16], "new_sbj_tok_span": [32, 35], "new_obj_tok_span": [15, 18]}, {"subject": "furanoquinone", "sbj_char_span": [108, 121], "object": "tyrosinase", "obj_char_span": [36, 46], "rel_type": "product or substrate", "sbj_tok_span": [30, 34], "obj_tok_span": [13, 16], "new_sbj_tok_span": [38, 42], "new_obj_tok_span": [15, 18]}], "umls_entity_list": [{"mention": "tyrosinase", "char_span": [36, 46], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [13, 16], "new_tok_span": [15, 18]}, {"mention": "tyrosinase", "char_span": [36, 46], "sem_type": "Gene or Genome", "tok_span": [13, 16], "new_tok_span": [15, 18]}, {"mention": "aminochrome", "char_span": [79, 90], "sem_type": "Organic Chemical", "tok_span": [21, 24], "new_tok_span": [26, 29]}, {"mention": "dopachrome", "char_span": [92, 102], "sem_type": "Organic Chemical", "tok_span": [25, 28], "new_tok_span": [32, 35]}], "new_text": "Dopamine, DOPA, and DOPAC underwent <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> tyrosinase <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> - catalyzed oxidation to generate <START=Organic Chemical> aminochrome <END=Organic Chemical>, <START=Organic Chemical> dopachrome <END=Organic Chemical>, and furanoquinone, respectively."}, {"PMID": 23631440, "id": 1, "text": "New series of pyrrolidine mercaptosulfide, 2-mercaptocyclopentane arylsulfonamide, and 3-mercapto-4-arylsulfonamido pyrrolidine matrix metalloproteinase inhibitors (MMPIs) were designed, synthesized, and evaluated.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [14, 41], "name": "pyrrolidine mercaptosulfide", "tok_span": [3, 10], "new_tok_span": [4, 11]}, {"ent_type": "CHEMICAL", "char_span": [43, 81], "name": "2-mercaptocyclopentane arylsulfonamide", "tok_span": [11, 25], "new_tok_span": [13, 27]}, {"ent_type": "CHEMICAL", "char_span": [87, 127], "name": "3-mercapto-4-arylsulfonamido pyrrolidine", "tok_span": [27, 43], "new_tok_span": [29, 45]}, {"ent_type": "GENE", "char_span": [128, 152], "name": "matrix metalloproteinase", "tok_span": [43, 46], "new_tok_span": [48, 51]}], "relation_list": [{"subject": "pyrrolidine mercaptosulfide", "sbj_char_span": [14, 41], "object": "matrix metalloproteinase", "obj_char_span": [128, 152], "rel_type": "inhibitor", "sbj_tok_span": [3, 10], "obj_tok_span": [43, 46], "new_sbj_tok_span": [4, 11], "new_obj_tok_span": [48, 51]}, {"subject": "2-mercaptocyclopentane arylsulfonamide", "sbj_char_span": [43, 81], "object": "matrix metalloproteinase", "obj_char_span": [128, 152], "rel_type": "inhibitor", "sbj_tok_span": [11, 25], "obj_tok_span": [43, 46], "new_sbj_tok_span": [13, 27], "new_obj_tok_span": [48, 51]}, {"subject": "3-mercapto-4-arylsulfonamido pyrrolidine", "sbj_char_span": [87, 127], "object": "matrix metalloproteinase", "obj_char_span": [128, 152], "rel_type": "inhibitor", "sbj_tok_span": [27, 43], "obj_tok_span": [43, 46], "new_sbj_tok_span": [29, 45], "new_obj_tok_span": [48, 51]}], "umls_entity_list": [{"mention": "pyrrolidine", "char_span": [14, 25], "sem_type": "Pharmacologic Substance", "tok_span": [3, 6], "new_tok_span": [4, 7]}, {"mention": "pyrrolidine", "char_span": [116, 127], "sem_type": "Pharmacologic Substance", "tok_span": [40, 43], "new_tok_span": [43, 46]}, {"mention": "matrix", "char_span": [128, 134], "sem_type": "Pharmacologic Substance", "tok_span": [43, 44], "new_tok_span": [48, 49]}], "new_text": "New series of <START=Pharmacologic Substance> pyrrolidine <END=Pharmacologic Substance> mercaptosulfide, 2 - mercaptocyclopentane arylsulfonamide, and 3 - mercapto - 4 - arylsulfonamido <START=Pharmacologic Substance> pyrrolidine <END=Pharmacologic Substance> <START=Pharmacologic Substance> matrix <END=Pharmacologic Substance> metalloproteinase inhibitors ( MMPIs ) were designed, synthesized, and evaluated."}, {"PMID": 15840408, "id": 4, "text": "ONO-AE1-259-01 a prostanoid EP2-receptor agonist, ONO-AE1-329, a prostanoid EP4-receptor agonist, and ONO-1301 inhibited TNF-alpha production and T-cell proliferation.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 11], "name": "ONO-AE1-259", "tok_span": [0, 8], "new_tok_span": [1, 9]}, {"ent_type": "CHEMICAL", "char_span": [50, 61], "name": "ONO-AE1-329", "tok_span": [20, 27], "new_tok_span": [25, 32]}, {"ent_type": "CHEMICAL", "char_span": [102, 110], "name": "ONO-1301", "tok_span": [39, 44], "new_tok_span": [47, 52]}, {"ent_type": "GENE", "char_span": [17, 40], "name": "prostanoid EP2-receptor", "tok_span": [11, 18], "new_tok_span": [14, 21]}, {"ent_type": "GENE", "char_span": [65, 88], "name": "prostanoid EP4-receptor", "tok_span": [29, 36], "new_tok_span": [36, 43]}, {"ent_type": "GENE", "char_span": [121, 130], "name": "TNF-alpha", "tok_span": [45, 48], "new_tok_span": [53, 56]}], "relation_list": [{"subject": "ONO-AE1-259", "sbj_char_span": [0, 11], "object": "prostanoid EP2-receptor", "obj_char_span": [17, 40], "rel_type": "agonist or antagonist", "sbj_tok_span": [0, 8], "obj_tok_span": [11, 18], "new_sbj_tok_span": [1, 9], "new_obj_tok_span": [14, 21]}, {"subject": "ONO-AE1-329", "sbj_char_span": [50, 61], "object": "prostanoid EP4-receptor", "obj_char_span": [65, 88], "rel_type": "agonist or antagonist", "sbj_tok_span": [20, 27], "obj_tok_span": [29, 36], "new_sbj_tok_span": [25, 32], "new_obj_tok_span": [36, 43]}, {"subject": "ONO-1301", "sbj_char_span": [102, 110], "object": "TNF-alpha", "obj_char_span": [121, 130], "rel_type": "regulator", "sbj_tok_span": [39, 44], "obj_tok_span": [45, 48], "new_sbj_tok_span": [47, 52], "new_obj_tok_span": [53, 56]}, {"subject": "ONO-AE1-259", "sbj_char_span": [0, 11], "object": "TNF-alpha", "obj_char_span": [121, 130], "rel_type": "regulator", "sbj_tok_span": [0, 8], "obj_tok_span": [45, 48], "new_sbj_tok_span": [1, 9], "new_obj_tok_span": [53, 56]}, {"subject": "ONO-AE1-329", "sbj_char_span": [50, 61], "object": "TNF-alpha", "obj_char_span": [121, 130], "rel_type": "regulator", "sbj_tok_span": [20, 27], "obj_tok_span": [45, 48], "new_sbj_tok_span": [25, 32], "new_obj_tok_span": [53, 56]}], "umls_entity_list": [{"mention": "ONO-AE1-259-01", "char_span": [0, 14], "sem_type": "Organic Chemical", "tok_span": [0, 10], "new_tok_span": [1, 11]}, {"mention": "prostanoid", "char_span": [17, 27], "sem_type": "Pharmacologic Substance", "tok_span": [11, 14], "new_tok_span": [14, 17]}, {"mention": "prostanoid", "char_span": [65, 75], "sem_type": "Pharmacologic Substance", "tok_span": [29, 32], "new_tok_span": [36, 39]}, {"mention": "ONO-AE1-329", "char_span": [50, 61], "sem_type": "Pharmacologic Substance", "tok_span": [20, 27], "new_tok_span": [25, 32]}], "new_text": "<START=Organic Chemical> ONO - AE1 - 259 - 01 <END=Organic Chemical> a <START=Pharmacologic Substance> prostanoid <END=Pharmacologic Substance> EP2 - receptor agonist, <START=Pharmacologic Substance> ONO - AE1 - 329 <END=Pharmacologic Substance>, a <START=Pharmacologic Substance> prostanoid <END=Pharmacologic Substance> EP4 - receptor agonist, and ONO - 1301 inhibited TNF - alpha production and T - cell proliferation."}, {"PMID": 23578993, "id": 7, "text": "Cytochrome P450 2E1 (CYP 450 2E1), activity was determined as hydroxylation of aniline in liver microsomes.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [79, 86], "name": "aniline", "tok_span": [22, 25], "new_tok_span": [25, 28]}, {"ent_type": "GENE", "char_span": [0, 19], "name": "Cytochrome P450 2E1", "tok_span": [0, 7], "new_tok_span": [1, 8]}, {"ent_type": "GENE", "char_span": [21, 32], "name": "CYP 450 2E1", "tok_span": [8, 13], "new_tok_span": [10, 15]}], "relation_list": [{"subject": "aniline", "sbj_char_span": [79, 86], "object": "Cytochrome P450 2E1", "obj_char_span": [0, 19], "rel_type": "product or substrate", "sbj_tok_span": [22, 25], "obj_tok_span": [0, 7], "new_sbj_tok_span": [25, 28], "new_obj_tok_span": [1, 8]}, {"subject": "aniline", "sbj_char_span": [79, 86], "object": "CYP 450 2E1", "obj_char_span": [21, 32], "rel_type": "product or substrate", "sbj_tok_span": [22, 25], "obj_tok_span": [8, 13], "new_sbj_tok_span": [25, 28], "new_obj_tok_span": [10, 15]}], "umls_entity_list": [{"mention": "Cytochrome P450 2E1", "char_span": [0, 19], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [0, 7], "new_tok_span": [1, 8]}, {"mention": "aniline", "char_span": [79, 86], "sem_type": "Organic Chemical", "tok_span": [22, 25], "new_tok_span": [25, 28]}], "new_text": "<START=Amino Acid, Peptide, or Protein> Cytochrome P450 2E1 <END=Amino Acid, Peptide, or Protein> ( CYP 450 2E1 ), activity was determined as hydroxylation of <START=Organic Chemical> aniline <END=Organic Chemical> in liver microsomes."}, {"PMID": 23305444, "id": 0, "text": "Discovery and evaluation of novel inhibitors of mycobacterium protein tyrosine phosphatase B from the 6-Hydroxy-benzofuran-5-carboxylic acid scaffold.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [102, 140], "name": "6-Hydroxy-benzofuran-5-carboxylic acid", "tok_span": [15, 29], "new_tok_span": [19, 33]}, {"ent_type": "CHEMICAL", "char_span": [70, 78], "name": "tyrosine", "tok_span": [10, 11], "new_tok_span": [13, 14]}, {"ent_type": "GENE", "char_span": [48, 92], "name": "mycobacterium protein tyrosine phosphatase B", "tok_span": [7, 13], "new_tok_span": [7, 13]}], "relation_list": [{"subject": "6-Hydroxy-benzofuran-5-carboxylic acid", "sbj_char_span": [102, 140], "object": "mycobacterium protein tyrosine phosphatase B", "obj_char_span": [48, 92], "rel_type": "inhibitor", "sbj_tok_span": [15, 29], "obj_tok_span": [7, 13], "new_sbj_tok_span": [19, 33], "new_obj_tok_span": [7, 13]}], "umls_entity_list": [{"mention": "protein", "char_span": [62, 69], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [9, 10], "new_tok_span": [10, 11]}, {"mention": "tyrosine phosphatase", "char_span": [70, 90], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [10, 12], "new_tok_span": [13, 15]}, {"mention": "benzofuran", "char_span": [112, 122], "sem_type": "Organic Chemical", "tok_span": [20, 23], "new_tok_span": [25, 28]}, {"mention": "carboxylic acid", "char_span": [125, 140], "sem_type": "Organic Chemical", "tok_span": [26, 29], "new_tok_span": [33, 36]}], "new_text": "Discovery and evaluation of novel inhibitors of mycobacterium <START=Amino Acid, Peptide, or Protein> protein <END=Amino Acid, Peptide, or Protein> <START=Amino Acid, Peptide, or Protein> tyrosine phosphatase <END=Amino Acid, Peptide, or Protein> B from the 6 - Hydroxy - <START=Organic Chemical> benzofuran <END=Organic Chemical> - 5 - <START=Organic Chemical> carboxylic acid <END=Organic Chemical> scaffold."}, {"PMID": 23624148, "id": 8, "text": "Moreover, sciadopitysin increased phosphorylation of cAMP-response element-binding protein (CREB) inhibited by antimycin A.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [10, 23], "name": "sciadopitysin", "tok_span": [2, 7], "new_tok_span": [3, 8]}, {"ent_type": "CHEMICAL", "char_span": [53, 57], "name": "cAMP", "tok_span": [10, 11], "new_tok_span": [12, 13]}, {"ent_type": "CHEMICAL", "char_span": [111, 122], "name": "antimycin A", "tok_span": [22, 25], "new_tok_span": [24, 27]}, {"ent_type": "GENE", "char_span": [53, 90], "name": "cAMP-response element-binding protein", "tok_span": [10, 17], "new_tok_span": [12, 19]}, {"ent_type": "GENE", "char_span": [92, 96], "name": "CREB", "tok_span": [18, 19], "new_tok_span": [20, 21]}], "relation_list": [{"subject": "sciadopitysin", "sbj_char_span": [10, 23], "object": "cAMP-response element-binding protein", "obj_char_span": [53, 90], "rel_type": "activator", "sbj_tok_span": [2, 7], "obj_tok_span": [10, 17], "new_sbj_tok_span": [3, 8], "new_obj_tok_span": [12, 19]}, {"subject": "sciadopitysin", "sbj_char_span": [10, 23], "object": "CREB", "obj_char_span": [92, 96], "rel_type": "activator", "sbj_tok_span": [2, 7], "obj_tok_span": [18, 19], "new_sbj_tok_span": [3, 8], "new_obj_tok_span": [20, 21]}, {"subject": "antimycin A", "sbj_char_span": [111, 122], "object": "cAMP-response element-binding protein", "obj_char_span": [53, 90], "rel_type": "inhibitor", "sbj_tok_span": [22, 25], "obj_tok_span": [10, 17], "new_sbj_tok_span": [24, 27], "new_obj_tok_span": [12, 19]}, {"subject": "antimycin A", "sbj_char_span": [111, 122], "object": "CREB", "obj_char_span": [92, 96], "rel_type": "inhibitor", "sbj_tok_span": [22, 25], "obj_tok_span": [18, 19], "new_sbj_tok_span": [24, 27], "new_obj_tok_span": [20, 21]}], "umls_entity_list": [{"mention": "sciadopitysin", "char_span": [10, 23], "sem_type": "Organic Chemical", "tok_span": [2, 7], "new_tok_span": [3, 8]}], "new_text": "Moreover, <START=Organic Chemical> sciadopitysin <END=Organic Chemical> increased phosphorylation of cAMP - response element - binding protein ( CREB ) inhibited by antimycin A."}, {"PMID": 23260350, "id": 0, "text": "Identification of benzofuran central cores for the inhibition of leukotriene A(4) hydrolase.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [18, 28], "name": "benzofuran", "tok_span": [2, 5], "new_tok_span": [3, 6]}, {"ent_type": "CHEMICAL", "char_span": [65, 81], "name": "leukotriene A(4)", "tok_span": [11, 18], "new_tok_span": [14, 21]}, {"ent_type": "GENE", "char_span": [65, 91], "name": "leukotriene A(4) hydrolase", "tok_span": [11, 21], "new_tok_span": [14, 24]}], "relation_list": [{"subject": "benzofuran", "sbj_char_span": [18, 28], "object": "leukotriene A(4) hydrolase", "obj_char_span": [65, 91], "rel_type": "inhibitor", "sbj_tok_span": [2, 5], "obj_tok_span": [11, 21], "new_sbj_tok_span": [3, 6], "new_obj_tok_span": [14, 24]}], "umls_entity_list": [{"mention": "benzofuran", "char_span": [18, 28], "sem_type": "Organic Chemical", "tok_span": [2, 5], "new_tok_span": [3, 6]}, {"mention": "leukotriene A(4) hydrolase", "char_span": [65, 91], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [11, 21], "new_tok_span": [14, 24]}], "new_text": "Identification of <START=Organic Chemical> benzofuran <END=Organic Chemical> central cores for the inhibition of <START=Amino Acid, Peptide, or Protein> leukotriene A ( 4 ) hydrolase <END=Amino Acid, Peptide, or Protein>."}, {"PMID": 2567596, "id": 5, "text": "However, the affinities of the tested H1-antagonists other than mepyramine for this binding site were quite low and the known stereospecificity displayed by the histamine H1-receptor for the enantiomers of chlorpheniramine and pheniramine was not found.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [64, 74], "name": "mepyramine", "tok_span": [13, 16], "new_tok_span": [14, 17]}, {"ent_type": "CHEMICAL", "char_span": [161, 170], "name": "histamine", "tok_span": [32, 33], "new_tok_span": [34, 35]}, {"ent_type": "CHEMICAL", "char_span": [206, 222], "name": "chlorpheniramine", "tok_span": [42, 47], "new_tok_span": [45, 50]}, {"ent_type": "CHEMICAL", "char_span": [227, 238], "name": "pheniramine", "tok_span": [48, 52], "new_tok_span": [55, 59]}, {"ent_type": "GENE", "char_span": [38, 40], "name": "H1", "tok_span": [7, 9], "new_tok_span": [7, 9]}, {"ent_type": "GENE", "char_span": [161, 182], "name": "histamine H1-receptor", "tok_span": [32, 37], "new_tok_span": [34, 39]}], "relation_list": [{"subject": "mepyramine", "sbj_char_span": [64, 74], "object": "H1", "obj_char_span": [38, 40], "rel_type": "agonist or antagonist", "sbj_tok_span": [13, 16], "obj_tok_span": [7, 9], "new_sbj_tok_span": [14, 17], "new_obj_tok_span": [7, 9]}], "umls_entity_list": [{"mention": "mepyramine", "char_span": [64, 74], "sem_type": "Pharmacologic Substance", "tok_span": [13, 16], "new_tok_span": [14, 17]}, {"mention": "chlorpheniramine", "char_span": [206, 222], "sem_type": "Pharmacologic Substance", "tok_span": [42, 47], "new_tok_span": [45, 50]}, {"mention": "pheniramine", "char_span": [211, 222], "sem_type": "Pharmacologic Substance", "tok_span": [43, 47], "new_tok_span": [47, 51]}, {"mention": "pheniramine", "char_span": [227, 238], "sem_type": "Pharmacologic Substance", "tok_span": [48, 52], "new_tok_span": [55, 59]}], "new_text": "However, the affinities of the tested H1 - antagonists other than <START=Pharmacologic Substance> mepyramine <END=Pharmacologic Substance> for this binding site were quite low and the known stereospecificity displayed by the histamine H1 - receptor for the enantiomers of <START=Pharmacologic Substance> chlor <START=Pharmacologic Substance>pheniramine <END=Pharmacologic Substance> <END=Pharmacologic Substance> and <START=Pharmacologic Substance> pheniramine <END=Pharmacologic Substance> was not found."}, {"PMID": 2857786, "id": 5, "text": "Ambenonium was a less potent antagonist of tissue responses to acetylcholine, and the underestimation in the pKB (as compared to that obtained with bethanechol) could be eliminated by prior treatment of tissues with the acetylcholinesterase inhibitor neostigmine.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 10], "name": "Ambenonium", "tok_span": [0, 3], "new_tok_span": [0, 3]}, {"ent_type": "CHEMICAL", "char_span": [63, 76], "name": "acetylcholine", "tok_span": [12, 13], "new_tok_span": [12, 13]}, {"ent_type": "CHEMICAL", "char_span": [148, 159], "name": "bethanechol", "tok_span": [29, 33], "new_tok_span": [32, 36]}, {"ent_type": "CHEMICAL", "char_span": [251, 262], "name": "neostigmine", "tok_span": [48, 52], "new_tok_span": [55, 59]}, {"ent_type": "GENE", "char_span": [220, 240], "name": "acetylcholinesterase", "tok_span": [44, 47], "new_tok_span": [49, 52]}], "relation_list": [{"subject": "neostigmine", "sbj_char_span": [251, 262], "object": "acetylcholinesterase", "obj_char_span": [220, 240], "rel_type": "inhibitor", "sbj_tok_span": [48, 52], "obj_tok_span": [44, 47], "new_sbj_tok_span": [55, 59], "new_obj_tok_span": [49, 52]}], "umls_entity_list": [{"mention": "pKB", "char_span": [109, 112], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [20, 22], "new_tok_span": [21, 23]}, {"mention": "bethanechol", "char_span": [148, 159], "sem_type": "Pharmacologic Substance", "tok_span": [29, 33], "new_tok_span": [32, 36]}, {"mention": "acetylcholinesterase inhibitor", "char_span": [220, 250], "sem_type": "Pharmacologic Substance", "tok_span": [44, 48], "new_tok_span": [49, 53]}, {"mention": "neostigmine", "char_span": [251, 262], "sem_type": "Pharmacologic Substance", "tok_span": [48, 52], "new_tok_span": [55, 59]}], "new_text": "Ambenonium was a less potent antagonist of tissue responses to acetylcholine, and the underestimation in the <START=Amino Acid, Peptide, or Protein> pKB <END=Amino Acid, Peptide, or Protein> ( as compared to that obtained with <START=Pharmacologic Substance> bethanechol <END=Pharmacologic Substance> ) could be eliminated by prior treatment of tissues with the <START=Pharmacologic Substance> acetylcholinesterase inhibitor <END=Pharmacologic Substance> <START=Pharmacologic Substance> neostigmine <END=Pharmacologic Substance>."}, {"PMID": 23517028, "id": 1, "text": "Biophysical fragment screening of a thermostabilized β1-adrenergic receptor (β1AR) using surface plasmon resonance (SPR) enabled the identification of moderate affinity, high ligand efficiency (LE) arylpiperazine hits 7 and 8.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [198, 212], "name": "arylpiperazine", "tok_span": [41, 45], "new_tok_span": [43, 47]}, {"ent_type": "GENE", "char_span": [53, 75], "name": "β1-adrenergic receptor", "tok_span": [9, 15], "new_tok_span": [9, 15]}, {"ent_type": "GENE", "char_span": [77, 81], "name": "β1AR", "tok_span": [16, 19], "new_tok_span": [18, 21]}], "relation_list": [{"subject": "arylpiperazine", "sbj_char_span": [198, 212], "object": "β1-adrenergic receptor", "obj_char_span": [53, 75], "rel_type": "regulator", "sbj_tok_span": [41, 45], "obj_tok_span": [9, 15], "new_sbj_tok_span": [43, 47], "new_obj_tok_span": [9, 15]}, {"subject": "arylpiperazine", "sbj_char_span": [198, 212], "object": "β1AR", "obj_char_span": [77, 81], "rel_type": "regulator", "sbj_tok_span": [41, 45], "obj_tok_span": [16, 19], "new_sbj_tok_span": [43, 47], "new_obj_tok_span": [18, 21]}], "umls_entity_list": [{"mention": "adrenergic", "char_span": [56, 66], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [12, 14], "new_tok_span": [13, 15]}, {"mention": "hits", "char_span": [213, 217], "sem_type": "Gene or Genome", "tok_span": [45, 46], "new_tok_span": [48, 49]}], "new_text": "Biophysical fragment screening of a thermostabilized β1 - <START=Amino Acid, Peptide, or Protein> adrenergic <END=Amino Acid, Peptide, or Protein> receptor ( β1AR ) using surface plasmon resonance ( SPR ) enabled the identification of moderate affinity, high ligand efficiency ( LE ) arylpiperazine <START=Gene or Genome> hits <END=Gene or Genome> 7 and 8."}, {"PMID": 17110146, "id": 13, "text": "Our results imply that P2Y12 has the potential to be inhibited by ADP/ATP analogs, and it suggests that P2Y12 acts as a target of new drugs that inhibit platelet aggregation.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [66, 69], "name": "ADP", "tok_span": [15, 16], "new_tok_span": [15, 16]}, {"ent_type": "CHEMICAL", "char_span": [70, 73], "name": "ATP", "tok_span": [17, 18], "new_tok_span": [17, 18]}, {"ent_type": "GENE", "char_span": [23, 28], "name": "P2Y12", "tok_span": [4, 8], "new_tok_span": [4, 8]}, {"ent_type": "GENE", "char_span": [104, 109], "name": "P2Y12", "tok_span": [24, 28], "new_tok_span": [24, 28]}], "relation_list": [{"subject": "ADP", "sbj_char_span": [66, 69], "object": "P2Y12", "obj_char_span": [23, 28], "rel_type": "inhibitor", "sbj_tok_span": [15, 16], "obj_tok_span": [4, 8], "new_sbj_tok_span": [15, 16], "new_obj_tok_span": [4, 8]}, {"subject": "ATP", "sbj_char_span": [70, 73], "object": "P2Y12", "obj_char_span": [23, 28], "rel_type": "inhibitor", "sbj_tok_span": [17, 18], "obj_tok_span": [4, 8], "new_sbj_tok_span": [17, 18], "new_obj_tok_span": [4, 8]}], "umls_entity_list": [], "new_text": "Our results imply that P2Y12 has the potential to be inhibited by ADP / ATP analogs, and it suggests that P2Y12 acts as a target of new drugs that inhibit platelet aggregation."}, {"PMID": 3002801, "id": 2, "text": "Enprofylline antagonized the 5'-N-ethylcarboxamidoadenosine (NECA)-induced stimulation of platelet adenylate cyclase activity with a KB of 130 microM.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 12], "name": "Enprofylline", "tok_span": [0, 4], "new_tok_span": [0, 4]}, {"ent_type": "CHEMICAL", "char_span": [29, 59], "name": "5'-N-ethylcarboxamidoadenosine", "tok_span": [7, 19], "new_tok_span": [7, 19]}, {"ent_type": "CHEMICAL", "char_span": [61, 65], "name": "NECA", "tok_span": [20, 22], "new_tok_span": [20, 22]}, {"ent_type": "CHEMICAL", "char_span": [99, 108], "name": "adenylate", "tok_span": [28, 30], "new_tok_span": [28, 30]}, {"ent_type": "GENE", "char_span": [99, 116], "name": "adenylate cyclase", "tok_span": [28, 31], "new_tok_span": [28, 31]}], "relation_list": [{"subject": "5'-N-ethylcarboxamidoadenosine", "sbj_char_span": [29, 59], "object": "adenylate cyclase", "obj_char_span": [99, 116], "rel_type": "activator", "sbj_tok_span": [7, 19], "obj_tok_span": [28, 31], "new_sbj_tok_span": [7, 19], "new_obj_tok_span": [28, 31]}, {"subject": "NECA", "sbj_char_span": [61, 65], "object": "adenylate cyclase", "obj_char_span": [99, 116], "rel_type": "activator", "sbj_tok_span": [20, 22], "obj_tok_span": [28, 31], "new_sbj_tok_span": [20, 22], "new_obj_tok_span": [28, 31]}, {"subject": "Enprofylline", "sbj_char_span": [0, 12], "object": "adenylate cyclase", "obj_char_span": [99, 116], "rel_type": "inhibitor", "sbj_tok_span": [0, 4], "obj_tok_span": [28, 31], "new_sbj_tok_span": [0, 4], "new_obj_tok_span": [28, 31]}], "umls_entity_list": [], "new_text": "Enprofylline antagonized the 5'- N - ethylcarboxamidoadenosine ( NECA ) - induced stimulation of platelet adenylate cyclase activity with a KB of 130 microM."}, {"PMID": 15646028, "id": 7, "text": "Pre-irradiation administration of RP-1 enhanced levels of GSH induced increase in complex I (upto 16 h), complex I/III (4 h) complex II/III activity (upto 24 h; p < 0.01) and inhibited the radiation-induced decrease in MMP significantly (24 h; p < 0.01).", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [58, 61], "name": "GSH", "tok_span": [11, 12], "new_tok_span": [14, 15]}, {"ent_type": "GENE", "char_span": [82, 91], "name": "complex I", "tok_span": [15, 17], "new_tok_span": [20, 22]}, {"ent_type": "GENE", "char_span": [105, 118], "name": "complex I/III", "tok_span": [24, 28], "new_tok_span": [31, 35]}, {"ent_type": "GENE", "char_span": [125, 139], "name": "complex II/III", "tok_span": [32, 36], "new_tok_span": [41, 45]}], "relation_list": [{"subject": "GSH", "sbj_char_span": [58, 61], "object": "complex I", "obj_char_span": [82, 91], "rel_type": "activator", "sbj_tok_span": [11, 12], "obj_tok_span": [15, 17], "new_sbj_tok_span": [14, 15], "new_obj_tok_span": [20, 22]}, {"subject": "GSH", "sbj_char_span": [58, 61], "object": "complex I/III", "obj_char_span": [105, 118], "rel_type": "activator", "sbj_tok_span": [11, 12], "obj_tok_span": [24, 28], "new_sbj_tok_span": [14, 15], "new_obj_tok_span": [31, 35]}, {"subject": "GSH", "sbj_char_span": [58, 61], "object": "complex II/III", "obj_char_span": [125, 139], "rel_type": "activator", "sbj_tok_span": [11, 12], "obj_tok_span": [32, 36], "new_sbj_tok_span": [14, 15], "new_obj_tok_span": [41, 45]}], "umls_entity_list": [{"mention": "GSH", "char_span": [58, 61], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [11, 12], "new_tok_span": [14, 15]}, {"mention": "RP", "char_span": [34, 36], "sem_type": "Gene or Genome", "tok_span": [5, 6], "new_tok_span": [6, 7]}, {"mention": "complex I", "char_span": [82, 91], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [15, 17], "new_tok_span": [20, 22]}, {"mention": "complex I", "char_span": [105, 114], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [24, 26], "new_tok_span": [31, 33]}, {"mention": "complex I", "char_span": [125, 134], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [32, 34], "new_tok_span": [41, 43]}, {"mention": "MMP", "char_span": [219, 222], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [57, 58], "new_tok_span": [69, 70]}, {"mention": "MMP", "char_span": [219, 222], "sem_type": "Gene or Genome", "tok_span": [57, 58], "new_tok_span": [69, 70]}], "new_text": "Pre - irradiation administration of <START=Gene or Genome> RP <END=Gene or Genome> - 1 enhanced levels of <START=Amino Acid, Peptide, or Protein> GSH <END=Amino Acid, Peptide, or Protein> induced increase in <START=Amino Acid, Peptide, or Protein> complex I <END=Amino Acid, Peptide, or Protein> ( upto 16 h ), <START=Amino Acid, Peptide, or Protein> complex I <END=Amino Acid, Peptide, or Protein> / III ( 4 h ) <START=Amino Acid, Peptide, or Protein> complex II <END=Amino Acid, Peptide, or Protein> / III activity ( upto 24 h ; p < 0. 01 ) and inhibited the radiation - induced decrease in <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> MMP <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> significantly ( 24 h ; p < 0. 01 )."}, {"PMID": 19203467, "id": 4, "text": "The effects of PLZ on both amino acids and their transaminases were blocked by pre-treatment with the MAO inhibitor tranylcypromine.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [116, 131], "name": "tranylcypromine", "tok_span": [25, 30], "new_tok_span": [28, 33]}, {"ent_type": "CHEMICAL", "char_span": [15, 18], "name": "PLZ", "tok_span": [3, 5], "new_tok_span": [3, 5]}, {"ent_type": "CHEMICAL", "char_span": [27, 38], "name": "amino acids", "tok_span": [7, 9], "new_tok_span": [7, 9]}, {"ent_type": "GENE", "char_span": [102, 105], "name": "MAO", "tok_span": [22, 24], "new_tok_span": [24, 26]}, {"ent_type": "GENE", "char_span": [49, 62], "name": "transaminases", "tok_span": [11, 14], "new_tok_span": [12, 15]}], "relation_list": [{"subject": "tranylcypromine", "sbj_char_span": [116, 131], "object": "MAO", "obj_char_span": [102, 105], "rel_type": "inhibitor", "sbj_tok_span": [25, 30], "obj_tok_span": [22, 24], "new_sbj_tok_span": [28, 33], "new_obj_tok_span": [24, 26]}, {"subject": "tranylcypromine", "sbj_char_span": [116, 131], "object": "transaminases", "obj_char_span": [49, 62], "rel_type": "inhibitor", "sbj_tok_span": [25, 30], "obj_tok_span": [11, 14], "new_sbj_tok_span": [28, 33], "new_obj_tok_span": [12, 15]}], "umls_entity_list": [{"mention": "transaminases", "char_span": [49, 62], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [11, 14], "new_tok_span": [12, 15]}, {"mention": "tranylcypromine", "char_span": [116, 131], "sem_type": "Pharmacologic Substance", "tok_span": [25, 30], "new_tok_span": [28, 33]}], "new_text": "The effects of PLZ on both amino acids and their <START=Amino Acid, Peptide, or Protein> transaminases <END=Amino Acid, Peptide, or Protein> were blocked by pre - treatment with the MAO inhibitor <START=Pharmacologic Substance> tranylcypromine <END=Pharmacologic Substance>."}, {"PMID": 10828060, "id": 2, "text": "Whereas glitazones are insulin sensitizers acting via activation of the peroxisome proliferator-activated receptor (PPAR) gamma subtype, fibrates exert their lipid-lowering activity via PPARalpha.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [8, 18], "name": "glitazones", "tok_span": [1, 5], "new_tok_span": [1, 5]}, {"ent_type": "CHEMICAL", "char_span": [137, 145], "name": "fibrates", "tok_span": [28, 30], "new_tok_span": [28, 30]}, {"ent_type": "GENE", "char_span": [23, 30], "name": "insulin", "tok_span": [6, 7], "new_tok_span": [6, 7]}, {"ent_type": "GENE", "char_span": [72, 127], "name": "peroxisome proliferator-activated receptor (PPAR) gamma", "tok_span": [15, 26], "new_tok_span": [15, 26]}, {"ent_type": "GENE", "char_span": [186, 195], "name": "PPARalpha", "tok_span": [37, 39], "new_tok_span": [37, 39]}], "relation_list": [{"subject": "glitazones", "sbj_char_span": [8, 18], "object": "peroxisome proliferator-activated receptor (PPAR) gamma", "obj_char_span": [72, 127], "rel_type": "activator", "sbj_tok_span": [1, 5], "obj_tok_span": [15, 26], "new_sbj_tok_span": [1, 5], "new_obj_tok_span": [15, 26]}], "umls_entity_list": [], "new_text": "Whereas glitazones are insulin sensitizers acting via activation of the peroxisome proliferator - activated receptor ( PPAR ) gamma subtype, fibrates exert their lipid - lowering activity via PPARalpha."}, {"PMID": 23566514, "id": 0, "text": "Discovery and synthesis of novel 4-aminopyrrolopyrimidine Tie-2 kinase inhibitors for the treatment of solid tumors.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [33, 57], "name": "4-aminopyrrolopyrimidine", "tok_span": [5, 13], "new_tok_span": [5, 13]}, {"ent_type": "GENE", "char_span": [58, 63], "name": "Tie-2", "tok_span": [13, 17], "new_tok_span": [14, 18]}, {"ent_type": "GENE", "char_span": [64, 70], "name": "kinase", "tok_span": [17, 18], "new_tok_span": [19, 20]}], "relation_list": [{"subject": "4-aminopyrrolopyrimidine", "sbj_char_span": [33, 57], "object": "Tie-2", "obj_char_span": [58, 63], "rel_type": "inhibitor", "sbj_tok_span": [5, 13], "obj_tok_span": [13, 17], "new_sbj_tok_span": [5, 13], "new_obj_tok_span": [14, 18]}, {"subject": "4-aminopyrrolopyrimidine", "sbj_char_span": [33, 57], "object": "kinase", "obj_char_span": [64, 70], "rel_type": "inhibitor", "sbj_tok_span": [5, 13], "obj_tok_span": [17, 18], "new_sbj_tok_span": [5, 13], "new_obj_tok_span": [19, 20]}], "umls_entity_list": [{"mention": "Tie-2", "char_span": [58, 63], "sem_type": "Gene or Genome", "tok_span": [13, 17], "new_tok_span": [14, 18]}], "new_text": "Discovery and synthesis of novel 4 - aminopyrrolopyrimidine <START=Gene or Genome> Tie - 2 <END=Gene or Genome> kinase inhibitors for the treatment of solid tumors."}, {"PMID": 23301897, "id": 7, "text": "In addition, the new compound perviridicin B (2), three known rocaglate derivatives (9, 11, 12), and a known sesquiterpene, 2-oxaisodauc-5-en-12-al (17), showed significant NF-κB (p65) inhibitory activity in an ELISA assay.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [30, 44], "name": "perviridicin B", "tok_span": [6, 11], "new_tok_span": [6, 11]}, {"ent_type": "CHEMICAL", "char_span": [62, 71], "name": "rocaglate", "tok_span": [17, 21], "new_tok_span": [17, 21]}, {"ent_type": "CHEMICAL", "char_span": [109, 122], "name": "sesquiterpene", "tok_span": [33, 38], "new_tok_span": [34, 39]}, {"ent_type": "CHEMICAL", "char_span": [124, 147], "name": "2-oxaisodauc-5-en-12-al", "tok_span": [39, 53], "new_tok_span": [43, 57]}, {"ent_type": "GENE", "char_span": [173, 178], "name": "NF-κB", "tok_span": [59, 63], "new_tok_span": [65, 69]}, {"ent_type": "GENE", "char_span": [180, 183], "name": "p65", "tok_span": [64, 66], "new_tok_span": [70, 72]}], "relation_list": [{"subject": "perviridicin B", "sbj_char_span": [30, 44], "object": "NF-κB", "obj_char_span": [173, 178], "rel_type": "inhibitor", "sbj_tok_span": [6, 11], "obj_tok_span": [59, 63], "new_sbj_tok_span": [6, 11], "new_obj_tok_span": [65, 69]}, {"subject": "perviridicin B", "sbj_char_span": [30, 44], "object": "p65", "obj_char_span": [180, 183], "rel_type": "inhibitor", "sbj_tok_span": [6, 11], "obj_tok_span": [64, 66], "new_sbj_tok_span": [6, 11], "new_obj_tok_span": [70, 72]}, {"subject": "rocaglate", "sbj_char_span": [62, 71], "object": "NF-κB", "obj_char_span": [173, 178], "rel_type": "inhibitor", "sbj_tok_span": [17, 21], "obj_tok_span": [59, 63], "new_sbj_tok_span": [17, 21], "new_obj_tok_span": [65, 69]}, {"subject": "rocaglate", "sbj_char_span": [62, 71], "object": "p65", "obj_char_span": [180, 183], "rel_type": "inhibitor", "sbj_tok_span": [17, 21], "obj_tok_span": [64, 66], "new_sbj_tok_span": [17, 21], "new_obj_tok_span": [70, 72]}, {"subject": "sesquiterpene", "sbj_char_span": [109, 122], "object": "NF-κB", "obj_char_span": [173, 178], "rel_type": "inhibitor", "sbj_tok_span": [33, 38], "obj_tok_span": [59, 63], "new_sbj_tok_span": [34, 39], "new_obj_tok_span": [65, 69]}, {"subject": "sesquiterpene", "sbj_char_span": [109, 122], "object": "p65", "obj_char_span": [180, 183], "rel_type": "inhibitor", "sbj_tok_span": [33, 38], "obj_tok_span": [64, 66], "new_sbj_tok_span": [34, 39], "new_obj_tok_span": [70, 72]}, {"subject": "2-oxaisodauc-5-en-12-al", "sbj_char_span": [124, 147], "object": "NF-κB", "obj_char_span": [173, 178], "rel_type": "inhibitor", "sbj_tok_span": [39, 53], "obj_tok_span": [59, 63], "new_sbj_tok_span": [43, 57], "new_obj_tok_span": [65, 69]}, {"subject": "2-oxaisodauc-5-en-12-al", "sbj_char_span": [124, 147], "object": "p65", "obj_char_span": [180, 183], "rel_type": "inhibitor", "sbj_tok_span": [39, 53], "obj_tok_span": [64, 66], "new_sbj_tok_span": [43, 57], "new_obj_tok_span": [70, 72]}], "umls_entity_list": [{"mention": "sesquiterpene", "char_span": [109, 122], "sem_type": "Organic Chemical", "tok_span": [33, 38], "new_tok_span": [34, 39]}, {"mention": "en", "char_span": [119, 121], "sem_type": "Gene or Genome", "tok_span": [36, 37], "new_tok_span": [38, 39]}, {"mention": "en", "char_span": [139, 141], "sem_type": "Gene or Genome", "tok_span": [48, 49], "new_tok_span": [53, 54]}], "new_text": "In addition, the new compound perviridicin B ( 2 ), three known rocaglate derivatives ( 9, 11, 12 ), and a known <START=Organic Chemical> sesquiter <START=Gene or Genome>pen <END=Gene or Genome>e <END=Organic Chemical>, 2 - oxaisodauc - 5 - <START=Gene or Genome> en <END=Gene or Genome> - 12 - al ( 17 ), showed significant NF - κB ( p65 ) inhibitory activity in an ELISA assay."}, {"PMID": 15322419, "id": 4, "text": "The single-nucleotide polymorphic allele of norepinephrine transporter gene G1287A was used as the genetic marker, and the genotypes were identified by restriction fragment length polymorphism analysis.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [11, 21], "name": "nucleotide", "tok_span": [3, 4], "new_tok_span": [3, 4]}, {"ent_type": "CHEMICAL", "char_span": [44, 58], "name": "norepinephrine", "tok_span": [7, 8], "new_tok_span": [11, 12]}, {"ent_type": "GENE", "char_span": [44, 70], "name": "norepinephrine transporter", "tok_span": [7, 9], "new_tok_span": [11, 13]}, {"ent_type": "GENE", "char_span": [76, 82], "name": "G1287A", "tok_span": [10, 14], "new_tok_span": [18, 22]}], "relation_list": [{"subject": "nucleotide", "sbj_char_span": [11, 21], "object": "norepinephrine transporter", "obj_char_span": [44, 70], "rel_type": "part of", "sbj_tok_span": [3, 4], "obj_tok_span": [7, 9], "new_sbj_tok_span": [3, 4], "new_obj_tok_span": [11, 13]}, {"subject": "nucleotide", "sbj_char_span": [11, 21], "object": "G1287A", "obj_char_span": [76, 82], "rel_type": "part of", "sbj_tok_span": [3, 4], "obj_tok_span": [10, 14], "new_sbj_tok_span": [3, 4], "new_obj_tok_span": [18, 22]}], "umls_entity_list": [{"mention": "allele", "char_span": [34, 40], "sem_type": "Gene or Genome", "tok_span": [5, 6], "new_tok_span": [6, 7]}, {"mention": "gene", "char_span": [71, 75], "sem_type": "Gene or Genome", "tok_span": [9, 10], "new_tok_span": [16, 17]}, {"mention": "gene", "char_span": [99, 103], "sem_type": "Gene or Genome", "tok_span": [18, 19], "new_tok_span": [27, 28]}, {"mention": "norepinephrine transporter", "char_span": [44, 70], "sem_type": "Gene or Genome", "tok_span": [7, 9], "new_tok_span": [11, 13]}, {"mention": "norepinephrine transporter", "char_span": [44, 70], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [7, 9], "new_tok_span": [11, 13]}], "new_text": "The single - nucleotide polymorphic <START=Gene or Genome> allele <END=Gene or Genome> of <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> norepinephrine transporter <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> <START=Gene or Genome> gene <END=Gene or Genome> G1287A was used as the <START=Gene or Genome> genetic <END=Gene or Genome> marker, and the genotypes were identified by restriction fragment length polymorphism analysis."}, {"PMID": 3828735, "id": 7, "text": "The activation may be accelerated by an acute inflammatory process provoked by oleate, which is supported by such clinical manifestations as mild fever, retrosternal pain leukocytosis and an increase in plasma fibrinogen level which was observed in all during the period.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [79, 85], "name": "oleate", "tok_span": [13, 15], "new_tok_span": [15, 17]}, {"ent_type": "GENE", "char_span": [210, 220], "name": "fibrinogen", "tok_span": [37, 38], "new_tok_span": [41, 42]}], "relation_list": [{"subject": "oleate", "sbj_char_span": [79, 85], "object": "fibrinogen", "obj_char_span": [210, 220], "rel_type": "regulator", "sbj_tok_span": [13, 15], "obj_tok_span": [37, 38], "new_sbj_tok_span": [15, 17], "new_obj_tok_span": [41, 42]}], "umls_entity_list": [{"mention": "oleate", "char_span": [79, 85], "sem_type": "Organic Chemical", "tok_span": [13, 15], "new_tok_span": [15, 17]}, {"mention": "oleate", "char_span": [79, 85], "sem_type": "Pharmacologic Substance", "tok_span": [13, 15], "new_tok_span": [15, 17]}], "new_text": "The activation may be accelerated by an acute inflammatory process provoked by <START=Organic Chemical> <START=Pharmacologic Substance> oleate <END=Organic Chemical> <END=Pharmacologic Substance>, which is supported by such clinical manifestations as mild fever, retrosternal pain leukocytosis and an increase in plasma fibrinogen level which was observed in all during the period."}, {"PMID": 8301142, "id": 9, "text": "RA inhibition of IL-6 protein production was associated with a comparable decrease in IL-6 mRNA accumulation and gene transcription. 13-cis-retinoic acid, retinol, retinaldehyde, all-trans etretin, Ro 13-6298, and 9-cis retinoic acid also inhibited IL-1-induced IL-6 production.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 2], "name": "RA", "tok_span": [0, 1], "new_tok_span": [0, 1]}, {"ent_type": "CHEMICAL", "char_span": [133, 153], "name": "13-cis-retinoic acid", "tok_span": [24, 31], "new_tok_span": [28, 35]}, {"ent_type": "CHEMICAL", "char_span": [155, 162], "name": "retinol", "tok_span": [32, 34], "new_tok_span": [37, 39]}, {"ent_type": "CHEMICAL", "char_span": [164, 177], "name": "retinaldehyde", "tok_span": [35, 37], "new_tok_span": [42, 44]}, {"ent_type": "CHEMICAL", "char_span": [179, 196], "name": "all-trans etretin", "tok_span": [38, 44], "new_tok_span": [46, 52]}, {"ent_type": "CHEMICAL", "char_span": [198, 208], "name": "Ro 13-6298", "tok_span": [45, 50], "new_tok_span": [56, 61]}, {"ent_type": "CHEMICAL", "char_span": [214, 233], "name": "9-cis retinoic acid", "tok_span": [52, 58], "new_tok_span": [64, 70]}, {"ent_type": "GENE", "char_span": [17, 21], "name": "IL-6", "tok_span": [3, 6], "new_tok_span": [3, 6]}, {"ent_type": "GENE", "char_span": [86, 90], "name": "IL-6", "tok_span": [15, 18], "new_tok_span": [19, 22]}, {"ent_type": "GENE", "char_span": [249, 253], "name": "IL-1", "tok_span": [60, 63], "new_tok_span": [72, 75]}, {"ent_type": "GENE", "char_span": [262, 266], "name": "IL-6", "tok_span": [65, 68], "new_tok_span": [77, 80]}], "relation_list": [{"subject": "RA", "sbj_char_span": [0, 2], "object": "IL-6", "obj_char_span": [17, 21], "rel_type": "regulator", "sbj_tok_span": [0, 1], "obj_tok_span": [3, 6], "new_sbj_tok_span": [0, 1], "new_obj_tok_span": [3, 6]}, {"subject": "RA", "sbj_char_span": [0, 2], "object": "IL-6", "obj_char_span": [86, 90], "rel_type": "regulator", "sbj_tok_span": [0, 1], "obj_tok_span": [15, 18], "new_sbj_tok_span": [0, 1], "new_obj_tok_span": [19, 22]}, {"subject": "13-cis-retinoic acid", "sbj_char_span": [133, 153], "object": "IL-6", "obj_char_span": [262, 266], "rel_type": "regulator", "sbj_tok_span": [24, 31], "obj_tok_span": [65, 68], "new_sbj_tok_span": [28, 35], "new_obj_tok_span": [77, 80]}, {"subject": "retinol", "sbj_char_span": [155, 162], "object": "IL-6", "obj_char_span": [262, 266], "rel_type": "regulator", "sbj_tok_span": [32, 34], "obj_tok_span": [65, 68], "new_sbj_tok_span": [37, 39], "new_obj_tok_span": [77, 80]}, {"subject": "retinaldehyde", "sbj_char_span": [164, 177], "object": "IL-6", "obj_char_span": [262, 266], "rel_type": "regulator", "sbj_tok_span": [35, 37], "obj_tok_span": [65, 68], "new_sbj_tok_span": [42, 44], "new_obj_tok_span": [77, 80]}, {"subject": "all-trans etretin", "sbj_char_span": [179, 196], "object": "IL-6", "obj_char_span": [262, 266], "rel_type": "regulator", "sbj_tok_span": [38, 44], "obj_tok_span": [65, 68], "new_sbj_tok_span": [46, 52], "new_obj_tok_span": [77, 80]}, {"subject": "Ro 13-6298", "sbj_char_span": [198, 208], "object": "IL-6", "obj_char_span": [262, 266], "rel_type": "regulator", "sbj_tok_span": [45, 50], "obj_tok_span": [65, 68], "new_sbj_tok_span": [56, 61], "new_obj_tok_span": [77, 80]}, {"subject": "9-cis retinoic acid", "sbj_char_span": [214, 233], "object": "IL-6", "obj_char_span": [262, 266], "rel_type": "regulator", "sbj_tok_span": [52, 58], "obj_tok_span": [65, 68], "new_sbj_tok_span": [64, 70], "new_obj_tok_span": [77, 80]}], "umls_entity_list": [{"mention": "retinol", "char_span": [155, 162], "sem_type": "Pharmacologic Substance", "tok_span": [32, 34], "new_tok_span": [37, 39]}, {"mention": "retinaldehyde", "char_span": [164, 177], "sem_type": "Pharmacologic Substance", "tok_span": [35, 37], "new_tok_span": [42, 44]}, {"mention": "etretin", "char_span": [189, 196], "sem_type": "Pharmacologic Substance", "tok_span": [41, 44], "new_tok_span": [50, 53]}, {"mention": "ro", "char_span": [23, 25], "sem_type": "Pharmacologic Substance", "tok_span": [6, 7], "new_tok_span": [7, 8]}, {"mention": "ro", "char_span": [31, 33], "sem_type": "Pharmacologic Substance", "tok_span": [7, 8], "new_tok_span": [10, 11]}, {"mention": "Ro", "char_span": [198, 200], "sem_type": "Pharmacologic Substance", "tok_span": [45, 46], "new_tok_span": [56, 57]}, {"mention": "ro", "char_span": [268, 270], "sem_type": "Pharmacologic Substance", "tok_span": [68, 69], "new_tok_span": [81, 82]}], "new_text": "RA inhibition of IL - 6 <START=Pharmacologic Substance> protein <END=Pharmacologic Substance> <START=Pharmacologic Substance> production <END=Pharmacologic Substance> was associated with a comparable decrease in IL - 6 mRNA accumulation and gene transcription. 13 - cis - retinoic acid, <START=Pharmacologic Substance> retinol <END=Pharmacologic Substance>, <START=Pharmacologic Substance> retinaldehyde <END=Pharmacologic Substance>, all - trans <START=Pharmacologic Substance> etretin <END=Pharmacologic Substance>, <START=Pharmacologic Substance> Ro <END=Pharmacologic Substance> 13 - 6298, and 9 - cis retinoic acid also inhibited IL - 1 - induced IL - 6 <START=Pharmacologic Substance> production <END=Pharmacologic Substance>."}, {"PMID": 23349483, "id": 1, "text": "We previously demonstrated that impaired glucose-induced insulin secretion (IS) and ATP elevation in islets of Goto-Kakizaki (GK) rats, a non-obese model of diabetes, were significantly restored by 30∼60 min suppression of endogenous reactive oxygen species (ROS) overproduction.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [243, 249], "name": "oxygen", "tok_span": [51, 52], "new_tok_span": [51, 52]}, {"ent_type": "CHEMICAL", "char_span": [41, 48], "name": "glucose", "tok_span": [5, 6], "new_tok_span": [5, 6]}, {"ent_type": "CHEMICAL", "char_span": [84, 87], "name": "ATP", "tok_span": [14, 15], "new_tok_span": [14, 15]}, {"ent_type": "GENE", "char_span": [57, 64], "name": "insulin", "tok_span": [8, 9], "new_tok_span": [8, 9]}], "relation_list": [{"subject": "glucose", "sbj_char_span": [41, 48], "object": "insulin", "obj_char_span": [57, 64], "rel_type": "regulator", "sbj_tok_span": [5, 6], "obj_tok_span": [8, 9], "new_sbj_tok_span": [5, 6], "new_obj_tok_span": [8, 9]}], "umls_entity_list": [], "new_text": "We previously demonstrated that impaired glucose - induced insulin secretion ( IS ) and ATP elevation in islets of Goto - Kakizaki ( GK ) rats, a non - obese model of diabetes, were significantly restored by 30∼60 min suppression of endogenous reactive oxygen species ( ROS ) overproduction."}, {"PMID": 17202804, "id": 10, "text": "In contrast to testosterone, GnRH-induced nuclear translocation did not transcriptionally activate the androgen receptor.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [15, 27], "name": "testosterone", "tok_span": [3, 4], "new_tok_span": [4, 5]}, {"ent_type": "CHEMICAL", "char_span": [29, 33], "name": "GnRH", "tok_span": [5, 6], "new_tok_span": [7, 8]}, {"ent_type": "GENE", "char_span": [29, 33], "name": "GnRH", "tok_span": [5, 6], "new_tok_span": [7, 8]}, {"ent_type": "GENE", "char_span": [103, 120], "name": "androgen receptor", "tok_span": [16, 18], "new_tok_span": [18, 20]}], "relation_list": [{"subject": "testosterone", "sbj_char_span": [15, 27], "object": "androgen receptor", "obj_char_span": [103, 120], "rel_type": "activator", "sbj_tok_span": [3, 4], "obj_tok_span": [16, 18], "new_sbj_tok_span": [4, 5], "new_obj_tok_span": [18, 20]}], "umls_entity_list": [{"mention": "testosterone", "char_span": [15, 27], "sem_type": "Pharmacologic Substance", "tok_span": [3, 4], "new_tok_span": [4, 5]}], "new_text": "In contrast to <START=Pharmacologic Substance> testosterone <END=Pharmacologic Substance>, GnRH - induced nuclear translocation did not transcriptionally activate the androgen receptor."}, {"PMID": 23380305, "id": 7, "text": "Systemic as well as intra-TMN administration of ABT-239 increased c-Fos expression in the NBM, and cortex, but not in the striatum or NAcc.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [48, 55], "name": "ABT-239", "tok_span": [11, 15], "new_tok_span": [12, 16]}, {"ent_type": "GENE", "char_span": [66, 71], "name": "c-Fos", "tok_span": [16, 20], "new_tok_span": [18, 22]}], "relation_list": [{"subject": "ABT-239", "sbj_char_span": [48, 55], "object": "c-Fos", "obj_char_span": [66, 71], "rel_type": "regulator", "sbj_tok_span": [11, 15], "obj_tok_span": [16, 20], "new_sbj_tok_span": [12, 16], "new_obj_tok_span": [18, 22]}], "umls_entity_list": [{"mention": "ABT", "char_span": [48, 51], "sem_type": "Organic Chemical", "tok_span": [11, 13], "new_tok_span": [12, 14]}], "new_text": "Systemic as well as intra - TMN administration of <START=Organic Chemical> ABT <END=Organic Chemical> - 239 increased c - Fos expression in the NBM, and cortex, but not in the striatum or NAcc."}, {"PMID": 2270485, "id": 0, "text": "Zinc mediation of the binding of human growth hormone to the human prolactin receptor.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 4], "name": "Zinc", "tok_span": [0, 2], "new_tok_span": [0, 2]}, {"ent_type": "GENE", "char_span": [33, 53], "name": "human growth hormone", "tok_span": [7, 10], "new_tok_span": [7, 10]}, {"ent_type": "GENE", "char_span": [61, 85], "name": "human prolactin receptor", "tok_span": [12, 16], "new_tok_span": [12, 16]}], "relation_list": [{"subject": "Zinc", "sbj_char_span": [0, 4], "object": "human growth hormone", "obj_char_span": [33, 53], "rel_type": "regulator", "sbj_tok_span": [0, 2], "obj_tok_span": [7, 10], "new_sbj_tok_span": [0, 2], "new_obj_tok_span": [7, 10]}, {"subject": "Zinc", "sbj_char_span": [0, 4], "object": "human prolactin receptor", "obj_char_span": [61, 85], "rel_type": "regulator", "sbj_tok_span": [0, 2], "obj_tok_span": [12, 16], "new_sbj_tok_span": [0, 2], "new_obj_tok_span": [12, 16]}], "umls_entity_list": [{"mention": "prolactin", "char_span": [67, 76], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [13, 15], "new_tok_span": [14, 16]}], "new_text": "Zinc mediation of the binding of human growth hormone to the human <START=Amino Acid, Peptide, or Protein> prolactin <END=Amino Acid, Peptide, or Protein> receptor."}, {"PMID": 17097861, "id": 5, "text": "When the PTB-binding site in insulin 1 mRNA was incubated with the islet cytosolic fraction, the RNA-protein complex level was increased in the cytosolic fraction obtained from GalN-treated rats compared to the level in control rats.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [177, 181], "name": "GalN", "tok_span": [33, 35], "new_tok_span": [33, 35]}, {"ent_type": "GENE", "char_span": [9, 25], "name": "PTB-binding site", "tok_span": [2, 7], "new_tok_span": [2, 7]}, {"ent_type": "GENE", "char_span": [29, 38], "name": "insulin 1", "tok_span": [8, 10], "new_tok_span": [8, 10]}], "relation_list": [{"subject": "GalN", "sbj_char_span": [177, 181], "object": "PTB-binding site", "obj_char_span": [9, 25], "rel_type": "regulator", "sbj_tok_span": [33, 35], "obj_tok_span": [2, 7], "new_sbj_tok_span": [33, 35], "new_obj_tok_span": [2, 7]}, {"subject": "GalN", "sbj_char_span": [177, 181], "object": "insulin 1", "obj_char_span": [29, 38], "rel_type": "regulator", "sbj_tok_span": [33, 35], "obj_tok_span": [8, 10], "new_sbj_tok_span": [33, 35], "new_obj_tok_span": [8, 10]}], "umls_entity_list": [], "new_text": "When the PTB - binding site in insulin 1 mRNA was incubated with the islet cytosolic fraction, the RNA - protein complex level was increased in the cytosolic fraction obtained from GalN - treated rats compared to the level in control rats."}, {"PMID": 12652111, "id": 1, "text": "We investigated the basis for the difference in the cardiotonic effects of the PDE3 inhibitors cilostazol and milrinone in the rabbit heart.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [110, 119], "name": "milrinone", "tok_span": [22, 25], "new_tok_span": [29, 32]}, {"ent_type": "CHEMICAL", "char_span": [95, 105], "name": "cilostazol", "tok_span": [17, 21], "new_tok_span": [22, 26]}, {"ent_type": "GENE", "char_span": [79, 83], "name": "PDE3", "tok_span": [14, 16], "new_tok_span": [17, 19]}], "relation_list": [{"subject": "cilostazol", "sbj_char_span": [95, 105], "object": "PDE3", "obj_char_span": [79, 83], "rel_type": "inhibitor", "sbj_tok_span": [17, 21], "obj_tok_span": [14, 16], "new_sbj_tok_span": [22, 26], "new_obj_tok_span": [17, 19]}, {"subject": "milrinone", "sbj_char_span": [110, 119], "object": "PDE3", "obj_char_span": [79, 83], "rel_type": "inhibitor", "sbj_tok_span": [22, 25], "obj_tok_span": [14, 16], "new_sbj_tok_span": [29, 32], "new_obj_tok_span": [17, 19]}], "umls_entity_list": [{"mention": "cardiotonic", "char_span": [52, 63], "sem_type": "Pharmacologic Substance", "tok_span": [9, 11], "new_tok_span": [10, 12]}, {"mention": "PDE3 inhibitors", "char_span": [79, 94], "sem_type": "Pharmacologic Substance", "tok_span": [14, 17], "new_tok_span": [17, 20]}, {"mention": "cilostazol", "char_span": [95, 105], "sem_type": "Pharmacologic Substance", "tok_span": [17, 21], "new_tok_span": [22, 26]}, {"mention": "milrinone", "char_span": [110, 119], "sem_type": "Pharmacologic Substance", "tok_span": [22, 25], "new_tok_span": [29, 32]}], "new_text": "We investigated the basis for the difference in the <START=Pharmacologic Substance> cardiotonic <END=Pharmacologic Substance> effects of the <START=Pharmacologic Substance> PDE3 inhibitors <END=Pharmacologic Substance> <START=Pharmacologic Substance> cilostazol <END=Pharmacologic Substance> and <START=Pharmacologic Substance> milrinone <END=Pharmacologic Substance> in the rabbit heart."}, {"PMID": 12652111, "id": 10, "text": "Our results suggest that in normal rabbit heart inhibition of PDE4 by milrinone may partly contribute to the greater cardiotonic effect of milrinone when compared to cilostazol.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [70, 79], "name": "milrinone", "tok_span": [13, 16], "new_tok_span": [16, 19]}, {"ent_type": "CHEMICAL", "char_span": [139, 148], "name": "milrinone", "tok_span": [26, 29], "new_tok_span": [33, 36]}, {"ent_type": "CHEMICAL", "char_span": [166, 176], "name": "cilostazol", "tok_span": [32, 36], "new_tok_span": [40, 44]}, {"ent_type": "GENE", "char_span": [62, 66], "name": "PDE4", "tok_span": [10, 12], "new_tok_span": [11, 13]}], "relation_list": [{"subject": "milrinone", "sbj_char_span": [70, 79], "object": "PDE4", "obj_char_span": [62, 66], "rel_type": "inhibitor", "sbj_tok_span": [13, 16], "obj_tok_span": [10, 12], "new_sbj_tok_span": [16, 19], "new_obj_tok_span": [11, 13]}], "umls_entity_list": [{"mention": "PDE4", "char_span": [62, 66], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [10, 12], "new_tok_span": [11, 13]}, {"mention": "cardiotonic", "char_span": [117, 128], "sem_type": "Pharmacologic Substance", "tok_span": [22, 24], "new_tok_span": [27, 29]}, {"mention": "milrinone", "char_span": [70, 79], "sem_type": "Pharmacologic Substance", "tok_span": [13, 16], "new_tok_span": [16, 19]}, {"mention": "milrinone", "char_span": [139, 148], "sem_type": "Pharmacologic Substance", "tok_span": [26, 29], "new_tok_span": [33, 36]}], "new_text": "Our results suggest that in normal rabbit heart inhibition of <START=Amino Acid, Peptide, or Protein> PDE4 <END=Amino Acid, Peptide, or Protein> by <START=Pharmacologic Substance> milrinone <END=Pharmacologic Substance> may partly contribute to the greater <START=Pharmacologic Substance> cardiotonic <END=Pharmacologic Substance> effect of <START=Pharmacologic Substance> milrinone <END=Pharmacologic Substance> when compared to cilostazol."}, {"PMID": 15148258, "id": 3, "text": "Amsacrine caused a negative shift in the voltage dependence of both activation (-7.6 mV) and inactivation (-7.6 mV). HERG current block by amsacrine was not frequency dependent. 5 The S6 domain mutations Y652A and F656A attenuated (Y652A) or abolished (F656A, Y652A/F656A) HERG current blockade, indicating that amsacrine binding requires a common drug receptor within the pore-S6 region. 6 In conclusion, these data demonstrate that the anticancer drug amsacrine is an antagonist of cloned HERG potassium channels, providing a molecular mechanism for the previously reported QTc interval prolongation during clinical administration of amsacrine.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 9], "name": "Amsacrine", "tok_span": [0, 2], "new_tok_span": [1, 3]}, {"ent_type": "CHEMICAL", "char_span": [139, 148], "name": "amsacrine", "tok_span": [35, 39], "new_tok_span": [46, 50]}, {"ent_type": "CHEMICAL", "char_span": [312, 321], "name": "amsacrine", "tok_span": [91, 95], "new_tok_span": [106, 110]}, {"ent_type": "CHEMICAL", "char_span": [454, 463], "name": "amsacrine", "tok_span": [120, 124], "new_tok_span": [141, 145]}, {"ent_type": "CHEMICAL", "char_span": [496, 505], "name": "potassium", "tok_span": [131, 132], "new_tok_span": [154, 155]}, {"ent_type": "CHEMICAL", "char_span": [636, 645], "name": "amsacrine", "tok_span": [151, 155], "new_tok_span": [176, 180]}, {"ent_type": "GENE", "char_span": [117, 121], "name": "HERG", "tok_span": [30, 32], "new_tok_span": [40, 42]}, {"ent_type": "GENE", "char_span": [184, 193], "name": "S6 domain", "tok_span": [46, 49], "new_tok_span": [59, 62]}, {"ent_type": "GENE", "char_span": [204, 209], "name": "Y652A", "tok_span": [50, 54], "new_tok_span": [64, 68]}, {"ent_type": "GENE", "char_span": [214, 219], "name": "F656A", "tok_span": [55, 59], "new_tok_span": [69, 73]}, {"ent_type": "GENE", "char_span": [232, 237], "name": "Y652A", "tok_span": [61, 65], "new_tok_span": [75, 79]}, {"ent_type": "GENE", "char_span": [253, 258], "name": "F656A", "tok_span": [69, 73], "new_tok_span": [83, 87]}, {"ent_type": "GENE", "char_span": [260, 265], "name": "Y652A", "tok_span": [74, 78], "new_tok_span": [88, 92]}, {"ent_type": "GENE", "char_span": [266, 271], "name": "F656A", "tok_span": [79, 83], "new_tok_span": [93, 97]}, {"ent_type": "GENE", "char_span": [273, 277], "name": "HERG", "tok_span": [84, 86], "new_tok_span": [98, 100]}, {"ent_type": "GENE", "char_span": [378, 380], "name": "S6", "tok_span": [105, 107], "new_tok_span": [124, 126]}, {"ent_type": "GENE", "char_span": [491, 514], "name": "HERG potassium channels", "tok_span": [129, 133], "new_tok_span": [151, 155]}], "relation_list": [{"subject": "amsacrine", "sbj_char_span": [139, 148], "object": "HERG", "obj_char_span": [117, 121], "rel_type": "inhibitor", "sbj_tok_span": [35, 39], "obj_tok_span": [30, 32], "new_sbj_tok_span": [46, 50], "new_obj_tok_span": [40, 42]}, {"subject": "amsacrine", "sbj_char_span": [454, 463], "object": "HERG potassium channels", "obj_char_span": [491, 514], "rel_type": "agonist or antagonist", "sbj_tok_span": [120, 124], "obj_tok_span": [129, 133], "new_sbj_tok_span": [141, 145], "new_obj_tok_span": [151, 155]}, {"subject": "amsacrine", "sbj_char_span": [312, 321], "object": "S6", "obj_char_span": [378, 380], "rel_type": "regulator", "sbj_tok_span": [91, 95], "obj_tok_span": [105, 107], "new_sbj_tok_span": [106, 110], "new_obj_tok_span": [124, 126]}], "umls_entity_list": [{"mention": "Amsacrine", "char_span": [0, 9], "sem_type": "Pharmacologic Substance", "tok_span": [0, 2], "new_tok_span": [1, 3]}, {"mention": "amsacrine", "char_span": [139, 148], "sem_type": "Pharmacologic Substance", "tok_span": [35, 39], "new_tok_span": [46, 50]}, {"mention": "amsacrine", "char_span": [312, 321], "sem_type": "Pharmacologic Substance", "tok_span": [91, 95], "new_tok_span": [106, 110]}, {"mention": "amsacrine", "char_span": [454, 463], "sem_type": "Pharmacologic Substance", "tok_span": [120, 124], "new_tok_span": [141, 145]}, {"mention": "amsacrine", "char_span": [636, 645], "sem_type": "Pharmacologic Substance", "tok_span": [151, 155], "new_tok_span": [176, 180]}, {"mention": "mV", "char_span": [85, 87], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [18, 19], "new_tok_span": [22, 23]}, {"mention": "mV", "char_span": [112, 114], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [27, 28], "new_tok_span": [35, 36]}, {"mention": "mV", "char_span": [85, 87], "sem_type": "Gene or Genome", "tok_span": [18, 19], "new_tok_span": [22, 23]}, {"mention": "mV", "char_span": [112, 114], "sem_type": "Gene or Genome", "tok_span": [27, 28], "new_tok_span": [35, 36]}, {"mention": "S6", "char_span": [184, 186], "sem_type": "Gene or Genome", "tok_span": [46, 48], "new_tok_span": [59, 61]}, {"mention": "S6", "char_span": [378, 380], "sem_type": "Gene or Genome", "tok_span": [105, 107], "new_tok_span": [124, 126]}, {"mention": "drug receptor", "char_span": [348, 361], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [99, 101], "new_tok_span": [116, 118]}, {"mention": "potassium channels", "char_span": [496, 514], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [131, 133], "new_tok_span": [154, 156]}], "new_text": "<START=Pharmacologic Substance> Amsacrine <END=Pharmacologic Substance> caused a negative shift in the voltage dependence of both activation ( - 7. 6 <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> mV <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> ) and inactivation ( - 7. 6 <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> mV <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> ). HERG current block by <START=Pharmacologic Substance> amsacrine <END=Pharmacologic Substance> was not frequency dependent. 5 The <START=Gene or Genome> S6 <END=Gene or Genome> domain mutations Y652A and F656A attenuated ( Y652A ) or abolished ( F656A, Y652A / F656A ) HERG current blockade, indicating that <START=Pharmacologic Substance> amsacrine <END=Pharmacologic Substance> binding requires a common <START=Amino Acid, Peptide, or Protein> drug receptor <END=Amino Acid, Peptide, or Protein> within the pore - <START=Gene or Genome> S6 <END=Gene or Genome> region. 6 In conclusion, these data demonstrate that the anticancer drug <START=Pharmacologic Substance> amsacrine <END=Pharmacologic Substance> is an antagonist of cloned HERG <START=Amino Acid, Peptide, or Protein> potassium channels <END=Amino Acid, Peptide, or Protein>, providing a molecular mechanism for the previously reported QTc interval prolongation during clinical administration of <START=Pharmacologic Substance> amsacrine <END=Pharmacologic Substance>."}, {"PMID": 12504781, "id": 2, "text": "The results indicate that the inhibition of [3H]candesartan binding by sanguinarine is independent of cell viability, since the alkaloid inhibited at a similar extent radioligand binding on both intact Chinese hamster ovary (CHO) cells transfected with the human angiotensin AT(1) receptor (hAT(1)) and their cell membranes (K(i)=0.14 and 1.10 microM, respectively).", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [44, 59], "name": "[3H]candesartan", "tok_span": [7, 14], "new_tok_span": [7, 14]}, {"ent_type": "CHEMICAL", "char_span": [71, 83], "name": "sanguinarine", "tok_span": [16, 20], "new_tok_span": [19, 23]}, {"ent_type": "CHEMICAL", "char_span": [263, 274], "name": "angiotensin", "tok_span": [54, 55], "new_tok_span": [62, 63]}, {"ent_type": "GENE", "char_span": [257, 289], "name": "human angiotensin AT(1) receptor", "tok_span": [53, 60], "new_tok_span": [61, 68]}, {"ent_type": "GENE", "char_span": [291, 297], "name": "hAT(1)", "tok_span": [61, 66], "new_tok_span": [69, 74]}], "relation_list": [{"subject": "[3H]candesartan", "sbj_char_span": [44, 59], "object": "human angiotensin AT(1) receptor", "obj_char_span": [257, 289], "rel_type": "regulator", "sbj_tok_span": [7, 14], "obj_tok_span": [53, 60], "new_sbj_tok_span": [7, 14], "new_obj_tok_span": [61, 68]}, {"subject": "[3H]candesartan", "sbj_char_span": [44, 59], "object": "hAT(1)", "obj_char_span": [291, 297], "rel_type": "regulator", "sbj_tok_span": [7, 14], "obj_tok_span": [61, 66], "new_sbj_tok_span": [7, 14], "new_obj_tok_span": [69, 74]}, {"subject": "sanguinarine", "sbj_char_span": [71, 83], "object": "human angiotensin AT(1) receptor", "obj_char_span": [257, 289], "rel_type": "inhibitor", "sbj_tok_span": [16, 20], "obj_tok_span": [53, 60], "new_sbj_tok_span": [19, 23], "new_obj_tok_span": [61, 68]}, {"subject": "sanguinarine", "sbj_char_span": [71, 83], "object": "hAT(1)", "obj_char_span": [291, 297], "rel_type": "inhibitor", "sbj_tok_span": [16, 20], "obj_tok_span": [61, 66], "new_sbj_tok_span": [19, 23], "new_obj_tok_span": [69, 74]}], "umls_entity_list": [{"mention": "candesartan", "char_span": [48, 59], "sem_type": "Pharmacologic Substance", "tok_span": [11, 14], "new_tok_span": [12, 15]}, {"mention": "sanguinarine", "char_span": [71, 83], "sem_type": "Pharmacologic Substance", "tok_span": [16, 20], "new_tok_span": [19, 23]}, {"mention": "alkaloid", "char_span": [128, 136], "sem_type": "Pharmacologic Substance", "tok_span": [28, 30], "new_tok_span": [34, 36]}, {"mention": "alkaloid", "char_span": [128, 136], "sem_type": "Organic Chemical", "tok_span": [28, 30], "new_tok_span": [34, 36]}], "new_text": "The results indicate that the inhibition of [ 3H ] <START=Pharmacologic Substance> candesartan <END=Pharmacologic Substance> binding by <START=Pharmacologic Substance> sanguinarine <END=Pharmacologic Substance> is independent of cell viability, since the <START=Pharmacologic Substance> <START=Organic Chemical> alkaloid <END=Pharmacologic Substance> <END=Organic Chemical> inhibited at a similar extent radioligand binding on both intact Chinese hamster ovary ( CHO ) cells transfected with the human angiotensin AT ( 1 ) receptor ( hAT ( 1 ) ) and their cell membranes ( K ( i ) = 0. 14 and 1. 10 microM, respectively )."}, {"PMID": 10411647, "id": 8, "text": "Infrared spectroscopic studies revealed a reduced thermal stability both of the apo-and the holo-hTH1 on binding of H4biopterin and Lerythro-dihydrobiopterin (H2biopterin).", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [116, 127], "name": "H4biopterin", "tok_span": [25, 31], "new_tok_span": [25, 31]}, {"ent_type": "CHEMICAL", "char_span": [132, 157], "name": "Lerythro-dihydrobiopterin", "tok_span": [32, 43], "new_tok_span": [32, 43]}, {"ent_type": "CHEMICAL", "char_span": [159, 170], "name": "H2biopterin", "tok_span": [44, 50], "new_tok_span": [44, 50]}, {"ent_type": "GENE", "char_span": [97, 101], "name": "hTH1", "tok_span": [19, 22], "new_tok_span": [19, 22]}], "relation_list": [{"subject": "H4biopterin", "sbj_char_span": [116, 127], "object": "hTH1", "obj_char_span": [97, 101], "rel_type": "regulator", "sbj_tok_span": [25, 31], "obj_tok_span": [19, 22], "new_sbj_tok_span": [25, 31], "new_obj_tok_span": [19, 22]}, {"subject": "Lerythro-dihydrobiopterin", "sbj_char_span": [132, 157], "object": "hTH1", "obj_char_span": [97, 101], "rel_type": "regulator", "sbj_tok_span": [32, 43], "obj_tok_span": [19, 22], "new_sbj_tok_span": [32, 43], "new_obj_tok_span": [19, 22]}, {"subject": "H2biopterin", "sbj_char_span": [159, 170], "object": "hTH1", "obj_char_span": [97, 101], "rel_type": "regulator", "sbj_tok_span": [44, 50], "obj_tok_span": [19, 22], "new_sbj_tok_span": [44, 50], "new_obj_tok_span": [19, 22]}], "umls_entity_list": [], "new_text": "Infrared spectroscopic studies revealed a reduced thermal stability both of the apo - and the holo - hTH1 on binding of H4biopterin and Lerythro - dihydrobiopterin ( H2biopterin )."}, {"PMID": 11716850, "id": 1, "text": "Mitiglinide (KAD-1229), a new anti-diabetic drug, is thought to stimulate insulin secretion by closing the ATP-sensitive K+ (K(ATP)) channels in pancreatic beta-cells.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 11], "name": "Mitiglinide", "tok_span": [0, 4], "new_tok_span": [0, 4]}, {"ent_type": "CHEMICAL", "char_span": [107, 110], "name": "ATP", "tok_span": [28, 29], "new_tok_span": [30, 31]}, {"ent_type": "CHEMICAL", "char_span": [121, 123], "name": "K+", "tok_span": [31, 33], "new_tok_span": [33, 35]}, {"ent_type": "CHEMICAL", "char_span": [125, 126], "name": "K", "tok_span": [34, 35], "new_tok_span": [36, 37]}, {"ent_type": "CHEMICAL", "char_span": [127, 130], "name": "ATP", "tok_span": [36, 37], "new_tok_span": [38, 39]}, {"ent_type": "CHEMICAL", "char_span": [13, 21], "name": "KAD-1229", "tok_span": [5, 10], "new_tok_span": [6, 11]}, {"ent_type": "GENE", "char_span": [107, 141], "name": "ATP-sensitive K+ (K(ATP)) channels", "tok_span": [28, 40], "new_tok_span": [30, 42]}, {"ent_type": "GENE", "char_span": [74, 81], "name": "insulin", "tok_span": [23, 24], "new_tok_span": [25, 26]}], "relation_list": [{"subject": "Mitiglinide", "sbj_char_span": [0, 11], "object": "insulin", "obj_char_span": [74, 81], "rel_type": "regulator", "sbj_tok_span": [0, 4], "obj_tok_span": [23, 24], "new_sbj_tok_span": [0, 4], "new_obj_tok_span": [25, 26]}, {"subject": "KAD-1229", "sbj_char_span": [13, 21], "object": "insulin", "obj_char_span": [74, 81], "rel_type": "regulator", "sbj_tok_span": [5, 10], "obj_tok_span": [23, 24], "new_sbj_tok_span": [6, 11], "new_obj_tok_span": [25, 26]}, {"subject": "Mitiglinide", "sbj_char_span": [0, 11], "object": "ATP-sensitive K+ (K(ATP)) channels", "obj_char_span": [107, 141], "rel_type": "inhibitor", "sbj_tok_span": [0, 4], "obj_tok_span": [28, 40], "new_sbj_tok_span": [0, 4], "new_obj_tok_span": [30, 42]}, {"subject": "KAD-1229", "sbj_char_span": [13, 21], "object": "ATP-sensitive K+ (K(ATP)) channels", "obj_char_span": [107, 141], "rel_type": "inhibitor", "sbj_tok_span": [5, 10], "obj_tok_span": [28, 40], "new_sbj_tok_span": [6, 11], "new_obj_tok_span": [30, 42]}], "umls_entity_list": [{"mention": "KAD", "char_span": [13, 16], "sem_type": "Pharmacologic Substance", "tok_span": [5, 7], "new_tok_span": [6, 8]}], "new_text": "Mitiglinide ( <START=Pharmacologic Substance> KAD <END=Pharmacologic Substance> - 1229 ), a new anti - diabetic drug, is thought to stimulate insulin secretion by closing the ATP - sensitive K + ( K ( ATP ) ) channels in pancreatic beta - cells."}, {"PMID": 7909690, "id": 5, "text": "The reaction, N-carbamyl-L-aspartate-->L-dihydroorotate (CA-asp-->DHO) catalyzed by malarial dihydroorotase is inhibited by L-6-thiodihydroorotate (TDHO) in vitro (Ki = 6.5 microM), and TDHO, as the free acid or methyl ester, induces a major accumulation of CA-asp in malaria.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [14, 36], "name": "N-carbamyl-L-aspartate", "tok_span": [3, 12], "new_tok_span": [3, 12]}, {"ent_type": "CHEMICAL", "char_span": [39, 55], "name": "L-dihydroorotate", "tok_span": [15, 22], "new_tok_span": [22, 29]}, {"ent_type": "CHEMICAL", "char_span": [57, 63], "name": "CA-asp", "tok_span": [23, 27], "new_tok_span": [31, 35]}, {"ent_type": "CHEMICAL", "char_span": [66, 69], "name": "DHO", "tok_span": [30, 32], "new_tok_span": [42, 44]}, {"ent_type": "CHEMICAL", "char_span": [124, 146], "name": "L-6-thiodihydroorotate", "tok_span": [44, 54], "new_tok_span": [58, 68]}, {"ent_type": "CHEMICAL", "char_span": [148, 152], "name": "TDHO", "tok_span": [55, 57], "new_tok_span": [69, 71]}, {"ent_type": "CHEMICAL", "char_span": [186, 190], "name": "TDHO", "tok_span": [71, 73], "new_tok_span": [85, 87]}, {"ent_type": "CHEMICAL", "char_span": [199, 208], "name": "free acid", "tok_span": [76, 78], "new_tok_span": [90, 92]}, {"ent_type": "CHEMICAL", "char_span": [212, 224], "name": "methyl ester", "tok_span": [79, 81], "new_tok_span": [93, 95]}, {"ent_type": "CHEMICAL", "char_span": [258, 264], "name": "CA-asp", "tok_span": [87, 91], "new_tok_span": [103, 107]}, {"ent_type": "GENE", "char_span": [84, 107], "name": "malarial dihydroorotase", "tok_span": [35, 41], "new_tok_span": [47, 53]}], "relation_list": [{"subject": "N-carbamyl-L-aspartate", "sbj_char_span": [14, 36], "object": "malarial dihydroorotase", "obj_char_span": [84, 107], "rel_type": "product or substrate", "sbj_tok_span": [3, 12], "obj_tok_span": [35, 41], "new_sbj_tok_span": [3, 12], "new_obj_tok_span": [47, 53]}, {"subject": "CA-asp", "sbj_char_span": [57, 63], "object": "malarial dihydroorotase", "obj_char_span": [84, 107], "rel_type": "product or substrate", "sbj_tok_span": [23, 27], "obj_tok_span": [35, 41], "new_sbj_tok_span": [31, 35], "new_obj_tok_span": [47, 53]}, {"subject": "L-dihydroorotate", "sbj_char_span": [39, 55], "object": "malarial dihydroorotase", "obj_char_span": [84, 107], "rel_type": "product or substrate", "sbj_tok_span": [15, 22], "obj_tok_span": [35, 41], "new_sbj_tok_span": [22, 29], "new_obj_tok_span": [47, 53]}, {"subject": "DHO", "sbj_char_span": [66, 69], "object": "malarial dihydroorotase", "obj_char_span": [84, 107], "rel_type": "product or substrate", "sbj_tok_span": [30, 32], "obj_tok_span": [35, 41], "new_sbj_tok_span": [42, 44], "new_obj_tok_span": [47, 53]}, {"subject": "L-6-thiodihydroorotate", "sbj_char_span": [124, 146], "object": "malarial dihydroorotase", "obj_char_span": [84, 107], "rel_type": "inhibitor", "sbj_tok_span": [44, 54], "obj_tok_span": [35, 41], "new_sbj_tok_span": [58, 68], "new_obj_tok_span": [47, 53]}, {"subject": "TDHO", "sbj_char_span": [148, 152], "object": "malarial dihydroorotase", "obj_char_span": [84, 107], "rel_type": "inhibitor", "sbj_tok_span": [55, 57], "obj_tok_span": [35, 41], "new_sbj_tok_span": [69, 71], "new_obj_tok_span": [47, 53]}, {"subject": "TDHO", "sbj_char_span": [186, 190], "object": "malarial dihydroorotase", "obj_char_span": [84, 107], "rel_type": "inhibitor", "sbj_tok_span": [71, 73], "obj_tok_span": [35, 41], "new_sbj_tok_span": [85, 87], "new_obj_tok_span": [47, 53]}], "umls_entity_list": [{"mention": "aspartate", "char_span": [27, 36], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [10, 12], "new_tok_span": [13, 15]}, {"mention": "L-dihydroorotate", "char_span": [39, 55], "sem_type": "Organic Chemical", "tok_span": [15, 22], "new_tok_span": [22, 29]}, {"mention": "dihydroorotase", "char_span": [93, 107], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [37, 41], "new_tok_span": [50, 54]}, {"mention": "ester", "char_span": [219, 224], "sem_type": "Organic Chemical", "tok_span": [80, 81], "new_tok_span": [95, 96]}, {"mention": "asp", "char_span": [27, 30], "sem_type": "Gene or Genome", "tok_span": [10, 11], "new_tok_span": [13, 14]}, {"mention": "asp", "char_span": [60, 63], "sem_type": "Gene or Genome", "tok_span": [25, 27], "new_tok_span": [35, 37]}, {"mention": "asp", "char_span": [261, 264], "sem_type": "Gene or Genome", "tok_span": [89, 91], "new_tok_span": [107, 109]}, {"mention": "asp", "char_span": [27, 30], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [10, 11], "new_tok_span": [13, 14]}, {"mention": "asp", "char_span": [60, 63], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [25, 27], "new_tok_span": [35, 37]}, {"mention": "asp", "char_span": [261, 264], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [89, 91], "new_tok_span": [107, 109]}], "new_text": "The reaction, N - carbamyl - L - <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> aspart <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein>ate <END=Amino Acid, Peptide, or Protein> - - > <START=Organic Chemical> L - dihydroorotate <END=Organic Chemical> ( CA - <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> asp <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> - - > DHO ) catalyzed by malarial <START=Amino Acid, Peptide, or Protein> dihydroorotase <END=Amino Acid, Peptide, or Protein> is inhibited by L - 6 - thiodihydroorotate ( TDHO ) in vitro ( Ki = 6. 5 microM ), and TDHO, as the free acid or methyl <START=Organic Chemical> ester <END=Organic Chemical>, induces a major accumulation of CA - <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> asp <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> in malaria."}, {"PMID": 23607712, "id": 8, "text": "Therefore, in addition to its previously described functions, synaptotagmin-1 is involved in a rapid vesicular Ca(2+) sequestration through a Ca(2+) /H(+) antiport.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [111, 117], "name": "Ca(2+)", "tok_span": [24, 29], "new_tok_span": [24, 29]}, {"ent_type": "CHEMICAL", "char_span": [142, 148], "name": "Ca(2+)", "tok_span": [33, 38], "new_tok_span": [33, 38]}, {"ent_type": "CHEMICAL", "char_span": [150, 154], "name": "H(+)", "tok_span": [39, 43], "new_tok_span": [39, 43]}, {"ent_type": "GENE", "char_span": [62, 77], "name": "synaptotagmin-1", "tok_span": [10, 17], "new_tok_span": [10, 17]}], "relation_list": [{"subject": "Ca(2+)", "sbj_char_span": [111, 117], "object": "synaptotagmin-1", "obj_char_span": [62, 77], "rel_type": "regulator", "sbj_tok_span": [24, 29], "obj_tok_span": [10, 17], "new_sbj_tok_span": [24, 29], "new_obj_tok_span": [10, 17]}, {"subject": "Ca(2+)", "sbj_char_span": [142, 148], "object": "synaptotagmin-1", "obj_char_span": [62, 77], "rel_type": "regulator", "sbj_tok_span": [33, 38], "obj_tok_span": [10, 17], "new_sbj_tok_span": [33, 38], "new_obj_tok_span": [10, 17]}, {"subject": "H(+)", "sbj_char_span": [150, 154], "object": "synaptotagmin-1", "obj_char_span": [62, 77], "rel_type": "regulator", "sbj_tok_span": [39, 43], "obj_tok_span": [10, 17], "new_sbj_tok_span": [39, 43], "new_obj_tok_span": [10, 17]}], "umls_entity_list": [], "new_text": "Therefore, in addition to its previously described functions, synaptotagmin - 1 is involved in a rapid vesicular Ca ( 2 + ) sequestration through a Ca ( 2 + ) / H ( + ) antiport."}, {"PMID": 14507899, "id": 0, "text": "P2Y(2) receptor agonist INS37217 enhances functional recovery after detachment caused by subretinal injection in normal and rds mice.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [24, 32], "name": "INS37217", "tok_span": [8, 12], "new_tok_span": [10, 14]}, {"ent_type": "GENE", "char_span": [0, 15], "name": "P2Y(2) receptor", "tok_span": [0, 7], "new_tok_span": [0, 7]}], "relation_list": [{"subject": "INS37217", "sbj_char_span": [24, 32], "object": "P2Y(2) receptor", "obj_char_span": [0, 15], "rel_type": "agonist or antagonist", "sbj_tok_span": [8, 12], "obj_tok_span": [0, 7], "new_sbj_tok_span": [10, 14], "new_obj_tok_span": [0, 7]}], "umls_entity_list": [{"mention": "receptor agonist", "char_span": [7, 23], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [6, 8], "new_tok_span": [7, 9]}], "new_text": "P2Y ( 2 ) <START=Amino Acid, Peptide, or Protein> receptor agonist <END=Amino Acid, Peptide, or Protein> INS37217 enhances functional recovery after detachment caused by subretinal injection in normal and rds mice."}, {"PMID": 23267011, "id": 4, "text": "During base excision repair of this mispair, DNA polymerase (pol) β is confronted with gap filling opposite 8-oxoG.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [108, 114], "name": "8-oxoG", "tok_span": [22, 27], "new_tok_span": [22, 27]}, {"ent_type": "GENE", "char_span": [45, 67], "name": "DNA polymerase (pol) β", "tok_span": [9, 15], "new_tok_span": [9, 15]}], "relation_list": [{"subject": "8-oxoG", "sbj_char_span": [108, 114], "object": "DNA polymerase (pol) β", "obj_char_span": [45, 67], "rel_type": "regulator", "sbj_tok_span": [22, 27], "obj_tok_span": [9, 15], "new_sbj_tok_span": [22, 27], "new_obj_tok_span": [9, 15]}], "umls_entity_list": [], "new_text": "During base excision repair of this mispair, DNA polymerase ( pol ) β is confronted with gap filling opposite 8 - oxoG."}, {"PMID": 17125913, "id": 2, "text": "Estradiol (E2) stimulates BC cells proliferation by binding the estrogen receptor (ER). Hormone-related cancers have been linked to estrogenic environmental contaminants.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 9], "name": "Estradiol", "tok_span": [0, 3], "new_tok_span": [0, 3]}, {"ent_type": "CHEMICAL", "char_span": [11, 13], "name": "E2", "tok_span": [4, 6], "new_tok_span": [4, 6]}, {"ent_type": "GENE", "char_span": [64, 81], "name": "estrogen receptor", "tok_span": [14, 16], "new_tok_span": [14, 16]}, {"ent_type": "GENE", "char_span": [83, 85], "name": "ER", "tok_span": [17, 18], "new_tok_span": [17, 18]}], "relation_list": [{"subject": "Estradiol", "sbj_char_span": [0, 9], "object": "estrogen receptor", "obj_char_span": [64, 81], "rel_type": "regulator", "sbj_tok_span": [0, 3], "obj_tok_span": [14, 16], "new_sbj_tok_span": [0, 3], "new_obj_tok_span": [14, 16]}, {"subject": "E2", "sbj_char_span": [11, 13], "object": "estrogen receptor", "obj_char_span": [64, 81], "rel_type": "regulator", "sbj_tok_span": [4, 6], "obj_tok_span": [14, 16], "new_sbj_tok_span": [4, 6], "new_obj_tok_span": [14, 16]}, {"subject": "Estradiol", "sbj_char_span": [0, 9], "object": "ER", "obj_char_span": [83, 85], "rel_type": "regulator", "sbj_tok_span": [0, 3], "obj_tok_span": [17, 18], "new_sbj_tok_span": [0, 3], "new_obj_tok_span": [17, 18]}, {"subject": "E2", "sbj_char_span": [11, 13], "object": "ER", "obj_char_span": [83, 85], "rel_type": "regulator", "sbj_tok_span": [4, 6], "obj_tok_span": [17, 18], "new_sbj_tok_span": [4, 6], "new_obj_tok_span": [17, 18]}], "umls_entity_list": [], "new_text": "Estradiol ( E2 ) stimulates BC cells proliferation by binding the estrogen receptor ( ER ). Hormone - related cancers have been linked to estrogenic environmental contaminants."}, {"PMID": 18708991, "id": 1, "text": "Risperidone is metabolized to its active metabolite, 9-hydroxyrisperidone, mainly by the cytochrome P450 enzymes CYP2D6 and 3A4. Its antipsychotic effect is assumed to be related to the active moiety, that is, the sum of risperidone and 9-hydroxyrisperidone.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 11], "name": "Risperidone", "tok_span": [0, 3], "new_tok_span": [1, 4]}, {"ent_type": "CHEMICAL", "char_span": [221, 232], "name": "risperidone", "tok_span": [54, 57], "new_tok_span": [59, 62]}, {"ent_type": "CHEMICAL", "char_span": [237, 257], "name": "9-hydroxyrisperidone", "tok_span": [58, 64], "new_tok_span": [64, 70]}, {"ent_type": "CHEMICAL", "char_span": [53, 73], "name": "9-hydroxyrisperidone", "tok_span": [11, 17], "new_tok_span": [13, 19]}, {"ent_type": "GENE", "char_span": [113, 127], "name": "CYP2D6 and 3A4", "tok_span": [25, 33], "new_tok_span": [29, 37]}, {"ent_type": "GENE", "char_span": [89, 104], "name": "cytochrome P450", "tok_span": [21, 24], "new_tok_span": [25, 28]}], "relation_list": [{"subject": "Risperidone", "sbj_char_span": [0, 11], "object": "cytochrome P450", "obj_char_span": [89, 104], "rel_type": "product or substrate", "sbj_tok_span": [0, 3], "obj_tok_span": [21, 24], "new_sbj_tok_span": [1, 4], "new_obj_tok_span": [25, 28]}, {"subject": "9-hydroxyrisperidone", "sbj_char_span": [53, 73], "object": "cytochrome P450", "obj_char_span": [89, 104], "rel_type": "product or substrate", "sbj_tok_span": [11, 17], "obj_tok_span": [21, 24], "new_sbj_tok_span": [13, 19], "new_obj_tok_span": [25, 28]}], "umls_entity_list": [{"mention": "Risperidone", "char_span": [0, 11], "sem_type": "Pharmacologic Substance", "tok_span": [0, 3], "new_tok_span": [1, 4]}, {"mention": "risperidone", "char_span": [62, 73], "sem_type": "Pharmacologic Substance", "tok_span": [14, 17], "new_tok_span": [17, 20]}, {"mention": "risperidone", "char_span": [221, 232], "sem_type": "Pharmacologic Substance", "tok_span": [54, 57], "new_tok_span": [59, 62]}, {"mention": "risperidone", "char_span": [246, 257], "sem_type": "Pharmacologic Substance", "tok_span": [61, 64], "new_tok_span": [68, 71]}], "new_text": "<START=Pharmacologic Substance> Risperidone <END=Pharmacologic Substance> is metabolized to its active metabolite, 9 - hydroxy <START=Pharmacologic Substance>risperidone <END=Pharmacologic Substance>, mainly by the cytochrome P450 enzymes CYP2D6 and 3A4. Its antipsychotic effect is assumed to be related to the active moiety, that is, the sum of <START=Pharmacologic Substance> risperidone <END=Pharmacologic Substance> and 9 - hydroxy <START=Pharmacologic Substance>risperidone <END=Pharmacologic Substance>."}, {"PMID": 23313663, "id": 5, "text": "Further, we also identified that MMR repression induced by 5 μM BaP was mediated through one of the MMR key proteins MSH6 as significant reduction in protein level was detected by western blot.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [64, 67], "name": "BaP", "tok_span": [14, 16], "new_tok_span": [18, 20]}, {"ent_type": "GENE", "char_span": [117, 121], "name": "MSH6", "tok_span": [26, 29], "new_tok_span": [36, 39]}], "relation_list": [{"subject": "BaP", "sbj_char_span": [64, 67], "object": "MSH6", "obj_char_span": [117, 121], "rel_type": "regulator", "sbj_tok_span": [14, 16], "obj_tok_span": [26, 29], "new_sbj_tok_span": [18, 20], "new_obj_tok_span": [36, 39]}], "umls_entity_list": [{"mention": "MMR", "char_span": [33, 36], "sem_type": "Gene or Genome", "tok_span": [6, 8], "new_tok_span": [7, 9]}, {"mention": "MMR", "char_span": [100, 103], "sem_type": "Gene or Genome", "tok_span": [22, 24], "new_tok_span": [29, 31]}, {"mention": "BaP", "char_span": [64, 67], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [14, 16], "new_tok_span": [18, 20]}, {"mention": "BaP", "char_span": [64, 67], "sem_type": "Gene or Genome", "tok_span": [14, 16], "new_tok_span": [18, 20]}, {"mention": "MSH6", "char_span": [117, 121], "sem_type": "Gene or Genome", "tok_span": [26, 29], "new_tok_span": [36, 39]}, {"mention": "MSH6", "char_span": [117, 121], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [26, 29], "new_tok_span": [36, 39]}], "new_text": "Further, we also identified that <START=Gene or Genome> MMR <END=Gene or Genome> repression induced by 5 μM <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> BaP <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> was mediated through one of the <START=Gene or Genome> MMR <END=Gene or Genome> key proteins <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> MSH6 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> as significant reduction in protein level was detected by western blot."}, {"PMID": 8882618, "id": 12, "text": "The interactions of GYKI 52466 and cyclothiazide on AMPA receptor-mediated e.p.s.cs in area CA1 of hippocampal slices provide evidence that the decay time constant of these synaptic events are not governed by desensitization.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [20, 30], "name": "GYKI 52466", "tok_span": [3, 9], "new_tok_span": [4, 10]}, {"ent_type": "CHEMICAL", "char_span": [35, 48], "name": "cyclothiazide", "tok_span": [10, 14], "new_tok_span": [13, 17]}, {"ent_type": "CHEMICAL", "char_span": [52, 56], "name": "AMPA", "tok_span": [15, 17], "new_tok_span": [21, 23]}, {"ent_type": "GENE", "char_span": [52, 65], "name": "AMPA receptor", "tok_span": [15, 18], "new_tok_span": [21, 24]}], "relation_list": [{"subject": "GYKI 52466", "sbj_char_span": [20, 30], "object": "AMPA receptor", "obj_char_span": [52, 65], "rel_type": "regulator", "sbj_tok_span": [3, 9], "obj_tok_span": [15, 18], "new_sbj_tok_span": [4, 10], "new_obj_tok_span": [21, 24]}, {"subject": "cyclothiazide", "sbj_char_span": [35, 48], "object": "AMPA receptor", "obj_char_span": [52, 65], "rel_type": "regulator", "sbj_tok_span": [10, 14], "obj_tok_span": [15, 18], "new_sbj_tok_span": [13, 17], "new_obj_tok_span": [21, 24]}], "umls_entity_list": [{"mention": "GYKI", "char_span": [20, 24], "sem_type": "Pharmacologic Substance", "tok_span": [3, 6], "new_tok_span": [4, 7]}, {"mention": "cyclothiazide", "char_span": [35, 48], "sem_type": "Pharmacologic Substance", "tok_span": [10, 14], "new_tok_span": [13, 17]}, {"mention": "AMPA receptor", "char_span": [52, 65], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [15, 18], "new_tok_span": [21, 24]}, {"mention": "P", "char_span": [54, 55], "sem_type": "Pharmacologic Substance", "tok_span": [15, 16], "new_tok_span": [21, 22]}, {"mention": "p", "char_span": [61, 62], "sem_type": "Pharmacologic Substance", "tok_span": [17, 18], "new_tok_span": [25, 26]}, {"mention": "p", "char_span": [77, 78], "sem_type": "Pharmacologic Substance", "tok_span": [22, 23], "new_tok_span": [33, 34]}, {"mention": "p", "char_span": [101, 102], "sem_type": "Pharmacologic Substance", "tok_span": [32, 33], "new_tok_span": [47, 48]}, {"mention": "p", "char_span": [102, 103], "sem_type": "Pharmacologic Substance", "tok_span": [32, 33], "new_tok_span": [47, 48]}, {"mention": "p", "char_span": [107, 108], "sem_type": "Pharmacologic Substance", "tok_span": [32, 33], "new_tok_span": [47, 48]}, {"mention": "p", "char_span": [118, 119], "sem_type": "Pharmacologic Substance", "tok_span": [34, 35], "new_tok_span": [53, 54]}, {"mention": "p", "char_span": [177, 178], "sem_type": "Pharmacologic Substance", "tok_span": [43, 44], "new_tok_span": [64, 65]}], "new_text": "The interactions of <START=Pharmacologic Substance> GYKI <END=Pharmacologic Substance> 52466 and <START=Pharmacologic Substance> cyclothiazide <END=Pharmacologic Substance> on <START=Amino Acid, Peptide, or Protein> <START=Pharmacologic Substance> AMP <END=Pharmacologic Substance>A <START=Pharmacologic Substance> receptor <END=Amino Acid, Peptide, or Protein> <END=Pharmacologic Substance> - mediated e. <START=Pharmacologic Substance> p <END=Pharmacologic Substance>. s. cs in area CA1 of <START=Pharmacologic Substance> <START=Pharmacologic Substance> <START=Pharmacologic Substance> hippocampal <END=Pharmacologic Substance> <END=Pharmacologic Substance> <END=Pharmacologic Substance> slices <START=Pharmacologic Substance> provide <END=Pharmacologic Substance> evidence that the decay time constant of these <START=Pharmacologic Substance> synaptic <END=Pharmacologic Substance> events are not governed by desensitization."}, {"PMID": 9336833, "id": 2, "text": "The structures of TK complexed with ADP at the ATP-site and deoxythymidine-5'-monophosphate (dTMP), deoxythymidine (dT), or idoxuridine-5'-phosphate (5-iodo-dUMP) at the substrate-site were refined to 2.75 A, 2.8 A, and 3.0 A resolution, respectively.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [36, 39], "name": "ADP", "tok_span": [7, 8], "new_tok_span": [7, 8]}, {"ent_type": "CHEMICAL", "char_span": [47, 50], "name": "ATP", "tok_span": [10, 11], "new_tok_span": [10, 11]}, {"ent_type": "CHEMICAL", "char_span": [60, 91], "name": "deoxythymidine-5'-monophosphate", "tok_span": [14, 27], "new_tok_span": [14, 27]}, {"ent_type": "CHEMICAL", "char_span": [93, 97], "name": "dTMP", "tok_span": [28, 30], "new_tok_span": [32, 34]}, {"ent_type": "CHEMICAL", "char_span": [100, 114], "name": "deoxythymidine", "tok_span": [32, 36], "new_tok_span": [36, 40]}, {"ent_type": "CHEMICAL", "char_span": [116, 118], "name": "dT", "tok_span": [37, 38], "new_tok_span": [41, 42]}, {"ent_type": "CHEMICAL", "char_span": [124, 148], "name": "idoxuridine-5'-phosphate", "tok_span": [41, 51], "new_tok_span": [46, 56]}, {"ent_type": "CHEMICAL", "char_span": [150, 161], "name": "5-iodo-dUMP", "tok_span": [52, 60], "new_tok_span": [63, 71]}, {"ent_type": "GENE", "char_span": [18, 20], "name": "TK", "tok_span": [3, 4], "new_tok_span": [3, 4]}], "relation_list": [{"subject": "ADP", "sbj_char_span": [36, 39], "object": "TK", "obj_char_span": [18, 20], "rel_type": "regulator", "sbj_tok_span": [7, 8], "obj_tok_span": [3, 4], "new_sbj_tok_span": [7, 8], "new_obj_tok_span": [3, 4]}], "umls_entity_list": [{"mention": "idoxuridine", "char_span": [124, 135], "sem_type": "Pharmacologic Substance", "tok_span": [41, 46], "new_tok_span": [46, 51]}, {"mention": "phosphate", "char_span": [82, 91], "sem_type": "Organic Chemical", "tok_span": [22, 27], "new_tok_span": [24, 29]}, {"mention": "phosphate", "char_span": [139, 148], "sem_type": "Organic Chemical", "tok_span": [50, 51], "new_tok_span": [58, 59]}, {"mention": "phosphate", "char_span": [82, 91], "sem_type": "Pharmacologic Substance", "tok_span": [22, 27], "new_tok_span": [24, 29]}, {"mention": "phosphate", "char_span": [139, 148], "sem_type": "Pharmacologic Substance", "tok_span": [50, 51], "new_tok_span": [58, 59]}, {"mention": "5-iodo-dUMP", "char_span": [150, 161], "sem_type": "Pharmacologic Substance", "tok_span": [52, 60], "new_tok_span": [63, 71]}], "new_text": "The structures of TK complexed with ADP at the ATP - site and deoxythymidine - 5'- <START=Organic Chemical> <START=Pharmacologic Substance> monophosphate <END=Organic Chemical> <END=Pharmacologic Substance> ( dTMP ), deoxythymidine ( dT ), or <START=Pharmacologic Substance> idoxuridine <END=Pharmacologic Substance> - 5'- <START=Organic Chemical> <START=Pharmacologic Substance> phosphate <END=Organic Chemical> <END=Pharmacologic Substance> ( <START=Pharmacologic Substance> 5 - iodo - dUMP <END=Pharmacologic Substance> ) at the substrate - site were refined to 2. 75 A, 2. 8 A, and 3. 0 A resolution, respectively."}, {"PMID": 23578392, "id": 5, "text": "Treatment of these mice with 3mg/kg body weight of the model CAR activator 1,4-bis-[2-(3,5-dichloropyridyloxy)]benzene (TCPOBOP) confirmed previous findings related to the coordinate regulation of drug metabolism by β-catenin and CAR. More importantly, the present study clarified that the impact of β-catenin signaling on CAR-mediated enzyme induction in the liver is not merely due to developmental defects caused by a postnatal lack of β-catenin, but depends on the presence of β-catenin at the time point of xenobiotic treatment.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [75, 118], "name": "1,4-bis-[2-(3,5-dichloropyridyloxy)]benzene", "tok_span": [16, 38], "new_tok_span": [17, 39]}, {"ent_type": "CHEMICAL", "char_span": [120, 127], "name": "TCPOBOP", "tok_span": [39, 42], "new_tok_span": [43, 46]}, {"ent_type": "GENE", "char_span": [216, 225], "name": "β-catenin", "tok_span": [55, 60], "new_tok_span": [59, 64]}, {"ent_type": "GENE", "char_span": [230, 233], "name": "CAR", "tok_span": [61, 62], "new_tok_span": [65, 66]}, {"ent_type": "GENE", "char_span": [300, 309], "name": "β-catenin", "tok_span": [74, 79], "new_tok_span": [78, 83]}, {"ent_type": "GENE", "char_span": [323, 326], "name": "CAR", "tok_span": [81, 82], "new_tok_span": [85, 86]}, {"ent_type": "GENE", "char_span": [439, 448], "name": "β-catenin", "tok_span": [102, 107], "new_tok_span": [106, 111]}, {"ent_type": "GENE", "char_span": [481, 490], "name": "β-catenin", "tok_span": [114, 119], "new_tok_span": [118, 123]}, {"ent_type": "GENE", "char_span": [61, 64], "name": "CAR", "tok_span": [14, 15], "new_tok_span": [14, 15]}], "relation_list": [{"subject": "1,4-bis-[2-(3,5-dichloropyridyloxy)]benzene", "sbj_char_span": [75, 118], "object": "CAR", "obj_char_span": [61, 64], "rel_type": "activator", "sbj_tok_span": [16, 38], "obj_tok_span": [14, 15], "new_sbj_tok_span": [17, 39], "new_obj_tok_span": [14, 15]}, {"subject": "TCPOBOP", "sbj_char_span": [120, 127], "object": "CAR", "obj_char_span": [61, 64], "rel_type": "activator", "sbj_tok_span": [39, 42], "obj_tok_span": [14, 15], "new_sbj_tok_span": [43, 46], "new_obj_tok_span": [14, 15]}], "umls_entity_list": [{"mention": "activator 1", "char_span": [65, 76], "sem_type": "Gene or Genome", "tok_span": [15, 17], "new_tok_span": [16, 18]}, {"mention": "benzene", "char_span": [111, 118], "sem_type": "Organic Chemical", "tok_span": [37, 38], "new_tok_span": [40, 41]}], "new_text": "Treatment of these mice with 3mg / kg body weight of the model CAR <START=Gene or Genome> activator 1 <END=Gene or Genome>, 4 - bis - [ 2 - ( 3, 5 - dichloropyridyloxy ) ] <START=Organic Chemical> benzene <END=Organic Chemical> ( TCPOBOP ) confirmed previous findings related to the coordinate regulation of drug metabolism by β - catenin and CAR. More importantly, the present study clarified that the impact of β - catenin signaling on CAR - mediated enzyme induction in the liver is not merely due to developmental defects caused by a postnatal lack of β - catenin, but depends on the presence of β - catenin at the time point of xenobiotic treatment."}, {"PMID": 23164673, "id": 9, "text": "Western blots showed a decrease in nuclear p65 protein expression after exposure to different concentrations of cinobufagin, while the phosphorylation of GSK-3β was simultaneously increased.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [112, 123], "name": "cinobufagin", "tok_span": [17, 22], "new_tok_span": [22, 27]}, {"ent_type": "GENE", "char_span": [154, 160], "name": "GSK-3β", "tok_span": [27, 31], "new_tok_span": [33, 37]}, {"ent_type": "GENE", "char_span": [43, 46], "name": "p65", "tok_span": [7, 9], "new_tok_span": [9, 11]}], "relation_list": [{"subject": "cinobufagin", "sbj_char_span": [112, 123], "object": "p65", "obj_char_span": [43, 46], "rel_type": "regulator", "sbj_tok_span": [17, 22], "obj_tok_span": [7, 9], "new_sbj_tok_span": [22, 27], "new_obj_tok_span": [9, 11]}, {"subject": "cinobufagin", "sbj_char_span": [112, 123], "object": "GSK-3β", "obj_char_span": [154, 160], "rel_type": "activator", "sbj_tok_span": [17, 22], "obj_tok_span": [27, 31], "new_sbj_tok_span": [22, 27], "new_obj_tok_span": [33, 37]}], "umls_entity_list": [{"mention": "p65", "char_span": [43, 46], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [7, 9], "new_tok_span": [9, 11]}, {"mention": "p65", "char_span": [43, 46], "sem_type": "Gene or Genome", "tok_span": [7, 9], "new_tok_span": [9, 11]}, {"mention": "cinobufagin", "char_span": [112, 123], "sem_type": "Pharmacologic Substance", "tok_span": [17, 22], "new_tok_span": [22, 27]}], "new_text": "Western blots showed a decrease in nuclear <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> p65 <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> protein expression after exposure to different concentrations of <START=Pharmacologic Substance> cinobufagin <END=Pharmacologic Substance>, while the phosphorylation of GSK - 3β was simultaneously increased."}, {"PMID": 23164673, "id": 11, "text": "However, combined treatment with cinobufagin and SB216367 resulted in a significant reduction in p65 and an increase in cleaved-PARP in U2OS cells.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [33, 44], "name": "cinobufagin", "tok_span": [5, 10], "new_tok_span": [6, 11]}, {"ent_type": "CHEMICAL", "char_span": [49, 57], "name": "SB216367", "tok_span": [11, 15], "new_tok_span": [13, 17]}, {"ent_type": "GENE", "char_span": [97, 100], "name": "p65", "tok_span": [21, 23], "new_tok_span": [23, 25]}, {"ent_type": "GENE", "char_span": [128, 132], "name": "PARP", "tok_span": [29, 30], "new_tok_span": [33, 34]}], "relation_list": [{"subject": "SB216367", "sbj_char_span": [49, 57], "object": "p65", "obj_char_span": [97, 100], "rel_type": "regulator", "sbj_tok_span": [11, 15], "obj_tok_span": [21, 23], "new_sbj_tok_span": [13, 17], "new_obj_tok_span": [23, 25]}, {"subject": "cinobufagin", "sbj_char_span": [33, 44], "object": "p65", "obj_char_span": [97, 100], "rel_type": "regulator", "sbj_tok_span": [5, 10], "obj_tok_span": [21, 23], "new_sbj_tok_span": [6, 11], "new_obj_tok_span": [23, 25]}, {"subject": "cinobufagin", "sbj_char_span": [33, 44], "object": "PARP", "obj_char_span": [128, 132], "rel_type": "regulator", "sbj_tok_span": [5, 10], "obj_tok_span": [29, 30], "new_sbj_tok_span": [6, 11], "new_obj_tok_span": [33, 34]}, {"subject": "SB216367", "sbj_char_span": [49, 57], "object": "PARP", "obj_char_span": [128, 132], "rel_type": "regulator", "sbj_tok_span": [11, 15], "obj_tok_span": [29, 30], "new_sbj_tok_span": [13, 17], "new_obj_tok_span": [33, 34]}], "umls_entity_list": [{"mention": "cinobufagin", "char_span": [33, 44], "sem_type": "Pharmacologic Substance", "tok_span": [5, 10], "new_tok_span": [6, 11]}, {"mention": "PARP", "char_span": [128, 132], "sem_type": "Gene or Genome", "tok_span": [29, 30], "new_tok_span": [33, 34]}, {"mention": "PARP", "char_span": [128, 132], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [29, 30], "new_tok_span": [33, 34]}], "new_text": "However, combined treatment with <START=Pharmacologic Substance> cinobufagin <END=Pharmacologic Substance> and SB216367 resulted in a significant reduction in p65 and an increase in cleaved - <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> PARP <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> in U2OS cells."}, {"PMID": 22846225, "id": 4, "text": "Chelerythrine, a redox-sensitive PKC inhibitor that inhibits PKMζ and disrupts LTP maintenance and memory storage, was also reported by Wu-Zhang et al. (2012) not to inhibit the expressed PKMζ fusion protein.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 13], "name": "Chelerythrine", "tok_span": [0, 4], "new_tok_span": [1, 5]}, {"ent_type": "GENE", "char_span": [33, 36], "name": "PKC", "tok_span": [9, 10], "new_tok_span": [11, 12]}, {"ent_type": "GENE", "char_span": [61, 65], "name": "PKMζ", "tok_span": [13, 16], "new_tok_span": [15, 18]}, {"ent_type": "GENE", "char_span": [188, 192], "name": "PKMζ", "tok_span": [43, 46], "new_tok_span": [47, 50]}], "relation_list": [{"subject": "Chelerythrine", "sbj_char_span": [0, 13], "object": "PKC", "obj_char_span": [33, 36], "rel_type": "inhibitor", "sbj_tok_span": [0, 4], "obj_tok_span": [9, 10], "new_sbj_tok_span": [1, 5], "new_obj_tok_span": [11, 12]}, {"subject": "Chelerythrine", "sbj_char_span": [0, 13], "object": "PKMζ", "obj_char_span": [61, 65], "rel_type": "inhibitor", "sbj_tok_span": [0, 4], "obj_tok_span": [13, 16], "new_sbj_tok_span": [1, 5], "new_obj_tok_span": [15, 18]}], "umls_entity_list": [{"mention": "Chelerythrine", "char_span": [0, 13], "sem_type": "Pharmacologic Substance", "tok_span": [0, 4], "new_tok_span": [1, 5]}, {"mention": "Wu", "char_span": [136, 138], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [29, 30], "new_tok_span": [32, 33]}, {"mention": "fusion protein", "char_span": [193, 207], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [46, 48], "new_tok_span": [51, 53]}], "new_text": "<START=Pharmacologic Substance> Chelerythrine <END=Pharmacologic Substance>, a redox - sensitive PKC inhibitor that inhibits PKMζ and disrupts LTP maintenance and memory storage, was also reported by <START=Amino Acid, Peptide, or Protein> Wu <END=Amino Acid, Peptide, or Protein> - Zhang et al. ( 2012 ) not to inhibit the expressed PKMζ <START=Amino Acid, Peptide, or Protein> fusion protein <END=Amino Acid, Peptide, or Protein>."}, {"PMID": 17513393, "id": 6, "text": "Hepatic betaine-homocysteine methyltransferase (Bhmt), which catalyzes one of the two ways that homocysteine can be remethylated to methionine, was downregulated by Cu deficiency.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [8, 15], "name": "betaine", "tok_span": [2, 4], "new_tok_span": [4, 6]}, {"ent_type": "CHEMICAL", "char_span": [16, 28], "name": "homocysteine", "tok_span": [5, 7], "new_tok_span": [7, 9]}, {"ent_type": "CHEMICAL", "char_span": [96, 108], "name": "homocysteine", "tok_span": [23, 25], "new_tok_span": [27, 29]}, {"ent_type": "CHEMICAL", "char_span": [132, 142], "name": "methionine", "tok_span": [31, 32], "new_tok_span": [36, 37]}, {"ent_type": "CHEMICAL", "char_span": [165, 167], "name": "Cu", "tok_span": [36, 37], "new_tok_span": [42, 43]}, {"ent_type": "GENE", "char_span": [8, 46], "name": "betaine-homocysteine methyltransferase", "tok_span": [2, 9], "new_tok_span": [4, 11]}, {"ent_type": "GENE", "char_span": [48, 52], "name": "Bhmt", "tok_span": [10, 12], "new_tok_span": [14, 16]}], "relation_list": [{"subject": "homocysteine", "sbj_char_span": [96, 108], "object": "betaine-homocysteine methyltransferase", "obj_char_span": [8, 46], "rel_type": "product or substrate", "sbj_tok_span": [23, 25], "obj_tok_span": [2, 9], "new_sbj_tok_span": [27, 29], "new_obj_tok_span": [4, 11]}, {"subject": "homocysteine", "sbj_char_span": [96, 108], "object": "Bhmt", "obj_char_span": [48, 52], "rel_type": "product or substrate", "sbj_tok_span": [23, 25], "obj_tok_span": [10, 12], "new_sbj_tok_span": [27, 29], "new_obj_tok_span": [14, 16]}, {"subject": "methionine", "sbj_char_span": [132, 142], "object": "betaine-homocysteine methyltransferase", "obj_char_span": [8, 46], "rel_type": "product or substrate", "sbj_tok_span": [31, 32], "obj_tok_span": [2, 9], "new_sbj_tok_span": [36, 37], "new_obj_tok_span": [4, 11]}, {"subject": "methionine", "sbj_char_span": [132, 142], "object": "Bhmt", "obj_char_span": [48, 52], "rel_type": "product or substrate", "sbj_tok_span": [31, 32], "obj_tok_span": [10, 12], "new_sbj_tok_span": [36, 37], "new_obj_tok_span": [14, 16]}], "umls_entity_list": [{"mention": "betaine-homocysteine methyltransferase", "char_span": [8, 46], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [2, 9], "new_tok_span": [4, 11]}, {"mention": "betaine-homocysteine methyltransferase", "char_span": [8, 46], "sem_type": "Gene or Genome", "tok_span": [2, 9], "new_tok_span": [4, 11]}, {"mention": "methionine", "char_span": [132, 142], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [31, 32], "new_tok_span": [36, 37]}], "new_text": "Hepatic <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> betaine - homocysteine methyltransferase <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> ( Bhmt ), which catalyzes one of the two ways that homocysteine can be remethylated to <START=Amino Acid, Peptide, or Protein> methionine <END=Amino Acid, Peptide, or Protein>, was downregulated by Cu deficiency."}, {"PMID": 11972287, "id": 3, "text": "Injections of m-CPBG, a selective 5-HT3 receptor agonist, induced a significant increase in blood glucose in non-stressed rats in both fasted and in fed states.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [14, 20], "name": "m-CPBG", "tok_span": [3, 7], "new_tok_span": [3, 7]}, {"ent_type": "CHEMICAL", "char_span": [98, 105], "name": "glucose", "tok_span": [23, 24], "new_tok_span": [23, 24]}, {"ent_type": "GENE", "char_span": [34, 39], "name": "5-HT3", "tok_span": [10, 14], "new_tok_span": [10, 14]}], "relation_list": [{"subject": "m-CPBG", "sbj_char_span": [14, 20], "object": "5-HT3", "obj_char_span": [34, 39], "rel_type": "agonist or antagonist", "sbj_tok_span": [3, 7], "obj_tok_span": [10, 14], "new_sbj_tok_span": [3, 7], "new_obj_tok_span": [10, 14]}], "umls_entity_list": [], "new_text": "Injections of m - CPBG, a selective 5 - HT3 receptor agonist, induced a significant increase in blood glucose in non - stressed rats in both fasted and in fed states."}, {"PMID": 23550028, "id": 5, "text": "Our results showed that 2-hydroxy-3-methylanthraquinone decreased phosphorylation-ERK1/2 (p-ERK1/2), and increased p-p38MAPK, but did not affect expressions of p-JNK1/2 in U937 cells.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [24, 55], "name": "2-hydroxy-3-methylanthraquinone", "tok_span": [4, 15], "new_tok_span": [5, 16]}, {"ent_type": "GENE", "char_span": [82, 88], "name": "ERK1/2", "tok_span": [18, 22], "new_tok_span": [28, 32]}, {"ent_type": "GENE", "char_span": [90, 98], "name": "p-ERK1/2", "tok_span": [23, 29], "new_tok_span": [33, 39]}, {"ent_type": "GENE", "char_span": [115, 124], "name": "p-p38MAPK", "tok_span": [33, 39], "new_tok_span": [45, 51]}, {"ent_type": "GENE", "char_span": [160, 168], "name": "p-JNK1/2", "tok_span": [46, 52], "new_tok_span": [60, 66]}], "relation_list": [{"subject": "2-hydroxy-3-methylanthraquinone", "sbj_char_span": [24, 55], "object": "p-p38MAPK", "obj_char_span": [115, 124], "rel_type": "activator", "sbj_tok_span": [4, 15], "obj_tok_span": [33, 39], "new_sbj_tok_span": [5, 16], "new_obj_tok_span": [45, 51]}], "umls_entity_list": [{"mention": "2-hydroxy-3-methylanthraquinone", "char_span": [24, 55], "sem_type": "Pharmacologic Substance", "tok_span": [4, 15], "new_tok_span": [5, 16]}, {"mention": "-", "char_span": [25, 26], "sem_type": "Pharmacologic Substance", "tok_span": [5, 6], "new_tok_span": [7, 8]}, {"mention": "-", "char_span": [33, 34], "sem_type": "Pharmacologic Substance", "tok_span": [7, 8], "new_tok_span": [11, 12]}, {"mention": "-", "char_span": [35, 36], "sem_type": "Pharmacologic Substance", "tok_span": [9, 10], "new_tok_span": [15, 16]}, {"mention": "-", "char_span": [81, 82], "sem_type": "Pharmacologic Substance", "tok_span": [17, 18], "new_tok_span": [26, 27]}, {"mention": "-", "char_span": [91, 92], "sem_type": "Pharmacologic Substance", "tok_span": [24, 25], "new_tok_span": [35, 36]}, {"mention": "-", "char_span": [116, 117], "sem_type": "Pharmacologic Substance", "tok_span": [34, 35], "new_tok_span": [47, 48]}, {"mention": "-", "char_span": [161, 162], "sem_type": "Pharmacologic Substance", "tok_span": [47, 48], "new_tok_span": [62, 63]}, {"mention": "JNK1", "char_span": [162, 166], "sem_type": "Gene or Genome", "tok_span": [48, 50], "new_tok_span": [65, 67]}], "new_text": "Our results showed that <START=Pharmacologic Substance> 2 <START=Pharmacologic Substance> - <END=Pharmacologic Substance> hydroxy <START=Pharmacologic Substance> - <END=Pharmacologic Substance> 3 <START=Pharmacologic Substance> - <END=Pharmacologic Substance> methylanthraquinone <END=Pharmacologic Substance> decreased phosphorylation <START=Pharmacologic Substance> - <END=Pharmacologic Substance> ERK1 / 2 ( p <START=Pharmacologic Substance> - <END=Pharmacologic Substance> ERK1 / 2 ), and increased p <START=Pharmacologic Substance> - <END=Pharmacologic Substance> p38MAPK, but did not affect expressions of p <START=Pharmacologic Substance> - <END=Pharmacologic Substance> <START=Gene or Genome> JNK1 <END=Gene or Genome> / 2 in U937 cells."}, {"PMID": 11430635, "id": 9, "text": "In view of the role of CA in acid-base balance as well as the fact that an increase or decrease in its activity is accompanied by an increase or decrease in intra- and extracellular pH, our results suggest that: firstly, CA activation induced by indomethacin might cause changes in COX activity; secondly, PGs are synthetized as a consequence of the changes in COX activity, a hypothesis that requires further study.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [246, 258], "name": "indomethacin", "tok_span": [50, 53], "new_tok_span": [50, 53]}, {"ent_type": "GENE", "char_span": [23, 25], "name": "CA", "tok_span": [6, 7], "new_tok_span": [6, 7]}, {"ent_type": "GENE", "char_span": [221, 223], "name": "CA", "tok_span": [46, 47], "new_tok_span": [46, 47]}, {"ent_type": "GENE", "char_span": [282, 285], "name": "COX", "tok_span": [57, 58], "new_tok_span": [57, 58]}, {"ent_type": "GENE", "char_span": [361, 364], "name": "COX", "tok_span": [75, 76], "new_tok_span": [75, 76]}], "relation_list": [{"subject": "indomethacin", "sbj_char_span": [246, 258], "object": "CA", "obj_char_span": [221, 223], "rel_type": "activator", "sbj_tok_span": [50, 53], "obj_tok_span": [46, 47], "new_sbj_tok_span": [50, 53], "new_obj_tok_span": [46, 47]}], "umls_entity_list": [], "new_text": "In view of the role of CA in acid - base balance as well as the fact that an increase or decrease in its activity is accompanied by an increase or decrease in intra - and extracellular pH, our results suggest that : firstly, CA activation induced by indomethacin might cause changes in COX activity ; secondly, PGs are synthetized as a consequence of the changes in COX activity, a hypothesis that requires further study."}, {"PMID": 23017408, "id": 4, "text": "BASO673 isolates with high levels of total phenols (66.0±1.2μg/mg, 78.1±1.8μg/mg, respectively) also showed high levels of PAL activities (20.5±3.1U/mg protein, 17.2±2.3U/mg protein, respectively) and strong antioxidant activities.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [43, 50], "name": "phenols", "tok_span": [10, 12], "new_tok_span": [13, 15]}, {"ent_type": "GENE", "char_span": [123, 126], "name": "PAL", "tok_span": [42, 44], "new_tok_span": [50, 52]}], "relation_list": [{"subject": "phenols", "sbj_char_span": [43, 50], "object": "PAL", "obj_char_span": [123, 126], "rel_type": "regulator", "sbj_tok_span": [10, 12], "obj_tok_span": [42, 44], "new_sbj_tok_span": [13, 15], "new_obj_tok_span": [50, 52]}], "umls_entity_list": [{"mention": "phenols", "char_span": [43, 50], "sem_type": "Pharmacologic Substance", "tok_span": [10, 12], "new_tok_span": [13, 15]}, {"mention": "isolate", "char_span": [8, 15], "sem_type": "Pharmacologic Substance", "tok_span": [4, 5], "new_tok_span": [5, 6]}, {"mention": "mg", "char_span": [63, 65], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [22, 23], "new_tok_span": [27, 28]}, {"mention": "mg", "char_span": [78, 80], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [33, 34], "new_tok_span": [40, 41]}, {"mention": "mg", "char_span": [149, 151], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [55, 56], "new_tok_span": [64, 65]}, {"mention": "mg", "char_span": [171, 173], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [67, 68], "new_tok_span": [78, 79]}], "new_text": "BASO673 <START=Pharmacologic Substance> isolates <END=Pharmacologic Substance> with high levels of total <START=Pharmacologic Substance> phenols <END=Pharmacologic Substance> ( 66. 0±1. 2μg / <START=Amino Acid, Peptide, or Protein> mg <END=Amino Acid, Peptide, or Protein>, 78. 1±1. 8μg / <START=Amino Acid, Peptide, or Protein> mg <END=Amino Acid, Peptide, or Protein>, respectively ) also showed high levels of PAL activities ( 20. 5±3. 1U / <START=Amino Acid, Peptide, or Protein> mg <END=Amino Acid, Peptide, or Protein> protein, 17. 2±2. 3U / <START=Amino Acid, Peptide, or Protein> mg <END=Amino Acid, Peptide, or Protein> protein, respectively ) and strong antioxidant activities."}, {"PMID": 11299519, "id": 3, "text": "Humans with FSH beta gene mutations tend to have a more severe phenotype than those with FSHR gene mutations, although infertility and varying degrees of impaired sex steroid production occur in both types of mutations.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [167, 174], "name": "steroid", "tok_span": [30, 31], "new_tok_span": [35, 36]}, {"ent_type": "GENE", "char_span": [12, 20], "name": "FSH beta", "tok_span": [3, 5], "new_tok_span": [4, 6]}, {"ent_type": "GENE", "char_span": [89, 93], "name": "FSHR", "tok_span": [17, 19], "new_tok_span": [20, 22]}], "relation_list": [{"subject": "steroid", "sbj_char_span": [167, 174], "object": "FSH beta", "obj_char_span": [12, 20], "rel_type": "product or substrate", "sbj_tok_span": [30, 31], "obj_tok_span": [3, 5], "new_sbj_tok_span": [35, 36], "new_obj_tok_span": [4, 6]}], "umls_entity_list": [{"mention": "FSH beta", "char_span": [12, 20], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [3, 5], "new_tok_span": [4, 6]}, {"mention": "FSHR gene", "char_span": [89, 98], "sem_type": "Gene or Genome", "tok_span": [17, 20], "new_tok_span": [20, 23]}, {"mention": "steroid", "char_span": [167, 174], "sem_type": "Pharmacologic Substance", "tok_span": [30, 31], "new_tok_span": [35, 36]}], "new_text": "Humans with <START=Amino Acid, Peptide, or Protein> FSH beta <END=Amino Acid, Peptide, or Protein> gene mutations tend to have a more severe phenotype than those with <START=Gene or Genome> FSHR gene <END=Gene or Genome> mutations, although infertility and varying degrees of impaired sex <START=Pharmacologic Substance> steroid <END=Pharmacologic Substance> production occur in both types of mutations."}, {"PMID": 12185406, "id": 1, "text": "RATIONALE: Bupropion is thought to treat major depression by blocking the dopamine transporter (DAT) because bupropion appears to have a selective affinity for the DAT. The validity of this mechanism has been questioned because the affinity of bupropion for the DAT is quite low.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [109, 118], "name": "bupropion", "tok_span": [24, 27], "new_tok_span": [24, 27]}, {"ent_type": "CHEMICAL", "char_span": [11, 20], "name": "Bupropion", "tok_span": [6, 9], "new_tok_span": [6, 9]}, {"ent_type": "CHEMICAL", "char_span": [244, 253], "name": "bupropion", "tok_span": [49, 52], "new_tok_span": [49, 52]}, {"ent_type": "CHEMICAL", "char_span": [74, 82], "name": "dopamine", "tok_span": [18, 19], "new_tok_span": [18, 19]}, {"ent_type": "GENE", "char_span": [164, 167], "name": "DAT", "tok_span": [35, 36], "new_tok_span": [35, 36]}, {"ent_type": "GENE", "char_span": [262, 265], "name": "DAT", "tok_span": [54, 55], "new_tok_span": [54, 55]}, {"ent_type": "GENE", "char_span": [74, 94], "name": "dopamine transporter", "tok_span": [18, 20], "new_tok_span": [18, 20]}, {"ent_type": "GENE", "char_span": [96, 99], "name": "DAT", "tok_span": [21, 22], "new_tok_span": [21, 22]}], "relation_list": [{"subject": "Bupropion", "sbj_char_span": [11, 20], "object": "dopamine transporter", "obj_char_span": [74, 94], "rel_type": "inhibitor", "sbj_tok_span": [6, 9], "obj_tok_span": [18, 20], "new_sbj_tok_span": [6, 9], "new_obj_tok_span": [18, 20]}, {"subject": "Bupropion", "sbj_char_span": [11, 20], "object": "DAT", "obj_char_span": [96, 99], "rel_type": "inhibitor", "sbj_tok_span": [6, 9], "obj_tok_span": [21, 22], "new_sbj_tok_span": [6, 9], "new_obj_tok_span": [21, 22]}, {"subject": "bupropion", "sbj_char_span": [109, 118], "object": "DAT", "obj_char_span": [164, 167], "rel_type": "regulator", "sbj_tok_span": [24, 27], "obj_tok_span": [35, 36], "new_sbj_tok_span": [24, 27], "new_obj_tok_span": [35, 36]}, {"subject": "bupropion", "sbj_char_span": [244, 253], "object": "DAT", "obj_char_span": [262, 265], "rel_type": "regulator", "sbj_tok_span": [49, 52], "obj_tok_span": [54, 55], "new_sbj_tok_span": [49, 52], "new_obj_tok_span": [54, 55]}], "umls_entity_list": [], "new_text": "RATIONALE : Bupropion is thought to treat major depression by blocking the dopamine transporter ( DAT ) because bupropion appears to have a selective affinity for the DAT. The validity of this mechanism has been questioned because the affinity of bupropion for the DAT is quite low."}, {"PMID": 16014042, "id": 7, "text": "Moreover, uptake of l-cystine also increased (about tenfold) in Xenopus oocytes expressing hxCT and h4F2hc.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [20, 29], "name": "l-cystine", "tok_span": [4, 8], "new_tok_span": [4, 8]}, {"ent_type": "GENE", "char_span": [91, 95], "name": "hxCT", "tok_span": [19, 22], "new_tok_span": [21, 24]}, {"ent_type": "GENE", "char_span": [100, 106], "name": "h4F2hc", "tok_span": [23, 29], "new_tok_span": [25, 31]}], "relation_list": [{"subject": "l-cystine", "sbj_char_span": [20, 29], "object": "hxCT", "obj_char_span": [91, 95], "rel_type": "product or substrate", "sbj_tok_span": [4, 8], "obj_tok_span": [19, 22], "new_sbj_tok_span": [4, 8], "new_obj_tok_span": [21, 24]}, {"subject": "l-cystine", "sbj_char_span": [20, 29], "object": "h4F2hc", "obj_char_span": [100, 106], "rel_type": "product or substrate", "sbj_tok_span": [4, 8], "obj_tok_span": [23, 29], "new_sbj_tok_span": [4, 8], "new_obj_tok_span": [25, 31]}], "umls_entity_list": [{"mention": "cystine", "char_span": [22, 29], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [6, 8], "new_tok_span": [7, 9]}], "new_text": "Moreover, uptake of l - <START=Amino Acid, Peptide, or Protein> cystine <END=Amino Acid, Peptide, or Protein> also increased ( about tenfold ) in Xenopus oocytes expressing hxCT and h4F2hc."}, {"PMID": 8836655, "id": 8, "text": "Chlorpheniramine (10 microM), another histamine H1 receptor antagonist without significant 5-HT receptor binding affinity, did not produce any inhibition of the eNANC contraction.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 16], "name": "Chlorpheniramine", "tok_span": [0, 5], "new_tok_span": [0, 5]}, {"ent_type": "CHEMICAL", "char_span": [38, 47], "name": "histamine", "tok_span": [12, 13], "new_tok_span": [13, 14]}, {"ent_type": "CHEMICAL", "char_span": [91, 95], "name": "5-HT", "tok_span": [19, 22], "new_tok_span": [23, 26]}, {"ent_type": "GENE", "char_span": [38, 59], "name": "histamine H1 receptor", "tok_span": [12, 16], "new_tok_span": [13, 17]}, {"ent_type": "GENE", "char_span": [91, 104], "name": "5-HT receptor", "tok_span": [19, 23], "new_tok_span": [23, 27]}], "relation_list": [{"subject": "Chlorpheniramine", "sbj_char_span": [0, 16], "object": "histamine H1 receptor", "obj_char_span": [38, 59], "rel_type": "agonist or antagonist", "sbj_tok_span": [0, 5], "obj_tok_span": [12, 16], "new_sbj_tok_span": [0, 5], "new_obj_tok_span": [13, 17]}], "umls_entity_list": [{"mention": "histamine H1 receptor antagonist", "char_span": [38, 70], "sem_type": "Pharmacologic Substance", "tok_span": [12, 17], "new_tok_span": [13, 18]}, {"mention": "antagonist", "char_span": [60, 70], "sem_type": "Pharmacologic Substance", "tok_span": [16, 17], "new_tok_span": [18, 19]}], "new_text": "Chlorpheniramine ( 10 microM ), another <START=Pharmacologic Substance> histamine H1 receptor <START=Pharmacologic Substance> antagonist <END=Pharmacologic Substance> <END=Pharmacologic Substance> without significant 5 - HT receptor binding affinity, did not produce any inhibition of the eNANC contraction."}, {"PMID": 12023506, "id": 7, "text": "The K(i) value of probenecid for hOAT2 was 766 microM, whereas those of probenecid, KW-3902, and betamipron for hOAT4 were 54.9, 20.7, and 502 microM, respectively.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [72, 82], "name": "probenecid", "tok_span": [24, 27], "new_tok_span": [27, 30]}, {"ent_type": "CHEMICAL", "char_span": [84, 91], "name": "KW-3902", "tok_span": [28, 33], "new_tok_span": [32, 37]}, {"ent_type": "CHEMICAL", "char_span": [97, 107], "name": "betamipron", "tok_span": [35, 39], "new_tok_span": [40, 44]}, {"ent_type": "GENE", "char_span": [33, 38], "name": "hOAT2", "tok_span": [11, 15], "new_tok_span": [13, 17]}, {"ent_type": "GENE", "char_span": [112, 117], "name": "hOAT4", "tok_span": [40, 44], "new_tok_span": [46, 50]}], "relation_list": [{"subject": "probenecid", "sbj_char_span": [72, 82], "object": "hOAT4", "obj_char_span": [112, 117], "rel_type": "inhibitor", "sbj_tok_span": [24, 27], "obj_tok_span": [40, 44], "new_sbj_tok_span": [27, 30], "new_obj_tok_span": [46, 50]}, {"subject": "KW-3902", "sbj_char_span": [84, 91], "object": "hOAT4", "obj_char_span": [112, 117], "rel_type": "inhibitor", "sbj_tok_span": [28, 33], "obj_tok_span": [40, 44], "new_sbj_tok_span": [32, 37], "new_obj_tok_span": [46, 50]}, {"subject": "betamipron", "sbj_char_span": [97, 107], "object": "hOAT4", "obj_char_span": [112, 117], "rel_type": "inhibitor", "sbj_tok_span": [35, 39], "obj_tok_span": [40, 44], "new_sbj_tok_span": [40, 44], "new_obj_tok_span": [46, 50]}], "umls_entity_list": [{"mention": "probenecid", "char_span": [18, 28], "sem_type": "Pharmacologic Substance", "tok_span": [7, 10], "new_tok_span": [8, 11]}, {"mention": "probenecid", "char_span": [72, 82], "sem_type": "Pharmacologic Substance", "tok_span": [24, 27], "new_tok_span": [27, 30]}, {"mention": "betamipron", "char_span": [97, 107], "sem_type": "Pharmacologic Substance", "tok_span": [35, 39], "new_tok_span": [40, 44]}], "new_text": "The K ( i ) value of <START=Pharmacologic Substance> probenecid <END=Pharmacologic Substance> for hOAT2 was 766 microM, whereas those of <START=Pharmacologic Substance> probenecid <END=Pharmacologic Substance>, KW - 3902, and <START=Pharmacologic Substance> betamipron <END=Pharmacologic Substance> for hOAT4 were 54. 9, 20. 7, and 502 microM, respectively."}, {"PMID": 7853212, "id": 3, "text": "Mepyramine bound specifically to P450 2D1, which suggests that it inhibits P450 2D activity.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 10], "name": "Mepyramine", "tok_span": [0, 3], "new_tok_span": [0, 3]}, {"ent_type": "GENE", "char_span": [33, 41], "name": "P450 2D1", "tok_span": [6, 11], "new_tok_span": [6, 11]}, {"ent_type": "GENE", "char_span": [75, 82], "name": "P450 2D", "tok_span": [17, 21], "new_tok_span": [17, 21]}], "relation_list": [{"subject": "Mepyramine", "sbj_char_span": [0, 10], "object": "P450 2D1", "obj_char_span": [33, 41], "rel_type": "regulator", "sbj_tok_span": [0, 3], "obj_tok_span": [6, 11], "new_sbj_tok_span": [0, 3], "new_obj_tok_span": [6, 11]}, {"subject": "Mepyramine", "sbj_char_span": [0, 10], "object": "P450 2D", "obj_char_span": [75, 82], "rel_type": "inhibitor", "sbj_tok_span": [0, 3], "obj_tok_span": [17, 21], "new_sbj_tok_span": [0, 3], "new_obj_tok_span": [17, 21]}], "umls_entity_list": [], "new_text": "Mepyramine bound specifically to P450 2D1, which suggests that it inhibits P450 2D activity."}, {"PMID": 23220413, "id": 9, "text": "Treatment with TDCPP also significantly increased transcription of genes involved in thyroid hormone synthesis (tshβ, slc5a5 and tg) and thyroid development (hhex, nkx2.1 and pax8) as a compensatory mechanism for decreased T4 concentrations.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [15, 20], "name": "TDCPP", "tok_span": [2, 5], "new_tok_span": [2, 5]}, {"ent_type": "GENE", "char_span": [112, 116], "name": "tshβ", "tok_span": [17, 20], "new_tok_span": [17, 20]}, {"ent_type": "GENE", "char_span": [118, 124], "name": "slc5a5", "tok_span": [21, 26], "new_tok_span": [21, 26]}, {"ent_type": "GENE", "char_span": [129, 131], "name": "tg", "tok_span": [27, 29], "new_tok_span": [27, 29]}, {"ent_type": "GENE", "char_span": [158, 162], "name": "hhex", "tok_span": [34, 36], "new_tok_span": [35, 37]}, {"ent_type": "GENE", "char_span": [164, 170], "name": "nkx2.1", "tok_span": [37, 42], "new_tok_span": [40, 45]}, {"ent_type": "GENE", "char_span": [175, 179], "name": "pax8", "tok_span": [43, 46], "new_tok_span": [49, 52]}], "relation_list": [{"subject": "TDCPP", "sbj_char_span": [15, 20], "object": "tshβ", "obj_char_span": [112, 116], "rel_type": "regulator", "sbj_tok_span": [2, 5], "obj_tok_span": [17, 20], "new_sbj_tok_span": [2, 5], "new_obj_tok_span": [17, 20]}, {"subject": "TDCPP", "sbj_char_span": [15, 20], "object": "slc5a5", "obj_char_span": [118, 124], "rel_type": "regulator", "sbj_tok_span": [2, 5], "obj_tok_span": [21, 26], "new_sbj_tok_span": [2, 5], "new_obj_tok_span": [21, 26]}, {"subject": "TDCPP", "sbj_char_span": [15, 20], "object": "tg", "obj_char_span": [129, 131], "rel_type": "regulator", "sbj_tok_span": [2, 5], "obj_tok_span": [27, 29], "new_sbj_tok_span": [2, 5], "new_obj_tok_span": [27, 29]}, {"subject": "TDCPP", "sbj_char_span": [15, 20], "object": "hhex", "obj_char_span": [158, 162], "rel_type": "regulator", "sbj_tok_span": [2, 5], "obj_tok_span": [34, 36], "new_sbj_tok_span": [2, 5], "new_obj_tok_span": [35, 37]}, {"subject": "TDCPP", "sbj_char_span": [15, 20], "object": "nkx2.1", "obj_char_span": [164, 170], "rel_type": "regulator", "sbj_tok_span": [2, 5], "obj_tok_span": [37, 42], "new_sbj_tok_span": [2, 5], "new_obj_tok_span": [40, 45]}, {"subject": "TDCPP", "sbj_char_span": [15, 20], "object": "pax8", "obj_char_span": [175, 179], "rel_type": "regulator", "sbj_tok_span": [2, 5], "obj_tok_span": [43, 46], "new_sbj_tok_span": [2, 5], "new_obj_tok_span": [49, 52]}], "umls_entity_list": [{"mention": "hhex", "char_span": [158, 162], "sem_type": "Gene or Genome", "tok_span": [34, 36], "new_tok_span": [35, 37]}, {"mention": "nkx2.1", "char_span": [164, 170], "sem_type": "Gene or Genome", "tok_span": [37, 42], "new_tok_span": [40, 45]}, {"mention": "pax8", "char_span": [175, 179], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [43, 46], "new_tok_span": [49, 52]}, {"mention": "pax8", "char_span": [175, 179], "sem_type": "Gene or Genome", "tok_span": [43, 46], "new_tok_span": [49, 52]}], "new_text": "Treatment with TDCPP also significantly increased transcription of genes involved in thyroid hormone synthesis ( tshβ, slc5a5 and tg ) and thyroid development ( <START=Gene or Genome> hhex <END=Gene or Genome>, <START=Gene or Genome> nkx2. 1 <END=Gene or Genome> and <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> pax8 <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> ) as a compensatory mechanism for decreased T4 concentrations."}, {"PMID": 2653642, "id": 7, "text": "Plasma insulin levels were likewise reduced transiently by cysteamine.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [59, 69], "name": "cysteamine", "tok_span": [8, 12], "new_tok_span": [9, 13]}, {"ent_type": "GENE", "char_span": [7, 14], "name": "insulin", "tok_span": [1, 2], "new_tok_span": [1, 2]}], "relation_list": [{"subject": "cysteamine", "sbj_char_span": [59, 69], "object": "insulin", "obj_char_span": [7, 14], "rel_type": "regulator", "sbj_tok_span": [8, 12], "obj_tok_span": [1, 2], "new_sbj_tok_span": [9, 13], "new_obj_tok_span": [1, 2]}], "umls_entity_list": [{"mention": "cysteamine", "char_span": [59, 69], "sem_type": "Pharmacologic Substance", "tok_span": [8, 12], "new_tok_span": [9, 13]}], "new_text": "Plasma insulin levels were likewise reduced transiently by <START=Pharmacologic Substance> cysteamine <END=Pharmacologic Substance>."}, {"PMID": 15562257, "id": 5, "text": "We further probed the interaction of mibefradil with inactivated Nav1.5 channels.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [37, 47], "name": "mibefradil", "tok_span": [6, 11], "new_tok_span": [8, 13]}, {"ent_type": "GENE", "char_span": [65, 71], "name": "Nav1.5", "tok_span": [13, 17], "new_tok_span": [16, 20]}], "relation_list": [{"subject": "mibefradil", "sbj_char_span": [37, 47], "object": "Nav1.5", "obj_char_span": [65, 71], "rel_type": "regulator", "sbj_tok_span": [6, 11], "obj_tok_span": [13, 17], "new_sbj_tok_span": [8, 13], "new_obj_tok_span": [16, 20]}], "umls_entity_list": [{"mention": "probe", "char_span": [11, 16], "sem_type": "Gene or Genome", "tok_span": [2, 3], "new_tok_span": [3, 4]}, {"mention": "Nav1.5", "char_span": [65, 71], "sem_type": "Gene or Genome", "tok_span": [13, 17], "new_tok_span": [16, 20]}], "new_text": "We further <START=Gene or Genome> probed <END=Gene or Genome> the interaction of mibefradil with inactivated <START=Gene or Genome> Nav1. 5 <END=Gene or Genome> channels."}, {"PMID": 15562257, "id": 7, "text": "In addition, inhibiting the binding of the fast inactivation lid (Nav1.5 ICM + MTSET) did not alter mibefradil block, confirming that the drug does not preferentially interact with the fast-inactivated state.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [100, 110], "name": "mibefradil", "tok_span": [26, 31], "new_tok_span": [27, 32]}, {"ent_type": "GENE", "char_span": [66, 72], "name": "Nav1.5", "tok_span": [12, 16], "new_tok_span": [12, 16]}], "relation_list": [{"subject": "mibefradil", "sbj_char_span": [100, 110], "object": "Nav1.5", "obj_char_span": [66, 72], "rel_type": "inhibitor", "sbj_tok_span": [26, 31], "obj_tok_span": [12, 16], "new_sbj_tok_span": [27, 32], "new_obj_tok_span": [12, 16]}], "umls_entity_list": [{"mention": "mibefradil", "char_span": [100, 110], "sem_type": "Pharmacologic Substance", "tok_span": [26, 31], "new_tok_span": [27, 32]}], "new_text": "In addition, inhibiting the binding of the fast inactivation lid ( Nav1. 5 ICM + MTSET ) did not alter <START=Pharmacologic Substance> mibefradil <END=Pharmacologic Substance> block, confirming that the drug does not preferentially interact with the fast - inactivated state."}, {"PMID": 17853709, "id": 13, "text": "The key difference in structure of Lp(a) and plasminogen is replacement of Arg with Ser at position 560.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [75, 78], "name": "Arg", "tok_span": [16, 17], "new_tok_span": [20, 21]}, {"ent_type": "CHEMICAL", "char_span": [84, 87], "name": "Ser", "tok_span": [18, 19], "new_tok_span": [22, 23]}, {"ent_type": "GENE", "char_span": [35, 40], "name": "Lp(a)", "tok_span": [6, 10], "new_tok_span": [8, 12]}, {"ent_type": "GENE", "char_span": [45, 56], "name": "plasminogen", "tok_span": [11, 13], "new_tok_span": [15, 17]}], "relation_list": [{"subject": "Arg", "sbj_char_span": [75, 78], "object": "Lp(a)", "obj_char_span": [35, 40], "rel_type": "part of", "sbj_tok_span": [16, 17], "obj_tok_span": [6, 10], "new_sbj_tok_span": [20, 21], "new_obj_tok_span": [8, 12]}, {"subject": "Ser", "sbj_char_span": [84, 87], "object": "Lp(a)", "obj_char_span": [35, 40], "rel_type": "part of", "sbj_tok_span": [18, 19], "obj_tok_span": [6, 10], "new_sbj_tok_span": [22, 23], "new_obj_tok_span": [8, 12]}, {"subject": "Arg", "sbj_char_span": [75, 78], "object": "plasminogen", "obj_char_span": [45, 56], "rel_type": "part of", "sbj_tok_span": [16, 17], "obj_tok_span": [11, 13], "new_sbj_tok_span": [20, 21], "new_obj_tok_span": [15, 17]}, {"subject": "Ser", "sbj_char_span": [84, 87], "object": "plasminogen", "obj_char_span": [45, 56], "rel_type": "part of", "sbj_tok_span": [18, 19], "obj_tok_span": [11, 13], "new_sbj_tok_span": [22, 23], "new_obj_tok_span": [15, 17]}], "umls_entity_list": [{"mention": "Lp(a)", "char_span": [35, 40], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [6, 10], "new_tok_span": [8, 12]}, {"mention": "Lp(a)", "char_span": [35, 40], "sem_type": "Gene or Genome", "tok_span": [6, 10], "new_tok_span": [8, 12]}], "new_text": "The key difference in structure of <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> Lp ( a ) <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> and plasminogen is replacement of Arg with Ser at position 560."}, {"PMID": 11102491, "id": 2, "text": "For example, we observed that with decreasing NR2B/NR2A subunit expression ratio, the block of NMDA receptor-mediated whole-cell responses by the NR2B-selective antagonist haloperidol was also decreased.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [95, 99], "name": "NMDA", "tok_span": [22, 23], "new_tok_span": [33, 34]}, {"ent_type": "CHEMICAL", "char_span": [172, 183], "name": "haloperidol", "tok_span": [38, 41], "new_tok_span": [55, 58]}, {"ent_type": "GENE", "char_span": [46, 50], "name": "NR2B", "tok_span": [8, 11], "new_tok_span": [10, 13]}, {"ent_type": "GENE", "char_span": [51, 55], "name": "NR2A", "tok_span": [12, 15], "new_tok_span": [18, 21]}, {"ent_type": "GENE", "char_span": [95, 108], "name": "NMDA receptor", "tok_span": [22, 24], "new_tok_span": [33, 35]}, {"ent_type": "GENE", "char_span": [146, 150], "name": "NR2B", "tok_span": [32, 35], "new_tok_span": [46, 49]}], "relation_list": [{"subject": "haloperidol", "sbj_char_span": [172, 183], "object": "NR2B", "obj_char_span": [146, 150], "rel_type": "agonist or antagonist", "sbj_tok_span": [38, 41], "obj_tok_span": [32, 35], "new_sbj_tok_span": [55, 58], "new_obj_tok_span": [46, 49]}, {"subject": "haloperidol", "sbj_char_span": [172, 183], "object": "NMDA receptor", "obj_char_span": [95, 108], "rel_type": "inhibitor", "sbj_tok_span": [38, 41], "obj_tok_span": [22, 24], "new_sbj_tok_span": [55, 58], "new_obj_tok_span": [33, 35]}], "umls_entity_list": [{"mention": "NR2B", "char_span": [46, 50], "sem_type": "Gene or Genome", "tok_span": [8, 11], "new_tok_span": [10, 13]}, {"mention": "NR2B", "char_span": [146, 150], "sem_type": "Gene or Genome", "tok_span": [32, 35], "new_tok_span": [46, 49]}, {"mention": "NR2A", "char_span": [51, 55], "sem_type": "Gene or Genome", "tok_span": [12, 15], "new_tok_span": [18, 21]}, {"mention": "subunit", "char_span": [56, 63], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [15, 16], "new_tok_span": [24, 25]}, {"mention": "NR2A", "char_span": [51, 55], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [12, 15], "new_tok_span": [18, 21]}, {"mention": "NR2B", "char_span": [46, 50], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [8, 11], "new_tok_span": [10, 13]}, {"mention": "NR2B", "char_span": [146, 150], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [32, 35], "new_tok_span": [46, 49]}, {"mention": "NMDA receptor", "char_span": [95, 108], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [22, 24], "new_tok_span": [33, 35]}, {"mention": "haloperidol", "char_span": [172, 183], "sem_type": "Pharmacologic Substance", "tok_span": [38, 41], "new_tok_span": [55, 58]}], "new_text": "For example, we observed that with decreasing <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> NR2B <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> / <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> NR2A <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> <START=Amino Acid, Peptide, or Protein> subunit <END=Amino Acid, Peptide, or Protein> expression ratio, the block of <START=Amino Acid, Peptide, or Protein> NMDA receptor <END=Amino Acid, Peptide, or Protein> - mediated whole - cell responses by the <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> NR2B <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> - selective antagonist <START=Pharmacologic Substance> haloperidol <END=Pharmacologic Substance> was also decreased."}, {"PMID": 20512624, "id": 11, "text": "The inhibitory action of beta-alanine and high concentrations of nipecotic acid and guvacine on GABA transport strongly suggests that also GAT2 or GAT3 (HUGO nomenclature) could play a role.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [25, 37], "name": "beta-alanine", "tok_span": [4, 7], "new_tok_span": [5, 8]}, {"ent_type": "CHEMICAL", "char_span": [65, 79], "name": "nipecotic acid", "tok_span": [11, 15], "new_tok_span": [14, 18]}, {"ent_type": "CHEMICAL", "char_span": [84, 92], "name": "guvacine", "tok_span": [16, 19], "new_tok_span": [21, 24]}, {"ent_type": "CHEMICAL", "char_span": [96, 100], "name": "GABA", "tok_span": [20, 21], "new_tok_span": [27, 28]}, {"ent_type": "GENE", "char_span": [139, 143], "name": "GAT2", "tok_span": [26, 29], "new_tok_span": [35, 38]}, {"ent_type": "GENE", "char_span": [147, 151], "name": "GAT3", "tok_span": [30, 33], "new_tok_span": [41, 44]}], "relation_list": [{"subject": "beta-alanine", "sbj_char_span": [25, 37], "object": "GAT2", "obj_char_span": [139, 143], "rel_type": "inhibitor", "sbj_tok_span": [4, 7], "obj_tok_span": [26, 29], "new_sbj_tok_span": [5, 8], "new_obj_tok_span": [35, 38]}, {"subject": "nipecotic acid", "sbj_char_span": [65, 79], "object": "GAT2", "obj_char_span": [139, 143], "rel_type": "inhibitor", "sbj_tok_span": [11, 15], "obj_tok_span": [26, 29], "new_sbj_tok_span": [14, 18], "new_obj_tok_span": [35, 38]}, {"subject": "guvacine", "sbj_char_span": [84, 92], "object": "GAT2", "obj_char_span": [139, 143], "rel_type": "inhibitor", "sbj_tok_span": [16, 19], "obj_tok_span": [26, 29], "new_sbj_tok_span": [21, 24], "new_obj_tok_span": [35, 38]}, {"subject": "GABA", "sbj_char_span": [96, 100], "object": "GAT2", "obj_char_span": [139, 143], "rel_type": "product or substrate", "sbj_tok_span": [20, 21], "obj_tok_span": [26, 29], "new_sbj_tok_span": [27, 28], "new_obj_tok_span": [35, 38]}, {"subject": "GABA", "sbj_char_span": [96, 100], "object": "GAT3", "obj_char_span": [147, 151], "rel_type": "product or substrate", "sbj_tok_span": [20, 21], "obj_tok_span": [30, 33], "new_sbj_tok_span": [27, 28], "new_obj_tok_span": [41, 44]}, {"subject": "beta-alanine", "sbj_char_span": [25, 37], "object": "GAT3", "obj_char_span": [147, 151], "rel_type": "inhibitor", "sbj_tok_span": [4, 7], "obj_tok_span": [30, 33], "new_sbj_tok_span": [5, 8], "new_obj_tok_span": [41, 44]}, {"subject": "nipecotic acid", "sbj_char_span": [65, 79], "object": "GAT3", "obj_char_span": [147, 151], "rel_type": "inhibitor", "sbj_tok_span": [11, 15], "obj_tok_span": [30, 33], "new_sbj_tok_span": [14, 18], "new_obj_tok_span": [41, 44]}, {"subject": "guvacine", "sbj_char_span": [84, 92], "object": "GAT3", "obj_char_span": [147, 151], "rel_type": "inhibitor", "sbj_tok_span": [16, 19], "obj_tok_span": [30, 33], "new_sbj_tok_span": [21, 24], "new_obj_tok_span": [41, 44]}], "umls_entity_list": [{"mention": "beta-alanine", "char_span": [25, 37], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [4, 7], "new_tok_span": [5, 8]}, {"mention": "nipecotic", "char_span": [65, 74], "sem_type": "Pharmacologic Substance", "tok_span": [11, 14], "new_tok_span": [14, 17]}, {"mention": "guvacine", "char_span": [84, 92], "sem_type": "Organic Chemical", "tok_span": [16, 19], "new_tok_span": [21, 24]}, {"mention": "GABA", "char_span": [96, 100], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [20, 21], "new_tok_span": [27, 28]}, {"mention": "GAT2", "char_span": [139, 143], "sem_type": "Gene or Genome", "tok_span": [26, 29], "new_tok_span": [35, 38]}, {"mention": "GAT3", "char_span": [147, 151], "sem_type": "Gene or Genome", "tok_span": [30, 33], "new_tok_span": [41, 44]}, {"mention": "HUGO", "char_span": [153, 157], "sem_type": "Gene or Genome", "tok_span": [34, 36], "new_tok_span": [47, 49]}], "new_text": "The inhibitory action of <START=Amino Acid, Peptide, or Protein> beta - alanine <END=Amino Acid, Peptide, or Protein> and high concentrations of <START=Pharmacologic Substance> nipecotic <END=Pharmacologic Substance> acid and <START=Organic Chemical> guvacine <END=Organic Chemical> on <START=Amino Acid, Peptide, or Protein> GABA <END=Amino Acid, Peptide, or Protein> transport strongly suggests that also <START=Gene or Genome> GAT2 <END=Gene or Genome> or <START=Gene or Genome> GAT3 <END=Gene or Genome> ( <START=Gene or Genome> HUGO <END=Gene or Genome> nomenclature ) could play a role."}, {"PMID": 1712335, "id": 10, "text": "In anesthetized spontaneously hypertensive rats, the antihypertensive activity of carvedilol was nearly abolished by combined pretreatment of the rats with high doses of the alpha 1 adrenoceptor antagonist, prazosin (1 mg/kg, iv), and the nonselective beta adrenoceptor antagonist, propranolol (3 mg/kg, iv), suggesting that the majority of the antihypertensive response produced by carvedilol may be accounted for by blockade of beta and alpha 1 adrenoceptors.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [82, 92], "name": "carvedilol", "tok_span": [11, 15], "new_tok_span": [13, 17]}, {"ent_type": "CHEMICAL", "char_span": [207, 215], "name": "prazosin", "tok_span": [36, 39], "new_tok_span": [38, 41]}, {"ent_type": "CHEMICAL", "char_span": [282, 293], "name": "propranolol", "tok_span": [59, 63], "new_tok_span": [61, 65]}, {"ent_type": "CHEMICAL", "char_span": [383, 393], "name": "carvedilol", "tok_span": [83, 87], "new_tok_span": [87, 91]}, {"ent_type": "GENE", "char_span": [174, 194], "name": "alpha 1 adrenoceptor", "tok_span": [29, 34], "new_tok_span": [31, 36]}, {"ent_type": "GENE", "char_span": [252, 269], "name": "beta adrenoceptor", "tok_span": [53, 57], "new_tok_span": [55, 59]}, {"ent_type": "GENE", "char_span": [430, 460], "name": "beta and alpha 1 adrenoceptors", "tok_span": [94, 102], "new_tok_span": [98, 106]}], "relation_list": [{"subject": "prazosin", "sbj_char_span": [207, 215], "object": "alpha 1 adrenoceptor", "obj_char_span": [174, 194], "rel_type": "agonist or antagonist", "sbj_tok_span": [36, 39], "obj_tok_span": [29, 34], "new_sbj_tok_span": [38, 41], "new_obj_tok_span": [31, 36]}, {"subject": "propranolol", "sbj_char_span": [282, 293], "object": "beta adrenoceptor", "obj_char_span": [252, 269], "rel_type": "agonist or antagonist", "sbj_tok_span": [59, 63], "obj_tok_span": [53, 57], "new_sbj_tok_span": [61, 65], "new_obj_tok_span": [55, 59]}], "umls_entity_list": [{"mention": "antihypertensive", "char_span": [53, 69], "sem_type": "Pharmacologic Substance", "tok_span": [7, 9], "new_tok_span": [8, 10]}, {"mention": "antihypertensive", "char_span": [345, 361], "sem_type": "Pharmacologic Substance", "tok_span": [78, 80], "new_tok_span": [81, 83]}], "new_text": "In anesthetized spontaneously hypertensive rats, the <START=Pharmacologic Substance> antihypertensive <END=Pharmacologic Substance> activity of carvedilol was nearly abolished by combined pretreatment of the rats with high doses of the alpha 1 adrenoceptor antagonist, prazosin ( 1 mg / kg, iv ), and the nonselective beta adrenoceptor antagonist, propranolol ( 3 mg / kg, iv ), suggesting that the majority of the <START=Pharmacologic Substance> antihypertensive <END=Pharmacologic Substance> response produced by carvedilol may be accounted for by blockade of beta and alpha 1 adrenoceptors."}, {"PMID": 23248236, "id": 4, "text": "Ebselen [2-phenyl-1,2 benzisoselenazol-3(2H)-one], a well-known antioxidant and a substrate for mammalian TrxR and Trx, is rapidly bacteriocidal for methicillin-resistant Staphylococcus aureus by an unknown mechanism.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 7], "name": "Ebselen", "tok_span": [0, 3], "new_tok_span": [1, 4]}, {"ent_type": "CHEMICAL", "char_span": [9, 48], "name": "2-phenyl-1,2 benzisoselenazol-3(2H)-one", "tok_span": [4, 24], "new_tok_span": [6, 26]}, {"ent_type": "CHEMICAL", "char_span": [149, 160], "name": "methicillin", "tok_span": [50, 52], "new_tok_span": [62, 64]}, {"ent_type": "GENE", "char_span": [96, 110], "name": "mammalian TrxR", "tok_span": [35, 39], "new_tok_span": [39, 43]}, {"ent_type": "GENE", "char_span": [115, 118], "name": "Trx", "tok_span": [40, 42], "new_tok_span": [50, 52]}], "relation_list": [{"subject": "Ebselen", "sbj_char_span": [0, 7], "object": "mammalian TrxR", "obj_char_span": [96, 110], "rel_type": "product or substrate", "sbj_tok_span": [0, 3], "obj_tok_span": [35, 39], "new_sbj_tok_span": [1, 4], "new_obj_tok_span": [39, 43]}, {"subject": "2-phenyl-1,2 benzisoselenazol-3(2H)-one", "sbj_char_span": [9, 48], "object": "mammalian TrxR", "obj_char_span": [96, 110], "rel_type": "product or substrate", "sbj_tok_span": [4, 24], "obj_tok_span": [35, 39], "new_sbj_tok_span": [6, 26], "new_obj_tok_span": [39, 43]}, {"subject": "Ebselen", "sbj_char_span": [0, 7], "object": "Trx", "obj_char_span": [115, 118], "rel_type": "product or substrate", "sbj_tok_span": [0, 3], "obj_tok_span": [40, 42], "new_sbj_tok_span": [1, 4], "new_obj_tok_span": [50, 52]}, {"subject": "2-phenyl-1,2 benzisoselenazol-3(2H)-one", "sbj_char_span": [9, 48], "object": "Trx", "obj_char_span": [115, 118], "rel_type": "product or substrate", "sbj_tok_span": [4, 24], "obj_tok_span": [40, 42], "new_sbj_tok_span": [6, 26], "new_obj_tok_span": [50, 52]}], "umls_entity_list": [{"mention": "Ebselen", "char_span": [0, 7], "sem_type": "Pharmacologic Substance", "tok_span": [0, 3], "new_tok_span": [1, 4]}, {"mention": "antioxidant", "char_span": [64, 75], "sem_type": "Pharmacologic Substance", "tok_span": [30, 31], "new_tok_span": [33, 34]}, {"mention": "Trx", "char_span": [106, 109], "sem_type": "Gene or Genome", "tok_span": [36, 38], "new_tok_span": [42, 44]}, {"mention": "Trx", "char_span": [115, 118], "sem_type": "Gene or Genome", "tok_span": [40, 42], "new_tok_span": [50, 52]}, {"mention": "Trx", "char_span": [106, 109], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [36, 38], "new_tok_span": [42, 44]}, {"mention": "Trx", "char_span": [115, 118], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [40, 42], "new_tok_span": [50, 52]}], "new_text": "<START=Pharmacologic Substance> Ebselen <END=Pharmacologic Substance> [ 2 - phenyl - 1, 2 benzisoselenazol - 3 ( 2H ) - one ], a well - known <START=Pharmacologic Substance> antioxidant <END=Pharmacologic Substance> and a substrate for mammalian <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> Trx <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein>R and <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> Trx <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein>, is rapidly bacteriocidal for methicillin - resistant Staphylococcus aureus by an unknown mechanism."}, {"PMID": 17315049, "id": 8, "text": "Like other DPP-4 inhibitors, sitagliptin reduces hemoglobin A1c (HbA1c), fasting and postprandial glucose by glucose-dependent stimulation of insulin secretion and inhibition of glucagon secretion.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [98, 105], "name": "glucose", "tok_span": [27, 28], "new_tok_span": [28, 29]}, {"ent_type": "CHEMICAL", "char_span": [109, 116], "name": "glucose", "tok_span": [29, 30], "new_tok_span": [32, 33]}, {"ent_type": "CHEMICAL", "char_span": [29, 40], "name": "sitagliptin", "tok_span": [7, 11], "new_tok_span": [7, 11]}, {"ent_type": "GENE", "char_span": [142, 149], "name": "insulin", "tok_span": [34, 35], "new_tok_span": [38, 39]}, {"ent_type": "GENE", "char_span": [178, 186], "name": "glucagon", "tok_span": [39, 40], "new_tok_span": [43, 44]}, {"ent_type": "GENE", "char_span": [11, 16], "name": "DPP-4", "tok_span": [2, 5], "new_tok_span": [2, 5]}, {"ent_type": "GENE", "char_span": [49, 63], "name": "hemoglobin A1c", "tok_span": [12, 16], "new_tok_span": [12, 16]}, {"ent_type": "GENE", "char_span": [65, 70], "name": "HbA1c", "tok_span": [17, 20], "new_tok_span": [17, 20]}], "relation_list": [{"subject": "sitagliptin", "sbj_char_span": [29, 40], "object": "DPP-4", "obj_char_span": [11, 16], "rel_type": "inhibitor", "sbj_tok_span": [7, 11], "obj_tok_span": [2, 5], "new_sbj_tok_span": [7, 11], "new_obj_tok_span": [2, 5]}, {"subject": "sitagliptin", "sbj_char_span": [29, 40], "object": "hemoglobin A1c", "obj_char_span": [49, 63], "rel_type": "regulator", "sbj_tok_span": [7, 11], "obj_tok_span": [12, 16], "new_sbj_tok_span": [7, 11], "new_obj_tok_span": [12, 16]}, {"subject": "sitagliptin", "sbj_char_span": [29, 40], "object": "HbA1c", "obj_char_span": [65, 70], "rel_type": "regulator", "sbj_tok_span": [7, 11], "obj_tok_span": [17, 20], "new_sbj_tok_span": [7, 11], "new_obj_tok_span": [17, 20]}, {"subject": "glucose", "sbj_char_span": [109, 116], "object": "glucagon", "obj_char_span": [178, 186], "rel_type": "regulator", "sbj_tok_span": [29, 30], "obj_tok_span": [39, 40], "new_sbj_tok_span": [32, 33], "new_obj_tok_span": [43, 44]}], "umls_entity_list": [{"mention": "glucose", "char_span": [98, 105], "sem_type": "Pharmacologic Substance", "tok_span": [27, 28], "new_tok_span": [28, 29]}, {"mention": "glucose", "char_span": [109, 116], "sem_type": "Pharmacologic Substance", "tok_span": [29, 30], "new_tok_span": [32, 33]}], "new_text": "Like other DPP - 4 inhibitors, sitagliptin reduces hemoglobin A1c ( HbA1c ), fasting and postprandial <START=Pharmacologic Substance> glucose <END=Pharmacologic Substance> by <START=Pharmacologic Substance> glucose <END=Pharmacologic Substance> - dependent stimulation of insulin secretion and inhibition of glucagon secretion."}]